0001493152-22-010106.txt : 20220415 0001493152-22-010106.hdr.sgml : 20220415 20220415164044 ACCESSION NUMBER: 0001493152-22-010106 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 82 CONFORMED PERIOD OF REPORT: 20211231 FILED AS OF DATE: 20220415 DATE AS OF CHANGE: 20220415 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OZOP ENERGY SOLUTIONS, INC. CENTRAL INDEX KEY: 0001679817 STANDARD INDUSTRIAL CLASSIFICATION: MISCELLANEOUS ELECTRICAL MACHINERY, EQUIPMENT & SUPPLIES [3690] IRS NUMBER: 352540672 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-55976 FILM NUMBER: 22830407 BUSINESS ADDRESS: STREET 1: 31 SANDFORT LN. CITY: WARWICK STATE: NY ZIP: 10990 BUSINESS PHONE: (845) 544-5112 MAIL ADDRESS: STREET 1: 31 SANDFORT LN. CITY: WARWICK STATE: NY ZIP: 10990 FORMER COMPANY: FORMER CONFORMED NAME: OZOP SURGICAL CORP. DATE OF NAME CHANGE: 20180521 FORMER COMPANY: FORMER CONFORMED NAME: Newmarkt Corp. DATE OF NAME CHANGE: 20160715 10-K 1 form10-k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-K

☒ Annual Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the fiscal year ended December 31, 2021

☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from __________ to __________

Commission file number 000-55976

OZOP ENERGY SOLUTIONS, INC.

(Exact name of registrant as specified in its charter)

Nevada

3841

35-2540672

(State or Other Jurisdiction of

Incorporation or Organization)

(Primary Standard Industrial

Classification Number)

(IRS Employer

Identification Number)

42 N Main Street

Florida, NY 10921

(845) 544-5112

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Securities registered under Section 12(b) of the Act: None

Securities registered pursuant to Section 12(g) of the Act: Common Stock, $0.001 par value

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicated by check mark whether the registrant has submitted electronically, if any, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. :

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☒	Smaller reporting company ☒
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use to the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 USC. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

The aggregate market value of the registrant’s common stock held by non-affiliates on June 30, 2021 was $340,168,153 (computed using the closing price of the common stock on June 30, 2021 as reported by the OTC Markets).

As of April 14, 2022, 4,622,362,997 shares of common stock of the registrant were outstanding.

Table of Contents

		Page
	PART I

Item 1	Business	4
Item 1A	Risk Factors	9
Item 1B	Unresolved Staff Comments	9
Item 2	Properties	9
Item 3	Legal Proceedings	9
Item 4	Mine Safety Disclosures	9

	PART II

Item 5	Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	10
Item 6	Selected Financial Data	10
Item 7	Management’s Discussion and Analysis of Financial Condition and Results of Operations	11
Item 7A	Quantitative and Qualitative Disclosures About Market Risk	19
Item 8	Financial Statements and Supplementary Data	19
Item 9	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	19
Item 9A	Controls and Procedures	19
Item 9B	Other Information	20

	PART III

Item 10	Directors, Executive Officers and Corporate Governance	21
Item 11	Executive Compensation	23
Item 12	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	24
Item 13	Certain Relationships and Related Transactions, and Director Independence	25
Item 14	Principal Accountant Fees and Services	25

	PART IV

Item 15	Exhibits and Financial Statement Schedules	25
	Signatures	28

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This report contains forward-looking statements. The Securities and Exchange Commission (the “SEC”) encourages companies to disclose forward-looking information so that investors can better understand a company’s future prospects and make informed investment decisions. This report and other written and oral statements that we make from time to time contain such forward-looking statements that set out anticipated results based on management’s plans and assumptions regarding future events or performance. We have tried, wherever possible, to identify such statements by using words such as “project”, “believe”, “anticipate”, “plan”, “expect”, “estimate”, “intend”, “should”, “would”, “could”, or “may”, or other such words, verbs in the future tense and words and phrases that convey similar meaning and uncertainty of future events or outcomes to identify these forward–looking statements. There are a number of important factors beyond our control that could cause actual results to differ materially from the results anticipated by these forward–looking statements. While we make these forward–looking statements based on various factors and using numerous assumptions, you have no assurance the factors and assumptions will prove to be materially accurate when the events they anticipate actually occur in the future. Factors that could cause our actual results of operations and financial condition to differ materially are discussed in greater detail under Item 1A, “Risk Factors” of this annual report on Form 10-K.

The forward–looking statements are based upon our beliefs and assumptions using information available at the time we make these statements. We caution you not to place undue reliance on our forward–looking statements as (i) these statements are neither predictions nor guaranties of future events or circumstances, and (ii) the assumptions, beliefs, expectations, forecasts and projections about future events may differ materially from actual results. We undertake no obligation to publicly update any forward–looking statement to reflect developments occurring after the date of this report.

PART I

Item 1. Description of Business

ORGANIZATION

Ozop Energy Solutions, Inc. (the” Company,” “we,” “us” or “our”) was originally incorporated as Newmarkt Corp. on July 17, 2015, under the laws of the State of Nevada.

Our corporate website is located at http://ozopenergy.com/, and the contents of our website are expressly not incorporated herein.

On October 29, 2020, the Company formed a new wholly owned subsidiary, Ozop Surgical Name Change Subsidiary, Inc., a Nevada corporation (“Merger Sub”). The Merger Sub was formed under the Nevada Revised Statutes for the sole purpose and effect of changing the Company’s name to “Ozop Energy Solutions, Inc.” That same day the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with the Merger Sub and filed Articles of Merger (the “Articles of Merger”) with the Nevada Secretary of State, merging the Merger Sub into the Company, which were stamped effective as of November 3, 2020. As permitted by the Section 92.A.180 of the Nevada Revised Statutes, the sole purpose and effect of the filing of Articles of Merger was to change the name of the Company to “Ozop Energy Solutions, Inc.”

On August 19, 2021, the Company formed Ozop Capital Partners, Inc. (“Ozop Capital”), a Delaware corporation. The Company is the majority shareholder of Ozop Capital with PJN Holdings LLC (“PJN”), a New York limited liability company, being the minority shareholder. Brian Conway was appointed as the sole officer and director of Ozop Capital and has voting control of Ozop Capital.

On October 29, 2021, EV Insurance Company, Inc. (“EVCO”) was formed as a captive insurance company in the State of Delaware. EVCO is a wholly owned subsidiary of Ozop Capital. On January 7, 2022, EVCO filed with New Castle County, Delaware DBA OZOP Plus.

Stock Purchase Agreement

On July 10, 2020, the Company entered into a Stock Purchase Agreement (the “SPA”) with Power Conversion Technologies, Inc., a Pennsylvania corporation (“PCTI”), and Catherine Chis (“Chis”), PCTI’s Chief Executive Officer (“CEO”) and its sole shareholder. Under the terms of the SPA, the Company acquired one thousand (1,000) shares of PCTI, which represents all of the outstanding shares of PCTI, from Chis in exchange for the issuance of 47,500 shares of the Company’s Series C Preferred Stock, 18,667 shares of the Company’s Series D Preferred Stock, and 500 shares of the Company’s Series E Preferred Stock to Chis. The Acquisition is being accounted for as a business combination and was treated as a reverse acquisition for accounting purposes with PCTI as the accounting acquirer in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 805, Business Combinations (“ASC 805”). In accordance with the accounting treatment for a reverse acquisition, the Company’s historical financial statements prior to the reverse merger were and will be replaced with the historical financial statements of PCTI prior to the reverse merger, in all future filings with the U.S. Securities and Exchange Commission (the “SEC”). The consolidated financial statements after completion of the reverse merger have and will include the assets, liabilities and results of operations of the combined company from and after the closing date of the reverse merger.

Corporate Matters

On July 7, 2020, the Company filed an Amended and Restated Certificate of Designation with the State of Nevada of the Company’s Series C Preferred Stock. Under the terms of the Amendment to Certificate of Designation of Series C Preferred Stock, 50,000 shares of the Company’s preferred remain designated as Series C Preferred Stock. The holders of Series C Preferred Stock have no conversion rights and no dividend rights. For so long as any shares of the Series C Preferred Stock remain issued and outstanding, the Holder thereof, voting separately as a class, shall have the right to vote on all shareholder matters equal to sixty-seven (67%) percent of the total vote. On July 10, 2020, pursuant to the SPA with PCTI, the Company issued 47,500 shares of Series C preferred Stock to Chis. On July 13, 2021, the Company purchased 47,500 shares of the Company’s Series C Preferred Stock held by Chis (see below). As of December 31, 2021, and 2020, there were 2,500 and 50,000 shares, respectively, of Series C Preferred Stock issued and outstanding. Mr. Conway owns 2,500 shares as of December 31, 2021.

On July 7, 2020, the Company filed a Certificate of Designation with the State of Nevada of the Company’s Series D Preferred Stock. Under the terms of the Certificate of Designation of Series D Preferred Stock, 20,000 shares of the Company’s preferred stock have been designated as Series D Convertible Preferred Stock. The holders of the Series D Convertible Preferred Stock shall not be entitled to receive dividends. The holders as a group may, at any time convert all of the shares of Series D Convertible Preferred Stock into a number of fully paid and nonassessable shares of common stock determined by multiplying the number of issued and outstanding shares of common stock of the Company on the date of conversion, by 3. Except as provided in the Certificate of Designation or as otherwise required by law, no holder of the Series D Convertible Preferred Stock shall be entitled to vote on any matter submitted to the shareholders of the Company for their vote, waiver, release or other action. The Series D Convertible Preferred Stock shall not bear any liquidation rights. On July 10, 2020, pursuant to the SPA with PCTI, the Company issued 18,667 shares of Series D preferred Stock to Chis, and on August 28, 2020. Pursuant to Mr. Conway’s employment agreement, the Company issued 1,333 shares of Series D Preferred Stock to Mr. Conway. On July 13, 2021, the Company purchased 18,667 shares of the Company’s Series D Preferred Stock held by Chis (see below).

On July 13, 2021, the Company entered into a Definitive Agreement (the “Agreement”) with Chis to purchase the 47,500 shares of the Company’s Series C Preferred Stock held by Chis and the 18,667 shares of the Company’s Series D Preferred Stock held by Chis for the total purchase price of $11,250,000. In conjunction with the Agreement, Chis resigned from any and all positions held in the Company’s wholly owned subsidiary, PCTI. Further, Chis agreed that upon her resignation and for a period of five years thereafter (the “Restriction Period”), she shall not, directly or indirectly, solicit the employment of, assist in the soliciting of the employment of, or hire any employee or officer of the Company, including those of any of its present or future subsidiaries, or induce any person who is an employee, officer, agent, consultant or contractor of the Company to terminate such relationship with the Company. Additionally, Chis agrees that during the Restriction Period, she shall not compete with the Company or PCTI anywhere worldwide or be employed by any competitor of the Company.

On July 27, 2021, the Company filed with the Secretary of State of the State of Nevada an Amended and Restated Certificate of Designation of Series D Preferred Stock (the “Series D Amendment”). Under the terms of the Series D Amendment, 4,570 shares of the Company’s preferred stock will be designated as Series D Convertible Preferred Stock. The holders of the Series D Convertible Preferred Stock shall not be entitled to receive dividends. Any holder may, at any time convert any number of shares of Series D Convertible Preferred Stock held by such holder into a number of fully paid and nonassessable shares of common stock determined by multiplying the number of issued and outstanding shares of common stock of the Company on the date of conversion, by 1.5 and dividing that number by the number of shares of Series D Convertible Preferred Stock being converted. Except as provided in the Series D Amendment or as otherwise required by law, no holder of the Series D Convertible Preferred Stock shall be entitled to vote on any matter submitted to the shareholders of the Company for their vote, waiver, release or other action. The Series D Convertible Preferred Stock shall not bear any liquidation rights. On July 28, 2021, the Company closed on a Stock and Warrant Purchase Agreement (the “Series D SPA”). Pursuant to the terms of Series D SPA, an investor in exchange for $13,200,000 purchased one share of Series D Preferred Stock, and a warrant to acquire 3,236 shares of Series D Preferred Stock. As of December 31, 2021, and 2020, there were 1,334 and 20,000 shares, respectively, of Series D Preferred Stock issued and outstanding and warrants to purchase 3,236 shares of Series D Preferred Stock are outstanding as of December 31, 2021. Mr. Conway owns 1,333 shares of Series D Preferred Stock as of December 31, 2021.

Recent Events

On February 25, 2022, the Company formed Ozop Engineering and Design, Inc. (“OED”) a Nevada corporation, as a wholly owned subsidiary of the Company. OED was formed to become a premier engineering and lighting control design firm. OED offers product and design support for lighting and solar projects with a focus on fast lead times and technical support. OED and our partners are able to offer the resources needed for lighting, solar and electrical design projects. OED will provide customers systems to coordinate the understanding of electrical usage with the relationship between lighting design and lighting controls, by developing more efficient ecofriendly designs. We work with architects, engineers, facility managers, electrical contractors and engineers.

On April 4, 2022, the Company and GHS Investments LLC (“GHS”). signed a Securities Purchase Agreement (the “GHS Purchase Agreement”) for the sale of up to Two Hundred Million (200,000,0000) shares of the Company’s common stock to GHS. We may sell shares of our common stock from time to time over a six (6)- month period ending October 4, 2022, at our sole discretion, to GHS under the GHS Purchase Agreement. The purchase price shall be 85% of lowest VWAP for the ten (10) days preceding the Company’s notice to GHS for the sale of the Company’s common stock. On April 8, 2022, the Company filed a Prospectus Supplement to the Registration Statement dated October 14, 2021, regarding the GHS Purchase Agreement.

Business Overview

Ozop Energy Systems

On December 11, 2020, the Company formed Ozop Energy Systems, Inc. (“OES”), a Nevada corporation and a wholly owned subsidiary of the Company. OES was formed to be a manufacturer and distributor of renewable energy products and is actively engaged in the renewable, electric vehicle (“EV”), energy storage and energy resiliency sectors. OES management has decades of experience in the renewable, storage and resilient energy businesses and associated markets, which include but are not limited to project finance, project development, equipment finance, construction, utility protocol, regulatory policy and technology assessment.

We are engaged in multiple business lines that include Project Development as well as Equipment Distribution. Our solar and energy storage projects involve large-scale battery and solar photovoltaics (PV) installations. The utility-scale storage business is based on an arbitrage business model in which we install multiple 1+ megawatt batteries, charge them with off-peak grid electricity under contract with the utility, then sell the power back during peak load hours at a premium, as dictated by prevailing electricity tariffs.

Equipment Distributor: OES has entered the component supply/distribution side of the renewable, resiliency and energy storage industries distributing the core components associated with residential and commercial solar PV systems as well as onsite battery storage and power generation. In April 2021, the Company signed a five- year lease (beginning June 1, 2021) of approximately 8,100 SF in California, for office and warehouse space to support the sales and distribution of our west coast operations. The components we are distributing include PV panels, solar inverters, solar mounting systems, stationary batteries, onsite generators and other associated electrical equipment and components that are all manufactured by multiple companies, both domestic and international. These core products are sourced from management-developed relationships and are distributed through our existing network and our in-house sales team. Sales were approximately $10.6 million for the year ended December 31, 2021.

Solar PV: Our PV business model involves the design and construction of electrical generating PV systems that can sell power to the utilities or be used for off grid use as part of our developing Neo-Grids solution. The Neo-Grids proprietary program, patents pending, was developed for the off-grid distribution of electricity to remove or reduce the dependency on utilities that currently burdens the EV Charging sectors. It will also reduce or eliminate the lengthy permitting processes and streamline the installations of those EV chargers.

Modular Energy Distribution System: The Neo-Grids, patent pending, is comprised of the design engineering, installation, and operational methodologies as well as the financial arbitrage of how we produce, capture and distribute electrical energy for the EV markets. Neo-Grids will serve both the private auto and the commercial sectors. OES has license rights to the proprietary “flow” that was filed with the United States Patent and Trademark Office in March 2021. The exponential growth of the EV industry has been accelerated by the recent major commitments of most of the major car manufacturers. Our Neo-Grids business model leverages this accelerated growth by offering (1) charging locations that can be installed with reduced delays, restricted areas or load limits and (2) EV charger electricity that is produced from renewable sources claiming little to no carbon footprint.

OES has developed a business plan for the Neo Grids distribution solution that is being executed now and will be coming out of Research and Development for proof of concept in Q4 2021. Having identified several manufacturers and established a supply line for EV chargers, we have entered into agreements for EV charger installations as part of this proof of concept and plan to service them under multi-year agreements.

Ozop Plus

On August 19, 2021, the Company formed Ozop Capital Partners, Inc. (“Ozop Capital”), a Delaware corporation. The Company is the majority shareholder of Ozop Capital. On October 29, 2021, EV Insurance Company, Inc. (“EVCO”) was formed as a captive insurance company in the State of Delaware. EVCO is a wholly owned subsidiary of Ozop Capital (DBA OZOP Plus). Ozop Plus plans on producing vehicle service contracts (“VSC’s”) for electric vehicles (EV’s). to respond to not only in filling the gap of a manufacturer’s warranty but to bring added value to EV owners by utilizing our partnerships and strengths in the renewable energy market to offer unique and innovative services. Among EV owners’ concerns are the EV battery repair and replacement costs, range anxiety, environmental responsibilities, roadside assistance, and the accelerated wear on additional components that EV vehicles experience. Management believes that the Ozop Plus VSC will give “peace of mind” to the EV buyer. The Company is currently in negotiations to complete the necessary agreements to launch the product in Q2 2022. Additionally, the Company is also in discussions with entities whereby Ozop Plus can re-insure the battery portion of another entity’s VSC.

PCTI

The following relates to PCTI activity during the year ended December 31, 2021. Due to supply chain issues and other factors, management is currently reviewing the current business model of PCTI, in determining the best course of action going forward.

PCTI designs, develops, manufactures and distributes standard and custom power electronic solutions. All of its products are manufactured in the United States.

Principal Products and Services

PCTI has four main product lines: DC Power Supplies from 5KW to 2MW, Battery chargers from 5KW to 2MW, DC/AC inverters to 1.5MVA and frequency converters up to 1MVA.

PCTI historically has manufactured the following product types:

●

DC & AC Power Supplies: Our DC power supplies use a multipulse SCR / IGBT design to achieve high efficiency, low ripple, precise regulation and low output noise, available in ratings from 5KW to 2MW.

●

High Voltage Battery Chargers: PCTI offers rugged high-current battery chargers to a variety of high-current industrial charging applications from 5KW to 2MW.

●

Converters/Inverters: DC/DC, DC/AC, AC/AC, solar cell power stations, power transmission, electrostatic precipitator.

●

400Hz Aircraft Ground Support Equipment: Distribution equipment, gate boxes, switchboards, line drop compensators, line protection modules.

●

Power Electronic Modules: Integrated modules with IGBTs, SCRs, MOSFET, Diodes, GTO, GTC-Bipolar.

●

Other Power Electronic Products: Prototyping, R&D, consulting.

Microgrids

Microgrids are becoming more necessary not just as a way to provide electricity to a remote region but also as a source of resiliency. Whether the entity is critical to society like a hospital, police station or container terminal or needs to maintain revenues by remaining operational (e.g. a manufacturer or food processor), a microgrid provides that unique function. Because PCTI’s inverters and battery chargers are in the highest power segments, they are uniquely suited for microgrid applications.

Sales and marketing

For legacy products, the Company uses a government contracting service that reviews the daily buying notices from the U.S. government and filters them via keywords specific to the company’s market sectors. Additionally, opportunities come through the U.S. Governments System of Award Management.

Competition

There are different competitors for each product line that are also further divided by power segment. By serving the high power products sector, we have sought to limit competition and commoditization of our products. We compete as a solution driven company, providing PCTI with what we believe are better margins and larger order values. As we are moving the direction of the company into the renewable energy storage market space, we are aware that some of the competitors have strong brand names. We believe PCTI offers a larger breath of product offering in these power ranges while our competition is fragmented in this area. In the high- power segment, we believe PCTI’s experience, technology and flexibility provides a great advantage over other competitors.

We compete with many companies in the various application segments including larger, more established companies with substantial capabilities, personnel and financial resources.

PCTI is positioning itself to compete in the high power segment, with a focus on renewable energy and EV markets. These two segments are continuously looking to advance their products, which makes it difficult for the larger companies to adjust. We believe this is how PCTI will have an advantage to compete as a solutions driven company.

Many of our competitors have a larger presence in global markets. PCTI is also looking to expend its global footprint.

Intellectual Property

PCTI has a 30-year design library that includes all four product lines as well as some related equipment. One of our advantages over our competitors is our proprietary digital signal processing (DSP) control currently in its 7^th generation. To the best of our knowledge, we believe that none of our competitors are using this sophisticated control topology at this time. DSP control permits great flexibility in our designs, allowing us to produce a wide variety of designs in a shorter period of time than our competitors. DSP allows for real-time control and monitoring of the equipment, which is faster than sequential control. This provides significant performance improvement as well as energy savings in the equipment.

PCTI additionally has trade secrets and know-how related to the design, manufacture, and testing of the equipment.

Research and Development

To maintain our level of continuous innovation, PCTI conducts numerous internal R&D projects. Additionally, the unique needs and applications of our customers require that we conduct R&D and engineering in order to provide them with the needed solutions and products.

Employees

As of the date of this filing, the Company employs 21 full time employees. Ozop and PCTI have contracts with various independent contractors and consultants to fulfill additional needs, including accounting, investor relations, business development, permitting, and other corporate functions, and may increase staff further as we expand activities and bring new projects on line.

ITEM 1A. RISK FACTORS

We are a smaller reporting Company and are not required to include disclosures under this item.

ITEM 1B. UNRESOLVED STAFF COMMENTS.

None.

ITEM 2. PROPERTIES.

We do not own any real estate or other properties. On October 25, 2019, PCTI executed a non-cancellable lease of office and industrial space totaling 11,800 square feet in Zelienople, PA., which began December 1, 2019 and expires on November 30, 2022. The lease terms include monthly rent of $7,000.

On January 2, 2021, the Company entered into a ten (10) year lease for a 6-bay garage storage facility of approximately 2,500 square feet. Pursuant to the lease the Company agreed to issue 100,000,000 shares of restricted common stock. The shares were certificated on March 8, 2021, with an effective date of January 2, 2021. The Company valued the shares $0.0063, (the market value of the common stock on the date of the agreement) and has recorded $630,000 as a prepaid expense. As of the date of this report, the Company has not yet taken possession of the space, and is in negotiations with the landlord regarding other potential properties.

ITEM 3. LEGAL PROCEEDINGS.

On March 4, 2021 a Complaint and Demand for Jury Trial (the “Complaint”) was filed by a plaintiff (the “Plaintiff”) in the United States District Court for the Southern District of New York. The Complaint named Ozop Energy Solutions, Inc. (“OZOP”) and Brian Conway, Ozop’s Chief Executive Officer, (the “CEO”). OZOP and the CEO are collectively referred to herein as “Defendants”. On May 12, 2021, the plaintiff and or their counsel, gave notice that the above action is voluntarily dismissed, pursuant to Rule 41(a)(1)(A)(i) of the Federal Rules of Civil Procedure, without prejudice against the defendants Brian Conway and OZOP Energy Solutions, Inc.

Other than the above, we know of no legal proceedings to which we are a party or to which any of our property is the subject, which are pending, threatened or contemplated or any unsatisfied judgments against the Company.

ITEM 4. MINE SAFETY DISCLOSURES.

Not applicable.

PART II

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

The Company’s common stock began trading on May 8, 2017, and currently trades on the OTC Pink Market under the symbol “OZSC.” The closing price of our common stock on April 8, 2022, was $0.0237.

Holders

As of December 31, 2021, the Company had 4,617,362,977 shares of our common stock issued and outstanding held by 112 holders of record.

Recent Sales of Unregistered Securities

The following table are all shares issued during the quarter ended December 31, 2021:

On October 8, 2021, the Company issued 2,500,000 shares pursuant to an employment agreement. The shares were valued at $0.0445 per share (the market price of the common stock on the date of the issuance), and $113,750 is included in stock-based compensation expense for the year ended December 31, 2021.

The Company issued the foregoing securities in reliance on an exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended, and/or Rule 506(b) promulgated thereunder, as there was no general solicitation to the investors and the transactions did not involve a public offering.

Dividends

We have not declared or paid dividends on our common stock since our formation, and we do not anticipate paying dividends in the foreseeable future. Declaration or payment of dividends, if any, in the future, will be at the discretion of our Board of Directors and will depend on our then current financial condition, results of operations, capital requirements and other factors deemed relevant by the Board of Directors. There are no contractual restrictions on our ability to declare or pay dividends.

Securities authorized for issuance under equity compensation plans

None

Purchases of Equity Securities by the Issuer and Affiliated Purchasers

None.

OTHER STOCKHOLDER MATTERS

None.

Item 6. Selected Financial Data

Not applicable to smaller reporting companies.

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following is management’s discussion and analysis of certain significant factors that have affected our financial position and operating results during the periods included in the accompanying consolidated financial statements, as well as information relating to the plans of our current management. This report includes forward-looking statements. Generally, the words “believes,” “anticipates,” “may,” “will,” “should,” “expect,” “intend,” “estimate,” “continue,” and similar expressions or the negative thereof or comparable terminology are intended to identify forward-looking statements. Such statements are subject to certain risks and uncertainties, including the matters set forth in this report or other reports or documents we file with the Securities and Exchange Commission from time to time, which could cause actual results or outcomes to differ materially from those projected. Undue reliance should not be placed on these forward-looking statements which speak only as of the date hereof. We undertake no obligation to update these forward-looking statements.

While our financial statements are presented on the basis that we are a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business over a reasonable length of time, our auditors have raised a substantial doubt about our ability to continue as a going concern.

THE COMPANY

Ozop Energy Solutions, Inc. (the “Company,” “we,” “us” or “our”) was originally incorporated as Newmarkt Corp. on July 17, 2015, under the laws of the State of Nevada.

On August 19, 2021, the Company formed Ozop Capital Partners, Inc. (“Ozop Capital”), a Delaware corporation. The Company is the majority shareholder of Ozop Capital with PJN Holdings LLC, a New York limited liability company, being the minority shareholder. Ozop Capital was formed as a holding company and seeks to develop a captive insurance company. Brian Conway was appointed as the sole officer and director of Ozop Capital and has voting control of Ozop Capital.

Stock Purchase Agreement

The Company utilized the Option Pricing Method (the “OPM”) to value the transaction. The OPM method treats all equity linked instruments as call options on the enterprise value, with exercise prices and liquidation preferences based on the terms of the various common, preferred, options, warrants, and convertible debt. Under this method, the common stock only has value if the funds available for distribution to the shareholders exceed the liquidation preferences of the preferred stock and face value of the convertible debt. The timing of a liquidity event is required to utilize this method. The OPM considers the various terms of the stockholder agreements—including the level of seniority among the securities, dividend policy, conversion ratios, and cash allocations—upon liquidation of the enterprise. In addition, the method implicitly considers the effect of the liquidation preference as of the future liquidation date, not as of the valuation date. A feature of the OPM is that it explicitly recognizes the option-like payoffs of the various share classes utilizing information in the underlying asset (that is, estimated volatility) and the risk-free rate to adjust for risk by adjusting the probabilities of future payoffs. The following table summarizes the preliminary value of the consideration issued and the preliminary purchase price allocation of the fair value of assets acquired and liabilities assumed in the transaction.

	Purchase Price Allocation
Fair value of OZOP equity consideration issued	$	818,444
Assets acquired	$	1,229,917
Goodwill		11,201,145
Liabilities assumed		(11,612,618	)
	$	818,444

The Company reviews the goodwill allocated to each of our reporting units for possible impairment annually and whenever events or changes in circumstances indicate the carrying amount may not be recoverable. Pursuant to that review, management has determined that the goodwill arising from the above transaction has been impaired and accordingly $11,201,145 has been recorded as an impairment expense for the year ended December 31, 2020.

Included in the audited Consolidated Statements of Comprehensive Loss for the years ended December 31, 2020, are the results of Ozop, the accounting acquiree, of revenues of $-0- and a loss before income taxes of $7,782,364. The following table provides unaudited pro forma results of operations for the year ended December 31, 2020, as if the acquisition had been consummated as of the beginning of that period. The pro forma results include the effect of certain purchase accounting adjustments, such as the estimated changes in depreciation and amortization expense on the acquired intangible assets. However, pro forma results do not include any anticipated cost savings (if any) of the combined companies. Accordingly, such amounts are not necessarily indicative of the results if the acquisition has occurred on the date indicated, or which may occur in the future.

	Unaudited pro forma results year ended December 31, 2020
Revenues	$	1,411,432
Loss before income taxes		(51,779,499	)
Basic and fully diluted loss per share	$	(0.02	)

Stock Redemption Agreement

Results of Operations for the years ended December 31, 2021 and 2020:

The following discussion relates to the historical financial statements of PCTI, and beginning on July 11, 2020 the consolidated financial statements include the assets, liabilities and results of operations of PCTI and Ozop, (the combined company from and after the closing date of the reverse merger).

Revenue

For the year ended December 31, 2021, the Company generated revenue of $11,928,605 compared to $1,411,432 for the year ended December 31, 2020. The increase in revenues is a result of revenues of $10,595,799 from Ozop Energy Systems, beginning May 2021, and are classified as sourced and distributed products. Sales are summarized as follows:

	Year ended December 31,
	2021		2020
Sourced and distributed products	$	10,595,799	$	-
Manufactured products		1,332,806		1,411,432
Total	$	11,928,605	$	1,411,432

Cost of sales

For the years ended December 31, 2021, and 2020, the Company recognized $10,342,413 and $1,404,348, respectively, of cost of sales.

	Year ended December 31,
	2021		2020
Sourced and distributed products	$	9,763,943	$	-
Manufactured products		578,470		1,404,358
Total	$	10,342,413	$	1,404,358

Based on the above cost of sales, gross margin was 13.3% and 0.5% for the years ended December 31, 2021, and 2020, respectively. The increase of gross margin for the current year is a result of the manufactured orders shipped in 2021 were at a higher margin than the manufactured orders were in 2020. While the improved margin was partially offset by the lower margins recognized on the sourced and distributed products, gross profit dollars increased from the sale of the sourced and distributed products. The sourced and distributed margins were approximately 7.9% for 2021. Due to product availability, increased buy prices and delivery issues that the solar industry experienced at the end of the 4^th quarter 2021, and into the first quarter of 2022, the Company expects that margins on sourced products may be temporarily reduced at the beginning of 2022. However, the Company anticipates that margins of sourced products will rise during the remainder of 2022. While the overall margin will be reduced, the higher gross profit dollars generated from the higher sourced and distributed products revenues will benefit the Company.

Operating expenses

Total operating expenses for the years ended December 31, 2021, and 2020, were $14,387,941 and $17,585,427, respectively. The operating expenses were comprised of:

	Year ended December 31,
	2021		2020
Management fees, related parties including stock-based compensation of $2,850,000 and $4,286,648, respectively	$	3,803,765	$	4,747,952
Stock-based compensation, other		6,472,751		-
Salaries, taxes and benefits		1,227,192		436,198
Professional and consulting fees		1,284,364		459,340
Advertising and marketing		41,712		55,249
Rent and office expenses		251,646		122,277
Insurance		262,682		58,461
Impairment		-		11,526,303
General and administrative. Other		1,043,829		179,647
Total	$	14,387,941	$	17,585,427

For the year ended December 31, 2020, the above amounts include expenses incurred by PCTI for the year ended December 31, 2020, and expenses incurred by Ozop for the period July 11, 2020 through December 31, 2020.

Wages and management fees- related parties, include amounts paid to our CEO and to the President (resigned July 2021) of PCTI. The CEO is eligible for additional bonuses as approved by the Board of Directors of the Company. Beginning January 1, 2021, the CEO was compensated $20,000 per month and effective September 1, 2021, an additional $10,000 per month for the management of Ozop Capital. The following table summarizes management fees:

	Year ended December 31,
	2021		2020
CEO, parent	$	812,099	$	377,804
CEO, parent- Series E Preferred Stock		2,850,000		-
CEO, parent- Series D Preferred Stock		-		4,286,648
President, subsidiary (resigned July 2021)		141,666		83,500
Total	$	3,803,765	$	4,747,952

The Series E Preferred Stock based compensation for the year ended December 31, 2021 is a result of on March 2, 2021, the BOD authorized the issuance of 1,800 shares of Series E Preferred Stock to Mr. Conway and on April 16, 2021, the BOD authorized the issuance of 1,050 to Mr. Conway. The issuances were for services performed. Pursuant to the terms and conditions of the Certificate of Designation of the Series E Preferred Stock, including the redemption value of $1,000 per share, the Company recorded $2,850,000 as stock-based compensation expense for year ended December 31, 2021.

The Series D Preferred Stock based compensation for the year ended December 31, 2020, of $4,286,648, is related to 1,333 shares of Series D Preferred Stock issued to Mr. Conway on August 28, 2020, pursuant to his employment agreement. The Series D Preferred Stock was convertible in the aggregate into three times the number of shares of common stock outstanding at the time of conversion. Mr. Conway owns 6.67% of the issued and outstanding Series D Preferred Stock, and based on the 3,107,037,634 shares outstanding on August 28, 2020, Mr. Conway’s Preferred Stock was convertible into 621,253,401 shares of common stock. Based on the share price of the common stock on that date of $0.0065, the shares were valued at $4,286,648.

Stock based compensation, other for the year ended December 31, 2021, of $6,472,751 is comprised of the following stock issuances:

	●	5,000,000 shares issued in April 2021 pursuant to a one-year consulting agreement. The Company valued the shares at $0.20 per share (the market price of the common stock on the date of the agreement), and $1,000,000 was recorded as deferred stock compensation, to be amortized over the one-year term of the agreement. The consultant was terminated in October 2021, and accordingly, for the year ended December 31, 2021, $1,000,000 is included in stock-based compensation expense.

	●	10,000,000 shares issued in April 2021 pursuant to a one-year consulting agreement. The Company valued the shares at $0.0076 per share (the market price of the common stock on the date of the agreement), and $76,000 was recorded as deferred stock-based compensation, to be amortized over the one-year term of the agreement. For the year ended December 31, 2021, the Company recorded $74,751 as stock-based compensation expense.

	●	5,000,000 shares issued in April 2021 for services. The Company valued the shares at $0.1392 per share (the market price of the common stock on the date of the agreement), and $696,000 is included in stock-based compensation expense for the year ended December 31, 2021.

	●	10,000,000 shares issued for services. The shares were valued at $0.0056 per share, the date the Company agreed to issue the shares. For the year ended December 31, 2021, the Company included $56,000 in stock compensation expense.

	●	10,000,000 shares issued pursuant to a consulting agreement dated February 24, 2021. The shares were valued at $0.2386 per share. For the year ended December 31, 2021, the Company included $2,386,000 in stock compensation expense.

	●	5,000,000 shares of common stock issued in the aggregate to two new employees pursuant to their offers of employment dated March 31, 2021. The shares were valued at $0.23 per share (the market price of the common stock on the date of the issuance). For the year ended December 31, 2021, the Company included $460,000 in stock compensation expense for the 5,000,000 shares of common stock.

	●	Issuance of 200 shares and 950 shares of Series E Preferred Stock, with a redemption value of $1,000 per share, resulting in stock compensation expense of $1,150,000 for the year ended December 31, 2021.

	●	5,000,000 shares of common stock issued in the aggregate to two employees pursuant to their offers of employment dated March 31, 2021. The shares were valued at $0.0745 per share (the market price of the common stock on the date of the issuance). For the year ended December 31, 2021, the Company included $372,500 in stock compensation expense for the 5,000,000 shares of common stock.

	●	452,080 shares of common stock issued for services. The shares were valued at $0.0553 per share (the market price of the common stock on the date of the agreement), and $25,000 is included in stock-based compensation expense for the year ended December 31, 2021.

	●	637,755 shares of common stock to be issued for services. The shares were valued at $0.0392 per share (the market price of the common stock on the date of the issuance), and $25,000 is included in stock-based compensation expense for the year ended December 31, 2021.

	●	5,000,000 shares of common stock issued in the aggregate to two employees pursuant to their offers of employment dated March 31, 2021. The shares were valued at $0.0455 per share (the market price of the common stock on the date of the issuance). For the year ended December 31, 2021, the Company included $227,500 in stock compensation expense for the 5,000,000 shares of common stock.

Salaries, taxes and benefits increased for the year ended December 31, 2021, compared to the year ended December 31, 2020. Included in the increase are the cost of OES employees in 2021. The California operation of OES had expenses of $378,232 for the year ended December 31, 2021. In addition to the California employees, OES had payroll expenses of $284,525 covering business development, sales, administration and IT.

Professional and consulting fees increased to $1,284,364 for the year ended December 31, 2021, compared to $459,340 for the year ended December 31, 2020. The increase was due to accounting and auditing expenses of Ozop included in the current year, the engagement of various consultants by OES as we initiated the Company’s business plan regarding distribution of renewable energy products, the inclusion of Ozop Capital’s consultants as well as an increase in legal fees in 2021. The Company’s consolidated current monthly professional and consulting fees is approximately $140,000.

Advertising and marketing expenses decreased for the year ended December 31, 2021, compared to the year ended December 31, 2020. The decrease was related to additional marketing programs during the year ended December 31, 2020, including brand awareness programs for both PCTI and Ozop.

Rent and office expense (including supplies, utilities and internet costs) increased for the year ended December 31, 2021 compared to the year ended December 31, 2020. The increase was the result of including in 2021, rent and office expense of approximately $41,983 for Ozop and $121,343 for OES. The Company estimates that the monthly OES rent and office expense for the California operation to be approximately $18,000 per month.

During the year ended December 31, 2020, the Company had the following expenses charged to impairment:

●

$11,201,145 for the impairment of goodwill related to the transaction between PCTI and Ozop. The impairment was calculated based on the balance of the assets acquired and the liabilities assumed as of December 31, 2020.

●

$130,207 for the impairment of license rights as management has decided not to go forward with the use of the license rights of Spinus.

●

$194,951 for the impairment of goodwill related to the transaction between Ozop and Spinus.

Other Income (Expenses)

Other expenses, net, for the years ended December 31, 2021, and 2020, was $182,501,302 and $3,389,890, respectively, and were as follows.

	Year ended December 31,
	2021		2020
Interest expense	$	53,252,232	$	3,409,393
Loss on change in fair value of derivatives		17,349,076		176,050
Debt restructure expense		16,450,000		-
Loss (gain) on extinguishment of debt		95,449,994		(195,553	)
Total other expense, net	$	182,501,302	$	3,389,890

The increase in other expense for the year ended December 31, 2021, is primarily a result of loss on extinguishment of debt related to the market value of shares of common stock issued in excess of the debt and accrued interest extinguished. The Company also issued 175,000,000 shares of restricted common stock related to the restructure of the deferred liability. The shares were valued at $0.094 per share and the Company recognized $16,450,000 of restructuring costs. Included in interest expense for the year ended December 31, 2021, is the initial $38,907,939 of fair value related to the issuance of 375,000,000 warrants. In addition, the increases were the result of the amortization of debt discounts and losses on changes in fair values of derivatives, related to convertible notes and warrants.

Net loss

The net loss for the year ended December 31, 2021, was $195,303,051 compared to $20,968,243 for the year ended December 31, 2020. The increase in the loss was primarily a result of the increase in other expenses of $179,111,412 described above partially offset by lower operating expenses and the increase in gross profit.

Liquidity and Capital Resources

Currently, our current capital and our other existing resources will be sufficient to provide the working capital needed for our current business, however, additional capital will be required to meet our debt obligations, and to further expand our business. We may be unable to obtain the additional capital required. If we are unable to generate capital or raise additional funds when required it will have a negative impact on our business development and financial results. These conditions raise substantial doubt about our ability to continue as a going concern as well as our recurring losses from operations, deficit in equity, and the need to raise additional capital to fund operations. This “going concern” could impair our ability to finance our operations through the sale of debt or equity securities. Management’s plans in regard to these factors are discussed below and also in Note 3 to the consolidated financial statements filed herein.

For the year ended December 31, 2021, we primarily funded our business operations with $15,000,000 of proceeds received pursuant to the issuances of promissory notes and $13,100,000 received from the Series D SPA (see Note 13 to the financial statements filed herein). Of the proceeds, $5,000,000 was used for the redemption of 5,000 shares of Series E Preferred Stock and $11,250,000 was used for the redemption of Chis’s Series C and Series D Preferred Stock (see Note 11 to the financial statements filed herein).

As of December 31, 2021, we had cash of $6,767,167 as compared to $1,808,476 at December 31, 2020. As of December 31, 2021, we had current liabilities of $38,385,016 (including $20,966,701 of non-cash derivative liabilities), compared to current assets of $10,159,108, which resulted in a working capital deficit of $28,225,908. The current liabilities are comprised of accounts payable, accrued expenses, convertible debt, derivative liabilities, customer deposits, lease obligations and notes payable.

In December 2019, a novel strain of coronavirus (COVID-19) emerged. Because COVID-19 infections have been reported throughout the United States, certain federal, state and local governmental authorities have issued stay-at-home orders, proclamations and/or directives aimed at minimizing the spread of COVID-19. The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak, new information which may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time but it may have a material adverse impact on our business, financial condition and results of operations. Management expects that its business will be impacted to some degree, but the significance of the impact of the COVID-19 outbreak on the Company’s business and the duration for which it may have an impact cannot be determined at this time.

Operating Activities

For the year ended December 31, 2021, net cash used in operating activities was $6,368,006 compared to $1,811,816 for the year ended December 31, 2020. For the year ended December 31, 2021, our net cash used in operating activities was primarily attributable to the net loss of $195,303,051, adjusted by loss on debt extinguishment of $95,499,996, non- cash interest expense of $51,492,115 (including $38,907,939 for the initial fair value of the 375,000,000 warrants issued), losses on the fair value changes in derivatives related to warrants and convertible notes of $17,349,075, debt restructuring costs of $16,450,000, stock-based compensation of $9,322,751 and the non-cash expenses of interest and amortization and depreciation of $189,348. Net changes of $1,318,240 in operating assets and liabilities increased the cash used in operating activities, primarily as a result of the start-up of the Company’s California operations in the support of inventory and accounts receivable.

For the year ended December 31, 2020, our net cash used in operating activities was primarily attributable to the net loss of $20,968.243, adjusted by impairment charges of $11,526,303, stock-based compensation of $4,286,647, the non-cash expenses of interest and amortization and depreciation of $2,984,251 and losses on the fair value changes in derivatives of $176,050. Net changes of $378,729 in operating assets and liabilities and a gain on extinguishment of debt of $195,553 reduced the cash used in operating activities.

Investing Activities

For the year ended December 31, 2021, the net cash used in investing activities was $116,836, compared to net cash provided by investing activities of $424.431 for the year ended December 31, 2020.

For the year ended December 31, 2020, the Company acquired $470,849 cash in an acquisition and purchased $46,418 of office furniture and equipment.

Financing Activities

For the year ended December 31, 2021, the net cash provided by financing activities was $11,443,533, compared to $3,168,487 for the year ended December 31, 2020. During the year ended December 31, 2021, we received $15,000,000 of proceeds from the issuances of $16,610,000 face value of promissory notes and $13,100,000 (net of costs) from the Series D SPA. During the year ended December 31, 2021, the Company acquired 47,500 shares of Series C Preferred Stock and 18,667 shares of Series D Preferred Stock from Chis for $11,250,000, redeemed 5,000 shares of the Series E Preferred Stock for $5,000,000, and repaid $392,833 of notes payable and $13,634 to shareholders.

During the year ended December 31, 2020, the Company received proceeds of $750,000 pursuant to an obligation to pay a perpetual 1.8% (as amended) fee of revenues, $489,000 of proceeds from the issuances of convertible note financings, $1,553,000 from the issuances of promissory notes, $400,000 advance from affiliate, $100,400 from the Payroll Protection Program and $42,420 from shareholders. During the year ended December 31, 2020, the Company repaid $101,864 of principal of convertible notes and notes payable and $74,470 to shareholders.

Critical Accounting Policies

Our significant accounting policies are described in more details in the notes to our financial statements appearing elsewhere in this Annual Report on Form 10-K. We believe the following accounting policies to be most critical to the judgement and estimates used in the preparation of our financial statements:

Basis of Presentation

The accompanying consolidated financial statements are prepared in accordance with Generally Accepted Accounting Principles in the United States of America (“US GAAP”). The consolidated financial statements include the accounts of the Company and PCTI and the Company’s other wholly owned subsidiaries Ozop Energy Systems, Inc., Ozop LLC, Ozop HK and Spinus, LLC (“Spinus”), and the Company’s majority owned subsidiary Ozop Capital Partners, Inc. All intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reported period. Actual results could differ from those estimates.

Intangible Assets

Intangible assets primarily represent purchased patent and license rights. The Company amortizes these costs over the shorter of the legal life of the patent or its estimated economic life using the straight-line method. The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to future undiscounted cash flows to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.

Revenue Recognition

Effective January 1, 2018, the Company adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. For the comparative periods, revenue has not been adjusted and continues to be reported under ASC 605 — Revenue Recognition. Under ASC 605, revenue is recognized when the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) the performance of service has been rendered to a customer or delivery has occurred; (3) the amount of fee to be paid by a customer is fixed and determinable; and (4) the collectability of the fee is reasonably assured. There was no impact on the Company’s financial statements as a result of adopting Topic 606 for the years ended December 31, 2021, and 2020.

Earnings (Loss) Per Share

The Company computes net loss per share in accordance with FASB ASC 260, “Earnings per Share.” ASC 260 requires presentation of both basic and diluted earnings per share (EPS) on the face of the statement of operations. Basic EPS is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period including stock options, using the treasury stock method, and convertible notes and stock warrants, using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options, warrants and conversion of convertible notes. Diluted EPS excludes all dilutive potential common shares if their effect is anti-dilutive.

OFF BALANCE SHEET ARRANGEMENTS

We have no off-balance sheet arrangements including arrangements that would affect our liquidity, capital resources, market risk support and credit risk support or other benefits.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not required for smaller reporting companies.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

See Index to Financial Statements and Financial Statement Schedules appearing on pages F1-F30 of this annual report on Form 10-K.

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.

None.

ITEM 9A. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

A review and evaluation was performed by the Company’s management, including the Company’s Chief Executive Officer (the “CEO”) and Chief Financial Officer (the “CFO”), as of the end of the period covered by this annual report on Form 10-K, of the effectiveness of the design and operation of the Company’s disclosure controls and procedures as of the end of the period covered by this annual report. Based on that review and evaluation, the CEO and CFO have concluded that as of December 31, 2021, disclosure controls and procedures were not effective at ensuring that the material information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported as required in the application of SEC rules and forms.

Management’s Report on Internal Controls over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Internal control over financial reporting is a set of processes designed by, or under the supervision of, a company’s principal executive and principal financial officers, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP and includes those policies and procedures that:

●

Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect our transactions and disposition of our assets;

	●	Provide reasonable assurance our transactions are recorded as necessary to permit preparation of our financial statements in accordance with GAAP, and that receipts and expenditures are being made only in accordance with authorizations of our management and directors; and
	●	Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. It should be noted that any system of internal control, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system will be met. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Our CEO and CFO have evaluated the effectiveness of our internal control over financial reporting as described in Exchange Act Rules 13a-15(e) and 15d-15(e) as of the end of the period covered by this report based upon criteria established in “Internal Control-Integrated Framework” issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). As a result of this evaluation, we concluded that our internal control over financial reporting was not effective as of December 31, 2021, as described below.

We assessed the effectiveness of the Company’s internal control over financial reporting as of evaluation date and identified the following material weaknesses:

Insufficient Resources: We have an inadequate number of personnel with requisite expertise in the key functional areas of finance and accounting.

Inadequate Segregation of Duties: We have an inadequate number of personnel to properly implement control procedures.

Lack of Audit Committee: We do not have a functioning audit committee, resulting in lack of independent oversight in the establishment and monitoring of required internal controls and procedures.

We are committed to improving the internal controls and will (1) consider using third party specialists to address shortfalls in staffing and to assist us with accounting and finance responsibilities, (2) increase the frequency of independent reconciliations of significant accounts which will mitigate the lack of segregation of duties until there are sufficient personnel and (3) may consider appointing additional outside directors and audit committee members in the future.

We have discussed the material weakness noted above with our independent registered public accounting firm. Due to the nature of these material weaknesses, there is a more than remote likelihood that misstatements which could be material to the annual or interim financial statements could occur that would not be prevented or detected.

This Annual Report does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by our independent registered public accounting firm pursuant to the rules of the SEC that permit us to provide only management’s report in this annual report.

Changes in Internal Control over Financial Reporting

There have been no changes in the Company’s internal controls over financial reporting that have materially affected, or are reasonably likely to materially affect, the Company’s internal controls over financial reporting.

ITEM 9B. OTHER INFORMATION

None.

OFF BALANCE SHEET ARRANGEMENTS

We have no off-balance sheet arrangements including arrangements that would affect our liquidity, capital resources, market risk support and credit risk support or other benefits.

PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

Identification of directors and executive officers.

The names and ages of our directors and executive officers are set forth below. Also included is their principal occupation(s). Our By-Laws provide for up to four directors. All directors are elected annually by the stockholders to serve until the next annual meeting of the stockholders and until their successors are duly elected and qualified.

Name		Age		Position		Beginning
Brian Conway		51		Chief Executive Officer and Interim Chief Financial Officer		February 28, 2020

Brian P. Conway, the Chief Executive Officer and Interim Chief Financial Officer brings 20 years of proven success in marketing and business development for both private and publicly traded companies. Starting off in database management and sales for Venture Direct on Madison Avenue, he crossed over to Wall Street as a co-founder of Waypoint Capital Partners. During this time, he was responsible for national sales, marketing, business and product development, national account customers, and new business relations with international and US companies while creating awareness for public companies with many of the nation’s top public relations firms. From October 1, 2014, through August 31, 2019, Mr. Conway was the CEO, CFO and Director of Ngen Technologies, Inc. (f/k/a/ Liberated Solutions, Inc.). His relationships and experience with investment bankers, non-dilutive financing, and public relations should be instrumental in moving the Company forward.

Family Relationships

None

Involvement in Certain Legal Proceedings

No director, executive officer, significant employee or control person of the Company has been involved in any legal proceeding listed in Item 401(f) of Regulation S-K in the past 10 years.

Corporate Governance

Our Board has not established any committees, including an audit committee, a compensation committee or a nominating committee, or any committee performing a similar function. The functions of those committees are being undertaken by our Board. Because we do not have any independent directors, our Board believes that the establishment of committees of our Board would not provide any benefits to our Company and could be considered more form than substance.

Given our relative size and lack of directors’ and officers’ insurance coverage, we do not anticipate that any of our stockholders will make such a recommendation in the near future. While there have been no nominations of additional directors proposed, in the event such a proposal is made, all current members of our Board will participate in the consideration of director nominees.

As with most small, early stage companies until such time as our Company further develops our business, achieves a revenue base and has sufficient working capital to purchase directors’ and officers’ insurance, we do not have any immediate prospects to attract independent directors. When we are able to expand our Board to include one or more independent directors, we intend to establish an audit committee of our Board of Directors. It is our intention that one or more of these independent directors will also qualify as an audit committee financial expert. Our securities are not quoted on an exchange that has requirements that a majority of our Board members be independent and we are not currently otherwise subject to any law, rule or regulation requiring that all or any portion of our Board of Directors include “independent” directors, nor are we required to establish or maintain an audit committee or other committee of our Board.

Code of Ethics

We adopted a Code of Ethics for Senior Financial Management to promote honest and ethical conduct and to deter wrongdoing. This Code applies to our Chief Executive Officer and Chief Financial Officer and other employees performing similar functions. The obligations of the Code of Ethics supplement, but do not replace, any other code of conduct or ethics policy applicable to our employees generally.

Under the Code of Ethics, all members of the senior financial management shall:

	●	Act honestly and ethically in the performance of their duties at our company,
	●	Avoid actual or apparent conflicts of interest between personal and professional relationships,
	●	Provide full, fair, accurate, timely and understandable disclosure in reports and documents that we file with, or submits to, the SEC and in other public communications by our company,
	●	Comply with rules and regulations of federal, state and local governments and other private and public regulatory agencies that effect the conduct of our business and our financial reporting,
	●	Act in good faith, responsibly, with due care, competence and diligence, without misrepresenting material facts or allowing the member’s independent judgment to be subordinated
	●	Respect the confidentiality of information in the course of work, except when authorized or legally obtained to disclosure such information,
	●	Share knowledge and maintain skills relevant to carrying out the member’s duties within our company,
	●	Proactively promote ethical behavior as a responsible partner among peers and colleagues in the work environment and community,
	●	Achieve responsible use of and control over all assets and resources of our company entrusted to the member, and
	●	Promptly bring to the attention of the Chief Executive Officer any information concerning (a) significant deficiencies in the design or operating of internal controls which could adversely affect to record, process, summarize and report financial data or (b) any fraud, whether or not material, that involves management or other employees who have a significant role in our financial reporting or internal controls.

Director Independence

None of the members of our Board of Directors qualifies as an independent director in accordance with the published listing requirements of the NASDAQ Global Market. The NASDAQ independence definition includes a series of objective tests, such as that the director is not, and has not been for at least three years, one of our employees and that neither the director, nor any of his family members has engaged in various types of business dealings with us. In addition, our Board has not made a subjective determination as to each director that no relationships exist which, in the opinion of our Board, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director, though such subjective determination is required by the NASDAQ rules. Had our Board of Directors made these determinations, our Board would have reviewed and discussed information provided by the directors and us with regard to each director’s business and personal activities and relationships as they may relate to us and our management.

In performing the functions of the audit committee, our board oversees our accounting and financial reporting process. In this function, our board performs several functions. Our board, among other duties, evaluates and assesses the qualifications of the Company’s independent auditors; determines whether to retain or terminate the existing independent auditors; meets with the independent auditors and financial management of the Company to review the scope of the proposed audit and audit procedures on an annual basis; reviews and approves the retention of independent auditors for any non-audit services; reviews the independence of the independent auditors; reviews with the independent auditors and with the Company’s financial accounting personnel the adequacy and effectiveness of accounting and financial controls and considers recommendations for improvement of such controls; reviews the financial statements to be included in our annual and quarterly reports filed with the Securities and Exchange Commission; and discusses with the Company’s management and the independent auditors the results of the annual audit and the results of our quarterly financial statements.

Our board as a whole will consider executive officer compensation, and our entire board participates in the consideration of director compensation. Our board as a whole oversees our compensation policies, plans and programs, reviews and approves corporate performance goals and objectives relevant to the compensation of our executive officers, if any, and administers our equity incentive and stock option plans, if any.

Each of our directors participates in the consideration of director nominees. In addition to nominees recommended by directors, our board will consider nominees recommended by shareholders if submitted in writing to our secretary. Our board believes that any candidate for director, whether recommended by shareholders or by the board, should be considered on the basis of all factors relevant to our needs and the credentials of the candidate at the time the candidate is proposed. Such factors include relevant business and industry experience and demonstrated character and judgment.

Compliance with Section 16(a) of the Securities Exchange Act of 1934

Section 16(a) of the Securities Exchange Act of 1934 requires the Company’s directors and executive officers, persons who beneficially own more than 10% of a registered class of the Company’s equity securities, and certain other persons to file reports of ownership and changes in ownership on Forms 3, 4 and 5 with the SEC, and to furnish the Company with copies of the forms. The Company does not believe that all of its directors, executive officers and greater than 10% beneficial owners complied with all such filing requirements during 2021.

ITEM 11. EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION SUMMARY COMPENSATION TABLE

The following table sets forth information regarding compensation earned in or with respect to our fiscal years 2021 and 2020:

(i)

our principal executive officer or other individual serving in a similar capacity during the fiscal years 2021, and 2020;

(ii)

our two most highly compensated executive officers other than our principal executive officers who were serving as executive officers at December 31, 2021, and 2020, whose compensation exceed $100,000; and

(iii)

up to two additional individuals for whom disclosure would have been required but for the fact that the individual was not serving as an executive officer at December 31, 2021. Compensation information is shown for the fiscal years ended December 31, 2021, and 2020:

Name and Principal Position	Year	Salary		Bonus		Stock Awards		Option Awards		All Other Compensation		Total
Brian P Conway ⁽¹⁾	2021	$	280,000	$	532,099	$	2,850,000	$	—	$	—	$	3,662,099
	2020	$	377,804	$	—	$	4,286,648	$	—	$	—	$	4,664,452
Catherine Chis⁽²⁾	2021	$	141,666	$	—	$	—	$	—	$	—	$	141,666
	2020	$	83,500	$	—	$	—	$	—	$	—	$	83,500

(1) On February 28, 2020, Mr. Conway was appointed as the Company’s Chief Executive Officer.

(2) Ms. Chis was the CEO of PCTI from 2018 until her resignation in July 2021.

2021 OPTION GRANTS

There were no options to purchase shares of our Common Stock issued and outstanding as of December 31, 2021, or December 31, 2020.

OUTSTANDING EQUITY AWARDS AT 2021 FISCAL YEAR-END

There were no outstanding equity awards for the years ended December 31, 2021, and 2020.

EXECUTIVE EMPLOYMENT AGREEMENTS

On July 10, 2020, pursuant to the PCTI transaction, the Company assumed an employment contract entered into on February 28, 2020, between the Company and Mr. Conway (the “Employment Agreement”). Pursuant to the terms of the Employment Agreement, Mr. Conway received an initial annual salary of $120,000, for his position of CEO of the Company, payable monthly. Mr. Conway was also issued 2,500 shares of Series C Preferred Stock. The Company valued the shares at $5,000. On August 28, 2020, Mr. Conway was issued 1,333 shares of Series D Preferred stock and 500 shares of series E Preferred Stock. At the time of issuance the aggregate shares of Series D Preferred Stock in its entirety, is convertible into three times the number of shares of common stock outstanding at the time of conversion. On August 28, 2020, Mr. Conway owned 6.67% of the issued and outstanding Series D Preferred Stock, and based on the 3,107,037,634 shares outstanding on August 28, 2020, Mr. Conway’s Preferred Stock was convertible into 621,253,401 shares of common stock. Based on the share price of the common stock on that date of $0.0065, the shares were valued at $4,286,648 and recognized as compensation during the year ended December 31, 2020.

Effective January 1, 2021, Mr. Conway’s compensation is $20,000 per month, and on September 1, 2021, Mr. Conway began receiving $10,000 per month from Ozop Capital.

Other than the foregoing, at this time, we do not have any written employment agreement or other formal compensation agreements with our officers and directors. Compensation arrangements are the subject of ongoing development and we will make appropriate additional disclosures as they are further developed and formalized.

DIRECTOR COMPENSATION

Director Compensation Policies

We have not compensated our directors for their service on our Board from our inception through fiscal 2020. There are no arrangements currently in place pursuant to which directors will be compensated in the future for any services provided as a director.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table shows the beneficial ownership of the Company’s shares as of April 14, 2022, (unless otherwise noted) by (i) each person known by the Company to own beneficially more than 5% of the outstanding shares, (ii) each director and director nominee of the Company, (iii) each executive officer of the Company named in the Summary Compensation Table (the “Named Executive Officers” or “NEOs”), and (iv) all executive officers and directors of the Company as a group. The table includes shares that may be acquired within 60 days of April 14, 2022, upon the exercise of stock options by employees or outside directors and shares of restricted stock.

Unless otherwise indicated, each of the persons or entities listed below exercises sole voting and dispositive power over the shares that each of them beneficially owns.

For the beneficial ownership of the stockholders owning 5% or more of the shares, the Company relied on publicly available filings and representations of the stockholders.

Name and Title:	Class of Security	Amount of beneficial ownership		Percent of Class (1)
Executive Officers and Directors:

Brian P Conway, CEO and Director (2)	Common Stock		2,022,410,243		30.4	%
	Series C Preferred Stock		2,500		100.0	%
	Series D Preferred Stock		1,333		99.9	%

(1) Percentages are based on 4,622,362,997 shares of the Company’s common stock, 2,500 shares of Series C Preferred Stock and 1,334 shares of Series D Preferred stock issued and outstanding as of April 14, 2022. The voting rights associated with the Series C Preferred Stock in the aggregate are equal to 67% of the total vote. Series C Preferred Stock has no conversion rights. Any holder may, at any time convert any number of shares of Series D Convertible Preferred Stock held by such holder into a number of fully paid and nonassessable shares of common stock determined by multiplying the number of issued and outstanding shares of common stock of the Company on the date of conversion, by 1.5 and dividing that number by the number of authorized shares of Series D Convertible Preferred Stock multiplied by the number of Series D shares being converted. Series D Preferred Stock has no voting rights.

(2) Includes 1,333 shares of Series D Preferred Stock convertible into 2,022,410,243 shares of common stock.

Item 13. Certain Relationships and Related Transactions

For the years ended December 31, 2021, and 2020, the Company recorded expenses to its officers in the following amounts:

	Year ended December 31,
	2021		2020
CEO, parent	$	812,099	$	377,804
CEO, parent- Series E Preferred Stock		2,850,000		-
CEO, parent- Series D Preferred Stock		-		4,286,648
President, subsidiary (resigned July 2021)		141,666		83,500
Total	$	3,803,765	$	4,747,952

As of December 31, 2020, included in related party payable is $9,120 for the amount owed the former CEO of PCTI.

Item 14. Principal Accountant Fees and Services

The following is a summary of the fees billed to us by Prager Metis CPAs LLC, our independent registered public accounting firm, for professional services rendered for the fiscal years ended December 31, 2021, and 2020.

	2021		2020
Audit Fees⁽¹⁾	$	76,000	$	54,500
Total Fees	$	76,000	$	54,500

(1)	Audit Fees are fees paid for professional services rendered for the audit of the Company’s annual consolidated financial statements, reviews of the Company’s interim consolidated financial statements and statutory audit requirements at certain non-U.S. locations.

PART IV

Item 15. Exhibits, Financial Statement Schedules

(a)	1.	Financial Statements

		The financial statements and Reports of Independent Registered Public Accounting Firms are listed in the “Index to Financial Statements and Schedules” on page F-1 and included on pages F-2 to F-30.

	2.	Financial Statement Schedules

		All schedules for which provision is made in the applicable accounting regulations of the Securities and Exchange Commission (the “Commission”) are either not required under the related instructions, are not applicable (and therefore have been omitted), or the required disclosures are contained in the financial statements included herein.

	3.	Exhibits (including those incorporated by reference).

Exhibit No.		Description

2.1		Share Exchange Agreement dated April 5, 2018 by and among Newmarkt Corp., the shareholders of Ozop Surgical, Inc., Ozop Surgical, Inc. and Denis Razvodovskij (Incorporated by reference to Exhibit 2.1 of the Current Report on Form 8-K filed on April 19, 2018).

2.2		Stock Purchase Agreement dated June 26, 2020, by and among Ozop Surgical Corp., Power Conversion Technologies, Inc. and Catherine Chis (Incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed on June 29, 2020).

2.3		Merger Agreement and Plan of Merger between Ozop Surgical Corp. and Ozop Surgical Name Change Subsidiary, Inc. (Incorporated by reference to Exhibit 2.1 of the Current Report on Form 8-K filed on November 13, 2020).

3.1		Articles of Incorporation (Incorporated by reference to our General Form for Registration of Securities on Form S-1 filed on August 1, 2016)

3.2		Bylaws (Incorporated by reference to our General Form for Registration of Securities on Form S-1 filed on August 1, 2016)

3.3		Certificate of Amendment of Amended and Restated Articles of Incorporation as filed with the Nevada Secretary of State on May 8, 2018 (Incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed on May 14, 2018).

3.4		Certificate of Designations for Series B Preferred Stock. (Incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed on April 2, 2019).

3.5		Amended and Restated Bylaws of Ozop Surgical Corp. adopted on May 22, 2019. (Incorporated by reference to Exhibit 3.2 of the Current Report on Form 8-K filed on May 22, 2019).

3.6		Amended and Restated Articles of Incorporation as filed with the Nevada Secretary of State on July 25, 2019. (Incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed on July 30, 2019).

3.7		Certificate of Designation of Series C Preferred Stock. (Incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed on September 24, 2019).

3.8		Certificate of Withdrawal of Series B Preferred Stock. (Incorporated by reference to Exhibit 3.2 of the Current Report on Form 8-K filed on September 24, 2019).

3.9		Amended and Restated Articles of Incorporation as filed with the Nevada Secretary of State on October 29, 2019. (Incorporated by reference to Exhibit 3.2 of the Current Report on Form 8-K filed on October 31, 2019).

3.10		Amended and Restated Articles of Incorporation as filed with the Nevada Secretary of State on December 30, 2020, (Incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed on December 31, 2019).

3.11		Amended and Restated Articles of Incorporation as filed with the Nevada Secretary of State on January 21, 2020. (Incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed on February 7, 2020).

3.12		Amended and Restated Certificate of Designation of Series C Preferred Stock. (Incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed on February 5, 2020).

3.13		Amendment to Certificate of Designation of Series C Preferred Stock dated July 7, 2020 (Incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed on July 10, 2020).

3.14		Certificate of Designation of Series D Preferred Stock dated July 7, 2020 (Incorporated by reference to Exhibit 3.2 of the Current Report on Form 8-K filed on July 10, 2020).

3.15		Certificate of Designation of Series E Preferred Stock dated July 7, 2020 (Incorporated by reference to Exhibit 3.3 of the Current Report on Form 8-K filed on July 10, 2020).

3.16		Articles of Incorporation of Ozop Surgical Name Change Subsidiary, Inc. (Incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed on November 13, 2020).

3.17		Articles of Merger between Ozop Surgical Corp. and Ozop Surgical Name Change Subsidiary, Inc. (Incorporated by reference to Exhibit 3.2 of the Current Report on Form 8-K filed on November 13, 2020).

3.18		Amended and Restated Certificate of Designation Series D Preferred Stock dated July 27, 2021 (Incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed on August 2, 2021).

3.19		Advisory agreement between Ozop Capital and RMA dated September 1, 2021 (Incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed on September 2, 2021)

10.1		Binding Letter of Intent dated February 28, 2020, by and between Ozop Surgical Corp. and Power Conversion Technologies, Inc, and Catherine Chis, (Incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed on February 28, 2020).

10.2+		Employment Agreement dated February 28, 2020, by and between Ozop Surgical Corp. and Brian Conway, (Incorporated by reference to Exhibit 10.3 of the Current Report on Form 8-K filed on February 28, 2020).

31.1*		Certification of Chief Executive Officer required by Rule 13a-14(1) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2*		Certification of Chief Financial Officer required by Rule 13a-14(1) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1*		Certification of Chief Executive Officer and the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and Section 1350 of 18 U.S.C. 63

101.INS*		Inline XBRL Instance Document
101.SCH*		Inline XBRL Taxonomy Extension Schema Document
101.CAL*		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Filed herewith.

+ Management contract or compensatory plan or arrangement.

ITEM 16. FORM 10-K SUMMARY

Not applicable.

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Ozop Energy Solutions, Inc.

By:	/s/ Brian P. Conway
	Brian P. Conway
	Chief Executive Officer

Date:	April 15, 2022

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Signature

Title

Date

/s/ Brian P. Conway

Brian P. Conway

Chairman and Chief Executive Officer (principal executive officer)

April 15, 2022

OZOP ENERGY SOLUTIONS, INC.

COSOLIDATED FINANCIAL STATEMENTS

Table of Contents

	Page
Reports of Independent Registered Public Accounting Firm (PCAOB ID # 237)	F-2

Consolidated Balance Sheets as of December 31, 2021 and 2020	F-3

Consolidated Statements of Comprehensive Loss for the years ended December 31, 2021 and 2020	F-4

Consolidated Statements of Stockholders’ Deficit as of December 31, 2021 and 2020	F-5

Consolidated Statements of Cash Flows for the years ended December 31, 2021 and 2020	F-6

Notes to Consolidated Financial Statements	F-7

F-1

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Stockholders of

Ozop Energy Solutions, Inc.

Opinion on the Consolidated Financial Statements

We have audited the accompanying consolidated balance sheets of Ozop Energy Solutions, Inc. (the Company) as of December 31, 2021, and 2020, and the related consolidated statements of comprehensive loss, stockholders’ equity (deficit), and cash flows for the years then ended, and the related notes (collectively referred to as the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021, and 2020, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.

Going Concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As described in Note 3 to the consolidated financial statements, As of December 31, 2021, the Company had an accumulated deficit of $217,326,611 and a working capital deficit of $28,225,908 (including derivative liabilities of $20,966,701). As of December 31, 2021, the Company was in default of $1,973,847 and accrued interest on debt instruments due to non-payment upon maturity dates, and subsequent to December 31, 2021, an additional $13,310,000 and accrued interest on debt instruments also were in default status due to non-payment upon maturity dates. These factors, among others, raise substantial doubt regarding the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 2 to the accompanying financial statements. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matters

The critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there were no critical audit matters.

/s/ Prager Metis CPA’s LLC

We have served as the Company’s auditor since 2018

Hackensack, New Jersey

April 15, 2022

F-2

OZOP ENERGY SOLUTIONS, INC.

CONSOLIDATED BALANCE SHEET

	2021			2020
	December 31,
	2021			2020
ASSETS
Current Assets
Cash	$	6,767,167		$	1,808,476
Prepaid assets		151,998			9,569
Accounts receivable		1,299,334			400
Inventory		1,065,982			359,347
Vendor deposits		874,627			-
Total Current Assets		10,159,108			2,177,792

Operating lease right-of-use asset, net		707,686			149,529
Property and equipment, net		132,889			60,671
Other Assets		568,249			-
TOTAL ASSETS	$	11,567,932		$	2,387,992

LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
Liabilities
Current Liabilities
Accounts payable and accrued expenses	$	3,246,342		$	1,678,007
Related party liabilities		-			9,120
Convertible notes payable, net of discounts		25,000			1,078,985
Current portion of notes payable, net of discounts		13,011,307			1,130,083
Customer deposits		169,849			188,518
Deferred liability		750,000			750,000
Derivative liabilities		20,966,701			3,299,684
Operating lease liability, current portion		194,366			75,340
Current portion of deferred revenues		21,451			17,876
Total Current Liabilities		38,385,016			8,227,613

Long Term Liabilities
Note payable, net of discount		389,423			389,423
Operating lease liability, net of current portion		517,890			74,189
Deferred revenue, net of current portion		25,026			46,477
TOTAL LIABILITIES		39,317,355			8,737,702

COMMITMENTS AND CONTINGENCIES		-			-

Stockholders’ Equity (Deficit)
Preferred stock (10,000,000 shares authorized, par value $0.001)
Series C Preferred Stock (50,000 shares authorized and 2,500 (2021) and 50,000 (2020) shares issued and outstanding, par value $0.001)		3			50
Series D Preferred Stock (4,570 (2021) and 20,000 (2020) shares authorized and 1,334 (2021) and 20,000 (2020) shares issued and outstanding, par value $0.001)		1			20
Series E Preferred Stock (3,000 shares authorized, -0- (2021) and 1,000 (2020) issued and outstanding, par value $0.001)		-			1
Preferred stock Value
Common stock (4,990,000,000 shares authorized par value $0.001; 4,617,362,997 (2021) and 3,397,958,292 (2020) shares issued and outstanding)		4,617,363			3,397,958
Common stock to be issued; 637,755 shares as of December 31, 2021		638			-
Additional paid in capital		196,464,222			12,530,933
Treasury Stock		(11,249,934	)		-
Accumulated Deficit		(217,326,611	)		(22,278,665	)
Accumulated comprehensive loss		-			(7	)
Total Ozop Energy Systems, Inc. stockholders’ equity (deficit)		(27,494,318	)		(6,349,710	)
Noncontrolling interest		(255,105	)		-
TOTAL STOCKHOLDERS’ EQUITY (DEFICIT)		(27,749,423	)		(6,349,710	)
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)	$	11,567,932		$	2,387,992

See notes to consolidated financial statements.

F-3

OZOP ENERGY SOLUTIONS, INC.

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (LOSS)

	2021			2020
	For the Year Ended December 31,
	2021			2020
Revenue	$	11,928,605		$	1,411,432
Cost of goods sold		10,342,413			1,404,358
Gross profit		1,586,192			7,074

Operating expenses:
General and administrative, related parties		3,803,765			4,747,952
General and administrative, other		10,584,176			1,311,172
Impairment of intangible assets		-			11,526,303
Total operating expenses		14,387,941			17,585,427

Loss from operations		(12,801,749	)		(17,578,353	)

Other (income) expenses:
Interest expense		53,252,232			3,409,393
Loss on change in fair value of derivatives		17,349,076			176,050
(Gain) loss on extinguishment of debt		95,449,994			(195,553	)
Debt restructure expense		16,450,000			-
Total Other (Income) Expenses		182,501,302			3,389,890

Income (loss) before income taxes		(195,303,051	)		(20,968,243	)
Income tax provision		-			-
Net Income (loss)		(195,303,051	)		(20,968,243	)
Less: net loss attributable to noncontrolling interest		(255,105	)		-
Net loss attributable to Ozop Energy Solutions, Inc.	$	(195,047,946	)	$	(20,968,243	)
Other comprehensive loss:
Foreign currency translation adjustment		-			(7	)
Comprehensive income (loss)		(195,303,051	)		(20,968,250	)
Less: comprehensive loss attributable to noncontrolling interest		(255,105	)		-
Comprehensive loss attributable to Ozop Energy Solutions, Inc.	$	(195,047,946	)	$	(20,968,250	)

Income (loss) per share basic and fully diluted	$	(0.04	)		(0.02	)

Weighted average shares outstanding
Basic and diluted		4,442,045,075			1,110,673,228

See notes to consolidated financial statements.

F-4

OZOP ENERGY SOLUTIONS, INC.

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT)

YEAR ENDED DECEMBER 31, 2021

	Shares		Amount		Shares			Amount			Shares			Amount			Shares			Amount			Shares		Amount		Stock			Loss			Capital			Deficit			Interest			(Deficit)
	Common stock to be issued				Series C Preferred Stock						Series D Preferred Stock						Series E Preferred Stock						Common Stock				Treasury			Accumulated Comprehensive			Additional Paid-in			Accumulated			Noncontrolling			Total Stockholders’ Equity
	Shares		Amount		Shares			Amount			Shares			Amount			Shares			Amount			Shares		Amount		Stock			Loss			Capital			Deficit			Interest			(Deficit)
Balances January 1, 2021		-	$	-		50,000		$	50			20,000		$	20			1,000		$	1			3,397,958,292	$	3,397,958	$	-			(7	)	$	12,530,933		$	(22,278,665	)	$	-		$	(6,349,710	)

Shares issued for conversions of notes and interest payable		-		-		-			-			-			-			-			-			483,154,618		483,155					-			102,055,875			-			-			102,539,030

Shares issued upon cashless exercise of warrants		-		-		-			-			-			-			-			-			405,797,987		405,798					-			47,704,503			-			-			48,110,301

Issuance of Series E Preferred Stock		-		-		-			-			-			-			4,000			4			-		-					-			3,999,996			-			-			4,000,000

Redemption of Series E Preferred Stock		-		-		-			-			-			-			(5,000	)		(5	)		-		-					-			(4,999,995	)		-			-			(5,000,000	)

Shares issued and to be issued for fees and services		637,755		638		-			-			-			-			-			-			55,452,080		55,452					-			5,267,910			-			-			5,324,000

Shares issued for lease agreement		-		-		-			-			-			-			-			-			100,000,000		100,000					-			530,000			-			-			630,000

Shares issued for debt restructure		-		-		-			-			-			-			-			-			175,000,000		175,000					-			16,275,000			-			-			16,450,000

Purchase of Series C and Series D stock for Treasury		-		-		(47,500	)		(48	)		(18,667	)		(19	)		-			-			-		-		(11,249,934	)		-			-			-			-			(11,250,000	)

Sale of Series D Preferred Stock and warrants		-		-		-			-			1			-			-			-			-		-		-			-			13,100,000			-			-			13,100,000

Foreign currency translation adjustment		-		-		-			-			-			-			-			-			-		-		-			7			-			-			-			7

Net loss		-		-		-			-			-			-			-			-			-		-		-			-			-			(195,047,946	)		(255,105	)		(195,303,051	)

Balances December 31, 2021		637,755	$	638		2,500		$	3			1,334		$	1			-		$	-			4,617,362,977	$	4,617,363	$	(11,249,934	)	$	-		$	196,464,222		$	(217,326,611	)	$	(255,105	)	$	(27,749,423	)

OZOP ENERGY SOLUTIONS, INC.

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT)

YEAR ENDED DECEMBER 31, 2020

	Common stock to be issued				Series C Preferred Stock				Series D Preferred Stock				Series E Preferred Stock				Common Stock				Treasury		Accumulated Comprehensive			Additional Paid-in			Accumulated			Noncontrolling		Total Stockholders’ Equity
	Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount		Stock		Income			Capital			Deficit			Interest		(Deficit)
Balances January 1, 2020		-		-		47,500	$	48		18,667	$	19		500	$	1		-	$	-		-	$	-		$	76,922		$	(1,310,422	)		-	$	(1,233,434	)
Balance		-		-		47,500	$	48		18,667	$	19		500	$	1		-	$	-		-	$	-		$	76,922		$	(1,310,422	)		-	$	(1,233,434	)

Reverse merger transaction						-		-		-		-		-		-		1,851,930,729		1,851,931				-			(1,033,489	)		-					818,442

Shares issued for conversions of note and interest payable						-		-		-		-		-		-		1,411,815,206		1,411,815				-			9,140,571			-					10,552,386

Shares issued upon cashless exercise of warrants						-		-		-		-		-		-		134,212,357		134,212				-			(134,212	)		-					-

Warrants issued in connection with issuance of debt						-		-		-		-		-		-		-		-				-			194,495			-					194,495

Shares issued pursuant to CEO contract						2,500		3		1,333		1		500		1		-		-				-			4,286,646			-					4,286,651

Foreign currency translation adjustment						-		-		-		-		-		-		-		-				(7	)		-			-					(7	)

Net loss		-		-		-		-		-		-		-		-		-		-		-		-			-			(20,968,243	)		-		(20,968,243	)

Balances December 31, 2020		-		-		50,000	$	50		20,000	$	20		1,000	$	1		3,397,958,292	$	3,397,958		-	$	(7	)	$	12,530,933		$	(22,278,665	)		-	$	(6,349,710	)
Balance		-		-		50,000	$	50		20,000	$	20		1,000	$	1		3,397,958,292	$	3,397,958		-	$	(7	)	$	12,530,933		$	(22,278,665	)		-	$	(6,349,710	)

See notes to consolidated financial statements.

F-5

OZOP ENERGY SOLUTIONS, INC.

CONSOLIDATED STATEMENT OF CASH FLOWS

	2021			2020
	For the Year Ended December 31,
	2021			2020
Cash flows from operating activities:
Net loss from continuing operations	$	(195,303,051	)	$	(20,968,243	)
Adjustments to reconcile net loss to net cash used in operations
Non-cash interest expense		51,492,115			2,915,952
Amortization and depreciation		189,348			68,299
Debt restructure expense		16,450,000			-
Loss on fair value change of derivatives		17,349,075			176,050
Loss (gain) on extinguishment of debt		95,449,994			(195,553	)
Stock compensation expense		9,322,751			4,286,647
Impairment		-			11,526,303
Changes in operating assets and liabilities:
Accounts receivable		(1,298,934	)		19,374
Inventory		(706,635	)		612,466
Prepaid expenses		(79,430	)		6,512
Vendor deposits		(874,627	)		-
Accounts payable and accrued expenses		1,818,095			207,937
Deferred revenue		(17,876	)		64,353
Operating lease liabilities		(140,161	)		(35,609	)
Customer deposits		(18,670	)		(496,304	)
Net cash used in operating activities		(6,368,006	)		(1,811,816	)

Cash flows from investing activities:
Cash acquired in acquisition		-			470,849
Purchase of office and computer equipment		(116,836	)		(46,418	)
Net cash used in (provided by) investing activities		(116,836	)		424,431

Cash flows from financing activities:
Proceeds from issuances of convertible notes payable		-			489,000
Proceeds from issuances of notes payable		15,000,000			1,553,000
Proceeds from sale of Series D preferred stock and warrants		13,100,000			-
Proceeds from Payroll Protection Program		-			100,400
Proceeds from Economic Disaster Loan		-			10,000
Proceeds received on deferred liability		-			750,000
Proceeds from shareholders		-			42,420
Payments to shareholders		(13,634	)		(74,470	)
Payments of principal of convertible note payable and notes payable		(392,833	)		(101,863	)
Redemption of Series E Preferred Stock		(5,000,000	)		-
Redemption of Series C and Series D Preferred Stock		(11,250,000	)		-
Advance from affiliate		-			400,000
Net cash provided by financing activities		11,443,533			3,168,487

Effects of exchange rate on cash		-			(7	)

Net increase in cash		4,958,691			1,781,094

Cash, Beginning of year		1,808,476			27,382

Cash, End of year	$	6,767,167		$	1,808,476

Supplemental disclosure of cash flow information:
Cash paid for interest	$	126,707		$	133,300
Cash paid for income taxes	$	-		$	-

Schedule of non-cash Investing or Financing Activity:
Original issue discount included in notes payable	$	1,610,000		$	548,333
Issuance of common stock upon convertible note and accrued interest conversion	$	743,555		$	2,383,801
Operating lease right-of-use assets and liabilities	$	702,888		$	185,139
Issuance of common stock and preferred stock for consulting fees and compensation	$	9,322,751		$	4,286,647
Issuance of common stock for lease agreement	$	630,000		$	-
Issuance of common stock for debt restructuring	$	16,450,000		$	-

See notes to consolidated financial statements.

F-6

OZOP ENERGY SOLUTIONS, INC.

Notes to Consolidated Financial Statements

December 31, 2021

NOTE 1 - ORGANIZATION

Business

Ozop Energy Solutions, Inc. (the” Company,” “we,” “us” or “our”) was originally incorporated as Newmarkt Corp. on July 17, 2015, under the laws of the State of Nevada.

Stock Purchase Agreement

On July 10, 2020, the Company entered into a Stock Purchase Agreement (the “SPA”) with Power Conversion Technologies, Inc., a Pennsylvania corporation (“PCTI”), and Catherine Chis (“Chis”), PCTI’s Chief Executive Officer (“CEO”) and its sole shareholder. Under the terms of the SPA, the Company acquired one thousand (1,000) shares of PCTI, which represents all of the outstanding shares of PCTI, from Chis in exchange for the issuance of 47,500 shares of the Company’s Series C Preferred Stock, 18,667 shares of the Company’s Series D Preferred Stock, and 500 shares of the Company’s Series E Preferred Stock to Chis. The Acquisition was accounted for as a business combination and was treated as a reverse acquisition for accounting purposes with PCTI as the accounting acquirer in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 805, Business Combinations (“ASC 805”). In accordance with the accounting treatment for a reverse acquisition, the Company’s historical financial statements prior to the reverse merger were and will be replaced with the historical financial statements of PCTI prior to the reverse merger, in all future filings with the U.S. Securities and Exchange Commission (the “SEC”). The consolidated financial statements after completion of the reverse merger have and will include the assets, liabilities and results of operations of the combined company from and after the closing date of the reverse merger.

PCTI designs, develops, manufactures and distributes standard and custom power electronic solutions. PCTI serves clients in several industries including energy storage, shore power, DEWs, microgrid, telecommunications, military, transportation, renewable energy, aerospace and mission critical defense systems. Customers include the United States military and other global military organizations. All of its products are manufactured in the United States. Because of the Company’s product scope and the high-power niche that their products occupy, the Company is targeting the rapidly growing renewable and energy storage markets. The Company’s mission is to be a global leader for high power electronics with a standard of continued innovation.

F-7

	Purchase Price Allocation
Fair value of OZOP equity consideration issued	$	818,444
Assets acquired	$	1,229,917
Goodwill		11,201,145
Liabilities assumed		(11,612,618	)
Total purchase price allocation	$	818,444

The Company reviews the goodwill allocated to each of our reporting units for possible impairment annually and whenever events or changes in circumstances indicate the carrying amount may not be recoverable. Pursuant to that review, management has determined that the goodwill arising from the above transaction has been impaired and accordingly $11,201,145 was recorded as an impairment expense for the year ended December 31, 2020.

NOTE 2 – RESTATEMENT

During the preparation of the financial statements as of March 31, 2021, and for the three months ended March 31, 2021, the Company discovered an error was made in the financial statements as of and for the period ended December 31, 2020. The error relates to the recognition of certain warrants as derivative liabilities due to the fact the Company has insufficient authorized shares to cover the exercises. Management believes that the error as of and for December 31, 2020, does not materially impact the balance sheet as December 31, 2020. New warrants issued in the year ended December 31, 2021, have been properly accounted for as derivatives, when necessary. The following table reflects the effect of the error on the balance sheet as of December 31, 2020:

	Adjusted December 31, 2020			December 31, 2020

Total assets	$	2,387,992		$	2,387,992
Current liabilities		8,227,613			6,885,845
Total liabilities		8,737,702			7,395,934
Total stockholders’ deficit		(6,349,710	)		(5,007,942	)

The change in the current and total liabilities is as a result of the fair value of $2,061,307 of warrants based on the Black-Scholes option pricing valuation method, and an increase in notes payable of $719,539 as a result of reclassifying amounts previously recorded as discounts on notes payable, related to the warrants.

F-8

NOTE 3 – GOING CONCERN AND MANAGEMENT’S PLANS

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As of December 31, 2021, the Company had an accumulated deficit of $217,326,611 and a working capital deficit of $28,225,908 (including derivative liabilities of $20,966,701). As of December 31, 2021, the Company was in default of $1,973,847 plus accrued interest on debt instruments due to non-payment upon maturity dates, and subsequent to December 31, 2021, an additional $13,310,000 plus accrued interest on debt instruments also were in default status due to non-payment upon maturity dates. These factors, among others, raise substantial doubt about the ability of the Company to continue as a going concern for one year from the date of the issuance of these financial statements. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.

Management’s Plans

As a public company, Management believes it will be able to access the public equities market for fund raising for product development, sales and marketing and inventory requirements as we expand our distribution in the U.S. market. On October 14, 2021, the Company received a Notice of effectiveness related to the Company’s Form S-3 Registration Statement (the “Registration Statement”). Pursuant to the Registration Statement the Company may offer and sell from time to time in one or more offerings of up to thirty million dollars ($30,000,000) in aggregate offering price. We may offer these securities in amounts, at prices and on terms determined at the time of offering. As of the date of this Report the Company has not sold any securities pursuant to this Registration Statement.

On April 4, 2022, the Company and GHS Investments LLC (“GHS”). signed a Securities Purchase Agreement (the “GHS Purchase Agreement”) for the sale of up to Two Hundred Million (200,000,000) shares of the Company’s common stock to GHS. We may sell shares of our common stock from time to time over a six (6)- month period ending October 4, 2022, at our sole discretion, to GHS under the GHS Purchase Agreement. The purchase price shall be 85% of lowest VWAP for the ten (10) days preceding the Company’s notice to GHS for the sale of the Company’s common stock. On April 8, 2022, the Company filed a Prospectus Supplement to the Registration Statement dated October 14, 2021, regarding the GHS Purchase Agreement.

The Company is in negotiations with its’ lenders related to the debt instruments that are currently in default, to extend the maturity dates.

During the year ended December 31, 2021, the Company raised $28,100,000 (of which $11,250,000 was used to redeem Series C and Series D shares of preferred stock from Chis) and has begun to implement the following business operations, plans and strategies:

OES is actively engaged in the renewable, electric vehicle (“EV”), energy storage and energy resiliency sectors. We are engaged in multiple business lines that include project development as well as equipment distribution. Our solar and energy storage projects involve large-scale battery and solar photovoltaics (PV) installations. Our utility-scale storage business model is based on an arbitrage business model in which we install multiple 1+ megawatt batteries, charge them with off-peak grid electricity under contract with the utility, then sell the power back during peak load hours at a premium, as dictated by prevailing electricity tariffs.

F-9

Solar PV: Our PV business model involves the design and construction of electrical generating PV systems that can sell power to the utilities or be used for off grid use as part of our developing Neo-Grids solution. The Neo-Grids proprietary program, patent pending, was developed for the off-grid distribution of electricity to remove or reduce the dependency on utilities that currently burdens the EV Charging sectors. It will also reduce or eliminate the lengthy permitting processes and streamline the installations of those EV chargers.

Modular Energy Distribution System: The Neo-Grids, patent pending, is comprised of the design engineering, installation, and operational methodologies as well as the financial arbitrage of how we produce, capture and distribute electrical energy for the EV markets. : OES has acquired the license rights to a proprietary system, the Neo-Grids^TM System (patent pending), for the capture and distribution of electrical energy for the EV market. The Neo-Grids^TM System will serve both the private auto and the commercial sectors. The exponential growth of the EV industry has been accelerated by the recent major commitments of most of the major car manufacturers. Our Neo-Grids^TM System leverages this accelerated growth by offering (1) charging locations that can be installed with reduced delays, restricted areas or load limits and (2) EV charger electricity that is produced from renewable sources claiming little to no carbon footprint.

OES has developed a business plan for the Neo Grids distribution, a solution to the stress forthcoming to the existing grid infrastructure. The Company has completed its’ Neo Grid research and development as well as the first set of engineered technical drawings. This first stage of engineered technical drawings allows us to move forward with stage two, as well as to begin to construct the first prototype or proof of concept, (“PoC”). Our PoC design is partially reliant on auto manufacturers establishing standardizations of the actual charging/discharging protocols of the batteries such as on-board inverters as well as bi-directional capabilities in electric vehicles, which have only recently been established. As the market growth rate of EV’s continues to rise, the stress on the existing grid-tied infrastructure shows the need for the continued development of our Neo-Grid solution.

OES management has decades of experience in the renewable, storage and resilient energy businesses and associated markets, which include but are not limited to project finance, project development, equipment finance, construction, utility protocol, regulatory policy and technology assessment.

Ozop Plus plans on producing vehicle service contracts (“VSC’s”) for electric vehicles (EV’s). to respond to not only in filling the gap of a manufacturer’s warranty but to bring added value to EV owners by utilizing our partnerships and strengths in the renewable energy market to offer unique and innovative services. Among EV owners’ concerns are the EV battery repair and replacement costs, range anxiety, environmental responsibilities, roadside assistance, and the accelerated wear on additional components that EV vehicles experience. Management believes that the Ozop Plus VSC will give “peace of mind” to the EV buyer. The Company is currently in negotiations to complete the necessary agreements to launch the product in Q2 2022. Additionally, the Company is also in discussions with entities whereby Ozop Plus can re-insure the battery portion of another entity’s VSC.

On February 25, 2022, the Company formed Ozop Engineering and Design, Inc. (“OED”) a Nevada corporation, as a wholly owned subsidiary of the Company. OED was formed to become a premier engineering and lighting control design firm. OED offers product and design support for lighting and solar projects with a focus on fast lead times and technical support. OED and our partners are able to offer the resources needed for lighting, solar and electrical design projects. OED will provide its’ customers systems to coordinate the understanding of electrical usage with the relationship between lighting design and lighting controls, by developing more efficient ecofriendly designs by working with architects, engineers, facility managers, electrical contractors and engineers.

F-10

NOTE 4 – SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS

Basis of Presentation

The accompanying consolidated financial statements are prepared in accordance with Generally Accepted Accounting Principles in the United States of America (“US GAAP”). The consolidated financial statements include the accounts of the Company and Ozop Energy Systems, Inc. and the Company’s other wholly owned subsidiaries PCTI, Ozop LLC, Ozop HK and Spinus, LLC (“Spinus”) and the Company’s majority owned subsidiary Ozop Capital Partners, Inc. All intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original term of three months or less to be cash equivalents. These investments are carried at cost, which approximates fair value. Cash and cash equivalent balances may, at certain times, exceed federally insured limits. The Company has no cash equivalents at December 31, 2021, and 2020.

Sales Concentration and credit risk

Following is a summary of customers who accounted for more than ten percent (10%) of the Company’s revenues for the years ended December 31, 2021, and 2020, and their accounts receivable balance as of December 31, 2021:

	Sales % Year Ended December 31, 2021			Sales % Year Ended December 31, 2020			Accounts receivable balance December 31, 2021
Customer A		17	%		N/A		$	782,179
Customer B		N/A			62	%		-
Customer C		N/A			15	%		-

For the year ended December 31, 2020, the above customers were of PCTI. PCTI, historically does not have year to year many recurring clients as the Company produces capital equipment for its’ customers.

Accounts Receivable

The Company records accounts receivable at the time products and services are delivered. An allowance for losses is established through a provision for losses charged to expenses. Receivables are charged against the allowance for losses when management believes collectability is unlikely. The allowance (if any) is an amount that management believes will be adequate to absorb estimated losses on existing receivables, based on evaluation of the collectability of the accounts and prior loss experience.

Inventory

Inventories are valued at the lower of cost or net realizable value, with cost determined on the first-in, first-out basis. Inventory costs include finished goods, material, labor and manufacturing overhead. In evaluating the net realizable value of inventory, management also considers, if applicable, other factors, including known trends, market conditions, currency exchange rates and other such issues.

F-11

The components of inventories at December 31, 2021, and 2020 are as follows:

SCHEDULE OF INVENTORY

	December 31, 2021		December 31, 2020

Raw materials	$	234,168	$	207,178
Work in process		43,704		142,526
Finished goods		788,110		9,643
Inventory net	$	1,065,982	$	359,347

Purchase concentration

OES purchases finished renewable energy products from its’ suppliers. For the year ended December 31, 2021, there were two suppliers that accounted for 42.6% and 20.4%, respectively. There are only a handful of major suppliers, and we currently have supply arrangements with some of those vendors. One of these vendors requires a 20% down payment with the balances due on shipment and delivery, while other vendors terms are due immediately prior to delivery. We also buy product from other distributors, if we are not able to purchase direct from the manufacturer. While management believes all of its relationships with its vendors are good, if we are unable to continue to use and/or find alternative suppliers, when we cannot buy direct, it may have a material negative effect on our business.

The principal purchases by PCTI are comprised of parts and raw materials that PCTI assembles and manufactures and sells to its customers. There were no suppliers who accounted for more than ten percent (10%) of PCTI’s purchases for the years ended December 31, 2021, and 2020. Suppliers to PCTI vary from period to period dependent upon our customer’s order specifications. In any specific reporting period, we may be relying on certain vendors, however these vendors will vary dependent on the parts and materials needed. PCTI believes it is not reliant on any particular vendor for future needs.

Property, plant and equipment

Property and equipment are stated at cost, and depreciation is provided by use of a straight-line method over the estimated useful lives of the assets.

The Company reviews property and equipment for potential impairment whenever events or changes in circumstances indicate that the carrying amounts of assets may not be recoverable. The estimated useful lives of property and equipment is as follows:

	Office furniture and equipment	3-5 years
	Warehouse equipment	7 years

Revenue Recognition

The Company recognizes revenue in accordance with ASC 606, from the commercial sales of products by: (1) identify the contract (if any) with a customer; (2) identify the performance obligations in the contract (if any); (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract (if any); and (5) recognize revenue when each performance obligation is satisfied. Under ASC 606, revenue is recognized when the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) the performance of service has been rendered to a customer or delivery has occurred; (3) the amount of fee to be paid by a customer is fixed and determinable; and (4) the collectability of the fee is reasonably assured. Other than The Company has no outstanding contracts with any of its’ customers. The Company recognizes revenue when title, ownership, and risk of loss pass to the customer, all of which occurs upon shipment or delivery of the product and is based on the applicable shipping terms.

For contracts with customers, ownership of the goods and associated revenue are transferred to customers at a point in time, generally upon shipment of a product to the customer or receipt of the product by the customer and without significant judgments. Advance payments are typically required for commercial customers and are recorded as current liability until revenue is recognized. Advance payments are not required for government customers. The majority of contracts typically require payment within 30 to 60 days after transfer of ownership to the customer.

F-12

For the periods covered herein, we did not have post shipment obligations such as training or installation, customer acceptance provisions, credits and discounts, rebates and price protection, or other similar privileges.

The following table disaggregates our revenue by major source for the year ended December 31, 2021:

DISAGGREGATION OF REVENUE

	Year ended December 31, 2021
Sourced and distributed products	$	10,595,799
Manufactured products		1,332,806
Total	$	11,928,605

Revenues from sourced and distributed products are purchased from suppliers as finished goods and the Company brings the finished goods into our California warehouse to fill orders as well as to build inventory for future sales orders. From time to time for some of our larger orders we may have our suppliers ship directly to our customers to avoid extra shipping charges. For manufactured products, there is usually a bidding process by branches of the military or other large firms that need mostly battery charging and storage systems for large industrial projects. We would then purchase the raw materials and parts needed to build out the project in our Pennsylvania warehouse. There was no disaggregation of revenues for the year ended December 31, 2020.

Advertising and Marketing Expenses

The Company expenses advertising and marketing costs as incurred. For the years ended December 31, 2021, and 2020, the Company recorded advertising and marketing expenses of $44,158 and $55,249, respectively.

Research and Development

Costs and expenses that can be clearly identified as research and development are charged to expense as incurred. For the years ended December 31, 2021, and 2020, the Company recorded $7,500 and -0- of research and development expenses.

Convertible Instruments

The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815, Derivatives and Hedging Activities.

Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.

The Company accounts for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of this note transaction and the effective conversion price embedded in this note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption.

The Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current fair value, with any difference recorded as a gain or loss on extinguishment of the two separate accounting liabilities.

F-13

Fair Value of Financial Instruments

The Company measures assets and liabilities at fair value based on an expected exit price as defined by the authoritative guidance on fair value measurements, which represents the amount that would be received on the sale of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level.

The following are the hierarchical levels of inputs to measure fair value:

	●	Level 1 - Observable inputs that reflect quoted market prices in active markets for identical assets or liabilities.
	●	Level 2 - Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means.
	●	Level 3 - Unobservable inputs reflecting the Company’s assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available.

From time to time, certain of the Company’s embedded conversion features on debt and outstanding warrants have been treated as derivative liabilities for accounting purposes under ASC 815 due to insufficient authorized shares to fully settle conversion features of the instruments if exercised. In this case, the Company utilized the latest inception date sequencing method to reclassify outstanding instruments as derivative instruments. These contracts were recognized at fair value with changes in fair value recognized in earnings until such time as the conditions giving rise to such derivative liability classification were settled.

The carrying amounts of the Company’s financial assets and liabilities, such as cash, prepaid expenses, other current assets, accounts payable and accrued expenses, certain notes payable and notes payable - related party, approximate their fair values because of the short maturity of these instruments.

The following table represents the Company’s derivative instruments that are measured at fair value on a recurring basis as of December 31, 2021 and 2020, for each fair value hierarchy level:

SCHEDULE OF DERIVATIVE INSTRUMENTS

December 31, 2021	Derivative Liabilities		Total
Level I	$	-	$	-
Level II	$	-	$	-
Level III	$	20,966,701	$	20,966,701

December 31, 2020	Derivative Liabilities		Total
Level I	$	-	$	-
Level II	$	-	$	-
Level III	$	3,299,684	$	3,299,684

F-14

Leases

The Company accounts for leases under ASU 2016-02 (see Note 14), applying the package of practical expedients to leases that commenced before the effective date whereby the Company elected to not reassess the following: (i) whether any expired or existing contracts contain leases; (ii) the lease classification for any expired or existing leases; and (iii) initial direct costs for any existing leases. For contracts entered into on or after the effective date, at the inception of a contract the Company assess whether the contract is, or contains, a lease. Our assessment is based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether we obtain the right to substantially all the economic benefit from the use of the asset throughout the period, and (3) whether we have the right to direct the use of the asset. We allocate the consideration in the contract to each lease component based on its relative stand-alone price to determine the lease payments.

Operating lease ROU assets represent the right to use the leased asset for the lease term and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate, the Company used an incremental borrowing rate of 7.5%, for the existing lease, based on the information available at the adoption date in determining the present value of future payments. Operating lease expense is recognized pursuant to on a straight-line basis over the lease term and is included in rent in the condensed consolidated statements of operations.

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance on deferred tax assets is established when management considers it is more likely than not that some portion or all of the deferred tax assets will not be realized.

Tax benefits from an uncertain tax position are only recognized if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution. Interest and penalties related to unrecognized tax benefits are recorded as incurred as a component of income tax expense. The Company has not recognized any tax benefits from uncertain tax positions for any of the reporting periods presented.

Segment Policy

The Company has no reportable segments as it operates in one segment; renewable energy.

Earnings (Loss) Per Share

The Company reports earnings (loss) per share in accordance with ASC 260, “Earnings per Share.” Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during each period. Diluted earnings per share is computed by dividing net loss by the weighted-average number of shares of common stock, common stock equivalents and other potentially dilutive securities outstanding during the period. As of December 31, 2021, and 2020, the Company’s dilutive securities are convertible into approximately 7,592,474,061 and 11,223,565,011, respectively, shares of common stock. The following table represents the classes of dilutive securities as of December 31, 2021, and 2020:

	December 31, 2021		December 31, 2020
Convertible preferred stock		6,918,544,466		10,193,874,467
Unexercised common stock purchase warrants		672,024,518		659,601,638
Convertible notes payable		1,905,077		370,087,556
Common stock to be issued		-		1,350
		7,592,474,061		11,223,565,011

F-15

Recent Accounting Pronouncements

In August 2020, the FASB issued Accounting Standards Update (“ASU”) No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging —Contracts in Entity’ Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’ Own Equity (“ASU 2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception, and it simplifies the diluted earnings per share calculation in certain areas. The Company does not believe the adoption of the ASU will have a material impact on the Company’s financial position, results of operations or cash flows.

Other than the above, there have no recent accounting pronouncements or changes in accounting pronouncements during the period ended December 31, 2021, that are of significance or potential significance to the Company.

NOTE 5 – PROPERTY AND EQUIPMENT

The following table summarizes the Company’s property and equipment:

PROPERTY AND EQUIPMENT

	December 31, 2021			December 31, 2020
Office equipment	$	260,083		$	143,247
Less: Accumulated Depreciation		(127,194	)		(82,576	)
Property and Equipment, Net	$	132,889		$	60,671

Depreciation expense was $44,618 and $11,857 for the years ended December 31, 2021, and 2020, respectively.

NOTE 6 - CONVERTIBLE NOTES PAYABLE

The transaction with PCTI is being accounted for as a business combination and was treated as a reverse acquisition for accounting purposes with PCTI as the accounting acquirer in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 805, Business Combinations (“ASC 805”). In accordance with the accounting treatment for a reverse acquisition, the Company’s historical financial statements prior to the reverse merger were and will be replaced with the historical financial statements of PCTI prior to the reverse merger. The consolidated financial statements after completion of the reverse merger have and will include the assets, liabilities and results of operations of the combined company from and after the closing date of the reverse merger.

On July 10, 2020, PCTI (the accounting acquirer) assumed the balance of a past-due 15% convertible note issued by the Company on September 13, 2017. As of December 31, 2021 and 2020, the outstanding principal balance of this note was $25,000.

On July 10, 2020, PCTI (the accounting acquirer) assumed the balance of a 12% convertible promissory note issued by the Company on June 1, 2020, (the “Issuance Date”) to an investor, pursuant to a Securities Purchase Agreement. This note matures 6 months after the Issuance Date. This note is convertible into shares of the Company’s common stock beginning on the Issuance Date at $0.025 for the first three months after the Issuance Date. After the first three months after the Issuance Date, the conversion price shall be equal to the lower of (i) $.025 or 50% of the lowest trading price for the thirty-five trading days prior to the conversion. As of July 10, 2020, the outstanding principal balance of this note was $127,500 with a carrying value of $27,625, net of unamortized discounts of $99,875. In conjunction with this note, the Company issued a warrant to purchase 6,375,000 shares of common stock at an exercise price of $0.02, subject to adjustments and expiring on the five-year anniversary of the Issuance Date. For the year December 31, 2021, the investor converted a total of $127,500 of the face value and $14,433 of accrued interest and fees into 88,708,118 shares of common stock at an average conversion price of $0.0016. On March 10, 2021, the investor received 6,355,008 shares of common stock upon the cashless exercise of the warrants. As of December 31, 2021, and 2020, the outstanding principal balance of this note was $-0- and $127,500, respectively.

F-16

On July 10, 2020, PCTI (the accounting acquirer) assumed the balance of a 15% convertible promissory note issued by the Company on June 30, 2020, (the “Issuance Date”) to an investor, pursuant to a Securities Purchase Agreement. This note matures 6 months after the Issuance Date. This note is convertible into shares of the Company’s common stock beginning on the Issuance Date at $0.025 for the first three months after the Issuance Date. After the first three months after the Issuance Date, the conversion price shall be equal to the lower of (i) $.025 or 50% of the lowest trading price for the thirty-five trading days prior to the conversion. As of July 10, 2020, the outstanding principal balance of this note was $129,500 with a carrying value of $8,375, net of unamortized discounts of $121,125. In conjunction with this note, the Company issued a warrant to purchase 6,375,000 shares of common stock at an exercise price of $0.02, subject to adjustments and expiring on the five-year anniversary of the Issuance Date. For the year December 31, 2021, the investor converted a total of $129,500 of the face value and $30,264 of accrued interest and fees into 110,946,972 shares of common stock at an average conversion price of $0.00144. On March 10, 2021, the investor received 6,355,008 shares of common stock upon the cashless exercise of the warrants. As of December 31, 2021, and 2020, the outstanding principal balance of this note was $-0- and $129,500, respectively, with a carrying value of $111,763 as of December 31, 2020, net of unamortized discounts of $10,416.

On July 10, 2020, PCTI (the accounting acquirer) assumed the balance of a 15% convertible promissory note issued by the Company on July 8, 2020, (the “Issuance Date”) to an investor, pursuant to a Securities Purchase Agreement. This note matures 6 months after the Issuance Date. This note is convertible into shares of the Company’s common stock beginning on the Issuance Date at $0.025 for the first three months after the Issuance Date. After the first three months after the Issuance Date, the conversion price shall be equal to the lower of (i) $.025 or 50% of the lowest trading price for the thirty-five trading days prior to the conversion. In conjunction with this note, the Company issued a warrant to purchase 12,500,000 shares of common stock at an exercise price of $0.02, subject to adjustments and expiring on the five-year anniversary of the Issuance Date. For the nine months ended December 31, 2021, amortization of the debt discounts of $10,416 was charged to interest expense. For the year December 31, 2021, the investor converted a total of $250,000 of the face value and $130,044 of accrued interest and fees into 243,012,455 shares of common stock at an average conversion price of $0.00156. On March 10, 2021, the investor received 12,460,800 shares of common stock upon the cashless exercise of the warrants. As of December 31, 2021, and December 31, 2020, the outstanding principal balance of this note was $-0- and $250,000, respectively, with a carrying value of $239,583 as of December 31, 2020, net of unamortized discounts of $10,416.

On February 26, 2020, (the “Issuance Date”) PCTI issued a 12% Convertible Promissory Note (the “Note”), in the principal amount of $106,950, to an investor. This note matures 12 months after the Issuance Date. This note is convertible into shares of the Company’s common stock beginning on the Issuance Date at 55% of the lowest trading price for the twenty-five trading days prior to the conversion. If the trading price cannot be calculated for such security on such date, the trading price shall be the fair market value as mutually determined by the Company and the investor for which the calculation of the trading price is required in order to determine the conversion price. PCTI received proceeds of $85,000 on February 26, 2020, and the Note included an original issue discount of $13,950 and lender costs of $8,000. This note proceeds were used by the Company for general working capital purposes. The Note also required a daily payment via ACH of $400. On June 25, 2020, the Note was amended to add $111,225 of additional principal to the outstanding balance. Pursuant to the PCTI transaction with Ozop, on July 10, 2020, the conversion price is equal to 45% multiplied by the lowest closing bid price during the twenty-five-trading day period ending on the last completed trading date in the OTC Markets prior to the date of conversion. Accordingly, the Company determined the conversion feature of the Notes represented an embedded derivative since the note is convertible into a variable number of shares upon conversion, as the note was not considered to be conventional debt under ASC 815 and the embedded conversion feature was bifurcated from the debt host and accounted for as a derivative liability. The embedded feature included in the note resulted in an initial debt discount of $85,000, interest expense of $135,786 and initial derivative liability of $220,786. For the year ended December 31, 2021, amortization of the debt discounts of $17,737 was charged to interest expense. For the year December 31, 2021, the investor converted a total of $50,550 of the face value and $11,265 of accrued interest and fees into 20,218,562 shares of common stock at an average conversion price of $0.00306. The Investor also amended the note to deduct the previously added principal amount of $111,225. As of December 31, 2021, and 2020, the outstanding principal balance of this note was $-0- and $161,775, respectively. The Company accounted for the amendment as an extinguishment of debt.

F-17

On July 15, 2020, (the “Issuance Date”) the Company issued a 15% convertible promissory note, in the principal amount of $127,500, to an investor. This note matures 6 months after the Issuance Date. This note is convertible into shares of the Company’s common stock beginning on the Issuance Date at $0.011 for the first three months after the Issuance Date. After the first three months after the Issuance Date, the conversion price shall be equal to the lower of (i) $.025 or 50% of the lowest trading price for the thirty-five trading days prior to the conversion. The Company received proceeds of $102,000 on July 22, 2020, and this note included an original issue discount of $25,500. This note proceeds will be used by the Company for general working capital purposes. In conjunction with this note, the Company issued a warrant to purchase 6,375,000 shares of common stock at an exercise price of $0.02, subject to adjustments and expiring on the five-year anniversary of the Issuance Date. The Company allocated the proceeds to the debt of $82,068 and to the warrant $19,932 based on the relative fair value. The embedded conversion feature included in this note resulted in an initial derivative liability of $207,699, a debt discount of $82,068 with the excess of $125,541 charged to interest expense of $125,541. On March 10, 2021, the investor received 6,355,008 shares of common stock upon the cashless exercise of the warrants. For the year ended December 31, 2021, amortization of the debt discounts of $10,792 was charged to interest expense. On May 6, 2021, the Company and the investor entered into a Settlement and Mutual Release Agreement (the “Settlement Agreement”). Pursuant to the Settlement Agreement, the investor agreed to cancel the July 15, 2020, note. The Company accounted for the cancelled note as a gain on debt extinguishment. As of December 31, 2021, and December 31, 2020, the outstanding principal balance of this note was $-0- and $127,500, respectively, with a carrying value of $116,708, net of unamortized discounts of $10,792 as of December 31, 2020.

On July 29, 2020, (the “Issuance Date”) the Company issued a 15% convertible promissory note, in the principal amount of $127,500, to an investor. This note matures 6 months after the Issuance Date. This note is convertible into shares of the Company’s common stock beginning on the Issuance Date at $0.011 for the first three months after the Issuance Date. After the first three months after the Issuance Date, the conversion price shall be equal to the lower of (i) $.025 or 50% of the lowest trading price for the thirty-five trading days prior to the conversion. The Company received proceeds of $100,000 on August 3, 2020, and this note included an original issue discount of $25,500. This note proceeds will be used by the Company for general working capital purposes. In conjunction with this note, the Company issued a warrant to purchase 12,750,000 shares of common stock at an exercise price of $0.01, subject to adjustments and expiring on the five-year anniversary of the Issuance Date. The Company allocated the proceeds to the debt $61,733 and warrant $40,267 based on the relative fair value. The embedded conversion feature included in this note resulted in an initial derivative liability of $198,239, a debt discount of $61,733 with the excess of $136,506 charged to interest expense. On March 10, 2021, the investor received 12,710,016 shares of common stock upon the cashless exercise of the warrants. For the year ended December 31, 2021, amortization of the debt discounts of $21,583 was charged to interest expense. On May 6, 2021, the investor, pursuant to the Settlement Agreement, agreed to cancel the July 29, 2020, note. The Company accounted for the cancelled note as a gain on debt extinguishment. As of December 31, 2021, and 2020, the outstanding principal balance of this note was $-0- and $127,500 with a carrying value of $105,917, net of unamortized discounts of $21,583 as of December 31, 2020.

On November 16, 2020, (the “Issuance Date”) the Company issued a promissory note, in the principal amount of $250,000, to an investor. The note carries a guaranteed interest payment of 15%, which is added to the principal on the Issuance Date. Principal payments shall be made in six instalments of $57,500 commencing May 21, 2021, and continuing each 30 days thereafter for 4 months. The Holder shall have the right from time to time, and at any time following an event of default, as defined on the agreement, to convert all or any part of the outstanding and unpaid principal, interest and any other amounts due into fully paid and non-assessable shares of common stock of the Company. This note is convertible into shares of the Company’s common stock beginning on the Issuance Date at $0.01 for the first three months after the Issuance Date. After the first three months after the Issuance Date, the conversion price shall be equal to the lower of (i) $.01 or the volume weighted average price of the common stock during the five (5) Trading Day period ending on the day prior to conversion. The Company received proceeds of $200,000 on November 19, 2020, and this note included an original issue discount of $50,000. This note proceeds will be used by the Company for general working capital purposes. The embedded conversion feature included in this note resulted in an initial derivative liability of $14,750 and a debt discount of $50,000. In conjunction with this note, the Company issued a warrant to purchase 35,000,000 shares of common stock at an exercise price of $0.25, subject to adjustments and expiring on the five-year anniversary of the Issuance Date. The warrants issued resulted in a debt discount of $3,050, with the offset to additional paid in capital. For the year ended December 31, 2021, amortization of the debt discounts of $59,264 was charged to interest expense. On May 6, 2021, the investor, pursuant to the Settlement Agreement, agreed to cancel the November 16, 2020, note and the warrant to purchase 35,000,000 shares. The Company accounted for the cancelled note and warrant as a gain on debt extinguishment. As of December 31, 2021, and December 31, 2020, the outstanding principal balance of this note was $-0- and $250,000 with a carrying value of $190,736, as of December 31, 2020, net of unamortized discounts of $59,264.

F-18

A summary of the convertible note balance as of December 31, 2021, and 2020, is as follows:

SCHEDULE OF DEBT

	December 31, 2021		December 31, 2020

Principal balance	$	25,000	$	1,198,775
Unamortized discount		-		(119,790	)
Ending balance, net	$	25,000	$	1,078,985

NOTE 7 – DERIVATIVE LIABILITIES

The Company determined the conversion feature of the convertible notes, which all contain variable conversion rates, represented an embedded derivative since the notes were convertible into a variable number of shares upon conversion. Accordingly, the notes are not considered to be conventional debt under ASC 815 and the embedded conversion feature was bifurcated from the debt host and accounted for as a derivative liability.

At any given time, certain of the Company’s embedded conversion features on debt and outstanding warrants may be treated as derivative liabilities for accounting purposes under ASC 815-40 due to insufficient authorized shares to settle these outstanding contracts. Pursuant to SEC staff guidance that permits a sequencing approach based on the use of ASC 815-15-25 which provides guidance for contracts that permit partial net share settlement. The sequencing approach may be applied in one of two ways: contracts may be evaluated based on (1) earliest issuance date or (2) latest maturity date. Pursuant to the sequencing approach, the Company evaluates its contracts based upon the latest maturity date.

The Company valued the derivative liabilities at December 31, 2021, and 2020, at $20,966,701 and $3,299,684, respectively. For the derivative liability associated with convertible notes, the Company used the Monte Carlo simulation valuation model with the following assumptions as of December 31, 2021, and 2020, risk free interest rates at 0.19% and 0.09%, respectively, and volatility of 92% and 48% to 61%, respectively. During the year ended December 31, 2021, the Company issued 375,000,000 warrants in conjunction with notes payable (see Note 8). Due to insufficient authorized shares (see above), the Company recorded a discount to notes payable of $14,982,815 and interest expense of $38,907,939, with the offset to derivative liabilities for the initial fair value of the warrants based on the Black-Scholes option pricing method of $53,890,754. The following assumptions were utilized in the Black-Scholes valuation, risk free interest rate of .48% to .99%, volatility of 344% to 366%, and exercise prices of $0.039 to $0.15. The Company revaluated the warrants outstanding at December 31, 2020, and based on the insufficient authorized shares, the Company determined that the warrants should have been classified as a liability, The accompanying financial statements have been adjusted to reflect the change from an equity classification to a liability classification (see Note 2).

A summary of the activity related to derivative liabilities for the years ended December 31, 2021, and 2020, is as follows:

	Derivative liabilities associated with warrants			Derivative liabilities associated with convertible notes			Total derivative liabilities
Balance- July 10, 2020, assumed pursuant to PCTI transaction	$	-		$	8,743,231		$	8,743,231
Issued during period		2,061,307			641,285			2,702,592
Converted or paid		-			(8,322,188	)		(8,322,188	)
Change in fair value recognized in operations		-			176,049			176,049
Balance December 31, 2020	$	2,061,307		$	1,238,377		$	3,299,684
Fair value of issuances during period		53,890,754			-			53,890,754
Notes converted or paid		-			(2,246,114	)		(2,246,114	)
Exercise of warrants		(48,110,301	)		-			(48,110,301	)
Warrants cancelled		(3,216,397	)		-			(3,216,397	)
Change in fair value		16,313,392			1,035,683			17,349,075
Balance December 31, 2021	$	20,938,755		$	27,946		$	20,966,701

F-19

NOTE 8 – NOTES PAYABLE

The Company has the following note payables outstanding:

SCHEDULE OF NOTES PAYABLE

	December 31, 2021		December 31, 2020
	$	134,681	$	151,469
Note payable bank, interest at 7.75%, matured December 5, 2021, currently in default	$	134,681	$	151,469
Note payable bank, interest at 6.5%, matures December 26, 2021, in default		344,166		345,211
Economic Injury Disaster Loan		10,000		10,000
Paycheck Protection Program loan		100,400		100,400
Notes payable, interest at 8%, matured January 5, 2020, in default		45,000		45,000
Other, due on demand, interest at 6%, currently in default		50,000		50,000
Note payable $203,000 face value, interest at 12%, matured June 25, 2021, net of discount of $13,185 at December 31, 2020		-		189,815
Note payable $750,000 face value, interest at 12%, matured August 24, 2021, net of discount of $540,562 (2020), in default		375,000		209,438
Note payable $389,423 face value, interest at 18%, matures November 6, 2023		389,423		389,423
Note payable $1,000,000 face value, interest at 12%, matures November 13, 2021, net of discount of $971,250 (2020), in default		1,000,000		28,750
Note payable $2,200,000 face value, interest at 12%, matures February 9, 2022, net of discount of $243,833		1,956,167		-
Note payable $11,110,000 face value, interest at 12%, matures March 17, 2022, net of discount of $2,314,583		8,795,417		-
Note payable $3,300,000 face value, interest at 12%, matures December 7, 2022, net of discount of $3,099,524		200,476
Sub- total notes payable		13,400,730		1,519,506
Less long-term portion		389,423		389,423
Current portion of notes payable, net of discount	$	13,011,307	$	1,130,083

On December 7, 2021, the Company entered into a 12%, $3,300,000 face value promissory note with a third- party lender with a maturity date of December 7, 2022. In exchange for the issuance of the $3,300,000 note, inclusive of an original issue discount of $300,000, the Company received proceeds of $3,000,000 on December 13, 2021, from the lender. In conjunction with the note, the Company issued a warrant to purchase 75,000,000 shares of common stock at $0.039 per share (subject to adjustments) with an expiry date on the three- year anniversary of the note. For the year ended December 31, 2021, amortization of the costs of $16,750 was charged to interest expense. The fair value of the warrant calculated by the Black- Scholes option pricing method of $2,982,815 has been recorded as an initial debt and an initial derivative liability of $2,982,815. For the year ended December 31, 2021, amortization of the warrant discount of $166,540 was charged to interest expense. As of December 31, 2021, the outstanding principal balance of this note was $3,300,000 with a carrying value of $200,476, net of unamortized discounts of $3,099,524.

F-20

On March 17, 2021, the Company entered into a 12%, $11,110,000 face value promissory note with a third- party lender with a maturity date of March 17, 2022. In exchange for the issuance of the $11,110,000 note, inclusive of an original issue discount of $1,000,000 and lender costs of $110,000 the Company received proceeds of $10,000,000 on March 23, 2021, from the lender. In conjunction with the note, the Company issued a warrant to purchase 250,000,000 shares of common stock at $0.13 per share (subject to adjustments) with an expiry date on the three- year anniversary of the note. For the year ended December 31, 2021, amortization of the costs of $878,750 was charged to interest expense. The fair value of the warrant calculated by the Black- Scholes option pricing method of $33,248,433 has been recorded as an initial debt discount of $10,000,000, interest expense of $23,248,433 and initial derivative liability of $32,248,433. For the year ended December 31, 2021, amortization of the warrant discount of $7,916,667 was charged to interest expense. As of December 31, 2021, the outstanding principal balance of this note was $11,110,000 with a carrying value of $8,795,417, net of unamortized discounts of $2,314,583. The Company is in discussions with the lender regarding the extension of the maturity date of this note.

On February 9, 2021, the Company entered into a 12%, $2,200,000 face value promissory note with a third- party lender with a maturity date of February 9, 2022. In exchange for the issuance of the $2,200,000 note, inclusive of an original issue discount of $200,000 the Company received proceeds of $2,000,000 on February 16, 2021, from the lender. In conjunction with the note, the Company issued a warrant to purchase 50,000,000 shares of common stock at $0.15 per share (subject to adjustments) with an expiry date on the three- year anniversary of the note. For the year ended December 31, 2021, amortization of the costs of $177,833 was charged to interest expense. The fair value of the warrant calculated by the Black- Scholes option pricing method of $17,659,506 has been recorded as an initial debt discount of $2,000,000, interest expense of $15,659,506 and initial derivative liability of $17,659,506. For the year ended December 31, 2021, amortization of the warrant discount of $1,778,333 was charged to interest expense. As of December 31, 2021, the outstanding principal balance of this note was $2,200,000 with a carrying value of $1,956,167, net of unamortized discounts of $243,833. The Company is in discussions with the lender regarding the extension of the maturity date of this note.

On November 13, 2020, the Company entered into a 12%, $1,000,000 face value promissory note with a third-party due November 13, 2021. Principal payments shall be made in six instalments of $166,667 commencing 180 days from the issue date and continuing each 30 days thereafter for 5 months and the final payment of principal and interest due on the maturity date. The Company received proceeds of $890,000 on November 20, 2020, and the Company reimbursed the investor for expenses for legal fees and due diligence of $110,000. For the year ended December 31, 2021, amortization of the costs of $96,250 was charged to interest expense. In conjunction with this note, the Company issued 2 common stock purchase warrants; each warrant entitles the Holder to purchase 125,000,000 shares of common stock at an exercise price of $0.008, subject to adjustments and expires on the five-year anniversary of the issue date. The warrants issued resulted in a debt discount of $1,000,000. For the year ended December 31, 2021, amortization of the warrant discount of $875,000 was charged to interest expense. As of December 31, 2021, and December 31, 2020, the outstanding principal balance of this note was $1,000,000 with a carrying value of $1,000,000 and $28,750, respectively, net of unamortized discounts of $971,250. This note is in default and the interest rate from the date of default is the lesser of 24% or the highest amount permitted by law. As of December 31, 2021, the accrued interest is $135,452. The Company is in discussions with the lender regarding the extension of the maturity date of this note.

On November 6, 2020, the Company entered into a Settlement Agreement with the holder of $120,000 of convertible notes with accrued and unpaid interest of $8,716 and a $210,000 Promissory Noted dated June 23, 2020 with accrued and unpaid interest of $15,707. The Company issued a new 12% Promissory Note with a face value of $389,423 and a maturity date of November 6, 2023. In conjunction with this settlement, the Company issued a warrant to purchase 60,000,000 shares of common stock at an exercise price of $0.0075, subject to adjustments and expires on the five-year anniversary of the issue date. The Company analyzed the transaction and concluded that this was a modification to the existing debt. The investor exercised the warrant on January 14, 2021.

On October 26, 2016, PCTI entered into a $210,000 note payable with a bank. On March 15, 2021, due to defaults with the terms of the note, the note was amended with the outstanding balance due December 5, 2021, and the interest rate changed to 7.75%. Borrowings are collateralized by substantially all of the assets of PCTI and the personal guarantee of PCTI’s former President. As of December 31, 2021, and December 31, 2020, $134,681 and $151,469, respectively, was outstanding on the note payable. This note is in default.

F-21

On March 15, 2021, PCTI renewed their $350,000 promissory note with a bank that provides for borrowings of up to $350,000. Interest is due monthly and the principal is due on December 26, 2021, interest rate changed to the prime rate plus 3.25% (6.5% at March 15, 2021). Borrowings are collateralized by substantially all of the assets of PCTI and the personal guarantee of PCTI’s former President. As of December 31, 2021, and December 31, 2020, $344,166 and $345,211, respectively, was outstanding on the promissory note. This note is in default.

On August 24, 2020 (the “Issue Date”), the Company entered into a 12%, $750,000 face value promissory note with a third-party (the “Holder”) due August 24, 2021 (the “Maturity Date”). Principal payments shall be made in six instalments of $125,000 commencing 180 days from the Issue Date and continuing each 30 days thereafter for 5 months and the final payment of principal and interest due on the Maturity Date. The Holder shall have the right from time to time, and at any time following an event of default, as defined on the agreement, to convert all or any part of the outstanding and unpaid principal, interest and any other amounts due into fully paid and non-assessable shares of common stock of the Company, at the lower of i) the Trading Price (as defined in the agreement) during the previous five trading days prior to the Issuance Date or ii) the volume weighted average price during the five trading days ending on the day preceding the conversion date. The Company received proceeds of $663,000 on August 25, 2020, and the Company reimbursed the investor for expenses for legal fees and due diligence of $87,000. For the year ended December 31, 2021, amortization of the costs of $56,188 was charged to interest expense. In conjunction with this Note, the Company issued 2 common stock purchase warrants; each warrant entitles the Holder to purchase 122,950,819 shares of common stock at an exercise price of $0.0061, subject to adjustments and expires on the five-year anniversary of the Issue Date. The warrants issued resulted in a debt discount of $750,000. For the year ended December 31, 2021, amortization of the debt discount of $484,376 was charged to interest expense. During the year ended December 31, 2021, the Company paid $375,000 to the Holder. On May 3, 2021, the Company issued 75,000,000 shares of common stock to the Holder, upon the cashless exercise of a portion of the warrants. As of December 31, 2021, and 2020, the outstanding principal balance of this note was $375,000 and $750,000, respectively, with a carrying value of $375,000 and $209,438, net of unamortized discounts of $540,562 as of December 31, 2020. This note is in default and the interest rate from the date of default is the lesser of 24% or the highest amount permitted by law. As of December 31, 2021, the accrued interest is $90,247. The Company is in discussions with the lender regarding the extension of the maturity date of this note.

On April 20, 2020, PCTI was granted a loan from Huntington Bank in the amount of $100,400, pursuant to the Paycheck Protection Program (“PPP”) under Division A, Title I of the CARES Act, which was enacted March 27, 2020. The loan matures on April 20, 2022 and bears interest at a rate of 1.0% per annum, payable monthly beginning on November 20, 2020. The loan may be prepaid at any time prior to maturity with no prepayment penalties. Payments are deferred until the SBA determines the amount to be forgiven. The Company utilized the proceeds of the PPP loan in a manner which will enable qualification as a forgivable loan. On March 26, 2021, the Company received notice from Huntington Bank the they have determined that PCTI’s loan forgiveness application has been approved and has been submitted to the SBA. On December 2, 2021, PCTI received a notice from Huntington Bank that the SBA has denied PCTI’s application for loan forgiveness, due to inaccurate statements in the loan application as submitted by the former CEO of PCTI. The balance on this PPP loan was $100,400 as of December 31, 2021, and 2020 and has been classified in notes payable.

On July 14, 2020, PCTI received $10,000 grant under the Economic Injury Disaster Loan (“EIDL”) program. Up to $10,000 of the EIDL can be forgiven as long as such funds were utilized to provide working capital. The first payment due is deferred one year. The loan as of December 31, 2021, and 2020 and has been classified in notes payable.

The following note was assumed on July 10, 2020, pursuant to the PCTI transaction:

On June 25, 2020, the Company entered into a 12%, $203,000 face value promissory note with a third-party lender with a maturity date of June 25, 2021. Principal payments shall be made in six instalments of $33,333 commencing 180 days from the issue date and continuing each 30 days thereafter for 5 months and the final payment of principal and interest due on the maturity date. The Holder shall have the right from time to time, and at any time following an event of default, as defined on the agreement, to convert all or any part of the outstanding and unpaid principal, interest and any other amounts due into fully paid and non-assessable shares of common stock of the Company, at the lower of i) the Trading Price (as defined in the agreement) during the previous five trading days prior to the issuance date or ii) the volume weighted average price during the five trading days ending on the day preceding the conversion date. The Company received proceeds of $176,000 on June 26, 2020, and the Company reimbursed the investor for expenses for legal fees and due diligence of $27,000. For the year ended December 31, 2021, amortization of the costs of $13,185 was charged to interest expense. In conjunction with this Note, the Company issued 2 common stock purchase warrants; each warrant entitles the Holder to purchase 10,000,000 shares of common stock at an exercise price of $0.02, subject to adjustments and expires on the five-year anniversary of the Issue Date. During the year ended December 31, 2021, the investor converted a total of $203,000 of the face value and $15,899 of accrued interest and fees into 20,268,511 shares of common stock at an average conversion price of $0.0108. On January 8, 2021, and January 15, 2021, the investor received 100,668,692 and 9,121,265 shares of common stock, respectively, upon the cashless exercise of the warrants. As of December 31, 2021, and December 31, 2020, the outstanding principal balance of this note was $-0- and $203,000, respectively.

F-22

NOTE 9 – DEFERRED LIABILITY

On September 2, 2020, PCTI entered into an agreement with a third- party. Pursuant to the terms of the agreement, in exchange for $750,000, PCTI agreed to pay the third-party a perpetual three percent (3%) payment of revenues, as defined in the agreement. Payments are due ninety (90) days after each calendar quarter, with the first payment due on or before March 31, 2021, for revenues for the quarter ending December 31, 2020. The Company has recorded the $750,000 as deferred liability on the December 31, 2021, and 2020, consolidated balance sheet. No payments have been made and the Company is in default of the agreement. On February 26, 2021, the agreement was assigned to Ozop and on March 4, 2021, the note was amended, whereby in exchange for 175,000,000 shares of common stock, the royalty percentage was amended to 1.8%. The Company valued the shares at $0.094 per share (the market value of the common stock on the date of the agreement) and recorded $16,450,000 as debt restructure expense on the consolidated statement of operations for the year ended December 31, 2021. As of December 31, 2021, the Company has recorded an expense and a liability of $215,151 on the consolidated financial statements.

NOTE 10 – DEFERRED REVENUE

During the year ended December 31, 2020, the Company received $64,353 form a customer for a payment of a three- year extended warranty. The extended warranty period is from, March 2021 through February 2024, and accordingly the Company will recognize the revenue over such period. For the year ended December 31, 2021, the Company recognized $17,876, of revenue. Of the remaining deferred revenue of $46,477, $21,451 is recognized as the current portion of deferred revenue and $25,026 is classified as a long- term liability on the consolidated financial statements. As of December 31, 2020, $17,876 is classified as the current portion and $46,477 is classified as a long- term liability on the consolidated financial statements.

NOTE 11 – RELATED PARTY TRANSACTIONS

Employment Agreement

On July 10, 2020, pursuant to the PCTI transaction, the Company assumed an employment contract entered into on February 28, 2020, between the Company and Mr. Conway (the “Employment Agreement”). Pursuant to the terms of the Employment Agreement, Mr. Conway is to receive an initial annual salary of $120,000, for his position of CEO of the Company, payable monthly. Mr. Conway was issued 2,500 shares of Series C Preferred Stock. The Company valued the shares at $5,000. On August 28, 2020, Mr. Conway was issued 1,333 shares of Series D Preferred stock and 500 shares of Series E Preferred Stock. The aggregate shares of Series D Preferred Stock in its entirety, is convertible into one and one-half times the number of shares of common stock outstanding at the time of conversion. On August 28, 2020, Mr. Conway owned 6.67% of the issued and outstanding Series D Preferred Stock, and based on the 3,107,037,634 shares outstanding on August 28, 2020, Mr. Conway’s Preferred Stock was convertible into 621,253,401 shares of common stock. Based on the share price of the common stock on that date of $0.0065, the shares were valued at $4,286,648 and recognized as compensation during the year ended December 31, 2020. Effective January 1, 2021, Mr. Conway’s compensation is $20,000 per month, and effective September 1, 2021, Mr. Conway is receiving $10,000 per month from Ozop Capital.

F-23

Series E Preferred Stock

On March 21, 2021, the Company issued 2,000 shares of Series E Preferred Stock (see Note 12), 1,800 of the shares were issued to Mr. Conway. Pursuant to the terms and conditions of the Certificate of Designation of the Series E Preferred Stock, including the redemption value of $1,000 per share, the Company recorded $1,800,000 as stock compensation expense for the Series E shares issued to Mr. Conway. On April 16, 2021, the Board of Directors (the “BOD”) of the Company authorized the issuance 2,000 shares of Series E Preferred stock, of which 1,050 were issued to Mr. Conway. The Company recorded $1,050,000 of expense related to the shares issued to Mr. Conway. During the year ended December 31, 2021, the Company redeemed the 2,850 shares issued to Mr. Conway.

Management Fees and related party payables

For the years ended December 31, 2021, and 2020, the Company recorded expenses to its officers in the following amounts:

SCHEDULE OF EXPENSES TO OFFICERS

	2021		2020
	Year ended December 31,
	2021		2020
CEO, parent (includes $5,000 stock-based compensation year ended December 31, 2020)	$	812,099	$	377,804
CEO, parent- Series E Preferred Stock		2,850,000		-
CEO, parent- Series D Preferred Stock		-		4,286,648
President, subsidiary (resigned July 2021)		141,666		83,500
Total	$	3,803,765	$	4,747,952

As of December 31, 2020, included in related party payable is $9,120 for the amount owed the former President of PCTI (resigned in July 2021).

Redemption of Series C and Series D Preferred Stock

On July 13, 2021, the Company entered into a Definitive Agreement (the “Agreement”) with Chis to purchase the 47,500 shares of the Company’s Series C Preferred Stock held by Chis and the 18,667 shares of the Company’s Series D Preferred Stock held by Chis for the total purchase price of $11,250,000. In conjunction with the Agreement, Chis resigned from any and all positions held in the Company’s wholly owned subsidiary, PCTI. Further, Chis agreed that upon her resignation and for a period of five years thereafter (the “Restriction Period”), she shall not, directly or indirectly, solicit the employment of, assist in the soliciting of the employment of, or hire any employee or officer of the Company, including those of any of its present or future subsidiaries, or induce any person who is an employee, officer, agent, consultant or contractor of the Company to terminate such relationship with the Company. Additionally, Chis agreed that during the Restriction Period, she shall not compete with the Company or PCTI anywhere worldwide or be employed by any competitor of the Company.

NOTE 12 – COMMITMENTS AND CONTINGENCIES

Leases

On January 2, 2021, the Company entered into a ten (10) year lease for a 6-bay garage storage facility of approximately 2,500 square feet. Pursuant to the lease the Company agreed to issue 100,000,000 shares of restricted common stock. The shares were certificated on March 8, 2021, with an effective date of January 2, 2021. The Company valued the shares $0.0063, (the market value of the common stock on the date of the agreement) and has recorded $630,000 as a prepaid expense. The Company has not yet taken occupancy of the space,

Agreements

On September 1, 2021, Ozop Capital entered into an advisory agreement (the “RMA Agreement”) with Risk Management Advisors, Inc. (“RMA”). Pursuant to the terms of the RMA Agreement, RMA will assist Ozop Capital in analyzing, structuring, and coordinating Ozop Capital’s participation in a captive insurance company. RMA will coordinate legal, accounting, tax, actuarial and other services necessary to implement the Company’s participation in a captive insurance company, including, but not limited to, the preparation of an actuarial feasibility study, filing of all required regulatory applications, domicile selection, structural selection, and coordination of the preparation of legal documentation. In connection with the services listed above, Ozop Capital agreed to pay $50,000 and to issue $50,000 of shares of restricted common stock. One-half of the cash and stock were due upon the signing of the RMA Agreement. Accordingly, RMA received $25,000 and 452,080 shares of restricted common stock of the Company in September 2021. The balance of the cash and stock became due on October 29, 2021, upon the issuance of the captive insurance company’s certificate of authority from the state of Delaware. The Company paid the $5,000 balance and recorded 637,755 shares of common stock to be issued. For the year ended December 31, 2021, the Company recorded $50,000 as stock compensation expense.

F-24

On April 13, 2021, the Company agreed to engage PJN Strategies, LLC (“PJN”) as a consultant. Pursuant to the agreement, the Company agreed to compensate PJN $20,000 per month. Effective September 1, 2021, a new agreement was entered into between PJN and Ozop Capital. Pursuant to the terms of the new one- year agreement Ozop Capital agreed to compensate PJN $84,000 per month. For the year ended December 31, 2021, the Company recorded $436,000,of consulting expenses.

On April 16, 2021, the Company signed a letter of agreement with Rubenstein Public Relations, Inc. (“RPR”). Pursuant to the letter of agreement, the Company agreed to engage RPR, effective May 1, 2021, on a month-to-month basis for $17,000 per month. For the year ended December 31, 2021, the Company recorded $102,000 of consulting expenses. The Company terminated the agreement in October 2021.

On March 30, 2021, OES hired 2 individuals as Co-Directors of Sales. Pursuant to their respective offers of employment, the Company agreed to an annual salary of $130,000 with a signing bonus of $20,000 for each and to issue each 2,500,000 shares of restricted common stock upon the execution of the agreements and every 90 days thereafter for the first year as long as the employee is still employed. The Company valued the initial shares at $0.092 per share (the market price of the common stock on the date of the agreement), and $460,000 is included in stock-based compensation expense for the year ended December 31, 2021. On July 1, 2021, the Company issued each of the Co-Directors the 2,500,000 shares due after the first ninety days of employment. The shares were valued at $0.0745 per share (the market price of the common stock on the date of the issuance), and $372,500 is included in stock-based compensation expense for the year ended December 31, 2021. On October 1, 2021, the Company issued each of the Co-Directors the 2,500,000 shares due after the first one hundred eighty days of employment. The shares were valued at $0.0445 per share (the market price of the common stock on the date of the issuance), and $227,500 is included in stock-based compensation expense for the year ended December 31, 2021. One of the individuals resigned on January 24, 2022.

On March 15, 2021, the Company entered into a consulting agreement with Aurora Enterprises (“Aurora”). Mr. Steven Martello is a principal of Aurora. Pursuant to the agreement Mr. Martello will provide strategic analysis regarding existing markets and revenue streams as well as the development of new lines of revenue. The Company agreed to a monthly retainer fee of $10,000 and to issue to Aurora or their designee 5,000,000 shares of restricted common stock. The shares were issued in April 2021. Aurora designated the shares to be issued to Pegasus Partners, Inc. The Company valued the shares at $0.1392 per share (the market price of the common stock on the date of the agreement), and $696,000 is included in stock-based compensation expense for the year ended December 31, 2021. For the year ended December 31, 2021, the Company has recorded $90,000 of consulting expenses.

On February 24, 2021, the Company entered into a consulting agreement with Christopher Ruppel. Pursuant to the agreement Mr. Ruppel was to join the Ozop Advisory Board. During the year ended December 31, 2021, the Company issued 10,000,000 shares of restricted common stock to Mr. Ruppel and agreed to a monthly fee of $2,500. The Company valued the shares at $0.2386 per share (the market price of the common stock on the date of the agreement), and $2,386,000 is included in stock-based compensation expense for the year ended December 31, 2021. Effective April 1, 2021, the agreement was amended to $10,000 per month. Effective May 1, 2021, the Company was no longer using the services of Mr. Ruppel. For the year ended December 31, 2021, the Company recorded $12,500 of consulting expenses.

On February 19, 2021, the Company entered into a Joint Business Alliance agreement with Grid and Energy Master Planning, LLC (“GEMM”). GEMM will provide advisory, financing and implementation solutions for behind-the-meter customers in the areas of energy efficiency, solar, EV charging, and battery storage for OES. The GEMM services allows OES to provide one-stop-shopping in these emerging and maturing sectors. As of December 31, 2021, there has not been any transactions related to this agreement and the Company is continuing to evaluate the accounting treatment of any future transactions.

F-25

On January 22, 2021, the Company issued 10,000,000 shares of restricted common stock for legal services performed in 2020 and approved by the BOD of the Company on December 1, 2020. The Company valued the shares at $0.0056 per share (the market price of the common stock on the date of the agreement), and $56,000 is included in stock-based compensation expense for the year ended December 31, 2021.

On January 14, 2021, the Company entered into a Consulting Agreement with Mr. Allen Sosis. Pursuant to the agreement, Mr. Sosis will provide services as the Director of Business Development for the Company’s wholly owned subsidiary. Pursuant to the agreement, as amended, the Company will pay Mr. Sosis a monthly fee of $15,000 and an additional $1,000 in benefits. The Company also agreed to issue Mr. Sosis 5,000,000 shares of restricted common stock. The shares were issued in April 2021. The Company valued the shares at $0.20 per share (the market price of the common stock on the date of the agreement), and $1,000,000 was recorded as deferred stock compensation, to be amortized over the one-year term of the agreement. The Company terminated Mr. Sosis’s employment in October 2021, and accordingly, for the year ended December 31, 2021, $1,000,000 is included in stock-based compensation expense. For the year ended December 31, 2021, the Company recorded $75,500 of consulting expenses, and effective June 1, 2021, Mr. Sosis became an employee of the Company through his termination with a $15,000 per month salary.

On January 6, 2021, the Company entered into a consulting agreement with Ezra Green to begin on February 8, 2021. The Company agreed to issue 10,000,000 shares of restricted common stock to Mr. Green and to a monthly fee of $2,500. The Company valued the shares at $0.0076 per share (the market price of the common stock on the date of the agreement), and $76,000 was recorded as deferred stock-based compensation, to be amortized over the one-year term of the agreement. For the year ended December 31, 2021, the Company recorded $74,751 as stock-based compensation expense. Effective April 1, 2021, the agreement was amended to $10,000 per month. On March 9, 2021, Mr. Green filed a provisional patent with the USPTO. The provisional patent covers proprietary methods and procedures that, will allow the expansion of OES into the EV charging and support industry. The provisional patent relates to the more efficient production, distribution, and delivery of energy, particularly renewable energy, to the EV end consumer and enables OES to build the support systems for such. For the year ended December 31, 2021, the Company recorded $94,500 of consulting expenses.

On March 4, 2019, the Company entered into a Separation Agreement (the “Separation Agreement”) with Salman J. Chaudhry, pursuant to which the Company agreed to pay Mr. Chaudry $227,200 (the “Outstanding Fees”) in certain increments as set forth in the Separation Agreement. As of December 31, 2021 and 2020, the balance owed Mr. Chaudhry is $162,085.

On September 2, 2020, PCTI entered into an Agreement with a third- party. Pursuant to the terms of the agreement, in exchange for $750,000, PCTI agreed to pay the third-party a perpetual three percent (3%) payment of revenues, as defined in the agreement. On February 26, 2021, the agreement was assigned to Ozop and on March 4, 2021, the agreement was amended, whereby in exchange for 175,000,000 shares of common stock, the royalty percentage was amended to 1.8% (see Note 9). The Company valued the shares at $0.094 per share (the market value of the common stock on the date of the agreement) and recorded $16,450,000 as debt restructure expense on the consolidated statement of operations for the year ended December 31, 2021. As of December 31, 2021, the Company has recorded $215,171 and is included in accounts payable and accrued expenses on the consolidated balance sheet presented herein.

Legal matters

We know of no material, existing or pending legal proceedings against our Company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our interest.

F-26

NOTE 13– STOCKHOLDERS’ EQUITY

Common stock

During the period from January 1, 2021, to December 31, 2021, holders of an aggregate of $760,550 in principal and $201,905 of accrued interest and fees of convertible and promissory notes, converted their debt into 483,154,618 shares of our common stock at an average conversion price of $0.002 per share.

During the year ended December 31, 2021, the Company also issued the following shares of restricted common stock:

	●	100,000,000 shares of restricted common stock pursuant to a lease agreement (see Note 10).
	●	175,000000 shares of restricted common stock pursuant to restructuring agreement related to a deferred liability (see Note 9).
	●	55,452,080 shares of restricted common stock in the aggregate for services and consulting agreements.

During the year ended December 31, 2021, the Company also issued 405,797,987 shares of common stock upon the cashless exercise of common stock purchase warrants.

As of December 31, 2021, the Company has 4,990,000,000 shares of $0.001 par value common stock authorized and there are 4,617,362,997 shares of common stock issued and outstanding.

Preferred stock

As of December 31, 2021, 10,000,000 shares have been authorized as preferred stock, par value $0.001 (the “Preferred Stock”), which such Preferred Stock shall be issuable in such series, and with such designations, rights and preferences as the Board of Directors may determine from time to time.

Series C Preferred Stock

On July 7, 2020, the Company filed an Amended and Restated Certificate of Designation with the State of Nevada of the Company’s Series C Preferred Stock. Under the terms of the Amendment to Certificate of Designation of Series C Preferred Stock, 50,000 shares of the Company’s preferred remain designated as Series C Preferred Stock. The holders of Series C Preferred Stock have no conversion rights and no dividend rights. For so long as any shares of the Series C Preferred Stock remain issued and outstanding, the Holder thereof, voting separately as a class, shall have the right to vote on all shareholder matters equal to sixty-seven (67%) percent of the total vote. On July 10, 2020, pursuant to the SPA with PCTI, the Company issued 47,500 shares of Series C preferred Stock to Chis. On July 13, 2021, the Company purchased 47,500 shares of the Company’s Series C Preferred Stock held by Chis (see Note 11). As of December 31, 2021, and 2020, there were 2,500 and 50,000 shares, respectively, of Series C Preferred Stock issued and outstanding, of which 2,500 shares are held by Mr. Conway.

Series D Preferred Stock

On July 7, 2020, the Company filed a Certificate of Designation with the State of Nevada of the Company’s Series D Preferred Stock. Under the terms of the Certificate of Designation of Series D Preferred Stock, 20,000 shares of the Company’s preferred stock have been designated as Series D Convertible Preferred Stock. The holders of the Series D Convertible Preferred Stock shall not be entitled to receive dividends. The holders as a group may, at any time convert all of the shares of Series D Convertible Preferred Stock into a number of fully paid and nonassessable shares of common stock determined by multiplying the number of issued and outstanding shares of common stock of the Company on the date of conversion, by 3. Except as provided in the Certificate of Designation or as otherwise required by law, no holder of the Series D Convertible Preferred Stock shall be entitled to vote on any matter submitted to the shareholders of the Company for their vote, waiver, release or other action. The Series D Convertible Preferred Stock shall not bear any liquidation rights. On July 10, 2020, pursuant to the SPA with PCTI, the Company issued 18,667 shares of Series D preferred Stock to Chis, and on August 28, 2020, pursuant to Mr. Conway’s employment agreement, the Company issued 1,333 shares of Series D Preferred Stock to Mr. Conway. Accordingly, on August 28, 2020, Mr. Conway owned 6.67% of the issued and outstanding Series D Preferred Stock, and based on the 3,107,037,634 shares outstanding on August 28, 2020, Mr. Conway’s Preferred Stock was convertible into 621,253,401 shares of common stock. Based on the share price of the common stock on that date of $0.0065, the shares were valued at $4,286,648. On July 13, 2021, the Company purchased 18,667 shares of the Company’s Series D Preferred Stock held by Chis (see Note 11).

F-27

The warrant has a 15- year term and Partial Warrant Lock Up and Leak-Out Period. The Holder may only exercise the Warrant and purchase Warrant Shares as follows:

	i.	Up to 162 (one hundred and sixty-two) Warrant Shares, at any time or times on or after the Initial Exercise Date and no later than on or before the Termination Date; and

	ii.	The Remainder of the Warrant representing up to 3,074 (three thousand and seventy-four) Warrant Shares (“Remaining Warrant Shares”) shall be locked up for a period of 36 (thirty-six) months from the Initial Exercise Date (“Lock Up Period”) and shall become exercisable at any time or times from the date that is the 36 (thirty-six) month anniversary of the Initial Exercise Date (“Lock Up Period Termination Date”) and no later than on or before the Termination Date, as follows:

During every 1(one) year period, starting on the day that is the Lock Up Period Termination Date, the Holder shall have the right to exercise the Remainder of the Warrant up to a maximum number of Remaining Warrant Shares that, if converted, would be equal to no more than a maximum of 5% (five percent) of the total number of outstanding shares of Common Stock of the Company during such given year (“Leak-Out Period”). The Leak-Out Period shall come into effect on the day that is the Lock Up Period Termination Date and remain effective on a yearly basis, for a period of 10 (ten) years thereafter, after which the Leak-Out Period will automatically terminate and become null and void. For clarity purposes the Remainder of the Warrant shall become freely exercisable at any time or times beginning on June 29, 2034 and until the Termination Date.

F-28

Series E Preferred Stock

On July 7, 2020, the Company filed a Certificate of Designation with the State of Nevada of the Company’s Series E Preferred Stock. Under the terms of the Certificate of Designation of Series E Preferred Stock, 3,000 shares of the Company’s preferred stock have been designated as Series E Preferred Stock. The holders of the Series E Convertible Preferred Stock shall not be entitled to receive dividends. No holder of the Series E Preferred Stock shall be entitled to vote on any matter submitted to the shareholders of the Corporation for their vote, waiver, release or other action, except as may be otherwise expressly required by law. At any time, the Corporation may redeem for cash out of funds legally available therefor, any or all of the outstanding Preferred Stock (“Optional Redemption”) at $1,000 (one thousand dollars) per share. The shares of Series E Preferred Stock have not been registered under the Securities Act of 1933 or the laws of any state of the United States and may not be transferred without such registration or an exemption from registration. On July 10, 2020, pursuant to the SPA with PCTI, the Company issued 500 shares of Series E preferred Stock to Chis, and on August 28, 2020. Pursuant to Mr. Conway’s employment agreement, the Company issued 500 shares of Series E Preferred Stock to Mr. Conway. On March 2, 2021, the BOD authorized the issuance of 1,800 shares of Series E Preferred Stock to Mr. Conway and 200 shares of Series E Preferred Stock to a third-party service provider. The issuances were for services performed. Pursuant to the terms and conditions of the Certificate of Designation of the Series E Preferred Stock, including the redemption value of $1,000 per share, the Company recorded $2,000,000 as stock-based compensation expense for year ended December 31, 2021. On March 24, 2021, the Company redeemed the 3,000 shares of Series E Preferred Stock outstanding on that date. On April 16, 2021, the BOD authorized the issuance of 2,000 shares of Series E Preferred stock, of which 1,050 were granted to Mr. Conway. The issuances were for services performed. Pursuant to the terms and conditions of the Certificate of Designation of the Series E Preferred Stock, including the redemption value of $1,000 per share, the Company recorded $2,000,000 as stock-based compensation expense for the year ended December 31, 2021. As of December 31, 2021, and 2020, there were -0- and 1,000 shares of Series E Preferred Stock issued and outstanding, respectively.

NOTE 14 – NONCONTROLLING INTEREST

On August 19, 2021, the Company formed Ozop Capital. Upon formation, the Company owned 51% with PJN owning 49%. Brian Conway was appointed as the sole officer and director of Ozop Capital and has voting control of Ozop Capital. The Company presents interest held by noncontrolling interest holders within noncontrolling interest in the consolidated financial statements. During the year ended December 31, 2021, there was no change in the ownership percentages. For the year ended December 31, 2021, Ozop Capital incurred a loss of $520,623, of which $255,105 is the loss attributed to the noncontrolling interest.

NOTE 15 - OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES

On October 25, 2019, PCTI executed a non-cancellable lease for office and industrial space which began December 1, 2019 and expires on November 30, 2022. Operating lease right-of-use assets and liabilities are recognized at the present value of the future lease payments at the lease commencement date. The interest rate used to determine the present value is our incremental borrowing rate, estimated to be 7.5%, as the interest rate implicit in most of our leases is not readily determinable. Prior to July 10, 2020, PCTI recorded monthly lease expense pursuant to the lease agreement and effective July 10, 2020, pursuant to the PCTI transaction, operating lease expense is recognized pursuant to ASC Topic 842. Leases (Topic 842) over the lease term. During the years ended December 31, 2020, the Company recorded $84,278 for rent expense. During the year ended December 31, 2020, upon adoption of ASC Topic 842, the Company recorded right-of-use assets and lease liabilities of $185,139 for this lease.

On April 14, 2021, the Company entered into a five-year lease which began on June 1, 2021, for approximately 8,100 square feet of office and warehouse space in Carlsbad, California, expiring May 31, 2026. Initial lease payments of $13,148 begin on June 1, 2021, and increase by approximately 2.4% annually thereafter. The interest rate used to determine the present value is our incremental borrowing rate, estimated to be 7.5%, as the interest rate implicit in most of our leases is not readily determinable. During the six months ended June 1, 2021, upon adoption of ASC Topic 842, the Company recorded right-of-use assets and lease liabilities of $702,888 for this lease.

In adopting Topic 842, the Company has elected the ‘package of practical expedients’, which permit it not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. The Company did not elect the use-of-hindsight or the practical expedient pertaining to land easements; the latter is not applicable to the Company. In addition, the Company elected not to apply ASC Topic 842 to arrangements with lease terms of 12 months or less.

F-29

Right-of- use assets are summarized below:

SCHEDULE OF RIGHT-OF-USE ASSETS

	December 31, 2021
Office and warehouse lease	$	888,026
Less accumulated amortization		(180,340	)
Right-of-us assets, net	$	707,686

Operating lease liabilities are summarized as follows:

SCHEDULE OF OPERATING LEASE LIABILITIES

	December 31, 2021
Lease liability	$	712,256
Less current portion		(194,366	)
Long term portion	$	517,890

Maturity of lease liabilities are as follows:

	Amount
For the year ending December 31, 2022	$	240,991
For the year ending December 31, 2023		167,858
For the year ended December 31, 2024		171,840
For the year ended December 31, 2025		175,942
For the year ended December 31, 2026		74,030
Total	$	830,661
Less: present value discount		(118,405	)
Lease liability	$	712,256

NOTE 16 – SUBSEQUENT EVENTS

Effective January 1, 2022, the Company entered into a new employment agreement with Mr. Conway. Pursuant to the agreement, Mr. Conway received a $250,000 contract renewal bonus and will receive an annual compensation of $240,000 from the Company and will also be eligible to receive bonuses and equity grants at the discretion of the BOD. The Company also agreed to compensate Mr. Conway for services provided directly to any of the Company’s subsidiaries. Ozop Capital began compensating Mr. Conway $20,000 per month in January 2022 and OES began compensating Mr. Conway $20,000 in March 2022.

On April 4th, 2022, the Company and GHS Investments LLC (“GHS”). signed a Securities Purchase Agreement (the “GHS Purchase Agreement”) for the sale of up to Two Hundred Million (200,000,000) shares of the Company’s common stock to GHS. We may sell shares of our common stock from time to time over a six (6)- month period ending October 4, 2022, at our sole discretion, to GHS under the GHS Purchase Agreement. The purchase price shall be 85% of lowest VWAP for the ten (10) days preceding the Company’s notice to GHS for the sale of the Company’s common stock. On April 8, 2022, the Company filed a Prospectus Supplement to the Registration Statement dated October 14, 2021, regarding the GHS Purchase Agreement.

The Company has evaluated subsequent events through the date the financial statements were issued. The Company has determined that there are no other such events that warrant disclosure or recognition in the financial statements, except as stated herein.

F-30

EX-31.1 2 ex31-1.htm

Exhibit 31.1

CERTIFICATION

I, Brian P. Conway, Chief Executive Officer of OZOP ENERGY SOLUTIONS, INC. (the “registrant”), certify that:

1.	I have reviewed this annual report on Form 10-K of the registrant for the period ended December 31, 2021;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c.	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d.	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: April 15, 2022

*/s/ Brian P. Conway*
Brian P Conway
Chief Executive Officer
(principal executive officer)

EX-31.2 3 ex31-2.htm

Exhibit 31.2

CERTIFICATION

I, Brian P. Conway, Interim Chief Financial Officer of OZOP ENERGY SOLUTIONS, INC. (the “registrant”), certify that:

1.	I have reviewed this annual report on Form 10-K of the registrant for the period ended December 31, 2021;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c.	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d.	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: April 15, 2022

*/s/ Brian P Conway*
Brian P Conway
Interim Chief Financial Officer
(principal financial and accounting officer)

EX-32.1 4 ex32-1.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Each of the undersigned hereby certifies, in his capacity as an officer of OZOP ENERGY SOLUTIONS, INC. (the “Company”), for the purposes of 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

(1) The Company’s Annual Report on Form 10-K for the period ended December 31, 2021 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: April 15, 2022

*/s/ Brian P Conway*
Brian P. Conway
Chief Executive Officer
(principal executive officer)
(principal financial and accounting officer)

EX-101.SCH 5 ozsc-20211231.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheet link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheet (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statement of Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statement of Changes in Stockholders' Equity (Deficit) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statement of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - ORGANIZATION link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - RESTATEMENT link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - GOING CONCERN AND MANAGEMENT’S PLANS link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - PROPERTY AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - CONVERTIBLE NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - DERIVATIVE LIABILITIES link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - DEFERRED LIABILITY link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - DEFERRED REVENUE link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - STOCKHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - NONCONTROLLING INTEREST link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Policies) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - ORGANIZATION (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - RESTATEMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - PROPERTY AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - CONVERTIBLE NOTES PAYABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - DERIVATIVE LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - NOTES PAYABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - RELATED PARTY TRANSACTIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - SCHEDULE OF RECOGNIZED IDENTIFIED ASSETS ACQUIRED AND LIABILITIES ASSUMED (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - ORGANIZATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - SCHEDULE OF ERROR CORRECTIONS AND PRIOR PERIOD ADJUSTMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - RESTATEMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - GOING CONCERN AND MANAGEMENT’S PLANS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - SCHEDULES OF CONCENTRATION OF RISK, BY RISK FACTOR (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - SCHEDULE OF INVENTORY (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - SCHEDULE OF USEFUL LIFE OF PROPERTY AND EQUIPMENT ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - DISAGGREGATION OF REVENUE (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - SCHEDULE OF DERIVATIVE INSTRUMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - PROPERTY AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - SCHEDULE OF DEBT (Details) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE (Details) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - DERIVATIVE LIABILITIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - SCHEDULE OF NOTES PAYABLE (Details) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - SCHEDULE OF NOTES PAYABLE (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - NOTES PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - DEFERRED LIABILITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000055 - Disclosure - DEFERRED REVENUE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000056 - Disclosure - SCHEDULE OF EXPENSES TO OFFICERS (Details) link:presentationLink link:calculationLink link:definitionLink 00000057 - Disclosure - SCHEDULE OF EXPENSES TO OFFICERS (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000058 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000059 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000060 - Disclosure - STOCKHOLDERS’ EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000061 - Disclosure - NONCONTROLLING INTEREST (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000062 - Disclosure - SCHEDULE OF RIGHT-OF-USE ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 00000063 - Disclosure - SCHEDULE OF OPERATING LEASE LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000064 - Disclosure - SCHEDULE OF MATURITY OF LEASE LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000065 - Disclosure - OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000066 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 ozsc-20211231_cal.xml XBRL CALCULATION FILE EX-101.DEF 7 ozsc-20211231_def.xml XBRL DEFINITION FILE EX-101.LAB 8 ozsc-20211231_lab.xml XBRL LABEL FILE Class of Stock [Axis] Series C Preferred Stock [Member] Series D Preferred Stock [Member] Series E Preferred Stock [Member] Equity Components [Axis] Common Stock To Be Issued [Member] Preferred Stock [Member] Common Stock [Member] Treasury Stock [Member] AOCI Attributable to Parent [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Noncontrolling Interest [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Securities Purchase Agreement [Member] Business Acquisition [Axis] Pennsylvania corporation [Member] Revision of Prior Period [Axis] Revision of Prior Period, Error Correction, Adjustment [Member] Previously Reported [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Registration Statement [Member] Award Type [Axis] GHS Investments LLC [Member] Customer [Axis] Suppliers One [Member] Concentration Risk Benchmark [Axis] Accounts Payable [Member] Concentration Risk Type [Axis] Supplier Concentration Risk [Member] Suppliers Two [Member] Two Vendor [Member] Customer A [Member] Accounts Receivable [Member] Customer Concentration Risk [Member] Customer B [Member] Customer C [Member] Statistical Measurement [Axis] Minimum [Member] Long-Lived Tangible Asset [Axis] Office Furniture And Equipment [Member] Maximum [Member] Warehouse Equipment [Member] Product and Service [Axis] Sourced and Distributed Products [Member] Manufactured Products [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Antidilutive Securities [Axis] Convertible Preferred Stock [Member] Unexercised Common Stock Purchase Warrants [Member] Convertible Notes Payable [Member] Office Equipment [Member] Debt Instrument [Axis] 15% Promissory Note [Member] 12% Promissory Note [Member] Title of Individual [Axis] Investor [Member] 15% Convertible Promissory Note [Member] 15% Convertible Promissory Note One [Member] 15% Convertible Promissory Note Two [Member] 12% Convertible Promissory Note Two [Member] 15% Convertible Promissory Note Three [Member] 15% Convertible Promissory Note Four [Member] Settlement Agreement [Member] Long-term Debt, Type [Axis] Convertible Debt [Member] Measurement Input Type [Axis] Measurement Input, Risk Free Interest Rate [Member] Measurement Input, Price Volatility [Member] Measurement Input Price Volatility One [Member] Measurement Input, Exercise Price [Member] Financial Instrument [Axis] Derivative Liabilities Associated With Warrants [Member] Derivative Liabilities Associated With Convertible Notes [Member] Short-term Debt, Type [Axis] Note Payable [Member] Note Payable One [Member] Economic Injury Disaster Loan [Member] Paycheck Protection Programloan [Member] Note Payable Two [Member] Other [Member] Note PayableThree [Member] Note Payable Four [Member] Note Payable Five [Member] Note Payable Six [Member] Note Payable Seven [Member] Note Payable Eight [Member] Note Payable Nine [Member] Promissory Note [Member] Lender [Member] December Seven Two Thousand Twenty Two [Member] Lenders [Member] Valuation Approach and Technique [Axis] Valuation Technique, Option Pricing Model [Member] Promissory Note One [Member] Third Party Lender [Member] Holder [Member] Holders [Member] Third-Party [Member] Legal Entity [Axis] PCTI [Member] Variable Rate [Axis] Prime Rate [Member] Personal Guarantee Of Chis [Member] Nine Instalments [Member] Paycheck Protection Program [Member] Exchange Agreement [Member] Related Party [Axis] Mr Conway [Member] Employment Agreement [Member] Chief Executive Officer [Member] Award Date [Axis] Per Month [Member] Definitive Agreement [Member] Chief Executive Officer Series E Preferred Stock [Member] Chief Executive Officer Series D Preferred Stock [Member] President Subsidiary [Member] Garage Storage Facility [Member] RMA Agreement [Member] PJN Strategies [Member] Rubenstein Public Relations, Inc. [Member] Co-Directors of Sales [Member] Restricted Stock [Member] Mr Steven Martello [Member] Consulting Agreement [Member] Aurora Enterprises [Member] Christopher Ruppel [Member] April 1, 2021 [Member] Mr Allen Sosis [Member] Restricted Common Stock [Member] Ezra Green [Member] Salman J. Chaudhry [Member] Seperation Agreement [Member] Lease Agreement [Member] Restructuring Agreement [Member] Certificates of Designation [Member] Chis [Member] Mr. Convay [Member] Series D Amendment [Member] Series DSPA [Member] Warrant [Member] Remaining Warrant Shares [Member] Ownership [Axis] Brian Conway [Member] Accounting Standards Update [Axis] Accounting Standards Update 2016-02 [Member] Geographical [Axis] CANADA Thereafter [Member] New Employment Agreement [Member] Ozop Capital [Member] OES [Member] GHS Investments [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material EX-101.PRE 9 ozsc-20211231_pre.xml XBRL PRESENTATION FILE XML 10 R1.htm IDEA: XBRL DOCUMENT

Cover - USD ($)	12 Months Ended
Cover - USD ($)	Dec. 31, 2021	Apr. 14, 2022	Jun. 30, 2021
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2021
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	000-55976
Entity Registrant Name	OZOP ENERGY SOLUTIONS, INC.
Entity Central Index Key	0001679817
Entity Tax Identification Number	35-2540672
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	42 N Main Street
Entity Address, City or Town	Florida
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10921
City Area Code	(845)
Local Phone Number	544-5112
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 340,168,153
Entity Common Stock, Shares Outstanding		4,622,362,997
ICFR Auditor Attestation Flag	false
Auditor Firm ID	237
Auditor Name	Prager Metis CPA’s LLC
Auditor Location	Hackensack, New Jersey

XML 11 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheet - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Current Assets
Cash	$ 6,767,167	$ 1,808,476
Prepaid assets	151,998	9,569
Accounts receivable	1,299,334	400
Inventory	1,065,982	359,347
Vendor deposits	874,627
Total Current Assets	10,159,108	2,177,792
Operating lease right-of-use asset, net	707,686	149,529
Property and equipment, net	132,889	60,671
Other Assets	568,249
TOTAL ASSETS	11,567,932	2,387,992
Current Liabilities
Accounts payable and accrued expenses	3,246,342	1,678,007
Related party liabilities		9,120
Convertible notes payable, net of discounts	25,000	1,078,985
Current portion of notes payable, net of discounts	13,011,307	1,130,083
Customer deposits	169,849	188,518
Deferred liability	750,000	750,000
Derivative liabilities	20,966,701	3,299,684
Operating lease liability, current portion	194,366	75,340
Current portion of deferred revenues	21,451	17,876
Total Current Liabilities	38,385,016	8,227,613
Long Term Liabilities
Note payable, net of discount	389,423	389,423
Operating lease liability, net of current portion	517,890	74,189
Deferred revenue, net of current portion	25,026	46,477
TOTAL LIABILITIES	39,317,355	8,737,702
COMMITMENTS AND CONTINGENCIES
Stockholders’ Equity (Deficit)
Common stock (4,990,000,000 shares authorized par value $0.001; 4,617,362,997 (2021) and 3,397,958,292 (2020) shares issued and outstanding)	4,617,363	3,397,958
Common stock to be issued; 637,755 shares as of December 31, 2021	638
Additional paid in capital	196,464,222	12,530,933
Treasury Stock	(11,249,934)
Accumulated Deficit	(217,326,611)	(22,278,665)
Accumulated comprehensive loss		(7)
Total Ozop Energy Systems, Inc. stockholders’ equity (deficit)	(27,494,318)	(6,349,710)
Noncontrolling interest	(255,105)
TOTAL STOCKHOLDERS’ EQUITY (DEFICIT)	(27,749,423)	(6,349,710)
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)	11,567,932	2,387,992
Series C Preferred Stock [Member]
Stockholders’ Equity (Deficit)
Preferred stock Value	3	50
Series D Preferred Stock [Member]
Stockholders’ Equity (Deficit)
Preferred stock Value	1	20
Series E Preferred Stock [Member]
Stockholders’ Equity (Deficit)
Preferred stock Value		$ 1

XML 12 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheet (Parenthetical)	Dec. 31, 2021 $ / shares shares
Preferred stock, shares authorized	10,000,000
Preferred stock, par value \| $ / shares	$ 0.001
Common stock, shares authorized	4,990,000,000
Common stock, par value \| $ / shares	$ 0.001
Common stock, shares issued	4,617,362,997
Common stock, shares outstanding	4,617,362,997
common stock to be issued	637,755
Series C Preferred Stock [Member]
Preferred stock, shares authorized	50,000
Preferred stock, par value \| $ / shares	$ 0.001
Preferred stock, shares issued	2,500
Preferred stock, shares outstanding	2,500
Series D Preferred Stock [Member]
Preferred stock, shares authorized	4,570
Preferred stock, par value \| $ / shares	$ 0.001
Preferred stock, shares issued	1,334
Preferred stock, shares outstanding	1,334
Series E Preferred Stock [Member]
Preferred stock, shares authorized	3,000
Preferred stock, par value \| $ / shares	$ 0.001
Preferred stock, shares issued	0
Preferred stock, shares outstanding	0

XML 13 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statement of Comprehensive Income (Loss) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Revenue	$ 11,928,605	$ 1,411,432
Cost of goods sold	10,342,413	1,404,358
Gross profit	1,586,192	7,074
Operating expenses:
General and administrative, related parties	3,803,765	4,747,952
General and administrative, other	10,584,176	1,311,172
Impairment of intangible assets		11,526,303
Total operating expenses	14,387,941	17,585,427
Loss from operations	(12,801,749)	(17,578,353)
Other (income) expenses:
Interest expense	53,252,232	3,409,393
Loss on change in fair value of derivatives	17,349,076	176,050
(Gain) loss on extinguishment of debt	95,449,994	(195,553)
Debt restructure expense	16,450,000
Total Other (Income) Expenses	182,501,302	3,389,890
Income (loss) before income taxes	(195,303,051)	(20,968,243)
Income tax provision
Net Income (loss)	(195,303,051)	(20,968,243)
Less: net loss attributable to noncontrolling interest	(255,105)
Net loss attributable to Ozop Energy Solutions, Inc.	(195,047,946)	(20,968,243)
Other comprehensive loss:
Foreign currency translation adjustment		(7)
Comprehensive income (loss)	(195,303,051)	(20,968,250)
Less: comprehensive loss attributable to noncontrolling interest	(255,105)
Comprehensive loss attributable to Ozop Energy Solutions, Inc.	$ (195,047,946)	$ (20,968,250)
Income (loss) per share basic and fully diluted	$ (0.04)	$ (0.02)
Weighted average shares outstanding
Basic and diluted	4,442,045,075	1,110,673,228

XML 14 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statement of Changes in Stockholders' Equity (Deficit) - USD ($)	Common Stock To Be Issued [Member]	Preferred Stock [Member] Series C Preferred Stock [Member]	Preferred Stock [Member] Series D Preferred Stock [Member]	Preferred Stock [Member] Series E Preferred Stock [Member]	Common Stock [Member]	Treasury Stock [Member]	AOCI Attributable to Parent [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Total
Balance at Dec. 31, 2019		$ 48	$ 19	$ 1				$ 76,922	$ (1,310,422)		$ (1,233,434)
Shares, Outstanding, Beginning Balance at Dec. 31, 2019		47,500	18,667	500
Shares issued for conversions of note and interest payable					$ 1,411,815			9,140,571			10,552,386
Shares issued for conversions of notes and interest payable, shares					1,411,815,206
Shares issued upon cashless exercise of warrants					$ 134,212			(134,212)
Shares issued upon cashless exercise of warrants, shares					134,212,357
Foreign currency translation adjustment							(7)				(7)
Net loss									(20,968,243)		(20,968,243)
Reverse merger transaction					$ 1,851,931			(1,033,489)			818,442
Stock Issued During Period, Shares, Acquisitions					1,851,930,729
Warrants issued in connection with issuance of debt								194,495			194,495
Shares issued pursuant to CEO contract		$ 3	$ 1	$ 1				4,286,646			4,286,651
Stock Issued During Period, Shares, New Issues		2,500	1,333	500
Balance at Dec. 31, 2020		$ 50	$ 20	$ 1	$ 3,397,958		(7)	12,530,933	(22,278,665)		(6,349,710)
Shares, Outstanding, Ending Balance at Dec. 31, 2020		50,000	20,000	1,000	3,397,958,292
Shares issued for conversions of note and interest payable					$ 483,155			102,055,875			102,539,030
Shares issued for conversions of notes and interest payable, shares					483,154,618
Shares issued upon cashless exercise of warrants					$ 405,798			47,704,503			48,110,301
Shares issued upon cashless exercise of warrants, shares					405,797,987
Issuance of Series E Preferred Stock				$ 4				3,999,996			4,000,000
Issuance of Series E Preferred Stock, shares				4,000
Redemption of Series E Preferred Stock				$ (5)				(4,999,995)			(5,000,000)
Redemption of Series E Preferred Stock, shares				(5,000)
Shares issued and to be issued for fees and services	$ 638				$ 55,452			5,267,910			5,324,000
Shares issued and to be issued for fees and services, shares	637,755				55,452,080
Shares issued for lease agreement					$ 100,000			530,000			630,000
Shares issued for lease agreement, shares					100,000,000
Shares issued for debt restructure					$ 175,000			16,275,000			16,450,000
Shares issued for debt restructure, shares					175,000,000
Purchase of Series C and Series D stock for Treasury		$ (48)	$ (19)			(11,249,934)					(11,250,000)
Purchase of Series C and Series D stock for Treasury, shares		(47,500)	(18,667)
Sale of Series D Preferred Stock and warrants								13,100,000			13,100,000
Sale of Series D Preferred Stock and warrants, shares			1
Foreign currency translation adjustment							7				7
Net loss									(195,047,946)	(255,105)	(195,303,051)
Balance at Dec. 31, 2021	$ 638	$ 3	$ 1		$ 4,617,363	$ (11,249,934)		$ 196,464,222	$ (217,326,611)	$ (255,105)	$ (27,749,423)
Shares, Outstanding, Ending Balance at Dec. 31, 2021	637,755	2,500	1,334		4,617,362,977

XML 15 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statement of Cash Flows - USD ($)	12 Months Ended
Consolidated Statement of Cash Flows - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net loss from continuing operations	$ (195,303,051)	$ (20,968,243)
Adjustments to reconcile net loss to net cash used in operations
Non-cash interest expense	51,492,115	2,915,952
Amortization and depreciation	189,348	68,299
Debt restructure expense	16,450,000
Loss on fair value change of derivatives	17,349,075	176,050
Loss (gain) on extinguishment of debt	95,449,994	(195,553)
Stock compensation expense	9,322,751	4,286,647
Impairment		11,526,303
Changes in operating assets and liabilities:
Accounts receivable	(1,298,934)	19,374
Inventory	(706,635)	612,466
Prepaid expenses	(79,430)	6,512
Vendor deposits	(874,627)
Accounts payable and accrued expenses	1,818,095	207,937
Deferred revenue	(17,876)	64,353
Operating lease liabilities	(140,161)	(35,609)
Customer deposits	(18,670)	(496,304)
Net cash used in operating activities	(6,368,006)	(1,811,816)
Cash flows from investing activities:
Cash acquired in acquisition		470,849
Purchase of office and computer equipment	(116,836)	(46,418)
Net cash used in (provided by) investing activities	(116,836)	424,431
Cash flows from financing activities:
Proceeds from issuances of convertible notes payable		489,000
Proceeds from issuances of notes payable	15,000,000	1,553,000
Proceeds from sale of Series D preferred stock and warrants	13,100,000
Proceeds from Payroll Protection Program		100,400
Proceeds from Economic Disaster Loan		10,000
Proceeds received on deferred liability		750,000
Proceeds from shareholders		42,420
Payments to shareholders	(13,634)	(74,470)
Payments of principal of convertible note payable and notes payable	(392,833)	(101,863)
Redemption of Series E Preferred Stock	(5,000,000)
Redemption of Series C and Series D Preferred Stock	(11,250,000)
Advance from affiliate		400,000
Net cash provided by financing activities	11,443,533	3,168,487
Effects of exchange rate on cash		(7)
Net increase in cash	4,958,691	1,781,094
Cash, Beginning of year	1,808,476	27,382
Cash, End of year	6,767,167	1,808,476
Supplemental disclosure of cash flow information:
Cash paid for interest	126,707	133,300
Cash paid for income taxes
Schedule of non-cash Investing or Financing Activity:
Original issue discount included in notes payable	1,610,000	548,333
Issuance of common stock upon convertible note and accrued interest conversion	743,555	2,383,801
Operating lease right-of-use assets and liabilities	702,888	185,139
Issuance of common stock and preferred stock for consulting fees and compensation	9,322,751	4,286,647
Issuance of common stock for lease agreement	630,000
Issuance of common stock for debt restructuring	$ 16,450,000

XML 16 R7.htm IDEA: XBRL DOCUMENT

ORGANIZATION

12 Months Ended

Dec. 31, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

ORGANIZATION

NOTE 1 - ORGANIZATION

Business

Ozop Energy Solutions, Inc. (the” Company,” “we,” “us” or “our”) was originally incorporated as Newmarkt Corp. on July 17, 2015, under the laws of the State of Nevada.

Stock Purchase Agreement

On July 10, 2020, the Company entered into a Stock Purchase Agreement (the “SPA”) with Power Conversion Technologies, Inc., a Pennsylvania corporation (“PCTI”), and Catherine Chis (“Chis”), PCTI’s Chief Executive Officer (“CEO”) and its sole shareholder. Under the terms of the SPA, the Company acquired one thousand (1,000) shares of PCTI, which represents all of the outstanding shares of PCTI, from Chis in exchange for the issuance of 47,500 shares of the Company’s Series C Preferred Stock, 18,667 shares of the Company’s Series D Preferred Stock, and 500 shares of the Company’s Series E Preferred Stock to Chis. The Acquisition was accounted for as a business combination and was treated as a reverse acquisition for accounting purposes with PCTI as the accounting acquirer in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 805, Business Combinations (“ASC 805”). In accordance with the accounting treatment for a reverse acquisition, the Company’s historical financial statements prior to the reverse merger were and will be replaced with the historical financial statements of PCTI prior to the reverse merger, in all future filings with the U.S. Securities and Exchange Commission (the “SEC”). The consolidated financial statements after completion of the reverse merger have and will include the assets, liabilities and results of operations of the combined company from and after the closing date of the reverse merger.

	Purchase Price Allocation
Fair value of OZOP equity consideration issued	$	818,444
Assets acquired	$	1,229,917
Goodwill		11,201,145
Liabilities assumed		(11,612,618	)
Total purchase price allocation	$	818,444

The Company reviews the goodwill allocated to each of our reporting units for possible impairment annually and whenever events or changes in circumstances indicate the carrying amount may not be recoverable. Pursuant to that review, management has determined that the goodwill arising from the above transaction has been impaired and accordingly $11,201,145 was recorded as an impairment expense for the year ended December 31, 2020.

XML 17 R8.htm IDEA: XBRL DOCUMENT

RESTATEMENT

12 Months Ended

Dec. 31, 2021

Accounting Changes and Error Corrections [Abstract]

RESTATEMENT

NOTE 2 – RESTATEMENT

	Adjusted December 31, 2020			December 31, 2020

Total assets	$	2,387,992		$	2,387,992
Current liabilities		8,227,613			6,885,845
Total liabilities		8,737,702			7,395,934
Total stockholders’ deficit		(6,349,710	)		(5,007,942	)

XML 18 R9.htm IDEA: XBRL DOCUMENT

GOING CONCERN AND MANAGEMENT’S PLANS

12 Months Ended

Dec. 31, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

GOING CONCERN AND MANAGEMENT’S PLANS

NOTE 3 – GOING CONCERN AND MANAGEMENT’S PLANS

Management’s Plans

On April 4, 2022, the Company and GHS Investments LLC (“GHS”). signed a Securities Purchase Agreement (the “GHS Purchase Agreement”) for the sale of up to Two Hundred Million (200,000,000) shares of the Company’s common stock to GHS. We may sell shares of our common stock from time to time over a six (6)- month period ending October 4, 2022, at our sole discretion, to GHS under the GHS Purchase Agreement. The purchase price shall be 85% of lowest VWAP for the ten (10) days preceding the Company’s notice to GHS for the sale of the Company’s common stock. On April 8, 2022, the Company filed a Prospectus Supplement to the Registration Statement dated October 14, 2021, regarding the GHS Purchase Agreement.

The Company is in negotiations with its’ lenders related to the debt instruments that are currently in default, to extend the maturity dates.

Solar PV: Our PV business model involves the design and construction of electrical generating PV systems that can sell power to the utilities or be used for off grid use as part of our developing Neo-Grids solution. The Neo-Grids proprietary program, patent pending, was developed for the off-grid distribution of electricity to remove or reduce the dependency on utilities that currently burdens the EV Charging sectors. It will also reduce or eliminate the lengthy permitting processes and streamline the installations of those EV chargers.

Modular Energy Distribution System: The Neo-Grids, patent pending, is comprised of the design engineering, installation, and operational methodologies as well as the financial arbitrage of how we produce, capture and distribute electrical energy for the EV markets. : OES has acquired the license rights to a proprietary system, the Neo-Grids^TM System (patent pending), for the capture and distribution of electrical energy for the EV market. The Neo-Grids^TM System will serve both the private auto and the commercial sectors. The exponential growth of the EV industry has been accelerated by the recent major commitments of most of the major car manufacturers. Our Neo-Grids^TM System leverages this accelerated growth by offering (1) charging locations that can be installed with reduced delays, restricted areas or load limits and (2) EV charger electricity that is produced from renewable sources claiming little to no carbon footprint.

On February 25, 2022, the Company formed Ozop Engineering and Design, Inc. (“OED”) a Nevada corporation, as a wholly owned subsidiary of the Company. OED was formed to become a premier engineering and lighting control design firm. OED offers product and design support for lighting and solar projects with a focus on fast lead times and technical support. OED and our partners are able to offer the resources needed for lighting, solar and electrical design projects. OED will provide its’ customers systems to coordinate the understanding of electrical usage with the relationship between lighting design and lighting controls, by developing more efficient ecofriendly designs by working with architects, engineers, facility managers, electrical contractors and engineers.

XML 19 R10.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS

12 Months Ended

Dec. 31, 2021

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS

NOTE 4 – SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS

Basis of Presentation

The accompanying consolidated financial statements are prepared in accordance with Generally Accepted Accounting Principles in the United States of America (“US GAAP”). The consolidated financial statements include the accounts of the Company and Ozop Energy Systems, Inc. and the Company’s other wholly owned subsidiaries PCTI, Ozop LLC, Ozop HK and Spinus, LLC (“Spinus”) and the Company’s majority owned subsidiary Ozop Capital Partners, Inc. All intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates

Cash and Cash Equivalents

Sales Concentration and credit risk

	Sales % Year Ended December 31, 2021			Sales % Year Ended December 31, 2020			Accounts receivable balance December 31, 2021
Customer A		17	%		N/A		$	782,179
Customer B		N/A			62	%		-
Customer C		N/A			15	%		-

Accounts Receivable

Inventory

The components of inventories at December 31, 2021, and 2020 are as follows:

SCHEDULE OF INVENTORY

	December 31, 2021		December 31, 2020

Raw materials	$	234,168	$	207,178
Work in process		43,704		142,526
Finished goods		788,110		9,643
Inventory net	$	1,065,982	$	359,347

Purchase concentration

Property, plant and equipment

Property and equipment are stated at cost, and depreciation is provided by use of a straight-line method over the estimated useful lives of the assets.

	Office furniture and equipment	3-5 years
	Warehouse equipment	7 years

Revenue Recognition

The following table disaggregates our revenue by major source for the year ended December 31, 2021:

DISAGGREGATION OF REVENUE

	Year ended December 31, 2021
Sourced and distributed products	$	10,595,799
Manufactured products		1,332,806
Total	$	11,928,605

Advertising and Marketing Expenses

Research and Development

Convertible Instruments

The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815, Derivatives and Hedging Activities.

Fair Value of Financial Instruments

The following are the hierarchical levels of inputs to measure fair value:

	●	Level 1 - Observable inputs that reflect quoted market prices in active markets for identical assets or liabilities.
	●	Level 2 - Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means.
	●	Level 3 - Unobservable inputs reflecting the Company’s assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available.

The following table represents the Company’s derivative instruments that are measured at fair value on a recurring basis as of December 31, 2021 and 2020, for each fair value hierarchy level:

SCHEDULE OF DERIVATIVE INSTRUMENTS

December 31, 2021	Derivative Liabilities		Total
Level I	$	-	$	-
Level II	$	-	$	-
Level III	$	20,966,701	$	20,966,701

December 31, 2020	Derivative Liabilities		Total
Level I	$	-	$	-
Level II	$	-	$	-
Level III	$	3,299,684	$	3,299,684

Leases

Income Taxes

Segment Policy

The Company has no reportable segments as it operates in one segment; renewable energy.

Earnings (Loss) Per Share

	December 31, 2021		December 31, 2020
Convertible preferred stock		6,918,544,466		10,193,874,467
Unexercised common stock purchase warrants		672,024,518		659,601,638
Convertible notes payable		1,905,077		370,087,556
Common stock to be issued		-		1,350
		7,592,474,061		11,223,565,011

Recent Accounting Pronouncements

XML 20 R11.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT

12 Months Ended

Dec. 31, 2021

Property, Plant and Equipment [Abstract]

PROPERTY AND EQUIPMENT

NOTE 5 – PROPERTY AND EQUIPMENT

The following table summarizes the Company’s property and equipment:

PROPERTY AND EQUIPMENT

	December 31, 2021			December 31, 2020
Office equipment	$	260,083		$	143,247
Less: Accumulated Depreciation		(127,194	)		(82,576	)
Property and Equipment, Net	$	132,889		$	60,671

Depreciation expense was $44,618 and $11,857 for the years ended December 31, 2021, and 2020, respectively.

XML 21 R12.htm IDEA: XBRL DOCUMENT

CONVERTIBLE NOTES PAYABLE

12 Months Ended

Dec. 31, 2021

Debt Disclosure [Abstract]

CONVERTIBLE NOTES PAYABLE

NOTE 6 - CONVERTIBLE NOTES PAYABLE

A summary of the convertible note balance as of December 31, 2021, and 2020, is as follows:

SCHEDULE OF DEBT

	December 31, 2021		December 31, 2020

Principal balance	$	25,000	$	1,198,775
Unamortized discount		-		(119,790	)
Ending balance, net	$	25,000	$	1,078,985

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

XML 22 R13.htm IDEA: XBRL DOCUMENT

DERIVATIVE LIABILITIES

12 Months Ended

Dec. 31, 2021

Derivative Liabilities

DERIVATIVE LIABILITIES

NOTE 7 – DERIVATIVE LIABILITIES

A summary of the activity related to derivative liabilities for the years ended December 31, 2021, and 2020, is as follows:

	Derivative liabilities associated with warrants			Derivative liabilities associated with convertible notes			Total derivative liabilities
Balance- July 10, 2020, assumed pursuant to PCTI transaction	$	-		$	8,743,231		$	8,743,231
Issued during period		2,061,307			641,285			2,702,592
Converted or paid		-			(8,322,188	)		(8,322,188	)
Change in fair value recognized in operations		-			176,049			176,049
Balance December 31, 2020	$	2,061,307		$	1,238,377		$	3,299,684
Fair value of issuances during period		53,890,754			-			53,890,754
Notes converted or paid		-			(2,246,114	)		(2,246,114	)
Exercise of warrants		(48,110,301	)		-			(48,110,301	)
Warrants cancelled		(3,216,397	)		-			(3,216,397	)
Change in fair value		16,313,392			1,035,683			17,349,075
Balance December 31, 2021	$	20,938,755		$	27,946		$	20,966,701

XML 23 R14.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE

12 Months Ended

Dec. 31, 2021

Notes Payable

NOTES PAYABLE

NOTE 8 – NOTES PAYABLE

The Company has the following note payables outstanding:

SCHEDULE OF NOTES PAYABLE

	December 31, 2021		December 31, 2020
	$	134,681	$	151,469
Note payable bank, interest at 7.75%, matured December 5, 2021, currently in default	$	134,681	$	151,469
Note payable bank, interest at 6.5%, matures December 26, 2021, in default		344,166		345,211
Economic Injury Disaster Loan		10,000		10,000
Paycheck Protection Program loan		100,400		100,400
Notes payable, interest at 8%, matured January 5, 2020, in default		45,000		45,000
Other, due on demand, interest at 6%, currently in default		50,000		50,000
Note payable $203,000 face value, interest at 12%, matured June 25, 2021, net of discount of $13,185 at December 31, 2020		-		189,815
Note payable $750,000 face value, interest at 12%, matured August 24, 2021, net of discount of $540,562 (2020), in default		375,000		209,438
Note payable $389,423 face value, interest at 18%, matures November 6, 2023		389,423		389,423
Note payable $1,000,000 face value, interest at 12%, matures November 13, 2021, net of discount of $971,250 (2020), in default		1,000,000		28,750
Note payable $2,200,000 face value, interest at 12%, matures February 9, 2022, net of discount of $243,833		1,956,167		-
Note payable $11,110,000 face value, interest at 12%, matures March 17, 2022, net of discount of $2,314,583		8,795,417		-
Note payable $3,300,000 face value, interest at 12%, matures December 7, 2022, net of discount of $3,099,524		200,476
Sub- total notes payable		13,400,730		1,519,506
Less long-term portion		389,423		389,423
Current portion of notes payable, net of discount	$	13,011,307	$	1,130,083

The following note was assumed on July 10, 2020, pursuant to the PCTI transaction:

XML 24 R15.htm IDEA: XBRL DOCUMENT

DEFERRED LIABILITY

12 Months Ended

Dec. 31, 2021

Deferred Liability

DEFERRED LIABILITY

NOTE 9 – DEFERRED LIABILITY

XML 25 R16.htm IDEA: XBRL DOCUMENT

DEFERRED REVENUE

12 Months Ended

Dec. 31, 2021

Revenue from Contract with Customer [Abstract]

DEFERRED REVENUE

NOTE 10 – DEFERRED REVENUE

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

+ Details

XML 26 R17.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS

12 Months Ended

Dec. 31, 2021

RELATED PARTY TRANSACTIONS

NOTE 11 – RELATED PARTY TRANSACTIONS

Employment Agreement

On July 10, 2020, pursuant to the PCTI transaction, the Company assumed an employment contract entered into on February 28, 2020, between the Company and Mr. Conway (the “Employment Agreement”). Pursuant to the terms of the Employment Agreement, Mr. Conway is to receive an initial annual salary of $120,000, for his position of CEO of the Company, payable monthly. Mr. Conway was issued 2,500 shares of Series C Preferred Stock. The Company valued the shares at $5,000. On August 28, 2020, Mr. Conway was issued 1,333 shares of Series D Preferred stock and 500 shares of Series E Preferred Stock. The aggregate shares of Series D Preferred Stock in its entirety, is convertible into one and one-half times the number of shares of common stock outstanding at the time of conversion. On August 28, 2020, Mr. Conway owned 6.67% of the issued and outstanding Series D Preferred Stock, and based on the 3,107,037,634 shares outstanding on August 28, 2020, Mr. Conway’s Preferred Stock was convertible into 621,253,401 shares of common stock. Based on the share price of the common stock on that date of $0.0065, the shares were valued at $4,286,648 and recognized as compensation during the year ended December 31, 2020. Effective January 1, 2021, Mr. Conway’s compensation is $20,000 per month, and effective September 1, 2021, Mr. Conway is receiving $10,000 per month from Ozop Capital.

Series E Preferred Stock

Management Fees and related party payables

For the years ended December 31, 2021, and 2020, the Company recorded expenses to its officers in the following amounts:

SCHEDULE OF EXPENSES TO OFFICERS

	2021		2020
	Year ended December 31,
	2021		2020
CEO, parent (includes $5,000 stock-based compensation year ended December 31, 2020)	$	812,099	$	377,804
CEO, parent- Series E Preferred Stock		2,850,000		-
CEO, parent- Series D Preferred Stock		-		4,286,648
President, subsidiary (resigned July 2021)		141,666		83,500
Total	$	3,803,765	$	4,747,952

As of December 31, 2020, included in related party payable is $9,120 for the amount owed the former President of PCTI (resigned in July 2021).

Redemption of Series C and Series D Preferred Stock

On July 13, 2021, the Company entered into a Definitive Agreement (the “Agreement”) with Chis to purchase the 47,500 shares of the Company’s Series C Preferred Stock held by Chis and the 18,667 shares of the Company’s Series D Preferred Stock held by Chis for the total purchase price of $11,250,000. In conjunction with the Agreement, Chis resigned from any and all positions held in the Company’s wholly owned subsidiary, PCTI. Further, Chis agreed that upon her resignation and for a period of five years thereafter (the “Restriction Period”), she shall not, directly or indirectly, solicit the employment of, assist in the soliciting of the employment of, or hire any employee or officer of the Company, including those of any of its present or future subsidiaries, or induce any person who is an employee, officer, agent, consultant or contractor of the Company to terminate such relationship with the Company. Additionally, Chis agreed that during the Restriction Period, she shall not compete with the Company or PCTI anywhere worldwide or be employed by any competitor of the Company.

XML 27 R18.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES

12 Months Ended

Dec. 31, 2021

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 12 – COMMITMENTS AND CONTINGENCIES

Leases

On January 2, 2021, the Company entered into a ten (10) year lease for a 6-bay garage storage facility of approximately 2,500 square feet. Pursuant to the lease the Company agreed to issue 100,000,000 shares of restricted common stock. The shares were certificated on March 8, 2021, with an effective date of January 2, 2021. The Company valued the shares $0.0063, (the market value of the common stock on the date of the agreement) and has recorded $630,000 as a prepaid expense. The Company has not yet taken occupancy of the space,

Agreements

Legal matters

XML 28 R19.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS’ EQUITY

12 Months Ended

Dec. 31, 2021

Equity [Abstract]

STOCKHOLDERS’ EQUITY

NOTE 13– STOCKHOLDERS’ EQUITY

Common stock

During the year ended December 31, 2021, the Company also issued the following shares of restricted common stock:

	●	100,000,000 shares of restricted common stock pursuant to a lease agreement (see Note 10).
	●	175,000000 shares of restricted common stock pursuant to restructuring agreement related to a deferred liability (see Note 9).
	●	55,452,080 shares of restricted common stock in the aggregate for services and consulting agreements.

During the year ended December 31, 2021, the Company also issued 405,797,987 shares of common stock upon the cashless exercise of common stock purchase warrants.

As of December 31, 2021, the Company has 4,990,000,000 shares of $0.001 par value common stock authorized and there are 4,617,362,997 shares of common stock issued and outstanding.

Preferred stock

Series C Preferred Stock

On July 7, 2020, the Company filed an Amended and Restated Certificate of Designation with the State of Nevada of the Company’s Series C Preferred Stock. Under the terms of the Amendment to Certificate of Designation of Series C Preferred Stock, 50,000 shares of the Company’s preferred remain designated as Series C Preferred Stock. The holders of Series C Preferred Stock have no conversion rights and no dividend rights. For so long as any shares of the Series C Preferred Stock remain issued and outstanding, the Holder thereof, voting separately as a class, shall have the right to vote on all shareholder matters equal to sixty-seven (67%) percent of the total vote. On July 10, 2020, pursuant to the SPA with PCTI, the Company issued 47,500 shares of Series C preferred Stock to Chis. On July 13, 2021, the Company purchased 47,500 shares of the Company’s Series C Preferred Stock held by Chis (see Note 11). As of December 31, 2021, and 2020, there were 2,500 and 50,000 shares, respectively, of Series C Preferred Stock issued and outstanding, of which 2,500 shares are held by Mr. Conway.

Series D Preferred Stock

On July 7, 2020, the Company filed a Certificate of Designation with the State of Nevada of the Company’s Series D Preferred Stock. Under the terms of the Certificate of Designation of Series D Preferred Stock, 20,000 shares of the Company’s preferred stock have been designated as Series D Convertible Preferred Stock. The holders of the Series D Convertible Preferred Stock shall not be entitled to receive dividends. The holders as a group may, at any time convert all of the shares of Series D Convertible Preferred Stock into a number of fully paid and nonassessable shares of common stock determined by multiplying the number of issued and outstanding shares of common stock of the Company on the date of conversion, by 3. Except as provided in the Certificate of Designation or as otherwise required by law, no holder of the Series D Convertible Preferred Stock shall be entitled to vote on any matter submitted to the shareholders of the Company for their vote, waiver, release or other action. The Series D Convertible Preferred Stock shall not bear any liquidation rights. On July 10, 2020, pursuant to the SPA with PCTI, the Company issued 18,667 shares of Series D preferred Stock to Chis, and on August 28, 2020, pursuant to Mr. Conway’s employment agreement, the Company issued 1,333 shares of Series D Preferred Stock to Mr. Conway. Accordingly, on August 28, 2020, Mr. Conway owned 6.67% of the issued and outstanding Series D Preferred Stock, and based on the 3,107,037,634 shares outstanding on August 28, 2020, Mr. Conway’s Preferred Stock was convertible into 621,253,401 shares of common stock. Based on the share price of the common stock on that date of $0.0065, the shares were valued at $4,286,648. On July 13, 2021, the Company purchased 18,667 shares of the Company’s Series D Preferred Stock held by Chis (see Note 11).

The warrant has a 15- year term and Partial Warrant Lock Up and Leak-Out Period. The Holder may only exercise the Warrant and purchase Warrant Shares as follows:

	i.	Up to 162 (one hundred and sixty-two) Warrant Shares, at any time or times on or after the Initial Exercise Date and no later than on or before the Termination Date; and

	ii.	The Remainder of the Warrant representing up to 3,074 (three thousand and seventy-four) Warrant Shares (“Remaining Warrant Shares”) shall be locked up for a period of 36 (thirty-six) months from the Initial Exercise Date (“Lock Up Period”) and shall become exercisable at any time or times from the date that is the 36 (thirty-six) month anniversary of the Initial Exercise Date (“Lock Up Period Termination Date”) and no later than on or before the Termination Date, as follows:

Series E Preferred Stock

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

XML 29 R20.htm IDEA: XBRL DOCUMENT

NONCONTROLLING INTEREST

12 Months Ended

Dec. 31, 2021

Equity [Abstract]

NONCONTROLLING INTEREST

NOTE 14 – NONCONTROLLING INTEREST

XML 30 R21.htm IDEA: XBRL DOCUMENT

OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES

12 Months Ended

Dec. 31, 2021

Operating Lease Right-of-use Assets And Operating Lease Liabilities

OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES

NOTE 15 - OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES

Right-of- use assets are summarized below:

SCHEDULE OF RIGHT-OF-USE ASSETS

	December 31, 2021
Office and warehouse lease	$	888,026
Less accumulated amortization		(180,340	)
Right-of-us assets, net	$	707,686

Operating lease liabilities are summarized as follows:

SCHEDULE OF OPERATING LEASE LIABILITIES

	December 31, 2021
Lease liability	$	712,256
Less current portion		(194,366	)
Long term portion	$	517,890

Maturity of lease liabilities are as follows:

	Amount
For the year ending December 31, 2022	$	240,991
For the year ending December 31, 2023		167,858
For the year ended December 31, 2024		171,840
For the year ended December 31, 2025		175,942
For the year ended December 31, 2026		74,030
Total	$	830,661
Less: present value discount		(118,405	)
Lease liability	$	712,256

XML 31 R22.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS

12 Months Ended

Dec. 31, 2021

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 16 – SUBSEQUENT EVENTS

XML 32 R23.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Policies)

12 Months Ended

Dec. 31, 2021

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

The accompanying consolidated financial statements are prepared in accordance with Generally Accepted Accounting Principles in the United States of America (“US GAAP”). The consolidated financial statements include the accounts of the Company and Ozop Energy Systems, Inc. and the Company’s other wholly owned subsidiaries PCTI, Ozop LLC, Ozop HK and Spinus, LLC (“Spinus”) and the Company’s majority owned subsidiary Ozop Capital Partners, Inc. All intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates

Use of Estimates

Cash and Cash Equivalents

Cash and Cash Equivalents

Sales Concentration and credit risk

Sales Concentration and credit risk

	Sales % Year Ended December 31, 2021			Sales % Year Ended December 31, 2020			Accounts receivable balance December 31, 2021
Customer A		17	%		N/A		$	782,179
Customer B		N/A			62	%		-
Customer C		N/A			15	%		-

Accounts Receivable

Accounts Receivable

Inventory

Inventory

The components of inventories at December 31, 2021, and 2020 are as follows:

SCHEDULE OF INVENTORY

	December 31, 2021		December 31, 2020

Raw materials	$	234,168	$	207,178
Work in process		43,704		142,526
Finished goods		788,110		9,643
Inventory net	$	1,065,982	$	359,347

Purchase concentration

Purchase concentration

Property, plant and equipment

Property, plant and equipment

Property and equipment are stated at cost, and depreciation is provided by use of a straight-line method over the estimated useful lives of the assets.

	Office furniture and equipment	3-5 years
	Warehouse equipment	7 years

Revenue Recognition

Revenue Recognition

The following table disaggregates our revenue by major source for the year ended December 31, 2021:

DISAGGREGATION OF REVENUE

	Year ended December 31, 2021
Sourced and distributed products	$	10,595,799
Manufactured products		1,332,806
Total	$	11,928,605

Advertising and Marketing Expenses

Advertising and Marketing Expenses

Research and Development

Research and Development

Convertible Instruments

Convertible Instruments

The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815, Derivatives and Hedging Activities.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

The following are the hierarchical levels of inputs to measure fair value:

	●	Level 1 - Observable inputs that reflect quoted market prices in active markets for identical assets or liabilities.
	●	Level 2 - Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means.
	●	Level 3 - Unobservable inputs reflecting the Company’s assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available.

The following table represents the Company’s derivative instruments that are measured at fair value on a recurring basis as of December 31, 2021 and 2020, for each fair value hierarchy level:

SCHEDULE OF DERIVATIVE INSTRUMENTS

December 31, 2021	Derivative Liabilities		Total
Level I	$	-	$	-
Level II	$	-	$	-
Level III	$	20,966,701	$	20,966,701

December 31, 2020	Derivative Liabilities		Total
Level I	$	-	$	-
Level II	$	-	$	-
Level III	$	3,299,684	$	3,299,684

Leases

Leases

Income Taxes

Income Taxes

Segment Policy

Segment Policy

The Company has no reportable segments as it operates in one segment; renewable energy.

Earnings (Loss) Per Share

Earnings (Loss) Per Share

	December 31, 2021		December 31, 2020
Convertible preferred stock		6,918,544,466		10,193,874,467
Unexercised common stock purchase warrants		672,024,518		659,601,638
Convertible notes payable		1,905,077		370,087,556
Common stock to be issued		-		1,350
		7,592,474,061		11,223,565,011

Recent Accounting Pronouncements

Recent Accounting Pronouncements

XML 33 R24.htm IDEA: XBRL DOCUMENT

ORGANIZATION (Tables)

12 Months Ended

Dec. 31, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

SCHEDULE OF RECOGNIZED IDENTIFIED ASSETS ACQUIRED AND LIABILITIES ASSUMED

	Purchase Price Allocation
Fair value of OZOP equity consideration issued	$	818,444
Assets acquired	$	1,229,917
Goodwill		11,201,145
Liabilities assumed		(11,612,618	)
Total purchase price allocation	$	818,444

XML 34 R25.htm IDEA: XBRL DOCUMENT

RESTATEMENT (Tables)

12 Months Ended

Dec. 31, 2021

Accounting Changes and Error Corrections [Abstract]

SCHEDULE OF ERROR CORRECTIONS AND PRIOR PERIOD ADJUSTMENTS

	Adjusted December 31, 2020			December 31, 2020

Total assets	$	2,387,992		$	2,387,992
Current liabilities		8,227,613			6,885,845
Total liabilities		8,737,702			7,395,934
Total stockholders’ deficit		(6,349,710	)		(5,007,942	)

XML 35 R26.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Tables)

12 Months Ended

Dec. 31, 2021

Accounting Policies [Abstract]

SCHEDULES OF CONCENTRATION OF RISK, BY RISK FACTOR

	Sales % Year Ended December 31, 2021			Sales % Year Ended December 31, 2020			Accounts receivable balance December 31, 2021
Customer A		17	%		N/A		$	782,179
Customer B		N/A			62	%		-
Customer C		N/A			15	%		-

SCHEDULE OF INVENTORY

The components of inventories at December 31, 2021, and 2020 are as follows:

SCHEDULE OF INVENTORY

	December 31, 2021		December 31, 2020

Raw materials	$	234,168	$	207,178
Work in process		43,704		142,526
Finished goods		788,110		9,643
Inventory net	$	1,065,982	$	359,347

SCHEDULE OF USEFUL LIFE OF PROPERTY AND EQUIPMENT ASSETS

	Office furniture and equipment	3-5 years
	Warehouse equipment	7 years

DISAGGREGATION OF REVENUE

The following table disaggregates our revenue by major source for the year ended December 31, 2021:

DISAGGREGATION OF REVENUE

	Year ended December 31, 2021
Sourced and distributed products	$	10,595,799
Manufactured products		1,332,806
Total	$	11,928,605

SCHEDULE OF DERIVATIVE INSTRUMENTS

The following table represents the Company’s derivative instruments that are measured at fair value on a recurring basis as of December 31, 2021 and 2020, for each fair value hierarchy level:

SCHEDULE OF DERIVATIVE INSTRUMENTS

December 31, 2021	Derivative Liabilities		Total
Level I	$	-	$	-
Level II	$	-	$	-
Level III	$	20,966,701	$	20,966,701

December 31, 2020	Derivative Liabilities		Total
Level I	$	-	$	-
Level II	$	-	$	-
Level III	$	3,299,684	$	3,299,684

SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE

	December 31, 2021		December 31, 2020
Convertible preferred stock		6,918,544,466		10,193,874,467
Unexercised common stock purchase warrants		672,024,518		659,601,638
Convertible notes payable		1,905,077		370,087,556
Common stock to be issued		-		1,350
		7,592,474,061		11,223,565,011

- Definition

Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959

+ Details

XML 36 R27.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT (Tables)

12 Months Ended

Dec. 31, 2021

Property, Plant and Equipment [Abstract]

PROPERTY AND EQUIPMENT

The following table summarizes the Company’s property and equipment:

PROPERTY AND EQUIPMENT

	December 31, 2021			December 31, 2020
Office equipment	$	260,083		$	143,247
Less: Accumulated Depreciation		(127,194	)		(82,576	)
Property and Equipment, Net	$	132,889		$	60,671

XML 37 R28.htm IDEA: XBRL DOCUMENT

CONVERTIBLE NOTES PAYABLE (Tables)

12 Months Ended

Dec. 31, 2021

Debt Disclosure [Abstract]

SCHEDULE OF DEBT

A summary of the convertible note balance as of December 31, 2021, and 2020, is as follows:

SCHEDULE OF DEBT

	December 31, 2021		December 31, 2020

Principal balance	$	25,000	$	1,198,775
Unamortized discount		-		(119,790	)
Ending balance, net	$	25,000	$	1,078,985

XML 38 R29.htm IDEA: XBRL DOCUMENT

DERIVATIVE LIABILITIES (Tables)

12 Months Ended

Dec. 31, 2021

Derivative Liabilities

SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE

A summary of the activity related to derivative liabilities for the years ended December 31, 2021, and 2020, is as follows:

	Derivative liabilities associated with warrants			Derivative liabilities associated with convertible notes			Total derivative liabilities
Balance- July 10, 2020, assumed pursuant to PCTI transaction	$	-		$	8,743,231		$	8,743,231
Issued during period		2,061,307			641,285			2,702,592
Converted or paid		-			(8,322,188	)		(8,322,188	)
Change in fair value recognized in operations		-			176,049			176,049
Balance December 31, 2020	$	2,061,307		$	1,238,377		$	3,299,684
Fair value of issuances during period		53,890,754			-			53,890,754
Notes converted or paid		-			(2,246,114	)		(2,246,114	)
Exercise of warrants		(48,110,301	)		-			(48,110,301	)
Warrants cancelled		(3,216,397	)		-			(3,216,397	)
Change in fair value		16,313,392			1,035,683			17,349,075
Balance December 31, 2021	$	20,938,755		$	27,946		$	20,966,701

XML 39 R30.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE (Tables)

12 Months Ended

Dec. 31, 2021

Notes Payable

SCHEDULE OF NOTES PAYABLE

The Company has the following note payables outstanding:

SCHEDULE OF NOTES PAYABLE

	December 31, 2021		December 31, 2020
	$	134,681	$	151,469
Note payable bank, interest at 7.75%, matured December 5, 2021, currently in default	$	134,681	$	151,469
Note payable bank, interest at 6.5%, matures December 26, 2021, in default		344,166		345,211
Economic Injury Disaster Loan		10,000		10,000
Paycheck Protection Program loan		100,400		100,400
Notes payable, interest at 8%, matured January 5, 2020, in default		45,000		45,000
Other, due on demand, interest at 6%, currently in default		50,000		50,000
Note payable $203,000 face value, interest at 12%, matured June 25, 2021, net of discount of $13,185 at December 31, 2020		-		189,815
Note payable $750,000 face value, interest at 12%, matured August 24, 2021, net of discount of $540,562 (2020), in default		375,000		209,438
Note payable $389,423 face value, interest at 18%, matures November 6, 2023		389,423		389,423
Note payable $1,000,000 face value, interest at 12%, matures November 13, 2021, net of discount of $971,250 (2020), in default		1,000,000		28,750
Note payable $2,200,000 face value, interest at 12%, matures February 9, 2022, net of discount of $243,833		1,956,167		-
Note payable $11,110,000 face value, interest at 12%, matures March 17, 2022, net of discount of $2,314,583		8,795,417		-
Note payable $3,300,000 face value, interest at 12%, matures December 7, 2022, net of discount of $3,099,524		200,476
Sub- total notes payable		13,400,730		1,519,506
Less long-term portion		389,423		389,423
Current portion of notes payable, net of discount	$	13,011,307	$	1,130,083

XML 40 R31.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS (Tables)

12 Months Ended

Dec. 31, 2021

SCHEDULE OF EXPENSES TO OFFICERS

For the years ended December 31, 2021, and 2020, the Company recorded expenses to its officers in the following amounts:

SCHEDULE OF EXPENSES TO OFFICERS

	2021		2020
	Year ended December 31,
	2021		2020
CEO, parent (includes $5,000 stock-based compensation year ended December 31, 2020)	$	812,099	$	377,804
CEO, parent- Series E Preferred Stock		2,850,000		-
CEO, parent- Series D Preferred Stock		-		4,286,648
President, subsidiary (resigned July 2021)		141,666		83,500
Total	$	3,803,765	$	4,747,952

XML 41 R32.htm IDEA: XBRL DOCUMENT

OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES (Tables)

12 Months Ended

Dec. 31, 2021

Operating Lease Right-of-use Assets And Operating Lease Liabilities

SCHEDULE OF RIGHT-OF-USE ASSETS

Right-of- use assets are summarized below:

SCHEDULE OF RIGHT-OF-USE ASSETS

	December 31, 2021
Office and warehouse lease	$	888,026
Less accumulated amortization		(180,340	)
Right-of-us assets, net	$	707,686

SCHEDULE OF OPERATING LEASE LIABILITIES

Operating lease liabilities are summarized as follows:

SCHEDULE OF OPERATING LEASE LIABILITIES

	December 31, 2021
Lease liability	$	712,256
Less current portion		(194,366	)
Long term portion	$	517,890

SCHEDULE OF MATURITY OF LEASE LIABILITIES

Maturity of lease liabilities are as follows:

	Amount
For the year ending December 31, 2022	$	240,991
For the year ending December 31, 2023		167,858
For the year ended December 31, 2024		171,840
For the year ended December 31, 2025		175,942
For the year ended December 31, 2026		74,030
Total	$	830,661
Less: present value discount		(118,405	)
Lease liability	$	712,256

XML 42 R33.htm IDEA: XBRL DOCUMENT

SCHEDULE OF RECOGNIZED IDENTIFIED ASSETS ACQUIRED AND LIABILITIES ASSUMED (Details)	Dec. 31, 2021 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Fair value of OZOP equity consideration issued	$ 818,444
Assets acquired	1,229,917
Goodwill	11,201,145
Liabilities assumed	(11,612,618)
Total purchase price allocation	$ 818,444

XML 43 R34.htm IDEA: XBRL DOCUMENT

ORGANIZATION (Details Narrative) - USD ($)		12 Months Ended
ORGANIZATION (Details Narrative) - USD ($)	Jul. 10, 2020	Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Goodwill, Impairment Loss		$ 11,201,145
Securities Purchase Agreement [Member] \| Pennsylvania corporation [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares acquired	1,000
Securities Purchase Agreement [Member] \| Pennsylvania corporation [Member] \| Series C Preferred Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock issued during period, shares, acquisitions	47,500
Securities Purchase Agreement [Member] \| Pennsylvania corporation [Member] \| Series D Preferred Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock issued during period, shares, acquisitions	18,667
Securities Purchase Agreement [Member] \| Pennsylvania corporation [Member] \| Series E Preferred Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock issued during period, shares, acquisitions	500

XML 44 R35.htm IDEA: XBRL DOCUMENT

SCHEDULE OF ERROR CORRECTIONS AND PRIOR PERIOD ADJUSTMENTS (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Total assets	$ 11,567,932	$ 2,387,992
Current liabilities	38,385,016	8,227,613
Total liabilities	39,317,355	8,737,702
Total stockholders’ deficit	$ (27,494,318)	(6,349,710)
Revision of Prior Period, Error Correction, Adjustment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Total assets		2,387,992
Current liabilities		8,227,613
Total liabilities		8,737,702
Total stockholders’ deficit		(6,349,710)
Previously Reported [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Total assets		2,387,992
Current liabilities		6,885,845
Total liabilities		7,395,934
Total stockholders’ deficit		$ (5,007,942)

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

+ Details

- Definition

Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

+ Details

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

XML 45 R36.htm IDEA: XBRL DOCUMENT

RESTATEMENT (Details Narrative) - USD ($)	12 Months Ended
RESTATEMENT (Details Narrative) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Accounting Changes and Error Corrections [Abstract]
Fair value adjustment of warrants	$ 53,890,754	$ 2,061,307
Increase (decrease) in notes payable, current		$ 719,539

XML 46 R37.htm IDEA: XBRL DOCUMENT

GOING CONCERN AND MANAGEMENT’S PLANS (Details Narrative) - USD ($)			12 Months Ended
	Apr. 04, 2022	Mar. 15, 2021	Dec. 31, 2021	Apr. 15, 2022	Apr. 30, 2021	Apr. 14, 2021	Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Retained Earnings (Accumulated Deficit)			$ 217,326,611				$ 22,278,665
Working capital deficit			28,225,908
Derivative Liability, Current			20,966,701				$ 3,299,684
Debt instrument default amount			1,973,847
Common stock maturity period		Dec. 26, 2021
Fund raised for business operations			28,100,000
Lease term					5 years	5 years
Long-term purchase commitment, amount			10,600,000
Series D Preferred Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Redemption amount			11,250,000
Series C Preferred Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Redemption amount			$ 11,250,000
Registration Statement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock issued during the period			30,000,000
Subsequent Event [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Debt additional default debt amount				$ 13,310,000
Subsequent Event [Member] \| Securities Purchase Agreement [Member] \| GHS Investments LLC [Member] \| Common Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock issued during the period	200,000,000
Common stock maturity period	Oct. 04, 2022
Agreement description	The purchase price shall be 85% of lowest VWAP for the ten (10) days preceding the Company’s notice to GHS for the sale of the Company’s common stock. On April 8, 2022, the Company filed a Prospectus Supplement to the Registration Statement dated October 14, 2021, regarding the GHS Purchase Agreement.

XML 47 R38.htm IDEA: XBRL DOCUMENT

SCHEDULES OF CONCENTRATION OF RISK, BY RISK FACTOR (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Customer A [Member]
Product Information [Line Items]
Accounts Receivable, after Allowance for Credit Loss	$ 782,179
Customer A [Member] \| Accounts Receivable [Member] \| Customer Concentration Risk [Member]
Product Information [Line Items]
Concentration Risk, Percentage	17.00%
Customer B [Member]
Product Information [Line Items]
Accounts Receivable, after Allowance for Credit Loss
Customer B [Member] \| Accounts Receivable [Member] \| Customer Concentration Risk [Member]
Product Information [Line Items]
Concentration Risk, Percentage		62.00%
Customer C [Member]
Product Information [Line Items]
Accounts Receivable, after Allowance for Credit Loss
Customer C [Member] \| Accounts Receivable [Member] \| Customer Concentration Risk [Member]
Product Information [Line Items]
Concentration Risk, Percentage		15.00%

XML 48 R39.htm IDEA: XBRL DOCUMENT

SCHEDULE OF INVENTORY (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Raw materials	$ 234,168	$ 207,178
Work in process	43,704	142,526
Finished goods	788,110	9,643
Inventory net	$ 1,065,982	$ 359,347

XML 49 R40.htm IDEA: XBRL DOCUMENT

SCHEDULE OF USEFUL LIFE OF PROPERTY AND EQUIPMENT ASSETS (Details)	12 Months Ended
	Dec. 31, 2021
Warehouse Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	7 years
Minimum [Member] \| Office Furniture And Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Maximum [Member] \| Office Furniture And Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years

XML 50 R41.htm IDEA: XBRL DOCUMENT

DISAGGREGATION OF REVENUE (Details) - USD ($)	12 Months Ended
DISAGGREGATION OF REVENUE (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Product Information [Line Items]
Total	$ 11,928,605	$ 1,411,432
Sourced and Distributed Products [Member]
Product Information [Line Items]
Total	10,595,799
Manufactured Products [Member]
Product Information [Line Items]
Total	$ 1,332,806

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

XML 51 R42.htm IDEA: XBRL DOCUMENT

SCHEDULE OF DERIVATIVE INSTRUMENTS (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Derivative Liabilities
Total
Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Derivative Liabilities
Total
Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Derivative Liabilities	20,966,701	3,299,684
Total	$ 20,966,701	$ 3,299,684

XML 52 R43.htm IDEA: XBRL DOCUMENT

SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares of common stock	7,592,474,061	11,223,565,011
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares of common stock	6,918,544,466	10,193,874,467
Unexercised Common Stock Purchase Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares of common stock	672,024,518	659,601,638
Convertible Notes Payable [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares of common stock	1,905,077	370,087,556
Common Stock To Be Issued [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares of common stock		1,350

XML 53 R44.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Product Information [Line Items]
Cash equivalents	$ 0	$ 0
Marketing and Advertising Expense	44,158	55,249
Research and development expense	$ 7,500	$ 0
Incremental borrowing percentage	7.50%
Income Tax Examination, Likelihood of Unfavorable Settlement	greater than fifty percent
Dilutive securities common stock, shares	7,592,474,061	11,223,565,011
Suppliers One [Member] \| Accounts Payable [Member] \| Supplier Concentration Risk [Member]
Product Information [Line Items]
Concentration of credit risk	42.60%
Suppliers Two [Member] \| Accounts Payable [Member] \| Supplier Concentration Risk [Member]
Product Information [Line Items]
Concentration of credit risk	20.40%
Two Vendor [Member] \| Accounts Payable [Member] \| Supplier Concentration Risk [Member]
Product Information [Line Items]
Concentration of credit risk	20.00%

XML 54 R45.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Less: Accumulated Depreciation	$ (127,194)	$ (82,576)
Property and Equipment, Net	132,889	60,671
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Office equipment	$ 260,083	$ 143,247

XML 55 R46.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	12 Months Ended
PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Depreciation	$ 44,618	$ 11,857

XML 56 R47.htm IDEA: XBRL DOCUMENT

SCHEDULE OF DEBT (Details) - Convertible Debt [Member] - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Principal balance	$ 25,000	$ 1,198,775
Unamortized discount		(119,790)
Ending balance, net	$ 25,000	$ 1,078,985

XML 57 R48.htm IDEA: XBRL DOCUMENT

CONVERTIBLE NOTES PAYABLE (Details Narrative) - USD ($)										9 Months Ended	12 Months Ended
CONVERTIBLE NOTES PAYABLE (Details Narrative) - USD ($)	Mar. 10, 2021	Nov. 19, 2020	Nov. 16, 2020	Sep. 30, 2020	Aug. 03, 2020	Jul. 29, 2020	Jul. 15, 2020	Jul. 10, 2020	Feb. 26, 2020	Dec. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 13, 2021	May 06, 2021	Jul. 22, 2020	Jun. 25, 2020	Oct. 26, 2016
Short-term Debt [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights										405,797,987	405,797,987
Debt Conversion, Converted Instrument, Shares Issued											483,154,618
Debt Instrument, Convertible, Conversion Price										$ 0.002	$ 0.002
Debt Instrument, Interest Rate, Stated Percentage									12.00%								7.75%
Amortization of Debt Discount (Premium)											$ 51,492,115	$ 2,915,952
Debt Instrument, Face Amount													$ 760,550
Proceeds from Convertible Debt												489,000
Derivative Liability								$ 8,743,231		$ 20,966,701	20,966,701	3,299,684
Fair Value Adjustment of Warrants											53,890,754	2,061,307
Settlement Agreement [Member]
Short-term Debt [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights														35,000,000
15% Promissory Note [Member]
Short-term Debt [Line Items]
Long term debt, gross										25,000	25,000	25,000
12% Promissory Note [Member]
Short-term Debt [Line Items]
Long term debt, gross								$ 127,500		$ 0	0	127,500
Debt Instrument, Maturity Date, Description								This note matures 6 months after the Issuance Date
Debt Instrument, Term								6 months
Debt Instrument, Description								This note is convertible into shares of the Company’s common stock beginning on the Issuance Date at $0.025 for the first three months after the Issuance Date
Debt Conversion, Description								After the first three months after the Issuance Date, the conversion price shall be equal to the lower of (i) $.025 or 50% of the lowest trading price for the thirty-five trading days prior to the conversion
Long-term Debt								$ 27,625
Debt Instrument, Unamortized Discount								$ 99,875
Class of Warrant or Right, Number of Securities Called by Warrants or Rights								6,375,000
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 0.02
Warrant term								5 years
12% Promissory Note [Member] \| Investor [Member]
Short-term Debt [Line Items]
Debt Conversion, Original Debt, Amount											127,500
Debt conversion accrued interest											$ 14,433
Debt Conversion, Converted Instrument, Shares Issued											88,708,118
Debt Instrument, Convertible, Conversion Price										$ 0.0016	$ 0.0016
Common stock upon the cashless exercise of the warrants	6,355,008
15% Convertible Promissory Note [Member]
Short-term Debt [Line Items]
Long term debt, gross								$ 129,500		$ 0	$ 0	129,500
Debt Instrument, Term				6 months
Debt Conversion, Description								After the first three months after the Issuance Date, the conversion price shall be equal to the lower of (i) $.025 or 50% of the lowest trading price for the thirty-five trading days prior to the conversion
Long-term Debt								$ 8,375				111,763
Debt Instrument, Unamortized Discount								$ 121,125				10,416
Class of Warrant or Right, Number of Securities Called by Warrants or Rights								6,375,000
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 0.02
Warrant term								5 years
Debt Conversion, Original Debt, Amount											129,500
Debt conversion accrued interest											$ 30,264
Debt Conversion, Converted Instrument, Shares Issued											110,946,972
Debt Instrument, Convertible, Conversion Price								$ 0.025		$ 0.00144	$ 0.00144
Common stock upon the cashless exercise of the warrants	6,355,008
15% Convertible Promissory Note One [Member]
Short-term Debt [Line Items]
Long term debt, gross										$ 0	$ 0	250,000
Debt Instrument, Term								6 months
Debt Instrument, Description								This note is convertible into shares of the Company’s common stock beginning on the Issuance Date at $0.025 for the first three months after the Issuance Date
Debt Conversion, Description								After the first three months after the Issuance Date, the conversion price shall be equal to the lower of (i) $.025 or 50% of the lowest trading price for the thirty-five trading days prior to the conversion
Long-term Debt												239,583
Debt Instrument, Unamortized Discount												10,416
Class of Warrant or Right, Number of Securities Called by Warrants or Rights								12,500,000
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 0.02
Warrant term								5 years
Debt conversion accrued interest											$ 130,044
Debt Conversion, Converted Instrument, Shares Issued											243,012,455
Debt Instrument, Convertible, Conversion Price										$ 0.00156	$ 0.00156
Common stock upon the cashless exercise of the warrants	12,460,800
Debt Instrument, Interest Rate, Stated Percentage								15.00%
Amortization of Debt Discount (Premium)										$ 10,416
Debt Conversion, Converted Instrument, Amount											$ 250,000
15% Convertible Promissory Note Two [Member]
Short-term Debt [Line Items]
Long term debt, gross										0	0	127,500
Debt Instrument, Maturity Date, Description							This note matures 6 months after the Issuance Date
Debt Instrument, Description							This note is convertible into shares of the Company’s common stock beginning on the Issuance Date at $0.011 for the first three months after the Issuance Date
Debt Conversion, Description							After the first three months after the Issuance Date, the conversion price shall be equal to the lower of (i) $.025 or 50% of the lowest trading price for the thirty-five trading days prior to the conversion
Long-term Debt												116,708
Debt Instrument, Unamortized Discount												10,792			$ 25,500
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							6,375,000
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 0.02
Warrant term							5 years
Debt Instrument, Interest Rate, Stated Percentage							15.00%
Amortization of Debt Discount (Premium)							$ 125,541
Debt Instrument, Face Amount							127,500		$ 106,950
Proceeds from Convertible Debt							102,000
Debt intstrument initial debt discount.							82,068
Interest Expense, Debt							125,541				10,792
Derivative Liability							207,699
Fair Value Adjustment of Warrants							$ 19,932
12% Convertible Promissory Note Two [Member]
Short-term Debt [Line Items]
Long term debt, gross										$ 0	0	161,775
Debt Instrument, Maturity Date, Description									This note matures 12 months after the Issuance Date
Debt Instrument, Unamortized Discount									$ 13,950
Debt Conversion, Original Debt, Amount											50,550
Debt conversion accrued interest											$ 11,265
Debt Conversion, Converted Instrument, Shares Issued											20,218,562
Debt Instrument, Convertible, Conversion Price										$ 0.00306	$ 0.00306
Amortization of Debt Discount (Premium)											$ 17,737
Debt Instrument, Face Amount										$ 111,225	111,225					$ 111,225
Conversion price percentage of discount on common share price								45.00%	55.00%
Proceeds from Convertible Debt									$ 85,000
Payments of Debt Issuance Costs									8,000
Debt Instrument, Periodic Payment									400
Debt intstrument initial debt discount.									85,000
Interest Expense, Debt									135,786
Derivative Liability									$ 220,786
15% Convertible Promissory Note Three [Member]
Short-term Debt [Line Items]
Long term debt, gross										0	0	127,500
Debt Instrument, Term						6 months
Debt Instrument, Description						This note is convertible into shares of the Company’s common stock beginning on the Issuance Date at $0.011 for the first three months after the Issuance Date
Debt Conversion, Description						After the first three months after the Issuance Date, the conversion price shall be equal to the lower of (i) $.025 or 50% of the lowest trading price for the thirty-five trading days prior to the conversion
Long-term Debt												105,917
Debt Instrument, Unamortized Discount					$ 25,500					21,583	21,583	21,583
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						12,750,000
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 0.01
Warrant term						5 years
Debt Instrument, Interest Rate, Stated Percentage						15.00%
Debt Instrument, Face Amount						$ 127,500
Proceeds from Convertible Debt					$ 100,000	61,733
Debt intstrument initial debt discount.						61,733
Interest Expense, Debt						136,506
Derivative Liability						198,239
Fair Value Adjustment of Warrants						$ 40,267
15% Convertible Promissory Note Three [Member] \| Investor [Member]
Short-term Debt [Line Items]
Common stock upon the cashless exercise of the warrants	12,710,016
15% Convertible Promissory Note Four [Member]
Short-term Debt [Line Items]
Long term debt, gross										$ 0	$ 0	250,000
Debt Conversion, Description			the conversion price shall be equal to the lower of (i) $.01 or the volume weighted average price of the common stock during the five (5) Trading Day period ending on the day prior to conversion
Long-term Debt												190,736
Debt Instrument, Unamortized Discount		$ 50,000	$ 3,050									$ 59,264
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			35,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.25
Warrant term			5 years
Debt Instrument, Convertible, Conversion Price			$ 0.01
Debt Instrument, Interest Rate, Stated Percentage			15.00%
Debt Instrument, Face Amount			$ 250,000
Proceeds from Convertible Debt		$ 200,000
Debt intstrument initial debt discount.			50,000
Derivative Liability			14,750
Debt Instrument, Periodic Payment, Principal			$ 57,500

XML 58 R49.htm IDEA: XBRL DOCUMENT

SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE (Details) - USD ($)	6 Months Ended	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2021
Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]
Derivative liability, beginning balance	$ 8,743,231	$ 3,299,684
Fair value of issuances during period	2,702,592	53,890,754
Notes converted or paid	(8,322,188)	(2,246,114)
Change in fair value	176,049	17,349,075
Exercise of warrants		(48,110,301)
Warrants cancelled		(3,216,397)
Derivative liability, ending balance	3,299,684	20,966,701
Derivative Liabilities Associated With Warrants [Member]
Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]
Derivative liability, beginning balance		2,061,307
Fair value of issuances during period	2,061,307	53,890,754
Notes converted or paid
Change in fair value		16,313,392
Exercise of warrants		(48,110,301)
Warrants cancelled		(3,216,397)
Derivative liability, ending balance	2,061,307	20,938,755
Derivative Liabilities Associated With Convertible Notes [Member]
Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]
Derivative liability, beginning balance	8,743,231	1,238,377
Fair value of issuances during period	641,285
Notes converted or paid	(8,322,188)	(2,246,114)
Change in fair value	176,049	1,035,683
Exercise of warrants
Warrants cancelled
Derivative liability, ending balance	$ 1,238,377	$ 27,946

XML 59 R50.htm IDEA: XBRL DOCUMENT

DERIVATIVE LIABILITIES (Details Narrative)	12 Months Ended
DERIVATIVE LIABILITIES (Details Narrative)	Dec. 31, 2021 USD ($) $ / shares shares	Dec. 31, 2020 USD ($)	Jul. 10, 2020 USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Liability	$ 20,966,701	$ 3,299,684	$ 8,743,231
Warrants in conjunction with notes payable \| shares	375,000,000
Notes payable discount	$ 14,982,815
Derivative liability interest expense	38,907,939
Fair Value Adjustment of Warrants	$ 53,890,754	$ 2,061,307
Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Liability, Measurement Input	0.19	0.09
Measurement Input, Risk Free Interest Rate [Member] \| Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Liability, Measurement Input	0.48
Measurement Input, Risk Free Interest Rate [Member] \| Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Liability, Measurement Input	0.99
Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Liability, Measurement Input		92
Measurement Input, Price Volatility [Member] \| Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Liability, Measurement Input		48
Measurement Input, Price Volatility [Member] \| Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Liability, Measurement Input		61
Measurement Input Price Volatility One [Member] \| Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Liability, Measurement Input	344
Measurement Input Price Volatility One [Member] \| Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Liability, Measurement Input	366
Measurement Input, Exercise Price [Member] \| Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Liability, Measurement Input \| $ / shares	0.039
Measurement Input, Exercise Price [Member] \| Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Liability, Measurement Input \| $ / shares	0.15

XML 60 R51.htm IDEA: XBRL DOCUMENT

SCHEDULE OF NOTES PAYABLE (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Short-term Debt [Line Items]
Sub- total notes payable	$ 13,400,730	$ 1,519,506
Less long-term portion	389,423	389,423
Current portion of notes payable, net of discount	13,011,307	1,130,083
Note Payable [Member]
Short-term Debt [Line Items]
Sub- total notes payable	134,681	151,469
Note Payable One [Member]
Short-term Debt [Line Items]
Sub- total notes payable	344,166	345,211
Economic Injury Disaster Loan [Member]
Short-term Debt [Line Items]
Sub- total notes payable	10,000	10,000
Paycheck Protection Programloan [Member]
Short-term Debt [Line Items]
Sub- total notes payable	100,400	100,400
Note Payable Two [Member]
Short-term Debt [Line Items]
Sub- total notes payable	45,000	45,000
Other [Member]
Short-term Debt [Line Items]
Sub- total notes payable	50,000	50,000
Note PayableThree [Member]
Short-term Debt [Line Items]
Sub- total notes payable		189,815
Note Payable Four [Member]
Short-term Debt [Line Items]
Sub- total notes payable	375,000	209,438
Note Payable Five [Member]
Short-term Debt [Line Items]
Sub- total notes payable	389,423	389,423
Note Payable Six [Member]
Short-term Debt [Line Items]
Sub- total notes payable	1,000,000	28,750
Note Payable Seven [Member]
Short-term Debt [Line Items]
Sub- total notes payable	1,956,167
Note Payable Eight [Member]
Short-term Debt [Line Items]
Sub- total notes payable	8,795,417
Note Payable Nine [Member]
Short-term Debt [Line Items]
Sub- total notes payable	$ 200,476

XML 61 R52.htm IDEA: XBRL DOCUMENT

SCHEDULE OF NOTES PAYABLE (Details) (Parenthetical) - USD ($)		12 Months Ended
	Mar. 15, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 13, 2021	Feb. 26, 2020	Oct. 26, 2016
Short-term Debt [Line Items]
Debt Instrument, interest rate, stated percentage					12.00%	7.75%
Debt Instrument, maturity date	Dec. 26, 2021
Debt Instrument, face amount				$ 760,550
Note Payable [Member]
Short-term Debt [Line Items]
Debt Instrument, interest rate, stated percentage		7.75%	7.75%
Debt Instrument, maturity date		Dec. 05, 2021	Dec. 05, 2021
Note Payable One [Member]
Short-term Debt [Line Items]
Debt Instrument, interest rate, stated percentage		6.50%	6.50%
Debt Instrument, maturity date		Dec. 26, 2021	Dec. 26, 2021
Note Payable Two [Member]
Short-term Debt [Line Items]
Debt Instrument, interest rate, stated percentage		8.00%	8.00%
Debt Instrument, maturity date		Jan. 05, 2020	Jan. 05, 2020
Other [Member]
Short-term Debt [Line Items]
Debt Instrument, interest rate, stated percentage		6.00%	6.00%
Note PayableThree [Member]
Short-term Debt [Line Items]
Debt Instrument, interest rate, stated percentage		12.00%	12.00%
Debt Instrument, maturity date		Jun. 25, 2021	Jun. 25, 2021
Debt Instrument, face amount		$ 203,000	$ 203,000
Debt Instrument, unamortized discount		$ 13,185	$ 13,185
Note Payable Four [Member]
Short-term Debt [Line Items]
Debt Instrument, interest rate, stated percentage		12.00%	12.00%
Debt Instrument, maturity date		Aug. 24, 2021	Aug. 24, 2021
Debt Instrument, face amount		$ 750,000	$ 750,000
Debt Instrument, unamortized discount			$ 540,562
Note Payable Five [Member]
Short-term Debt [Line Items]
Debt Instrument, interest rate, stated percentage		18.00%	18.00%
Debt Instrument, maturity date		Nov. 06, 2023	Nov. 06, 2023
Debt Instrument, face amount		$ 389,423	$ 389,423
Note Payable Six [Member]
Short-term Debt [Line Items]
Debt Instrument, interest rate, stated percentage		12.00%	12.00%
Debt Instrument, maturity date		Nov. 13, 2021	Nov. 13, 2021
Debt Instrument, face amount		$ 1,000,000	$ 1,000,000
Debt Instrument, unamortized discount			$ 971,250
Note Payable Seven [Member]
Short-term Debt [Line Items]
Debt Instrument, interest rate, stated percentage		12.00%	12.00%
Debt Instrument, maturity date		Feb. 09, 2022	Feb. 09, 2022
Debt Instrument, face amount		$ 2,200,000	$ 2,200,000
Debt Instrument, unamortized discount		$ 243,833	$ 243,833
Note Payable Eight [Member]
Short-term Debt [Line Items]
Debt Instrument, interest rate, stated percentage		12.00%	12.00%
Debt Instrument, maturity date		Mar. 17, 2022	Mar. 17, 2022
Debt Instrument, face amount		$ 11,110,000	$ 11,110,000
Debt Instrument, unamortized discount		$ 2,314,583	$ 2,314,583
Note Payable Nine [Member]
Short-term Debt [Line Items]
Debt Instrument, interest rate, stated percentage		12.00%	12.00%
Debt Instrument, maturity date		Dec. 07, 2022	Dec. 07, 2022
Debt Instrument, face amount		$ 3,300,000	$ 3,300,000
Debt Instrument, unamortized discount		$ 3,099,524	$ 3,099,524

XML 62 R53.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE (Details Narrative) - USD ($)																				12 Months Ended
NOTES PAYABLE (Details Narrative) - USD ($)	Dec. 13, 2021	Dec. 07, 2021	Mar. 23, 2021	Mar. 17, 2021	Mar. 15, 2021	Feb. 16, 2021	Feb. 09, 2021	Jan. 15, 2021	Jan. 08, 2021	Nov. 20, 2020	Nov. 13, 2020	Nov. 06, 2020	Aug. 25, 2020	Aug. 24, 2020	Jul. 23, 2020	Jul. 14, 2020	Jun. 26, 2020	Jun. 25, 2020	Apr. 20, 2020	Dec. 31, 2021	Dec. 31, 2020	May 03, 2021	Jul. 10, 2020	Feb. 26, 2020	Oct. 26, 2016
Debt Instrument, Interest Rate, Stated Percentage																								12.00%	7.75%
Debt Instrument, Face Amount	$ 760,550
Debt Instrument, Maturity Date					Dec. 26, 2021
Proceeds from Notes Payable																				$ 15,000,000	$ 1,553,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																				405,797,987
Amortization of Debt Discount (Premium)																				$ 51,492,115	2,915,952
Derivative Liability																				20,966,701	3,299,684		$ 8,743,231
Fair value of adjustment of warrants																				53,890,754	2,061,307
Notes Payable																				13,400,730	$ 1,519,506
Debt Instrument, Increase, Accrued Interest																				$ 201,905
Notes Payable to Bank					$ 350,000																				$ 210,000
Short-term Bank Loans and Notes Payable					$ 350,000
Common Stock, Shares, Issued																				4,617,362,997	3,397,958,292
Debt Conversion, Converted Instrument, Shares Issued																				483,154,618
Debt Instrument, Convertible, Conversion Price																				$ 0.002
Paycheck Protection Program [Member]
Debt Instrument, Maturity Date																			Apr. 20, 2022
Loans Payable to Bank																			$ 100,400	$ 100,400	$ 100,400
Accounts Payable, Interest-bearing, Interest Rate																			1.00%
PCTI [Member]
Notes Payable																				134,681	151,469
PCTI [Member] \| Personal Guarantee Of Chis [Member]
Notes Payable																				344,166	345,211
Economic Injury Disaster Loan [Member]
Proceeds from Notes Payable																$ 10,000
Debt Instrument, Description																The first payment due is deferred one year. The loan as of December 31, 2021, and 2020 and has been classified in notes payable
Forgiveness of debt																$ 10,000
Lender [Member]
Debt Instrument, Face Amount																				11,110,000
Lender [Member] \| December Seven Two Thousand Twenty Two [Member]
Debt Instrument, Face Amount																				3,300,000
Third Party Lender [Member]
Debt Instrument, Face Amount																				$ 1,956,167
Holder [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																				125,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights																				$ 0.008
Warrants and Rights Outstanding, Term																				5 years
Promissory Note [Member]
Debt Instrument, Face Amount																				$ 375,000	750,000
Debt Instrument, Unamortized Discount																					540,562
Amortization of Debt Discount (Premium)																				484,376
Accrued interest																					90,247
Notes Payable																				375,000	209,438
Common Stock, Shares, Issued																						75,000,000
Promissory Note [Member] \| Maximum [Member]
Debt Instrument, Interest Rate, Stated Percentage					6.50%
Promissory Note [Member] \| Prime Rate [Member]
Debt Instrument, Interest Rate, Stated Percentage					325.00%
Promissory Note [Member] \| Lender [Member]
Debt Instrument, Interest Rate, Stated Percentage				12.00%
Debt Instrument, Face Amount				$ 11,110,000																8,795,417
Debt Instrument, Maturity Date				Mar. 17, 2022
Debt Instrument, Unamortized Discount				$ 1,000,000																2,314,583
Proceeds from Notes Payable			$ 10,000,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				250,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.13
Amortization of Debt Discount (Premium)																				878,750
[custom:AmortizationOfWarrantDiscount-0]																				$ 7,916,667
Lender costs				$ 110,000
Debt Conversion, Converted Instrument, Shares Issued																				20,268,511
Promissory Note [Member] \| Lender [Member] \| Valuation Technique, Option Pricing Model [Member]
Debt Instrument, Unamortized Discount																				$ 10,000,000
Interest Expense																				23,248,433
Derivative Liability																				32,248,433
Fair value of adjustment of warrants																				33,248,433
Promissory Note [Member] \| Lender [Member] \| December Seven Two Thousand Twenty Two [Member]
Debt Instrument, Interest Rate, Stated Percentage		12.00%
Debt Instrument, Face Amount		$ 3,300,000																		200,476
Debt Instrument, Maturity Date		Dec. 07, 2022
Debt Instrument, Unamortized Discount		$ 300,000																		3,099,524
Proceeds from Notes Payable	$ 3,000,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		75,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.039
Amortization of Debt Discount (Premium)																				16,750
Interest Expense																				2,982,815
[custom:AmortizationOfWarrantDiscount-0]																				166,540
Promissory Note [Member] \| Lenders [Member] \| December Seven Two Thousand Twenty Two [Member]
Derivative Liability																				2,982,815
Promissory Note [Member] \| Holder [Member]
Debt Instrument, Interest Rate, Stated Percentage											12.00%	12.00%		12.00%				12.00%
Debt Instrument, Face Amount											$ 1,000,000	$ 389,423		$ 750,000	$ 210,000			$ 203,000		$ 203,000
Debt Instrument, Maturity Date											Nov. 13, 2021	Nov. 06, 2023						Jun. 25, 2021
Proceeds from Notes Payable										$ 890,000			$ 663,000				$ 176,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights												60,000,000		122,950,819				10,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights												$ 0.0075		$ 0.0061						$ 0.02
Interest Expense																				$ 13,185
Debt Instrument, Description											Principal payments shall be made in six instalments of $166,667 commencing 180 days from the issue date and continuing each 30 days thereafter for 5 months and the final payment of principal and interest due on the maturity date			Principal payments shall be made in six instalments of $125,000 commencing 180 days from the Issue Date and continuing each 30 days thereafter for 5 months and the final payment of principal and interest due on the Maturity Date. The Holder shall have the right from time to time, and at any time following an event of default, as defined on the agreement, to convert all or any part of the outstanding and unpaid principal, interest and any other amounts due into fully paid and non-assessable shares of common stock of the Company, at the lower of i) the Trading Price (as defined in the agreement) during the previous five trading days prior to the Issuance Date or ii) the volume weighted average price during the five trading days ending on the day preceding the conversion date				Principal payments shall be made in six instalments of $33,333 commencing 180 days from the issue date and continuing each 30 days thereafter for 5 months and the final payment of principal and interest due on the maturity date. The Holder shall have the right from time to time, and at any time following an event of default, as defined on the agreement, to convert all or any part of the outstanding and unpaid principal, interest and any other amounts due into fully paid and non-assessable shares of common stock of the Company, at the lower of i) the Trading Price (as defined in the agreement) during the previous five trading days prior to the issuance date or ii) the volume weighted average price during the five trading days ending on the day preceding the conversion date
Legal Fees										$ 110,000			$ 87,000				$ 27,000
Warrants and Rights Outstanding, Term												5 years								5 years
Long-term Debt																				$ 0	203,000
Notes Payable												$ 120,000
Debt Instrument, Increase, Accrued Interest												$ 8,716			$ 15,707
Interest Payable, Current																				$ 15,899
Debt Instrument, Convertible, Conversion Price																				$ 0.0108
Number shares issued for cashless								9,121,265	100,668,692
Promissory Note [Member] \| Holder [Member] \| Nine Instalments [Member]
Interest Expense																				$ 56,188
Adjustments to Additional Paid in Capital, Warrant Issued																				750,000
Promissory Note [Member] \| Third-Party [Member]
Debt Instrument, Face Amount																					1,000,000
Promissory Note One [Member] \| Lender [Member]
Debt Instrument, Interest Rate, Stated Percentage							12.00%
Debt Instrument, Face Amount							$ 2,200,000													2,200,000
Debt Instrument, Maturity Date							Feb. 09, 2022
Debt Instrument, Unamortized Discount							$ 200,000													243,833
Proceeds from Notes Payable						$ 2,000,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							50,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 0.15
Amortization of Debt Discount (Premium)																				177,833
Promissory Note One [Member] \| Lender [Member] \| Valuation Technique, Option Pricing Model [Member]
Debt Instrument, Unamortized Discount																				2,000,000
Interest Expense																				15,659,506
Fair value of adjustment of warrants																				17,659,506
Promissory Note One [Member] \| Lenders [Member]
[custom:AmortizationOfWarrantDiscount-0]																				1,778,333
Promissory Note One [Member] \| Lenders [Member] \| Valuation Technique, Option Pricing Model [Member]
Derivative Liability																				17,659,506
Promissory Note One [Member] \| Holder [Member]
Debt Instrument, Unamortized Discount																				971,250
Amortization of Debt Discount (Premium)																				96,250
Adjustments to Additional Paid in Capital, Warrant Issued																				1,000,000
Promissory Note One [Member] \| Holders [Member]
[custom:AmortizationOfWarrantDiscount-0]																				875,000
Promissory Note One [Member] \| Third-Party [Member]
Long-term Debt																				1,000,000	$ 28,750
Accrued interest																				$ 135,452

XML 63 R54.htm IDEA: XBRL DOCUMENT

DEFERRED LIABILITY (Details Narrative) - USD ($)			12 Months Ended
DEFERRED LIABILITY (Details Narrative) - USD ($)	Feb. 26, 2021	Sep. 02, 2020	Dec. 31, 2021	Dec. 31, 2020
Deferred liability, current			$ 750,000	$ 750,000
Liabilities			$ 39,317,355	$ 8,737,702
PCTI [Member] \| Exchange Agreement [Member]
Deferred liability, current		$ 750,000
Product liability contingency, third party recovery, percentage		3.00%
Deferred compensation exchanged for common stock	175,000,000
Royalty percentage	1.80%
Shares issued, price per share			$ 0.094
Payments of debt restructuring costs			$ 16,450,000
Liabilities			$ 215,151

- Definition

+ References

+ Details

XML 64 R55.htm IDEA: XBRL DOCUMENT

DEFERRED REVENUE (Details Narrative) - USD ($)	12 Months Ended
DEFERRED REVENUE (Details Narrative) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Revenue from Contract with Customer [Abstract]
Due from related parties		$ 64,353
Extended product warranty description		payment of a three- year extended warranty
Revenue recognized	$ 17,876
Deferred revenue	46,477
Deferred revenue, current	21,451	$ 17,876
Deferred revenue, non-current	$ 25,026	$ 46,477

XML 65 R56.htm IDEA: XBRL DOCUMENT

SCHEDULE OF EXPENSES TO OFFICERS (Details) - USD ($)	12 Months Ended
SCHEDULE OF EXPENSES TO OFFICERS (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Related Party Transaction [Line Items]
Total	$ 3,803,765	$ 4,747,952
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Total	812,099	377,804
Chief Executive Officer Series E Preferred Stock [Member]
Related Party Transaction [Line Items]
Total	2,850,000
Chief Executive Officer Series D Preferred Stock [Member]
Related Party Transaction [Line Items]
Total		4,286,648
President Subsidiary [Member]
Related Party Transaction [Line Items]
Total	$ 141,666	$ 83,500

XML 66 R57.htm IDEA: XBRL DOCUMENT

SCHEDULE OF EXPENSES TO OFFICERS (Details) (Parenthetical) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Related Party Transactions [Abstract]
Stock based compensation	$ 227,500	$ 5,000

XML 67 R58.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS (Details Narrative)								12 Months Ended
RELATED PARTY TRANSACTIONS (Details Narrative)	Jul. 13, 2021 USD ($) shares	Apr. 16, 2021 USD ($) shares	Mar. 24, 2021 shares	Mar. 21, 2021 USD ($) $ / shares shares	Aug. 28, 2020 USD ($) $ / shares shares	Jul. 10, 2020 shares	Feb. 28, 2020 USD ($) shares	Dec. 31, 2021 USD ($) $ / shares shares	Dec. 31, 2020 USD ($) shares
Related Party Transaction [Line Items]
Amount of initial annual salary \| $								$ 50,000
Number of shares issued, value \| $							$ 5,000		$ 4,286,651
Number of common stock shares outstanding								4,617,362,997	3,397,958,292
Number of shares converted \| $ / shares								$ 0.002
Stock based compensation \| $								$ 227,500	$ 5,000
Number of preferred stock shares authorized								10,000,000	10,000,000
Due to related party payable \| $									$ 9,120
Series C Preferred Stock [Member]
Related Party Transaction [Line Items]
Number of preferred stock shares authorized								50,000	50,000
Series D Preferred Stock [Member]
Related Party Transaction [Line Items]
Number of preferred stock shares authorized								4,570	20,000
Series E Preferred Stock [Member]
Related Party Transaction [Line Items]
Number of shares issued, shares				2,000
Number of preferred stock shares authorized		2,000						3,000	3,000
Number of redeemed shares issued		2,000	3,000
Chief Executive Officer [Member] \| Series C Preferred Stock [Member]
Related Party Transaction [Line Items]
Number of shares issued, shares							2,500
Definitive Agreement [Member] \| Series C Preferred Stock [Member]
Related Party Transaction [Line Items]
Number of shares purchased	47,500
Number of shares purchased, value \| $	$ 11,250,000
Definitive Agreement [Member] \| Series D Preferred Stock [Member]
Related Party Transaction [Line Items]
Number of shares purchased	18,667
Mr Conway [Member]
Related Party Transaction [Line Items]
Number of shares issued, shares		1,050		1,800
Stock based compensation \| $		$ 1,050,000
Number of redeemed shares issued								2,850
Mr Conway [Member] \| Per Month [Member]
Related Party Transaction [Line Items]
Compensation value \| $								$ 20,000
Officers compensation received \| $								$ 10,000
Mr Conway [Member] \| Series D Preferred Stock [Member]
Related Party Transaction [Line Items]
Number of shares issued, shares					1,333
Debt owned percentage					0.0667
Mr Conway [Member] \| Series E Preferred Stock [Member]
Related Party Transaction [Line Items]
Number of shares issued, shares					500
Number of common stock shares outstanding					3,107,037,634
Number of shares converted \| $ / shares					$ 621,253,401
Shares issued price per shares \| $ / shares					$ 0.0065
Number of common stock shares outstanding, value \| $					$ 4,286,648
Preferred stock redemption price per share \| $ / shares				$ 1,000
Stock based compensation \| $				$ 1,800,000
Mr Conway [Member] \| Employment Agreement [Member]
Related Party Transaction [Line Items]
Amount of initial annual salary \| $							$ 120,000
Mr Conway [Member] \| Employment Agreement [Member] \| Series E Preferred Stock [Member]
Related Party Transaction [Line Items]
Number of shares issued, shares						500

XML 68 R59.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES (Details Narrative)														1 Months Ended		12 Months Ended
COMMITMENTS AND CONTINGENCIES (Details Narrative)	Oct. 01, 2021 $ / shares shares	Sep. 02, 2021 USD ($)	Sep. 01, 2021 USD ($)	Apr. 16, 2021 USD ($)	Apr. 13, 2021 USD ($)	Mar. 30, 2021 USD ($) $ / shares shares	Mar. 15, 2021 USD ($) $ / shares shares	Feb. 26, 2021 shares	Jan. 22, 2021 $ / shares shares	Jan. 14, 2021 USD ($) $ / shares shares	Jan. 06, 2021 USD ($) $ / shares shares	Jan. 02, 2021 USD ($) ft² $ / shares shares	Sep. 02, 2020 USD ($)	Sep. 30, 2021 USD ($)	Jul. 31, 2021 $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares	Dec. 31, 2020 USD ($)	Mar. 04, 2019 USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Cash payments																$ 5,000
Issuance of common stock \| shares																637,755
Stock based compensation expense																$ 50,000
Share based compensation expenses																227,500	$ 5,000
Notes payable																13,400,730	1,519,506
Accounts payable and accrued expenses																215,171
PCTI [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Notes payable																134,681	151,469
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of restricted shares issued \| shares									10,000,000
Shares issued, price per share \| $ / shares									$ 0.0056
Share based compensation expenses																56,000
PJN Strategies [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Consulting expense			$ 84,000		$ 20,000											436,000
Rubenstein Public Relations, Inc. [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Consulting expense				$ 17,000												102,000
Co-Directors of Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued, price per share \| $ / shares	$ 0.0445														$ 0.0745
Annual salary						$ 130,000
Bonus amount						$ 20,000
Number of shares issued, shares \| shares	2,500,000														2,500,000
Share based compensation expenses																372,500
Co-Directors of Sales [Member] \| Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued, price per share \| $ / shares						$ 0.092
Number of shares issued, shares \| shares						2,500,000
Share based compensation expenses																$ 460,000
Christopher Ruppel [Member] \| Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of restricted shares issued \| shares																10,000,000
Shares issued, price per share \| $ / shares																$ 0.2386
Consulting expense																$ 12,500
Share based compensation expenses																2,386,000
Professional fees																2,500
Christopher Ruppel [Member] \| Restricted Stock [Member] \| April 1, 2021 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Professional fees																10,000
Ezra Green [Member] \| Restricted Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued, price per share \| $ / shares											$ 0.0076
Consulting expense																94,500
Share based compensation expenses																$ 74,751
Professional fees											$ 2,500
Due to officers or stockholders											10,000
Deferred compensation equity											$ 76,000
Garage Storage Facility [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Lease term												10 years
Land subject to ground leases \| ft²												2,500
Number of restricted shares issued \| shares												100,000,000
Shares issued, price per share \| $ / shares												$ 0.0063
Prepaid expense												$ 630,000
RMA Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Payments of stock issuance costs		$ 50,000
Number of restricted stock issued, value		$ 50,000												$ 452,080
Payments of stock issuance costs														$ 25,000
Consulting Agreement [Member] \| Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares issued, shares \| shares																55,452,080
Consulting Agreement [Member] \| Mr Steven Martello [Member] \| Aurora Enterprises [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of restricted shares issued \| shares							5,000,000
Shares issued, price per share \| $ / shares							$ 0.1392
Consulting expense																$ 90,000
Share based compensation expenses																696,000
Legal fees							$ 10,000
Consulting Agreement [Member] \| Mr Allen Sosis [Member] \| Restricted Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of restricted shares issued \| shares										5,000,000
Shares issued, price per share \| $ / shares										$ 0.20
Consulting expense																75,500
Share based compensation expenses																1,000,000
Due to officers or stockholders										$ 15,000
Accrued employee benefits, current										1,000
Deferred compensation equity										1,000,000
Salary										$ 15,000
Consulting Agreement [Member] \| Ezra Green [Member] \| Restricted Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of restricted shares issued \| shares											10,000,000
Seperation Agreement [Member] \| Salman J. Chaudhry [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Due to officers or stockholders, current																		$ 227,200
Notes payable																$ 162,085	$ 162,085
Exchange Agreement [Member] \| PCTI [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued, price per share \| $ / shares																$ 0.094
Professional fees													$ 750,000
Collaborative arrangement, rights and obligations													PCTI agreed to pay the third-party a perpetual three percent (3%) payment of revenues, as defined in the agreement
Number of common stock exchanged \| shares								175,000,000
Royalty percentage								1.80%
Payments of debt restructuring costs																$ 16,450,000

XML 69 R60.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)									1 Months Ended	12 Months Ended
STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)	Jul. 13, 2021	Apr. 16, 2021	Mar. 24, 2021	Mar. 21, 2021	Mar. 02, 2021	Aug. 28, 2020	Jul. 10, 2020	Jul. 07, 2020	Jul. 28, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 13, 2021	Jul. 27, 2021
Class of Stock [Line Items]
Debt instrument principal												$ 760,550
Debt instrument, accrued interest										$ 201,905
Debt conversion, converted instrument, shares issued										483,154,618
Debt instrument, convertible, conversion price										$ 0.002
Purchase of warrants										405,797,987
Common stock, shares authorized										4,990,000,000	4,990,000,000
Common stock, price per share										$ 0.001	$ 0.001
Common stock, shares, issued										4,617,362,997	3,397,958,292
Common stock, shares, outstanding										4,617,362,997	3,397,958,292
Preferred stock, shares authorized										10,000,000	10,000,000
Preferred stock, price per share										$ 0.001	$ 0.001
Common stock, value, issued										$ 4,617,363	$ 3,397,958
Share-based payment arrangement, expense										$ 227,500	$ 5,000
Mr Conway [Member]
Class of Stock [Line Items]
Number of shares issued, shares		1,050		1,800
Preferred stock, shares										2,500
Share-based payment arrangement, expense		$ 1,050,000
Number of stock redeemed										2,850
Series C Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized										50,000	50,000
Preferred stock, price per share										$ 0.001	$ 0.001
Preferred stock shares issued										2,500	50,000
Preferred stock shares outstanding										2,500	50,000
Preferred stock, redemption amount										$ 11,250,000
Series C Preferred Stock [Member] \| Chis [Member]
Class of Stock [Line Items]
Number of purchased shares	47,500
Series D Preferred Stock [Member]
Class of Stock [Line Items]
Purchase of warrants										3,236
Preferred stock, shares authorized										4,570	20,000
Preferred stock, price per share										$ 0.001	$ 0.001
Preferred stock shares issued										1,334	20,000
Preferred stock shares outstanding										1,334	20,000
Preferred stock, redemption amount										$ 11,250,000
Series D Preferred Stock [Member] \| Mr. Convay [Member]
Class of Stock [Line Items]
Preferred stock shares outstanding						3,107,037,634
Preferred stock issued and oustanding percentage						6.67%
Series D Preferred Stock [Member] \| Mr Conway [Member]
Class of Stock [Line Items]
Number of shares issued, shares						1,333
Series D Preferred Stock [Member] \| Chis [Member]
Class of Stock [Line Items]
Number of purchased shares	18,667
Preferred Stock [Member] \| Mr. Convay [Member]
Class of Stock [Line Items]
Common stock, price per share						$ 0.0065
Conversion of stock, shares converted						621,253,401
Common stock, value, issued						$ 4,286,648
Series E Preferred Stock [Member]
Class of Stock [Line Items]
Number of shares issued, shares				2,000
Preferred stock, shares authorized		2,000								3,000	3,000
Preferred stock, price per share										$ 0.001	$ 0.001
Preferred stock shares issued										0	1,000
Preferred stock shares outstanding										0	1,000
Number of stock redeemed		2,000	3,000
Series E Preferred Stock [Member] \| Mr. Convay [Member]
Class of Stock [Line Items]
Number of shares issued, shares					1,800
Preferred stock, redemption price per share		$ 1,000			$ 1,000
Share-based payment arrangement, expense										$ 2,000,000
Number of stock redeemed		1,050
Series E Preferred Stock [Member] \| Third-Party [Member]
Class of Stock [Line Items]
Number of shares issued, shares					200
Series E Preferred Stock [Member] \| Mr Conway [Member]
Class of Stock [Line Items]
Debt instrument, convertible, conversion price						$ 621,253,401
Number of shares issued, shares						500
Common stock, shares, outstanding						3,107,037,634
Preferred stock, redemption price per share				$ 1,000
Share-based payment arrangement, expense				$ 1,800,000
Restructuring Agreement [Member]
Class of Stock [Line Items]
Deferred compensation shares issued										175,000,000
Certificates of Designation [Member] \| Series C Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized								50,000
Preferred stock, voting rights								The holders of Series C Preferred Stock have no conversion rights and no dividend rights. For so long as any shares of the Series C Preferred Stock remain issued and outstanding, the Holder thereof, voting separately as a class, shall have the right to vote on all shareholder matters equal to sixty-seven (67%) percent of the total vote
Certificates of Designation [Member] \| Series D Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized								20,000
Certificates of Designation [Member] \| Series E Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized								3,000
Preferred stock, redemption amount								$ 1,000
Securities Purchase Agreement [Member] \| Series C Preferred Stock [Member] \| PCTI [Member]
Class of Stock [Line Items]
Number of shares issued, shares							47,500
Securities Purchase Agreement [Member] \| Series D Preferred Stock [Member] \| PCTI [Member]
Class of Stock [Line Items]
Number of shares issued, shares							18,667
Securities Purchase Agreement [Member] \| Series E Preferred Stock [Member] \| PCTI [Member]
Class of Stock [Line Items]
Number of shares issued, shares							500
Employment Agreement [Member] \| Series D Preferred Stock [Member] \| Mr. Convay [Member]
Class of Stock [Line Items]
Number of shares issued, shares						1,333
Employment Agreement [Member] \| Series E Preferred Stock [Member] \| Mr Conway [Member]
Class of Stock [Line Items]
Number of shares issued, shares							500
Series D Amendment [Member] \| Series D Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized													4,570
Preferred stock, convertible, conversion price													$ 1.5
Series DSPA [Member] \| Series D Preferred Stock [Member] \| Investor [Member]
Class of Stock [Line Items]
Purchase of warrants									3,236
Proceeds from issuance of preferred stock									$ 13,200,000
Restricted Stock [Member]
Class of Stock [Line Items]
Share-based payment arrangement, expense										$ 56,000
Restricted Stock [Member] \| Lease Agreement [Member]
Class of Stock [Line Items]
Number of shares issued, shares										100,000,000
Restricted Stock [Member] \| Consulting Agreement [Member]
Class of Stock [Line Items]
Number of shares issued, shares										55,452,080
Warrant [Member]
Class of Stock [Line Items]
Warrants term										15 years
Warrant exercise										162
Warrant exercise, description										During every 1(one) year period, starting on the day that is the Lock Up Period Termination Date, the Holder shall have the right to exercise the Remainder of the Warrant up to a maximum number of Remaining Warrant Shares that, if converted, would be equal to no more than a maximum of 5% (five percent) of the total number of outstanding shares of Common Stock of the Company during such given year (“Leak-Out Period”). The Leak-Out Period shall come into effect on the day that is the Lock Up Period Termination Date and remain effective on a yearly basis, for a period of 10 (ten) years thereafter, after which the Leak-Out Period will automatically terminate and become null and void. For clarity purposes the Remainder of the Warrant shall become freely exercisable at any time or times beginning on June 29, 2034 and until the Termination Date
Remaining Warrant Shares [Member]
Class of Stock [Line Items]
Warrant exercise										3,074

XML 70 R61.htm IDEA: XBRL DOCUMENT

NONCONTROLLING INTEREST (Details Narrative) - USD ($)	12 Months Ended
NONCONTROLLING INTEREST (Details Narrative) - USD ($)	Dec. 31, 2021	Aug. 19, 2021	Dec. 31, 2020
Noncontrolling interest loss	$ 520,623
Noncontrolling interest	$ 255,105
PJN Strategies [Member]
Noncontrolling interest percentage		51.00%
Brian Conway [Member]
Noncontrolling interest percentage		49.00%

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(24))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.31)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(22))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

+ Details

XML 71 R62.htm IDEA: XBRL DOCUMENT

SCHEDULE OF RIGHT-OF-USE ASSETS (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Operating Lease Right-of-use Assets And Operating Lease Liabilities
Office and warehouse lease	$ 888,026
Less accumulated amortization	(180,340)
Right-of-us assets, net	$ 707,686	$ 149,529

XML 72 R63.htm IDEA: XBRL DOCUMENT

SCHEDULE OF OPERATING LEASE LIABILITIES (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Operating Lease Right-of-use Assets And Operating Lease Liabilities
Lease liability	$ 712,256
Less current portion	(194,366)	$ (75,340)
Long term portion	$ 517,890	$ 74,189

XML 73 R64.htm IDEA: XBRL DOCUMENT

SCHEDULE OF MATURITY OF LEASE LIABILITIES (Details)	Dec. 31, 2021 USD ($)
Operating Lease Right-of-use Assets And Operating Lease Liabilities
For the year ending December 31, 2022	$ 240,991
For the year ending December 31, 2023	167,858
For the year ended December 31, 2024	171,840
For the year ended December 31, 2025	175,942
For the year ended December 31, 2026	74,030
Total	830,661
Less: present value discount	(118,405)
Lease liability	$ 712,256

XML 74 R65.htm IDEA: XBRL DOCUMENT

OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES (Details Narrative)		12 Months Ended
	Apr. 14, 2021 USD ($) ft²	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Jun. 04, 2021 USD ($)	Jun. 01, 2021 USD ($)	Apr. 30, 2021
Lease expiration date		Nov. 30, 2022
operating lease disount rate		7.50%
operating lease rent expense			$ 84,278
RIght of use of asset		$ 707,686	149,529
Operating lease liability		$ 712,256
Operating lease term	5 years					5 years
Area of land \| ft²	8,100
Thereafter [Member]
Debt instrument insterest rate	2.40%
CANADA
Lease expiration date	May 31, 2026
Operating lease payments	$ 13,148
Debt instrument insterest rate	7.50%
Accounting Standards Update 2016-02 [Member]
RIght of use of asset			185,139	$ 702,888
Operating lease liability			$ 185,139		$ 702,888

XML 75 R66.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS (Details Narrative) - USD ($)				12 Months Ended
SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Apr. 04, 2022	Jan. 02, 2022	Mar. 15, 2021	Dec. 31, 2021
Subsequent Event [Line Items]
Common stock maturity period			Dec. 26, 2021
Registration Statement [Member]
Subsequent Event [Line Items]
Number of shares issued, shares				30,000,000
Subsequent Event [Member] \| Registration Statement [Member] \| GHS Investments [Member] \| Common Stock [Member]
Subsequent Event [Line Items]
Number of shares issued, shares	200,000,000
Common stock maturity period	Oct. 04, 2022
Subsequent Event [Member] \| Mr Conway [Member] \| New Employment Agreement [Member]
Subsequent Event [Line Items]
Contract renewal bonus		$ 250,000
Annual compensation		240,000
Subsequent Event [Member] \| Mr Conway [Member] \| New Employment Agreement [Member] \| Ozop Capital [Member]
Subsequent Event [Line Items]
Annual compensation		20,000
Subsequent Event [Member] \| Mr Conway [Member] \| New Employment Agreement [Member] \| OES [Member]
Subsequent Event [Line Items]
Annual compensation		$ 20,000

XML 76 form10-k_htm.xml IDEA: XBRL DOCUMENT 0001679817 2021-01-01 2021-12-31 0001679817 2021-06-30 0001679817 2022-04-14 0001679817 2021-12-31 0001679817 2020-12-31 0001679817 us-gaap:SeriesCPreferredStockMember 2021-12-31 0001679817 us-gaap:SeriesCPreferredStockMember 2020-12-31 0001679817 us-gaap:SeriesDPreferredStockMember 2021-12-31 0001679817 us-gaap:SeriesDPreferredStockMember 2020-12-31 0001679817 us-gaap:SeriesEPreferredStockMember 2021-12-31 0001679817 us-gaap:SeriesEPreferredStockMember 2020-12-31 0001679817 2020-01-01 2020-12-31 0001679817 OZSC:CommonStockToBeIssuedMember 2020-12-31 0001679817 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001679817 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001679817 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001679817 us-gaap:CommonStockMember 2020-12-31 0001679817 us-gaap:TreasuryStockMember 2020-12-31 0001679817 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001679817 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001679817 us-gaap:RetainedEarningsMember 2020-12-31 0001679817 us-gaap:NoncontrollingInterestMember 2020-12-31 0001679817 OZSC:CommonStockToBeIssuedMember 2019-12-31 0001679817 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0001679817 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0001679817 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0001679817 us-gaap:CommonStockMember 2019-12-31 0001679817 us-gaap:TreasuryStockMember 2019-12-31 0001679817 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001679817 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001679817 us-gaap:RetainedEarningsMember 2019-12-31 0001679817 us-gaap:NoncontrollingInterestMember 2019-12-31 0001679817 2019-12-31 0001679817 OZSC:CommonStockToBeIssuedMember 2021-01-01 2021-12-31 0001679817 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001679817 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001679817 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001679817 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001679817 us-gaap:TreasuryStockMember 2021-01-01 2021-12-31 0001679817 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0001679817 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001679817 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001679817 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-12-31 0001679817 OZSC:CommonStockToBeIssuedMember 2020-01-01 2020-12-31 0001679817 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-12-31 0001679817 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-12-31 0001679817 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-12-31 0001679817 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001679817 us-gaap:TreasuryStockMember 2020-01-01 2020-12-31 0001679817 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0001679817 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001679817 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001679817 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-12-31 0001679817 OZSC:CommonStockToBeIssuedMember 2021-12-31 0001679817 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001679817 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001679817 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001679817 us-gaap:CommonStockMember 2021-12-31 0001679817 us-gaap:TreasuryStockMember 2021-12-31 0001679817 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001679817 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001679817 us-gaap:RetainedEarningsMember 2021-12-31 0001679817 us-gaap:NoncontrollingInterestMember 2021-12-31 0001679817 OZSC:PennsylvaniaCorporationMember OZSC:SecuritiesPurchaseAgreementMember 2020-07-01 2020-07-10 0001679817 OZSC:PennsylvaniaCorporationMember us-gaap:SeriesCPreferredStockMember OZSC:SecuritiesPurchaseAgreementMember 2020-07-01 2020-07-10 0001679817 OZSC:PennsylvaniaCorporationMember us-gaap:SeriesDPreferredStockMember OZSC:SecuritiesPurchaseAgreementMember 2020-07-01 2020-07-10 0001679817 OZSC:PennsylvaniaCorporationMember us-gaap:SeriesEPreferredStockMember OZSC:SecuritiesPurchaseAgreementMember 2020-07-01 2020-07-10 0001679817 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2020-12-31 0001679817 srt:ScenarioPreviouslyReportedMember 2020-12-31 0001679817 us-gaap:SubsequentEventMember 2022-04-15 0001679817 OZSC:RegistrationStatementMember 2021-01-01 2021-12-31 0001679817 OZSC:GHSInvestmentsLLCMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember OZSC:SecuritiesPurchaseAgreementMember 2022-04-01 2022-04-04 0001679817 2021-04-30 0001679817 OZSC:SuppliersOneMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2021-01-01 2021-12-31 0001679817 OZSC:SuppliersTwoMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2021-01-01 2021-12-31 0001679817 OZSC:TwoVendorMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2021-01-01 2021-12-31 0001679817 OZSC:CustomerAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001679817 OZSC:CustomerAMember 2021-12-31 0001679817 OZSC:CustomerBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001679817 OZSC:CustomerBMember 2021-12-31 0001679817 OZSC:CustomerCMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001679817 OZSC:CustomerCMember 2021-12-31 0001679817 srt:MinimumMember OZSC:OfficeFurnitureAndEquipmentMember 2021-01-01 2021-12-31 0001679817 srt:MaximumMember OZSC:OfficeFurnitureAndEquipmentMember 2021-01-01 2021-12-31 0001679817 OZSC:WarehouseEquipmentMember 2021-01-01 2021-12-31 0001679817 OZSC:SourcedAndDistributedProductsMember 2021-01-01 2021-12-31 0001679817 OZSC:ManufacturedProductsMember 2021-01-01 2021-12-31 0001679817 us-gaap:FairValueInputsLevel1Member 2021-12-31 0001679817 us-gaap:FairValueInputsLevel2Member 2021-12-31 0001679817 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001679817 us-gaap:FairValueInputsLevel1Member 2020-12-31 0001679817 us-gaap:FairValueInputsLevel2Member 2020-12-31 0001679817 us-gaap:FairValueInputsLevel3Member 2020-12-31 0001679817 us-gaap:ConvertiblePreferredStockMember 2021-01-01 2021-12-31 0001679817 us-gaap:ConvertiblePreferredStockMember 2020-01-01 2020-12-31 0001679817 OZSC:UnexercisedCommonStockPurchaseWarrantsMember 2021-01-01 2021-12-31 0001679817 OZSC:UnexercisedCommonStockPurchaseWarrantsMember 2020-01-01 2020-12-31 0001679817 us-gaap:ConvertibleNotesPayableMember 2021-01-01 2021-12-31 0001679817 us-gaap:ConvertibleNotesPayableMember 2020-01-01 2020-12-31 0001679817 OZSC:CommonStockToBeIssuedMember 2021-01-01 2021-12-31 0001679817 OZSC:CommonStockToBeIssuedMember 2020-01-01 2020-12-31 0001679817 us-gaap:OfficeEquipmentMember 2021-12-31 0001679817 us-gaap:OfficeEquipmentMember 2020-12-31 0001679817 OZSC:FifteenPercentPromissoryNoteMember 2021-12-31 0001679817 OZSC:FifteenPercentPromissoryNoteMember 2020-12-31 0001679817 OZSC:TwelvePercentPromissoryNoteMember 2020-07-09 2020-07-10 0001679817 OZSC:TwelvePercentPromissoryNoteMember 2020-07-10 0001679817 us-gaap:InvestorMember OZSC:TwelvePercentPromissoryNoteMember 2021-01-01 2021-12-31 0001679817 us-gaap:InvestorMember OZSC:TwelvePercentPromissoryNoteMember 2021-12-31 0001679817 us-gaap:InvestorMember OZSC:TwelvePercentPromissoryNoteMember 2021-03-08 2021-03-10 0001679817 OZSC:TwelvePercentPromissoryNoteMember 2021-12-31 0001679817 OZSC:TwelvePercentPromissoryNoteMember 2020-12-31 0001679817 OZSC:FifteenPercentConvertiblePromissoryNoteMember 2020-09-28 2020-09-30 0001679817 OZSC:FifteenPercentConvertiblePromissoryNoteMember 2020-07-10 0001679817 OZSC:FifteenPercentConvertiblePromissoryNoteMember 2020-07-09 2020-07-10 0001679817 OZSC:FifteenPercentConvertiblePromissoryNoteMember 2021-01-01 2021-12-31 0001679817 OZSC:FifteenPercentConvertiblePromissoryNoteMember 2021-12-31 0001679817 OZSC:FifteenPercentConvertiblePromissoryNoteMember 2021-03-08 2021-03-10 0001679817 OZSC:FifteenPercentConvertiblePromissoryNoteMember 2020-12-31 0001679817 OZSC:FifteenPercentConvertiblePromissoryNoteOneMember 2020-07-10 0001679817 OZSC:FifteenPercentConvertiblePromissoryNoteOneMember 2020-07-09 2020-07-10 0001679817 OZSC:FifteenPercentConvertiblePromissoryNoteOneMember 2021-04-01 2021-12-31 0001679817 OZSC:FifteenPercentConvertiblePromissoryNoteOneMember 2021-01-01 2021-12-31 0001679817 OZSC:FifteenPercentConvertiblePromissoryNoteOneMember 2021-12-31 0001679817 OZSC:FifteenPercentConvertiblePromissoryNoteOneMember 2021-03-08 2021-03-10 0001679817 OZSC:FifteenPercentConvertiblePromissoryNoteOneMember 2020-12-31 0001679817 2020-02-26 0001679817 OZSC:FifteenPercentConvertiblePromissoryNoteTwoMember 2020-02-26 0001679817 OZSC:TwelvePercentConvertiblePromissoryNoteTwoMember 2020-02-25 2020-02-26 0001679817 OZSC:TwelvePercentConvertiblePromissoryNoteTwoMember 2020-02-26 0001679817 OZSC:TwelvePercentConvertiblePromissoryNoteTwoMember 2020-06-25 0001679817 OZSC:TwelvePercentConvertiblePromissoryNoteTwoMember 2020-07-10 0001679817 OZSC:TwelvePercentConvertiblePromissoryNoteTwoMember 2021-01-01 2021-12-31 0001679817 OZSC:TwelvePercentConvertiblePromissoryNoteTwoMember 2021-12-31 0001679817 OZSC:TwelvePercentConvertiblePromissoryNoteTwoMember 2020-12-31 0001679817 OZSC:FifteenPercentConvertiblePromissoryNoteTwoMember 2020-07-15 0001679817 OZSC:FifteenPercentConvertiblePromissoryNoteTwoMember 2020-07-01 2020-07-15 0001679817 OZSC:FifteenPercentConvertiblePromissoryNoteTwoMember 2020-07-22 0001679817 OZSC:FifteenPercentConvertiblePromissoryNoteTwoMember 2021-01-01 2021-12-31 0001679817 OZSC:FifteenPercentConvertiblePromissoryNoteTwoMember 2021-12-31 0001679817 OZSC:FifteenPercentConvertiblePromissoryNoteTwoMember 2020-12-31 0001679817 OZSC:FifteenPercentConvertiblePromissoryNoteThreeMember 2020-07-29 0001679817 OZSC:FifteenPercentConvertiblePromissoryNoteThreeMember 2020-07-28 2020-07-29 0001679817 OZSC:FifteenPercentConvertiblePromissoryNoteThreeMember 2020-08-02 2020-08-03 0001679817 OZSC:FifteenPercentConvertiblePromissoryNoteThreeMember 2020-08-03 0001679817 us-gaap:InvestorMember OZSC:FifteenPercentConvertiblePromissoryNoteThreeMember 2021-03-08 2021-03-10 0001679817 OZSC:FifteenPercentConvertiblePromissoryNoteThreeMember 2021-12-31 0001679817 OZSC:FifteenPercentConvertiblePromissoryNoteThreeMember 2020-12-31 0001679817 OZSC:FifteenPercentConvertiblePromissoryNoteFourMember 2020-11-16 0001679817 OZSC:FifteenPercentConvertiblePromissoryNoteFourMember 2020-11-15 2020-11-16 0001679817 OZSC:FifteenPercentConvertiblePromissoryNoteFourMember 2020-11-18 2020-11-19 0001679817 OZSC:FifteenPercentConvertiblePromissoryNoteFourMember 2020-11-19 0001679817 OZSC:FifteenPercentConvertiblePromissoryNoteFourMember 2020-12-31 0001679817 OZSC:SettlementAgreementMember 2021-05-06 0001679817 OZSC:FifteenPercentConvertiblePromissoryNoteFourMember 2021-12-31 0001679817 us-gaap:ConvertibleDebtMember 2021-12-31 0001679817 us-gaap:ConvertibleDebtMember 2020-12-31 0001679817 us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001679817 us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-12-31 0001679817 us-gaap:MeasurementInputPriceVolatilityMember 2020-12-31 0001679817 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember 2020-12-31 0001679817 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember 2020-12-31 0001679817 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001679817 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001679817 srt:MinimumMember OZSC:MeasurementInputPriceVolatilityOneMember 2021-12-31 0001679817 srt:MaximumMember OZSC:MeasurementInputPriceVolatilityOneMember 2021-12-31 0001679817 srt:MinimumMember us-gaap:MeasurementInputExercisePriceMember 2021-12-31 0001679817 srt:MaximumMember us-gaap:MeasurementInputExercisePriceMember 2021-12-31 0001679817 OZSC:DerivativeLiabilitiesAssociatedWithWarrantsMember 2020-07-10 0001679817 OZSC:DerivativeLiabilitiesAssociatedWithConvertibleNotesMember 2020-07-10 0001679817 2020-07-10 0001679817 OZSC:DerivativeLiabilitiesAssociatedWithWarrantsMember 2020-07-11 2020-12-31 0001679817 OZSC:DerivativeLiabilitiesAssociatedWithConvertibleNotesMember 2020-07-11 2020-12-31 0001679817 2020-07-11 2020-12-31 0001679817 OZSC:DerivativeLiabilitiesAssociatedWithWarrantsMember 2020-12-31 0001679817 OZSC:DerivativeLiabilitiesAssociatedWithConvertibleNotesMember 2020-12-31 0001679817 OZSC:DerivativeLiabilitiesAssociatedWithWarrantsMember 2021-01-01 2021-12-31 0001679817 OZSC:DerivativeLiabilitiesAssociatedWithConvertibleNotesMember 2021-01-01 2021-12-31 0001679817 OZSC:DerivativeLiabilitiesAssociatedWithWarrantsMember 2021-12-31 0001679817 OZSC:DerivativeLiabilitiesAssociatedWithConvertibleNotesMember 2021-12-31 0001679817 OZSC:NotePayableMember 2021-12-31 0001679817 OZSC:NotePayableMember 2020-12-31 0001679817 OZSC:NotePayableOneMember 2021-12-31 0001679817 OZSC:NotePayableOneMember 2020-12-31 0001679817 OZSC:EconomicInjuryDisasterLoanMember 2021-12-31 0001679817 OZSC:EconomicInjuryDisasterLoanMember 2020-12-31 0001679817 OZSC:PaycheckProtectionProgramloanMember 2021-12-31 0001679817 OZSC:PaycheckProtectionProgramloanMember 2020-12-31 0001679817 OZSC:NotePayableTwoMember 2021-12-31 0001679817 OZSC:NotePayableTwoMember 2020-12-31 0001679817 OZSC:OtherMember 2021-12-31 0001679817 OZSC:OtherMember 2020-12-31 0001679817 OZSC:NotePayableThreeMember 2021-12-31 0001679817 OZSC:NotePayableThreeMember 2020-12-31 0001679817 OZSC:NotePayableFourMember 2021-12-31 0001679817 OZSC:NotePayableFourMember 2020-12-31 0001679817 OZSC:NotePayableFiveMember 2021-12-31 0001679817 OZSC:NotePayableFiveMember 2020-12-31 0001679817 OZSC:NotePayableSixMember 2021-12-31 0001679817 OZSC:NotePayableSixMember 2020-12-31 0001679817 OZSC:NotePayableSevenMember 2021-12-31 0001679817 OZSC:NotePayableSevenMember 2020-12-31 0001679817 OZSC:NotePayableEightMember 2021-12-31 0001679817 OZSC:NotePayableEightMember 2020-12-31 0001679817 OZSC:NotePayableNineMember 2021-12-31 0001679817 OZSC:NotePayableMember 2021-01-01 2021-12-31 0001679817 OZSC:NotePayableMember 2020-01-01 2020-12-31 0001679817 OZSC:NotePayableOneMember 2021-01-01 2021-12-31 0001679817 OZSC:NotePayableOneMember 2020-01-01 2020-12-31 0001679817 OZSC:NotePayableTwoMember 2021-01-01 2021-12-31 0001679817 OZSC:NotePayableTwoMember 2020-01-01 2020-12-31 0001679817 OZSC:NotePayableThreeMember 2021-01-01 2021-12-31 0001679817 OZSC:NotePayableThreeMember 2020-01-01 2020-12-31 0001679817 OZSC:NotePayableFourMember 2021-01-01 2021-12-31 0001679817 OZSC:NotePayableFourMember 2020-01-01 2020-12-31 0001679817 OZSC:NotePayableFiveMember 2021-01-01 2021-12-31 0001679817 OZSC:NotePayableFiveMember 2020-01-01 2020-12-31 0001679817 OZSC:NotePayableSixMember 2021-01-01 2021-12-31 0001679817 OZSC:NotePayableSixMember 2020-01-01 2020-12-31 0001679817 OZSC:NotePayableSevenMember 2021-01-01 2021-12-31 0001679817 OZSC:NotePayableSevenMember 2020-01-01 2020-12-31 0001679817 OZSC:NotePayableEightMember 2021-01-01 2021-12-31 0001679817 OZSC:NotePayableEightMember 2020-01-01 2020-12-31 0001679817 OZSC:NotePayableNineMember 2020-12-31 0001679817 OZSC:NotePayableNineMember 2021-01-01 2021-12-31 0001679817 OZSC:NotePayableNineMember 2020-01-01 2020-12-31 0001679817 OZSC:LenderMember OZSC:DecemberSevenTwoThousandTwentyTwoMember OZSC:PromissoryNoteMember 2021-12-07 0001679817 OZSC:LenderMember OZSC:DecemberSevenTwoThousandTwentyTwoMember OZSC:PromissoryNoteMember 2021-12-05 2021-12-07 0001679817 OZSC:LenderMember OZSC:DecemberSevenTwoThousandTwentyTwoMember OZSC:PromissoryNoteMember 2021-12-12 2021-12-13 0001679817 OZSC:LenderMember OZSC:DecemberSevenTwoThousandTwentyTwoMember OZSC:PromissoryNoteMember 2021-01-01 2021-12-31 0001679817 OZSC:LendersMember OZSC:DecemberSevenTwoThousandTwentyTwoMember OZSC:PromissoryNoteMember 2021-12-31 0001679817 OZSC:LenderMember OZSC:DecemberSevenTwoThousandTwentyTwoMember OZSC:PromissoryNoteMember 2021-12-31 0001679817 OZSC:LenderMember OZSC:DecemberSevenTwoThousandTwentyTwoMember 2021-12-31 0001679817 OZSC:LenderMember OZSC:PromissoryNoteMember 2021-03-17 0001679817 OZSC:LenderMember OZSC:PromissoryNoteMember 2021-03-16 2021-03-17 0001679817 OZSC:LenderMember OZSC:PromissoryNoteMember 2021-03-22 2021-03-23 0001679817 OZSC:LenderMember OZSC:PromissoryNoteMember 2021-01-01 2021-12-31 0001679817 OZSC:LenderMember OZSC:PromissoryNoteMember us-gaap:ValuationTechniqueOptionPricingModelMember 2021-01-01 2021-12-31 0001679817 OZSC:LenderMember OZSC:PromissoryNoteMember us-gaap:ValuationTechniqueOptionPricingModelMember 2021-12-31 0001679817 OZSC:LenderMember OZSC:PromissoryNoteMember 2021-12-31 0001679817 OZSC:LenderMember 2021-12-31 0001679817 OZSC:LenderMember OZSC:PromissoryNoteOneMember 2021-02-09 0001679817 OZSC:LenderMember OZSC:PromissoryNoteOneMember 2021-02-08 2021-02-09 0001679817 OZSC:LenderMember OZSC:PromissoryNoteOneMember 2021-02-15 2021-02-16 0001679817 OZSC:LenderMember OZSC:PromissoryNoteOneMember 2021-01-01 2021-12-31 0001679817 OZSC:LenderMember OZSC:PromissoryNoteOneMember us-gaap:ValuationTechniqueOptionPricingModelMember 2021-01-01 2021-12-31 0001679817 OZSC:LenderMember OZSC:PromissoryNoteOneMember us-gaap:ValuationTechniqueOptionPricingModelMember 2021-12-31 0001679817 OZSC:LendersMember OZSC:PromissoryNoteOneMember us-gaap:ValuationTechniqueOptionPricingModelMember 2021-12-31 0001679817 OZSC:LendersMember OZSC:PromissoryNoteOneMember 2021-12-31 0001679817 OZSC:LenderMember OZSC:PromissoryNoteOneMember 2021-12-31 0001679817 OZSC:ThirdPartyLenderMember 2021-12-31 0001679817 OZSC:HolderMember OZSC:PromissoryNoteMember 2020-11-13 0001679817 OZSC:HolderMember OZSC:PromissoryNoteMember 2020-11-12 2020-11-13 0001679817 OZSC:HolderMember OZSC:PromissoryNoteMember 2020-11-17 2020-11-20 0001679817 OZSC:HolderMember OZSC:PromissoryNoteOneMember 2021-01-01 2021-12-31 0001679817 OZSC:HolderMember 2021-12-31 0001679817 OZSC:HoldersMember OZSC:PromissoryNoteOneMember 2021-12-31 0001679817 OZSC:ThirdPartyMember OZSC:PromissoryNoteMember 2020-12-31 0001679817 OZSC:ThirdPartyMember OZSC:PromissoryNoteOneMember 2021-12-31 0001679817 OZSC:ThirdPartyMember OZSC:PromissoryNoteOneMember 2020-12-31 0001679817 OZSC:HolderMember OZSC:PromissoryNoteOneMember 2021-12-31 0001679817 OZSC:HolderMember OZSC:PromissoryNoteMember 2020-11-06 0001679817 OZSC:HolderMember OZSC:PromissoryNoteMember 2020-11-05 2020-11-06 0001679817 OZSC:HolderMember OZSC:PromissoryNoteMember 2020-07-23 0001679817 OZSC:HolderMember OZSC:PromissoryNoteMember 2020-07-20 2020-07-23 0001679817 2016-10-26 0001679817 OZSC:PCTIMember 2021-12-31 0001679817 OZSC:PCTIMember 2020-12-31 0001679817 2021-03-15 0001679817 2021-03-14 2021-03-15 0001679817 OZSC:PromissoryNoteMember us-gaap:PrimeRateMember 2021-03-15 0001679817 srt:MaximumMember OZSC:PromissoryNoteMember 2021-03-15 0001679817 OZSC:PersonalGuaranteeOfChisMember OZSC:PCTIMember 2021-12-31 0001679817 OZSC:PersonalGuaranteeOfChisMember OZSC:PCTIMember 2020-12-31 0001679817 OZSC:HolderMember OZSC:PromissoryNoteMember 2020-08-24 0001679817 OZSC:HolderMember OZSC:PromissoryNoteMember 2020-08-23 2020-08-24 0001679817 OZSC:HolderMember OZSC:PromissoryNoteMember 2020-08-22 2020-08-25 0001679817 OZSC:HolderMember OZSC:PromissoryNoteMember OZSC:NineInstalmentsMember 2021-01-01 2021-12-31 0001679817 OZSC:HolderMember OZSC:PromissoryNoteMember 2021-12-31 0001679817 OZSC:PromissoryNoteMember 2021-01-01 2021-12-31 0001679817 OZSC:PromissoryNoteMember 2021-12-31 0001679817 OZSC:PromissoryNoteMember 2021-05-03 0001679817 OZSC:PromissoryNoteMember 2020-12-31 0001679817 OZSC:PaycheckProtectionProgramMember 2020-04-20 0001679817 OZSC:PaycheckProtectionProgramMember 2020-04-19 2020-04-20 0001679817 OZSC:PaycheckProtectionProgramMember 2021-12-31 0001679817 OZSC:PaycheckProtectionProgramMember 2020-12-31 0001679817 OZSC:EconomicInjuryDisasterLoanMember 2020-07-11 2020-07-14 0001679817 OZSC:HolderMember OZSC:PromissoryNoteMember 2020-06-25 0001679817 OZSC:HolderMember OZSC:PromissoryNoteMember 2020-06-24 2020-06-25 0001679817 OZSC:HolderMember OZSC:PromissoryNoteMember 2020-06-24 2020-06-26 0001679817 OZSC:HolderMember OZSC:PromissoryNoteMember 2021-01-01 2021-12-31 0001679817 OZSC:HolderMember OZSC:PromissoryNoteMember 2021-01-07 2021-01-08 0001679817 OZSC:HolderMember OZSC:PromissoryNoteMember 2021-01-13 2021-01-15 0001679817 OZSC:HolderMember OZSC:PromissoryNoteMember 2020-12-31 0001679817 OZSC:ExchangeAgreementMember OZSC:PCTIMember 2020-09-02 0001679817 OZSC:ExchangeAgreementMember OZSC:PCTIMember 2020-08-30 2020-09-02 0001679817 OZSC:ExchangeAgreementMember OZSC:PCTIMember 2021-02-25 2021-02-26 0001679817 OZSC:ExchangeAgreementMember OZSC:PCTIMember 2021-12-31 0001679817 OZSC:ExchangeAgreementMember OZSC:PCTIMember 2021-01-01 2021-12-31 0001679817 OZSC:MrConwayMember OZSC:EmploymentAgreementMember 2020-02-25 2020-02-28 0001679817 srt:ChiefExecutiveOfficerMember us-gaap:SeriesCPreferredStockMember 2020-02-25 2020-02-28 0001679817 2020-02-25 2020-02-28 0001679817 OZSC:MrConwayMember us-gaap:SeriesDPreferredStockMember 2020-08-27 2020-08-28 0001679817 OZSC:MrConwayMember us-gaap:SeriesEPreferredStockMember 2020-08-27 2020-08-28 0001679817 OZSC:MrConwayMember us-gaap:SeriesEPreferredStockMember 2020-08-28 0001679817 OZSC:PerMonthMember OZSC:MrConwayMember 2021-01-01 2021-12-31 0001679817 us-gaap:SeriesEPreferredStockMember 2021-03-20 2021-03-21 0001679817 OZSC:MrConwayMember 2021-03-20 2021-03-21 0001679817 OZSC:MrConwayMember us-gaap:SeriesEPreferredStockMember 2021-03-21 0001679817 OZSC:MrConwayMember us-gaap:SeriesEPreferredStockMember 2021-03-20 2021-03-21 0001679817 us-gaap:SeriesEPreferredStockMember 2021-04-16 0001679817 OZSC:MrConwayMember 2021-04-15 2021-04-16 0001679817 OZSC:MrConwayMember 2021-01-01 2021-12-31 0001679817 us-gaap:SeriesCPreferredStockMember OZSC:DefinitiveAgreementMember 2021-07-12 2021-07-13 0001679817 us-gaap:SeriesDPreferredStockMember OZSC:DefinitiveAgreementMember 2021-07-12 2021-07-13 0001679817 srt:ChiefExecutiveOfficerMember 2021-01-01 2021-12-31 0001679817 srt:ChiefExecutiveOfficerMember 2020-01-01 2020-12-31 0001679817 OZSC:ChiefExecutiveOfficerSeriesEPreferredStockMember 2021-01-01 2021-12-31 0001679817 OZSC:ChiefExecutiveOfficerSeriesEPreferredStockMember 2020-01-01 2020-12-31 0001679817 OZSC:ChiefExecutiveOfficerSeriesDPreferredStockMember 2021-01-01 2021-12-31 0001679817 OZSC:ChiefExecutiveOfficerSeriesDPreferredStockMember 2020-01-01 2020-12-31 0001679817 OZSC:PresidentSubsidiaryMember 2021-01-01 2021-12-31 0001679817 OZSC:PresidentSubsidiaryMember 2020-01-01 2020-12-31 0001679817 OZSC:GarageStorageFacilityMember 2021-01-02 0001679817 OZSC:GarageStorageFacilityMember 2021-01-01 2021-01-02 0001679817 OZSC:RMAAgreementMember 2021-08-28 2021-09-02 0001679817 OZSC:RMAAgreementMember 2021-09-03 2021-09-30 0001679817 OZSC:PJNStrategiesMember 2021-04-12 2021-04-13 0001679817 OZSC:PJNStrategiesMember 2021-08-30 2021-09-01 0001679817 OZSC:PJNStrategiesMember 2021-01-01 2021-12-31 0001679817 OZSC:RubensteinPublicRelationsMember 2021-04-15 2021-04-16 0001679817 OZSC:RubensteinPublicRelationsMember 2021-01-01 2021-12-31 0001679817 OZSC:CoDirectorsOfSalesMember 2021-03-29 2021-03-30 0001679817 OZSC:CoDirectorsOfSalesMember us-gaap:RestrictedStockMember 2021-03-29 2021-03-30 0001679817 OZSC:CoDirectorsOfSalesMember us-gaap:RestrictedStockMember 2021-03-30 0001679817 OZSC:CoDirectorsOfSalesMember us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0001679817 OZSC:CoDirectorsOfSalesMember 2021-07-01 2021-07-31 0001679817 OZSC:CoDirectorsOfSalesMember 2021-07-31 0001679817 OZSC:CoDirectorsOfSalesMember 2021-01-01 2021-12-31 0001679817 OZSC:CoDirectorsOfSalesMember 2021-09-28 2021-10-01 0001679817 OZSC:CoDirectorsOfSalesMember 2021-10-01 0001679817 OZSC:MrStevenMartelloMember OZSC:ConsultingAgreementMember OZSC:AuroraEnterprisesMember 2021-03-14 2021-03-15 0001679817 OZSC:MrStevenMartelloMember OZSC:ConsultingAgreementMember OZSC:AuroraEnterprisesMember 2021-03-15 0001679817 OZSC:MrStevenMartelloMember OZSC:ConsultingAgreementMember OZSC:AuroraEnterprisesMember 2021-01-01 2021-12-31 0001679817 OZSC:ChristopherRuppelMember us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0001679817 OZSC:ChristopherRuppelMember us-gaap:RestrictedStockMember 2021-12-31 0001679817 OZSC:ChristopherRuppelMember OZSC:AprilOneTwoThousandAndTwentyOneMember us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0001679817 us-gaap:RestrictedStockMember 2021-01-21 2021-01-22 0001679817 us-gaap:RestrictedStockMember 2021-01-22 0001679817 us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0001679817 OZSC:MrAllenSosisMember OZSC:RestrictedCommonStockMember OZSC:ConsultingAgreementMember 2021-01-14 0001679817 OZSC:MrAllenSosisMember OZSC:RestrictedCommonStockMember OZSC:ConsultingAgreementMember 2021-01-13 2021-01-14 0001679817 OZSC:MrAllenSosisMember OZSC:RestrictedCommonStockMember OZSC:ConsultingAgreementMember 2021-01-01 2021-12-31 0001679817 OZSC:EzraGreenMember OZSC:RestrictedCommonStockMember OZSC:ConsultingAgreementMember 2021-01-05 2021-01-06 0001679817 OZSC:EzraGreenMember OZSC:RestrictedCommonStockMember 2021-01-05 2021-01-06 0001679817 OZSC:EzraGreenMember OZSC:RestrictedCommonStockMember 2021-01-06 0001679817 OZSC:EzraGreenMember OZSC:RestrictedCommonStockMember 2021-01-01 2021-12-31 0001679817 OZSC:SalmanJChaudhryMember OZSC:SeparationAgreementMember 2019-03-04 0001679817 OZSC:SalmanJChaudhryMember OZSC:SeparationAgreementMember 2021-12-31 0001679817 OZSC:SalmanJChaudhryMember OZSC:SeparationAgreementMember 2020-12-31 0001679817 OZSC:ExchangeAgreementMember OZSC:PCTIMember 2020-09-01 2020-09-02 0001679817 2021-12-13 0001679817 us-gaap:RestrictedStockMember OZSC:LeaseAgreementMember 2021-01-01 2021-12-31 0001679817 OZSC:RestructuringAgreementMember 2021-01-01 2021-12-31 0001679817 us-gaap:RestrictedStockMember OZSC:ConsultingAgreementMember 2021-01-01 2021-12-31 0001679817 us-gaap:SeriesCPreferredStockMember OZSC:CertificatesOfDesignationMember 2020-07-07 0001679817 us-gaap:SeriesCPreferredStockMember OZSC:CertificatesOfDesignationMember 2020-07-06 2020-07-07 0001679817 us-gaap:SeriesCPreferredStockMember OZSC:SecuritiesPurchaseAgreementMember OZSC:PCTIMember 2020-07-06 2020-07-10 0001679817 us-gaap:SeriesCPreferredStockMember OZSC:ChisMember 2021-07-01 2021-07-13 0001679817 OZSC:MrConwayMember 2021-12-31 0001679817 us-gaap:SeriesDPreferredStockMember OZSC:CertificatesOfDesignationMember 2020-07-07 0001679817 us-gaap:SeriesDPreferredStockMember OZSC:SecuritiesPurchaseAgreementMember OZSC:PCTIMember 2020-07-06 2020-07-10 0001679817 OZSC:MrConvayMember us-gaap:SeriesDPreferredStockMember OZSC:EmploymentAgreementMember 2020-08-27 2020-08-28 0001679817 OZSC:MrConvayMember us-gaap:SeriesDPreferredStockMember 2020-08-28 0001679817 OZSC:MrConvayMember us-gaap:PreferredStockMember 2020-08-27 2020-08-28 0001679817 OZSC:MrConvayMember us-gaap:PreferredStockMember 2020-08-28 0001679817 us-gaap:SeriesDPreferredStockMember OZSC:ChisMember 2021-07-01 2021-07-13 0001679817 us-gaap:SeriesDPreferredStockMember OZSC:SeriesDAmendmentMember 2021-07-27 0001679817 us-gaap:InvestorMember us-gaap:SeriesDPreferredStockMember OZSC:SeriesDSPAMember 2021-07-01 2021-07-28 0001679817 us-gaap:InvestorMember us-gaap:SeriesDPreferredStockMember OZSC:SeriesDSPAMember 2021-07-28 0001679817 us-gaap:WarrantMember 2021-12-31 0001679817 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001679817 OZSC:RemainingWarrantSharesMember 2021-01-01 2021-12-31 0001679817 us-gaap:SeriesEPreferredStockMember OZSC:CertificatesOfDesignationMember 2020-07-07 0001679817 us-gaap:SeriesEPreferredStockMember OZSC:SecuritiesPurchaseAgreementMember OZSC:PCTIMember 2020-07-06 2020-07-10 0001679817 OZSC:MrConwayMember us-gaap:SeriesEPreferredStockMember OZSC:EmploymentAgreementMember 2020-07-06 2020-07-10 0001679817 OZSC:MrConvayMember us-gaap:SeriesEPreferredStockMember 2021-03-01 2021-03-02 0001679817 OZSC:ThirdPartyMember us-gaap:SeriesEPreferredStockMember 2021-03-01 2021-03-02 0001679817 OZSC:MrConvayMember us-gaap:SeriesEPreferredStockMember 2021-03-02 0001679817 OZSC:MrConvayMember us-gaap:SeriesEPreferredStockMember 2021-01-01 2021-12-31 0001679817 us-gaap:SeriesEPreferredStockMember 2021-03-22 2021-03-24 0001679817 us-gaap:SeriesEPreferredStockMember 2021-04-15 2021-04-16 0001679817 OZSC:MrConvayMember us-gaap:SeriesEPreferredStockMember 2021-04-15 2021-04-16 0001679817 OZSC:MrConvayMember us-gaap:SeriesEPreferredStockMember 2021-04-16 0001679817 OZSC:PJNStrategiesMember 2021-08-19 0001679817 OZSC:BrianConwayMember 2021-08-19 0001679817 us-gaap:AccountingStandardsUpdate201602Member 2020-12-31 0001679817 2021-04-14 0001679817 country:CA 2021-04-11 2021-04-14 0001679817 OZSC:ThereafterMember 2021-04-14 0001679817 country:CA 2021-04-14 0001679817 us-gaap:AccountingStandardsUpdate201602Member 2021-06-04 0001679817 us-gaap:AccountingStandardsUpdate201602Member 2021-06-01 0001679817 OZSC:MrConwayMember us-gaap:SubsequentEventMember OZSC:NewEmploymentAgreementMember 2021-12-29 2022-01-02 0001679817 OZSC:MrConwayMember us-gaap:SubsequentEventMember OZSC:NewEmploymentAgreementMember OZSC:OzopCapitalMember 2021-12-29 2022-01-02 0001679817 OZSC:MrConwayMember us-gaap:SubsequentEventMember OZSC:NewEmploymentAgreementMember OZSC:OESMember 2021-12-29 2022-01-02 0001679817 us-gaap:CommonStockMember us-gaap:SubsequentEventMember OZSC:RegistrationStatementMember OZSC:GHSInvestmentsMember 2022-04-01 2022-04-04 iso4217:USD shares iso4217:USD shares utr:sqft pure 0001679817 false FY

P5Y

P5Y P5Y P5Y P5Y P5Y P5Y

P5Y

10-K true 2021-12-31 --12-31 2021 false 000-55976 OZOP ENERGY SOLUTIONS, INC. NV 35-2540672 42 N Main Street Florida NY 10921 (845) 544-5112 No No Yes Yes Non-accelerated Filer true false false false 340168153 4622362997 237 Prager Metis CPA’s LLC Hackensack, New Jersey

6767167

1808476

151998

9569

1299334

400

1065982

359347

874627

10159108

2177792

707686

149529

132889

60671

568249

11567932

2387992

3246342

1678007

9120

25000 1078985

13011307

1130083

169849 188518 750000 750000

20966701

3299684

194366

75340

21451

17876

38385016

8227613

389423

517890

74189

25026

46477

39317355

8737702

10000000

0.001

50000

2500

50000

0.001

4570

20000

1334

20000

0.001

3000

1000

0.001

4990000000

0.001

4617362997

3397958292

4617363

3397958

637755 638

196464222

12530933

11249934

-217326611

-22278665

-7

-27494318

-6349710

-255105

-27749423

-6349710

11567932

2387992

11928605

1411432

10342413

1404358

1586192

7074

3803765 4747952

10584176

1311172

11526303

14387941

17585427

-12801749

-17578353

53252232

3409393

17349076

176050

-95449994

195553

16450000

-182501302

-3389890

-195303051

-20968243

-195303051

-20968243

-255105

-195047946

-20968243

-7

-195303051

-20968250

-255105

-195047946

-20968250

-0.04

-0.02

4442045075

1110673228

50000

20000

1000

3397958292

3397958

-7

12530933

-22278665

-6349710

483154618

483155

102055875

102539030

405797987 405798 47704503 48110301 4000 4 3999996 4000000 -5000 -5 -4999995 -5000000

637755

638

55452080

55452

5267910

5324000

100000000 100000 530000 630000

175000000

175000

16275000

16450000

-47500

-18667

11249934

11250000

13100000

7 7

-195047946

-255105

-195303051

637755

638

2500

1334

4617362977

4617363

-11249934

196464222

-217326611

-255105

-27749423

47500

18667

500

76922

-1310422

-1233434

47500

18667

500

76922

-1310422

-1233434

1851930729

1851931

-1033489

818442

1411815206

1411815

9140571

10552386

134212357 134212 -134212 194495 194495

2500

1333

500

4286646

4286651

-7 -7

-20968243

50000

20000

1000

3397958292

3397958

-7

12530933

-22278665

-6349710

50000

20000

1000

3397958292

3397958

-7

12530933

-22278665

-6349710

-195303051

-20968243

51492115

2915952

189348

68299

16450000 17349075 176050

-95449994

195553

9322751

4286647

11526303

1298934

-19374

706635

-612466

79430

-6512

874627

1818095

207937

-17876

64353

-140161

-35609

-18670

-496304

-6368006

-1811816

470849

116836

46418

-116836

424431

489000

15000000

1553000

13100000 100400 10000 750000 42420 13634 74470

392833

101863

5000000 11250000

400000

11443533

3168487

-7

4958691

1781094

1808476

27382

6767167

1808476

126707

133300

1610000 548333 743555 2383801 702888 185139 9322751 4286647 630000 16450000

<p id="xdx_80D_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zOufpZTzt3K1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NOTE 1 - ORGANIZATION Business Ozop Energy Solutions, Inc. (the” Company,” “we,” “us” or “our”) was originally incorporated as Newmarkt Corp. on July 17, 2015, under the laws of the State of Nevada. On October 29, 2020, the Company formed a new wholly owned subsidiary, Ozop Surgical Name Change Subsidiary, Inc., a Nevada corporation (“Merger Sub”). The Merger Sub was formed under the Nevada Revised Statutes for the sole purpose and effect of changing the Company’s name to “Ozop Energy Solutions, Inc.” That same day the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with the Merger Sub and filed Articles of Merger (the “Articles of Merger”) with the Nevada Secretary of State, merging the Merger Sub into the Company, which were stamped effective as of November 3, 2020. As permitted by the Section 92.A.180 of the Nevada Revised Statutes, the sole purpose and effect of the filing of Articles of Merger was to change the name of the Company from Ozop Surgical Corp to “Ozop Energy Solutions, Inc.” On December 11, 2020, the Company formed Ozop Energy Systems, Inc. (“OES”), a Nevada corporation and a wholly owned subsidiary of the Company. OES was formed to be a manufacturer and distributor of renewable energy products. On August 19, 2021, the Company formed Ozop Capital Partners, Inc. (“Ozop Capital”), a Delaware corporation. The Company is the majority shareholder of Ozop Capital with PJN Holdings LLC (“PJN”), a New York limited liability company, being the minority shareholder. Brian Conway was appointed as the sole officer and director of Ozop Capital and has voting control of Ozop Capital. On October 29, 2021, EV Insurance Company, Inc. (“EVCO”) was formed as a captive insurance company in the State of Delaware. EVCO is a wholly owned subsidiary of Ozop Capital. On January 7, 2022, EVCO filed with New Castle County, Delaware DBA OZOP Plus. Stock Purchase Agreement On July 10, 2020, the Company entered into a Stock Purchase Agreement (the “SPA”) with Power Conversion Technologies, Inc., a Pennsylvania corporation (“PCTI”), and Catherine Chis (“Chis”), PCTI’s Chief Executive Officer (“CEO”) and its sole shareholder. Under the terms of the SPA, the Company acquired one thousand (<span id="xdx_90B_ecustom--BusinessAcquisitionNumberOfSharesAcquired_pid_c20200701__20200710__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--PennsylvaniaCorporationMember_zWDCF1z3zss3" title="Number of shares acquired">1,000) shares of PCTI, which represents all of the outstanding shares of PCTI, from Chis in exchange for the issuance of <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pid_c20200701__20200710__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--BusinessAcquisitionAxis__custom--PennsylvaniaCorporationMember_zTDzwUd5V2t9" title="Stock issued during period, shares, acquisitions">47,500 shares of the Company’s Series C Preferred Stock, <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pid_c20200701__20200710__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__us-gaap--BusinessAcquisitionAxis__custom--PennsylvaniaCorporationMember_zNmEKaM4NWph" title="Stock issued during period, shares, acquisitions">18,667 shares of the Company’s Series D Preferred Stock, and <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pid_c20200701__20200710__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember__us-gaap--BusinessAcquisitionAxis__custom--PennsylvaniaCorporationMember_zf0l8ky04x01" title="Stock issued during period, shares, acquisitions">500 shares of the Company’s Series E Preferred Stock to Chis. The Acquisition was accounted for as a business combination and was treated as a reverse acquisition for accounting purposes with PCTI as the accounting acquirer in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 805, Business Combinations (“ASC 805”). In accordance with the accounting treatment for a reverse acquisition, the Company’s historical financial statements prior to the reverse merger were and will be replaced with the historical financial statements of PCTI prior to the reverse merger, in all future filings with the U.S. Securities and Exchange Commission (the “SEC”). The consolidated financial statements after completion of the reverse merger have and will include the assets, liabilities and results of operations of the combined company from and after the closing date of the reverse merger. PCTI designs, develops, manufactures and distributes standard and custom power electronic solutions. PCTI serves clients in several industries including energy storage, shore power, DEWs, microgrid, telecommunications, military, transportation, renewable energy, aerospace and mission critical defense systems. Customers include the United States military and other global military organizations. All of its products are manufactured in the United States. Because of the Company’s product scope and the high-power niche that their products occupy, the Company is targeting the rapidly growing renewable and energy storage markets. The Company’s mission is to be a global leader for high power electronics with a standard of continued innovation. The Company utilized the Option Pricing Method (the “OPM”) to value the transaction. The OPM method treats all equity linked instruments as call options on the enterprise value, with exercise prices and liquidation preferences based on the terms of the various common, preferred, options, warrants, and convertible debt. Under this method, the common stock only has value if the funds available for distribution to the shareholders exceed the liquidation preferences of the preferred stock and face value of the convertible debt. The timing of a liquidity event is required to utilize this method. The OPM considers the various terms of the stockholder agreements—including the level of seniority among the securities, dividend policy, conversion ratios, and cash allocations—upon liquidation of the enterprise. In addition, the method implicitly considers the effect of the liquidation preference as of the future liquidation date, not as of the valuation date. A feature of the OPM is that it explicitly recognizes the option-like payoffs of the various share classes utilizing information in the underlying asset (that is, estimated volatility) and the risk-free rate to adjust for risk by adjusting the probabilities of future payoffs. The following table summarizes the preliminary value of the consideration issued and the preliminary purchase price allocation of the fair value of assets acquired and liabilities assumed in the transaction. SCHEDULE OF RECOGNIZED IDENTIFIED ASSETS ACQUIRED AND LIABILITIES ASSUMED <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20211231_zjVN7wjnEw5d" style="border-bottom: Black 1.5pt solid; text-align: center">Purchase Price Allocation</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_406_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFairValueOfConsiderationIssued_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left; padding-bottom: 2.5pt">Fair value of OZOP equity consideration issued</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">818,444</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_407_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipmentAssetsAcquired_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Assets acquired</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,229,917</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--Goodwill_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Goodwill</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,201,145</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iNI_pp0p0_di_zfW6qAGTgMxb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Liabilities assumed</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(11,612,618</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total purchase price allocation</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">818,444</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The Company reviews the goodwill allocated to each of our reporting units for possible impairment annually and whenever events or changes in circumstances indicate the carrying amount may not be recoverable. Pursuant to that review, management has determined that the goodwill arising from the above transaction has been impaired and accordingly $11,201,145 was recorded as an impairment expense for the year ended December 31, 2020.

1000

47500

18667

500

SCHEDULE OF RECOGNIZED IDENTIFIED ASSETS ACQUIRED AND LIABILITIES ASSUMED <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20211231_zjVN7wjnEw5d" style="border-bottom: Black 1.5pt solid; text-align: center">Purchase Price Allocation</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_406_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFairValueOfConsiderationIssued_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left; padding-bottom: 2.5pt">Fair value of OZOP equity consideration issued</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">818,444</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_407_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipmentAssetsAcquired_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Assets acquired</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,229,917</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--Goodwill_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Goodwill</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,201,145</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iNI_pp0p0_di_zfW6qAGTgMxb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Liabilities assumed</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(11,612,618</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total purchase price allocation</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">818,444</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

818444 1229917

11201145

11612618

818444

11201145

NOTE 2 – RESTATEMENT During the preparation of the financial statements as of March 31, 2021, and for the three months ended March 31, 2021, the Company discovered an error was made in the financial statements as of and for the period ended December 31, 2020. The error relates to the recognition of certain warrants as derivative liabilities due to the fact the Company has insufficient authorized shares to cover the exercises. Management believes that the error as of and for December 31, 2020, does not materially impact the balance sheet as December 31, 2020. New warrants issued in the year ended December 31, 2021, have been properly accounted for as derivatives, when necessary. The following table reflects the effect of the error on the balance sheet as of December 31, 2020: <p id="xdx_89A_eus-gaap--ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_zYloqDXq4hk4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> SCHEDULE OF ERROR CORRECTIONS AND PRIOR PERIOD ADJUSTMENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20201231__srt--RestatementAxis__srt--RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_zmYNUEq97TBk" style="border-bottom: Black 1.5pt solid; text-align: center">Adjusted December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20201231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z66mkoAZX73g" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_400_eus-gaap--Assets_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 20%; text-align: right">2,387,992</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 20%; text-align: right">2,387,992</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LiabilitiesCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Current liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">8,227,613</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">6,885,845</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--Liabilities_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">8,737,702</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">7,395,934</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--StockholdersEquity_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total stockholders’ deficit</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(6,349,710</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(5,007,942</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> The change in the current and total liabilities is as a result of the fair value of $2,061,307 of warrants based on the Black-Scholes option pricing valuation method, and an increase in notes payable of $719,539 as a result of reclassifying amounts previously recorded as discounts on notes payable, related to the warrants.

<p id="xdx_89A_eus-gaap--ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_zYloqDXq4hk4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> SCHEDULE OF ERROR CORRECTIONS AND PRIOR PERIOD ADJUSTMENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20201231__srt--RestatementAxis__srt--RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_zmYNUEq97TBk" style="border-bottom: Black 1.5pt solid; text-align: center">Adjusted December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20201231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z66mkoAZX73g" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_400_eus-gaap--Assets_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 20%; text-align: right">2,387,992</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 20%; text-align: right">2,387,992</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LiabilitiesCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Current liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">8,227,613</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">6,885,845</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--Liabilities_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">8,737,702</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">7,395,934</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--StockholdersEquity_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total stockholders’ deficit</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(6,349,710</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(5,007,942</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>

2387992

8227613

6885845

8737702

7395934

-6349710

-5007942

2061307

719539

NOTE 3 – GOING CONCERN AND MANAGEMENT’S PLANS The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As of December 31, 2021, the Company had an accumulated deficit of $217,326,611 and a working capital deficit of $28,225,908 (including derivative liabilities of $20,966,701). As of December 31, 2021, the Company was in default of $1,973,847 plus accrued interest on debt instruments due to non-payment upon maturity dates, and subsequent to December 31, 2021, an additional $13,310,000 plus accrued interest on debt instruments also were in default status due to non-payment upon maturity dates. These factors, among others, raise substantial doubt about the ability of the Company to continue as a going concern for one year from the date of the issuance of these financial statements. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern. In December 2019, a novel strain of coronavirus (COVID-19) emerged. Because COVID-19 infections have been reported throughout the United States, certain federal, state and local governmental authorities have issued stay-at-home orders, proclamations and/or directives aimed at minimizing the spread of COVID-19. The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak, new information which may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time but it may have a material adverse impact on our business, financial condition and results of operations. Management expects that its business will be impacted to some degree, but the significance of the impact of the COVID-19 outbreak on the Company’s business and the duration for which it may have an impact cannot be determined at this time. Management’s Plans As a public company, Management believes it will be able to access the public equities market for fund raising for product development, sales and marketing and inventory requirements as we expand our distribution in the U.S. market. On October 14, 2021, the Company received a Notice of effectiveness related to the Company’s Form S-3 Registration Statement (the “Registration Statement”). Pursuant to the Registration Statement the Company may offer and sell from time to time in one or more offerings of up to thirty million dollars ($30,000,000) in aggregate offering price. We may offer these securities in amounts, at prices and on terms determined at the time of offering. As of the date of this Report the Company has not sold any securities pursuant to this Registration Statement. On April 4, 2022, the Company and GHS Investments LLC (“GHS”). signed a Securities Purchase Agreement (the “GHS Purchase Agreement”) for the sale of up to Two Hundred Million (<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220401__20220404__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAiTdUOaXjOd" title="Stock issued during the period">200,000,000) shares of the Company’s common stock to GHS. We may sell shares of our common stock from time to time over a six (6)- month period ending <span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_dd_c20220401__20220404__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGO0xBIC5lwb" title="Common stock maturity period">October 4, 2022, at our sole discretion, to GHS under the GHS Purchase Agreement. <span id="xdx_904_eus-gaap--DebtInstrumentDescription_c20220401__20220404__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKxPASShwil5" title="Agreement description">The purchase price shall be 85% of lowest VWAP for the ten (10) days preceding the Company’s notice to GHS for the sale of the Company’s common stock. On April 8, 2022, the Company filed a Prospectus Supplement to the Registration Statement dated October 14, 2021, regarding the GHS Purchase Agreement. The Company is in negotiations with its’ lenders related to the debt instruments that are currently in default, to extend the maturity dates. During the year ended December 31, 2021, the Company raised $28,100,000 (of which $11,250,000 was used to redeem Series C and Series D shares of preferred stock from Chis) and has begun to implement the following business operations, plans and strategies: OES is actively engaged in the renewable, electric vehicle (“EV”), energy storage and energy resiliency sectors. We are engaged in multiple business lines that include project development as well as equipment distribution. Our solar and energy storage projects involve large-scale battery and solar photovoltaics (PV) installations. Our utility-scale storage business model is based on an arbitrage business model in which we install multiple 1+ megawatt batteries, charge them with off-peak grid electricity under contract with the utility, then sell the power back during peak load hours at a premium, as dictated by prevailing electricity tariffs. Equipment Distributor: OES has entered the component supply/distribution side of the renewable, resiliency and energy storage industries distributing the core components associated with residential and commercial solar PV systems as well as onsite battery storage and power generation. In April 2021, the Company signed a five- year lease (beginning June 1, 2021) of approximately 8,100 SF in California, for office and warehouse space to support the sales and distribution of our west coast operations. The components we are distributing include PV panels, solar inverters, solar mounting systems, stationary batteries, onsite generators and other associated electrical equipment and components that are all manufactured by multiple companies, both domestic and international. These core products are sourced from management-developed relationships and are distributed through our existing network and our in-house sales team. Sales were approximately $10.6 million for the year ended December 31, 2021. Solar PV: Our PV business model involves the design and construction of electrical generating PV systems that can sell power to the utilities or be used for off grid use as part of our developing Neo-Grids solution. The Neo-Grids proprietary program, patent pending, was developed for the off-grid distribution of electricity to remove or reduce the dependency on utilities that currently burdens the EV Charging sectors. It will also reduce or eliminate the lengthy permitting processes and streamline the installations of those EV chargers. Modular Energy Distribution System: The Neo-Grids, patent pending, is comprised of the design engineering, installation, and operational methodologies as well as the financial arbitrage of how we produce, capture and distribute electrical energy for the EV markets. : OES has acquired the license rights to a proprietary system, the Neo-GridsTM System (patent pending), for the capture and distribution of electrical energy for the EV market. The Neo-GridsTM System will serve both the private auto and the commercial sectors. The exponential growth of the EV industry has been accelerated by the recent major commitments of most of the major car manufacturers. Our Neo-GridsTM System leverages this accelerated growth by offering (1) charging locations that can be installed with reduced delays, restricted areas or load limits and (2) EV charger electricity that is produced from renewable sources claiming little to no carbon footprint. OES has developed a business plan for the Neo Grids distribution, a solution to the stress forthcoming to the existing grid infrastructure. The Company has completed its’ Neo Grid research and development as well as the first set of engineered technical drawings. This first stage of engineered technical drawings allows us to move forward with stage two, as well as to begin to construct the first prototype or proof of concept, (“PoC”). Our PoC design is partially reliant on auto manufacturers establishing standardizations of the actual charging/discharging protocols of the batteries such as on-board inverters as well as bi-directional capabilities in electric vehicles, which have only recently been established. As the market growth rate of EV’s continues to rise, the stress on the existing grid-tied infrastructure shows the need for the continued development of our Neo-Grid solution. OES management has decades of experience in the renewable, storage and resilient energy businesses and associated markets, which include but are not limited to project finance, project development, equipment finance, construction, utility protocol, regulatory policy and technology assessment. Ozop Plus plans on producing vehicle service contracts (“VSC’s”) for electric vehicles (EV’s). to respond to not only in filling the gap of a manufacturer’s warranty but to bring added value to EV owners by utilizing our partnerships and strengths in the renewable energy market to offer unique and innovative services. Among EV owners’ concerns are the EV battery repair and replacement costs, range anxiety, environmental responsibilities, roadside assistance, and the accelerated wear on additional components that EV vehicles experience. Management believes that the Ozop Plus VSC will give “peace of mind” to the EV buyer. The Company is currently in negotiations to complete the necessary agreements to launch the product in Q2 2022. Additionally, the Company is also in discussions with entities whereby Ozop Plus can re-insure the battery portion of another entity’s VSC. On February 25, 2022, the Company formed Ozop Engineering and Design, Inc. (“OED”) a Nevada corporation, as a wholly owned subsidiary of the Company. OED was formed to become a premier engineering and lighting control design firm. OED offers product and design support for lighting and solar projects with a focus on fast lead times and technical support. OED and our partners are able to offer the resources needed for lighting, solar and electrical design projects. OED will provide its’ customers systems to coordinate the understanding of electrical usage with the relationship between lighting design and lighting controls, by developing more efficient ecofriendly designs by working with architects, engineers, facility managers, electrical contractors and engineers.

-217326611

28225908

20966701

1973847

13310000

30000000

200000000

2022-10-04

The purchase price shall be 85% of lowest VWAP for the ten (10) days preceding the Company’s notice to GHS for the sale of the Company’s common stock. On April 8, 2022, the Company filed a Prospectus Supplement to the Registration Statement dated October 14, 2021, regarding the GHS Purchase Agreement.

28100000

11250000

10600000

NOTE 4 – SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS Basis of Presentation The accompanying consolidated financial statements are prepared in accordance with Generally Accepted Accounting Principles in the United States of America (“US GAAP”). The consolidated financial statements include the accounts of the Company and Ozop Energy Systems, Inc. and the Company’s other wholly owned subsidiaries PCTI, Ozop LLC, Ozop HK and Spinus, LLC (“Spinus”) and the Company’s majority owned subsidiary Ozop Capital Partners, Inc. All intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reported period. Actual results could differ from those estimates. Cash and Cash Equivalents The Company considers all highly liquid investments with an original term of three months or less to be cash equivalents. These investments are carried at cost, which approximates fair value. Cash and cash equivalent balances may, at certain times, exceed federally insured limits. The Company has no cash equivalents at December 31, 2021, and 2020. Sales Concentration and credit risk Following is a summary of customers who accounted for more than ten percent (10%) of the Company’s revenues for the years ended December 31, 2021, and 2020, and their accounts receivable balance as of December 31, 2021: SCHEDULES OF CONCENTRATION OF RISK, BY RISK FACTOR <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Sales % Year Ended December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Sales % Year Ended December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Accounts receivable balance December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify">Customer A</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z3hnHT4Mu1D6" title="Concentration Risk, Percentage">17</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">N/A</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">782,179</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Customer B</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">N/A</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200101__20201231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zy4sVKJkk8jc" title="Concentration Risk, Percentage">62</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Customer C</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">N/A</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200101__20201231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zPDpk4FE7X15" title="Concentration Risk, Percentage">15</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> </table> For the year ended December 31, 2020, the above customers were of PCTI. PCTI, historically does not have year to year many recurring clients as the Company produces capital equipment for its’ customers. Accounts Receivable The Company records accounts receivable at the time products and services are delivered. An allowance for losses is established through a provision for losses charged to expenses. Receivables are charged against the allowance for losses when management believes collectability is unlikely. The allowance (if any) is an amount that management believes will be adequate to absorb estimated losses on existing receivables, based on evaluation of the collectability of the accounts and prior loss experience. Inventory Inventories are valued at the lower of cost or net realizable value, with cost determined on the first-in, first-out basis. Inventory costs include finished goods, material, labor and manufacturing overhead. In evaluating the net realizable value of inventory, management also considers, if applicable, other factors, including known trends, market conditions, currency exchange rates and other such issues. The components of inventories at December 31, 2021, and 2020 are as follows: SCHEDULE OF INVENTORY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20211231_zDlkFmAwNSS7" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20201231_zZhu9Q5ffbN6" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_403_eus-gaap--InventoryRawMaterials_iI_maCzAkd_maINzA2c_zAjhCmu80Euf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Raw materials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">234,168</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">207,178</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--InventoryWorkInProcess_iI_maCzAkd_maINzA2c_zFrpgVz9dcla" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Work in process</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43,704</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">142,526</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--InventoryFinishedGoods_iI_maCzAkd_maINzA2c_z43FsMWXV634" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">788,110</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,643</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--InventoryNet_iTI_pp0p0_mtINzA2c_zMfchbVZPazi" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Inventory net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,065,982</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">359,347</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Purchase concentration OES purchases finished renewable energy products from its’ suppliers. For the year ended December 31, 2021, there were two suppliers that accounted for <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__srt--MajorCustomersAxis__custom--SuppliersOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_z2j8z7sfboci" title="Concentration of credit risk">42.6% and <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__srt--MajorCustomersAxis__custom--SuppliersTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zoLSOKqy3ryj" title="Concentration of credit risk">20.4%, respectively. There are only a handful of major suppliers, and we currently have supply arrangements with some of those vendors. One of these vendors requires a <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__srt--MajorCustomersAxis__custom--TwoVendorMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zUeFgBZyjz44" title="Concentration of credit risk">20% down payment with the balances due on shipment and delivery, while other vendors terms are due immediately prior to delivery. We also buy product from other distributors, if we are not able to purchase direct from the manufacturer. While management believes all of its relationships with its vendors are good, if we are unable to continue to use and/or find alternative suppliers, when we cannot buy direct, it may have a material negative effect on our business. The principal purchases by PCTI are comprised of parts and raw materials that PCTI assembles and manufactures and sells to its customers. There were no suppliers who accounted for more than ten percent (10%) of PCTI’s purchases for the years ended December 31, 2021, and 2020. Suppliers to PCTI vary from period to period dependent upon our customer’s order specifications. In any specific reporting period, we may be relying on certain vendors, however these vendors will vary dependent on the parts and materials needed. PCTI believes it is not reliant on any particular vendor for future needs. Property, plant and equipment Property and equipment are stated at cost, and depreciation is provided by use of a straight-line method over the estimated useful lives of the assets. The Company reviews property and equipment for potential impairment whenever events or changes in circumstances indicate that the carrying amounts of assets may not be recoverable. The estimated useful lives of property and equipment is as follows: SCHEDULE OF USEFUL LIFE OF PROPERTY AND EQUIPMENT ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 35%; text-align: justify">Office furniture and equipment </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: justify"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndEquipmentMember_zbu9PLG0kCA1">3-<span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndEquipmentMember_zHNJmWll8Z0f" title="Property, Plant and Equipment, Useful Life">5 years</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Warehouse equipment </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--WarehouseEquipmentMember_zYz1pQRCVVt5" title="Property, Plant and Equipment, Useful Life">7 years</td></tr> </table> Revenue Recognition The Company recognizes revenue in accordance with ASC 606, from the commercial sales of products by: (1) identify the contract (if any) with a customer; (2) identify the performance obligations in the contract (if any); (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract (if any); and (5) recognize revenue when each performance obligation is satisfied. Under ASC 606, revenue is recognized when the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) the performance of service has been rendered to a customer or delivery has occurred; (3) the amount of fee to be paid by a customer is fixed and determinable; and (4) the collectability of the fee is reasonably assured. Other than The Company has no outstanding contracts with any of its’ customers. The Company recognizes revenue when title, ownership, and risk of loss pass to the customer, all of which occurs upon shipment or delivery of the product and is based on the applicable shipping terms. For contracts with customers, ownership of the goods and associated revenue are transferred to customers at a point in time, generally upon shipment of a product to the customer or receipt of the product by the customer and without significant judgments. Advance payments are typically required for commercial customers and are recorded as current liability until revenue is recognized. Advance payments are not required for government customers. The majority of contracts typically require payment within 30 to 60 days after transfer of ownership to the customer. For the periods covered herein, we did not have post shipment obligations such as training or installation, customer acceptance provisions, credits and discounts, rebates and price protection, or other similar privileges. The following table disaggregates our revenue by major source for the year ended December 31, 2021: DISAGGREGATION OF REVENUE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Year ended December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Sourced and distributed products</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 26%; text-align: right">10,595,799</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Manufactured products</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,332,806</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,928,605</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Revenues from sourced and distributed products are purchased from suppliers as finished goods and the Company brings the finished goods into our California warehouse to fill orders as well as to build inventory for future sales orders. From time to time for some of our larger orders we may have our suppliers ship directly to our customers to avoid extra shipping charges. For manufactured products, there is usually a bidding process by branches of the military or other large firms that need mostly battery charging and storage systems for large industrial projects. We would then purchase the raw materials and parts needed to build out the project in our Pennsylvania warehouse. There was no disaggregation of revenues for the year ended December 31, 2020. Advertising and Marketing Expenses The Company expenses advertising and marketing costs as incurred. For the years ended December 31, 2021, and 2020, the Company recorded advertising and marketing expenses of $44,158 and $55,249, respectively. Research and Development Costs and expenses that can be clearly identified as research and development are charged to expense as incurred. For the years ended December 31, 2021, and 2020, the Company recorded $7,500 and -0- of research and development expenses. Convertible Instruments The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815, Derivatives and Hedging Activities. Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. The Company accounts for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of this note transaction and the effective conversion price embedded in this note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption. The Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current fair value, with any difference recorded as a gain or loss on extinguishment of the two separate accounting liabilities. Fair Value of Financial Instruments The Company measures assets and liabilities at fair value based on an expected exit price as defined by the authoritative guidance on fair value measurements, which represents the amount that would be received on the sale of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level. The following are the hierarchical levels of inputs to measure fair value: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 1 - Observable inputs that reflect quoted market prices in active markets for identical assets or liabilities.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2 - Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3 - Unobservable inputs reflecting the Company’s assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available.</td></tr> </table> From time to time, certain of the Company’s embedded conversion features on debt and outstanding warrants have been treated as derivative liabilities for accounting purposes under ASC 815 due to insufficient authorized shares to fully settle conversion features of the instruments if exercised. In this case, the Company utilized the latest inception date sequencing method to reclassify outstanding instruments as derivative instruments. These contracts were recognized at fair value with changes in fair value recognized in earnings until such time as the conditions giving rise to such derivative liability classification were settled. The carrying amounts of the Company’s financial assets and liabilities, such as cash, prepaid expenses, other current assets, accounts payable and accrued expenses, certain notes payable and notes payable - related party, approximate their fair values because of the short maturity of these instruments. The following table represents the Company’s derivative instruments that are measured at fair value on a recurring basis as of December 31, 2021 and 2020, for each fair value hierarchy level: SCHEDULE OF DERIVATIVE INSTRUMENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid">December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Derivative Liabilities</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Level I</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pdp0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zoSd8wOONUH4" style="text-align: right" title="Derivative Liabilities">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueNetAssetLiability_iI_pdp0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_znGUA8K1N3Vb" style="text-align: right" title="Total">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Level II</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pdp0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zwIDqiBrtZ27" style="text-align: right" title="Derivative Liabilities">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--FairValueNetAssetLiability_iI_pdp0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zpOdP4BVe08k" style="text-align: right" title="Total">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Level III</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5pWVE7xwpXd" style="width: 16%; text-align: right" title="Derivative Liabilities">20,966,701</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z7AGpDobUM5l" style="width: 16%; text-align: right" title="Total">20,966,701</td><td style="width: 1%; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid">December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Derivative Liabilities</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Level I</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pdp0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z9uZPRvu7mV2" style="text-align: right" title="Derivative Liabilities">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--FairValueNetAssetLiability_iI_pdp0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zeD7fEe7Hug1" style="text-align: right" title="Total">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Level II</td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pdp0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zJe75OYaNxv9" style="text-align: right" title="Derivative Liabilities">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--FairValueNetAssetLiability_iI_pdp0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zDJELCYNeTPc" style="text-align: right" title="Total">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Level III</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zV5hjfQd6sd4" style="width: 16%; text-align: right" title="Derivative Liabilities">3,299,684</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zmIVg0ihwVDi" style="width: 16%; text-align: right" title="Total">3,299,684</td><td style="width: 1%; text-align: left"> </td></tr> </table> Leases The Company accounts for leases under ASU 2016-02 (see Note 14), applying the package of practical expedients to leases that commenced before the effective date whereby the Company elected to not reassess the following: (i) whether any expired or existing contracts contain leases; (ii) the lease classification for any expired or existing leases; and (iii) initial direct costs for any existing leases. For contracts entered into on or after the effective date, at the inception of a contract the Company assess whether the contract is, or contains, a lease. Our assessment is based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether we obtain the right to substantially all the economic benefit from the use of the asset throughout the period, and (3) whether we have the right to direct the use of the asset. We allocate the consideration in the contract to each lease component based on its relative stand-alone price to determine the lease payments. Operating lease ROU assets represent the right to use the leased asset for the lease term and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate, the Company used an incremental borrowing rate of 7.5%, for the existing lease, based on the information available at the adoption date in determining the present value of future payments. Operating lease expense is recognized pursuant to on a straight-line basis over the lease term and is included in rent in the condensed consolidated statements of operations. Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance on deferred tax assets is established when management considers it is more likely than not that some portion or all of the deferred tax assets will not be realized. Tax benefits from an uncertain tax position are only recognized if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution. Interest and penalties related to unrecognized tax benefits are recorded as incurred as a component of income tax expense. The Company has not recognized any tax benefits from uncertain tax positions for any of the reporting periods presented. Segment Policy The Company has no reportable segments as it operates in one segment; renewable energy. Earnings (Loss) Per Share The Company reports earnings (loss) per share in accordance with ASC 260, “Earnings per Share.” Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during each period. Diluted earnings per share is computed by dividing net loss by the weighted-average number of shares of common stock, common stock equivalents and other potentially dilutive securities outstanding during the period. As of December 31, 2021, and 2020, the Company’s dilutive securities are convertible into approximately 7,592,474,061 and 11,223,565,011, respectively, shares of common stock. The following table represents the classes of dilutive securities as of December 31, 2021, and 2020: <p id="xdx_891_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zRpNgslIqbU1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left">Convertible preferred stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zLcI0gi19iu8" style="width: 22%; text-align: right" title="Anti-dilutive shares of common stock">6,918,544,466</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zwODEaRj5xri" style="width: 22%; text-align: right" title="Anti-dilutive shares of common stock">10,193,874,467</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Unexercised common stock purchase warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnexercisedCommonStockPurchaseWarrantsMember_zOs4XZghMqU9" style="text-align: right" title="Anti-dilutive shares of common stock">672,024,518</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnexercisedCommonStockPurchaseWarrantsMember_zbeueMkkLY31" style="text-align: right" title="Anti-dilutive shares of common stock">659,601,638</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Convertible notes payable</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleNotesPayableMember_zeYB872nQOc4" style="text-align: right" title="Anti-dilutive shares of common stock">1,905,077</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleNotesPayableMember_zryYf4Fac2l2" style="text-align: right" title="Anti-dilutive shares of common stock">370,087,556</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Common stock to be issued</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockToBeIssuedMember_zJaG4uCDxJ9c" style="border-bottom: Black 1.5pt solid; text-align: right" title="Anti-dilutive shares of common stock">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockToBeIssuedMember_z17IfAsIt8Wl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Anti-dilutive shares of common stock">1,350</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231_zRqfGxqDg8ha" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive shares of common stock">7,592,474,061</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20201231_zoTFP7vGpEhg" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive shares of common stock">11,223,565,011</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Recent Accounting Pronouncements In August 2020, the FASB issued Accounting Standards Update (“ASU”) No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging —Contracts in Entity’ Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’ Own Equity (“ASU 2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception, and it simplifies the diluted earnings per share calculation in certain areas. The Company does not believe the adoption of the ASU will have a material impact on the Company’s financial position, results of operations or cash flows. Other than the above, there have no recent accounting pronouncements or changes in accounting pronouncements during the period ended December 31, 2021, that are of significance or potential significance to the Company.

Basis of Presentation The accompanying consolidated financial statements are prepared in accordance with Generally Accepted Accounting Principles in the United States of America (“US GAAP”). The consolidated financial statements include the accounts of the Company and Ozop Energy Systems, Inc. and the Company’s other wholly owned subsidiaries PCTI, Ozop LLC, Ozop HK and Spinus, LLC (“Spinus”) and the Company’s majority owned subsidiary Ozop Capital Partners, Inc. All intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reported period. Actual results could differ from those estimates.

Cash and Cash Equivalents The Company considers all highly liquid investments with an original term of three months or less to be cash equivalents. These investments are carried at cost, which approximates fair value. Cash and cash equivalent balances may, at certain times, exceed federally insured limits. The Company has no cash equivalents at December 31, 2021, and 2020.

Sales Concentration and credit risk Following is a summary of customers who accounted for more than ten percent (10%) of the Company’s revenues for the years ended December 31, 2021, and 2020, and their accounts receivable balance as of December 31, 2021: SCHEDULES OF CONCENTRATION OF RISK, BY RISK FACTOR <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Sales % Year Ended December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Sales % Year Ended December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Accounts receivable balance December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify">Customer A</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z3hnHT4Mu1D6" title="Concentration Risk, Percentage">17</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">N/A</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">782,179</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Customer B</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">N/A</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200101__20201231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zy4sVKJkk8jc" title="Concentration Risk, Percentage">62</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Customer C</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">N/A</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200101__20201231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zPDpk4FE7X15" title="Concentration Risk, Percentage">15</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> </table> For the year ended December 31, 2020, the above customers were of PCTI. PCTI, historically does not have year to year many recurring clients as the Company produces capital equipment for its’ customers.

Following is a summary of customers who accounted for more than ten percent (10%) of the Company’s revenues for the years ended December 31, 2021, and 2020, and their accounts receivable balance as of December 31, 2021: SCHEDULES OF CONCENTRATION OF RISK, BY RISK FACTOR <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Sales % Year Ended December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Sales % Year Ended December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Accounts receivable balance December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify">Customer A</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z3hnHT4Mu1D6" title="Concentration Risk, Percentage">17</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">N/A</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">782,179</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Customer B</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">N/A</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200101__20201231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zy4sVKJkk8jc" title="Concentration Risk, Percentage">62</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Customer C</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">N/A</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200101__20201231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zPDpk4FE7X15" title="Concentration Risk, Percentage">15</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> </table>

0.17

782179

0.62

0.15

Accounts Receivable The Company records accounts receivable at the time products and services are delivered. An allowance for losses is established through a provision for losses charged to expenses. Receivables are charged against the allowance for losses when management believes collectability is unlikely. The allowance (if any) is an amount that management believes will be adequate to absorb estimated losses on existing receivables, based on evaluation of the collectability of the accounts and prior loss experience.

Inventory Inventories are valued at the lower of cost or net realizable value, with cost determined on the first-in, first-out basis. Inventory costs include finished goods, material, labor and manufacturing overhead. In evaluating the net realizable value of inventory, management also considers, if applicable, other factors, including known trends, market conditions, currency exchange rates and other such issues. The components of inventories at December 31, 2021, and 2020 are as follows: SCHEDULE OF INVENTORY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20211231_zDlkFmAwNSS7" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20201231_zZhu9Q5ffbN6" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_403_eus-gaap--InventoryRawMaterials_iI_maCzAkd_maINzA2c_zAjhCmu80Euf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Raw materials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">234,168</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">207,178</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--InventoryWorkInProcess_iI_maCzAkd_maINzA2c_zFrpgVz9dcla" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Work in process</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43,704</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">142,526</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--InventoryFinishedGoods_iI_maCzAkd_maINzA2c_z43FsMWXV634" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">788,110</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,643</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--InventoryNet_iTI_pp0p0_mtINzA2c_zMfchbVZPazi" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Inventory net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,065,982</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">359,347</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

The components of inventories at December 31, 2021, and 2020 are as follows: SCHEDULE OF INVENTORY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20211231_zDlkFmAwNSS7" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20201231_zZhu9Q5ffbN6" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_403_eus-gaap--InventoryRawMaterials_iI_maCzAkd_maINzA2c_zAjhCmu80Euf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Raw materials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">234,168</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">207,178</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--InventoryWorkInProcess_iI_maCzAkd_maINzA2c_zFrpgVz9dcla" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Work in process</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43,704</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">142,526</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--InventoryFinishedGoods_iI_maCzAkd_maINzA2c_z43FsMWXV634" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">788,110</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,643</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--InventoryNet_iTI_pp0p0_mtINzA2c_zMfchbVZPazi" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Inventory net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,065,982</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">359,347</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

234168

207178

43704

142526

788110

9643

1065982

359347

Purchase concentration OES purchases finished renewable energy products from its’ suppliers. For the year ended December 31, 2021, there were two suppliers that accounted for <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__srt--MajorCustomersAxis__custom--SuppliersOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_z2j8z7sfboci" title="Concentration of credit risk">42.6% and <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__srt--MajorCustomersAxis__custom--SuppliersTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zoLSOKqy3ryj" title="Concentration of credit risk">20.4%, respectively. There are only a handful of major suppliers, and we currently have supply arrangements with some of those vendors. One of these vendors requires a <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__srt--MajorCustomersAxis__custom--TwoVendorMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zUeFgBZyjz44" title="Concentration of credit risk">20% down payment with the balances due on shipment and delivery, while other vendors terms are due immediately prior to delivery. We also buy product from other distributors, if we are not able to purchase direct from the manufacturer. While management believes all of its relationships with its vendors are good, if we are unable to continue to use and/or find alternative suppliers, when we cannot buy direct, it may have a material negative effect on our business. The principal purchases by PCTI are comprised of parts and raw materials that PCTI assembles and manufactures and sells to its customers. There were no suppliers who accounted for more than ten percent (10%) of PCTI’s purchases for the years ended December 31, 2021, and 2020. Suppliers to PCTI vary from period to period dependent upon our customer’s order specifications. In any specific reporting period, we may be relying on certain vendors, however these vendors will vary dependent on the parts and materials needed. PCTI believes it is not reliant on any particular vendor for future needs.

0.426

0.204

0.20

Property, plant and equipment Property and equipment are stated at cost, and depreciation is provided by use of a straight-line method over the estimated useful lives of the assets. The Company reviews property and equipment for potential impairment whenever events or changes in circumstances indicate that the carrying amounts of assets may not be recoverable. The estimated useful lives of property and equipment is as follows: SCHEDULE OF USEFUL LIFE OF PROPERTY AND EQUIPMENT ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 35%; text-align: justify">Office furniture and equipment </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: justify"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndEquipmentMember_zbu9PLG0kCA1">3-<span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndEquipmentMember_zHNJmWll8Z0f" title="Property, Plant and Equipment, Useful Life">5 years</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Warehouse equipment </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--WarehouseEquipmentMember_zYz1pQRCVVt5" title="Property, Plant and Equipment, Useful Life">7 years</td></tr> </table>

SCHEDULE OF USEFUL LIFE OF PROPERTY AND EQUIPMENT ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 35%; text-align: justify">Office furniture and equipment </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: justify"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndEquipmentMember_zbu9PLG0kCA1">3-<span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndEquipmentMember_zHNJmWll8Z0f" title="Property, Plant and Equipment, Useful Life">5 years</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Warehouse equipment </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--WarehouseEquipmentMember_zYz1pQRCVVt5" title="Property, Plant and Equipment, Useful Life">7 years</td></tr> </table>

P3Y

P5Y

P7Y

Revenue Recognition The Company recognizes revenue in accordance with ASC 606, from the commercial sales of products by: (1) identify the contract (if any) with a customer; (2) identify the performance obligations in the contract (if any); (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract (if any); and (5) recognize revenue when each performance obligation is satisfied. Under ASC 606, revenue is recognized when the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) the performance of service has been rendered to a customer or delivery has occurred; (3) the amount of fee to be paid by a customer is fixed and determinable; and (4) the collectability of the fee is reasonably assured. Other than The Company has no outstanding contracts with any of its’ customers. The Company recognizes revenue when title, ownership, and risk of loss pass to the customer, all of which occurs upon shipment or delivery of the product and is based on the applicable shipping terms. For contracts with customers, ownership of the goods and associated revenue are transferred to customers at a point in time, generally upon shipment of a product to the customer or receipt of the product by the customer and without significant judgments. Advance payments are typically required for commercial customers and are recorded as current liability until revenue is recognized. Advance payments are not required for government customers. The majority of contracts typically require payment within 30 to 60 days after transfer of ownership to the customer. For the periods covered herein, we did not have post shipment obligations such as training or installation, customer acceptance provisions, credits and discounts, rebates and price protection, or other similar privileges. The following table disaggregates our revenue by major source for the year ended December 31, 2021: DISAGGREGATION OF REVENUE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Year ended December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Sourced and distributed products</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 26%; text-align: right">10,595,799</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Manufactured products</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,332,806</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,928,605</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Revenues from sourced and distributed products are purchased from suppliers as finished goods and the Company brings the finished goods into our California warehouse to fill orders as well as to build inventory for future sales orders. From time to time for some of our larger orders we may have our suppliers ship directly to our customers to avoid extra shipping charges. For manufactured products, there is usually a bidding process by branches of the military or other large firms that need mostly battery charging and storage systems for large industrial projects. We would then purchase the raw materials and parts needed to build out the project in our Pennsylvania warehouse. There was no disaggregation of revenues for the year ended December 31, 2020.

The following table disaggregates our revenue by major source for the year ended December 31, 2021: DISAGGREGATION OF REVENUE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Year ended December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Sourced and distributed products</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 26%; text-align: right">10,595,799</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Manufactured products</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,332,806</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,928,605</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

10595799

1332806

11928605

Advertising and Marketing Expenses The Company expenses advertising and marketing costs as incurred. For the years ended December 31, 2021, and 2020, the Company recorded advertising and marketing expenses of $44,158 and $55,249, respectively.

44158

55249

Research and Development Costs and expenses that can be clearly identified as research and development are charged to expense as incurred. For the years ended December 31, 2021, and 2020, the Company recorded $7,500 and -0- of research and development expenses.

7500

Convertible Instruments The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815, Derivatives and Hedging Activities. Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. The Company accounts for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of this note transaction and the effective conversion price embedded in this note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption. The Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current fair value, with any difference recorded as a gain or loss on extinguishment of the two separate accounting liabilities.

Fair Value of Financial Instruments The Company measures assets and liabilities at fair value based on an expected exit price as defined by the authoritative guidance on fair value measurements, which represents the amount that would be received on the sale of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level. The following are the hierarchical levels of inputs to measure fair value: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 1 - Observable inputs that reflect quoted market prices in active markets for identical assets or liabilities.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2 - Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3 - Unobservable inputs reflecting the Company’s assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available.</td></tr> </table> From time to time, certain of the Company’s embedded conversion features on debt and outstanding warrants have been treated as derivative liabilities for accounting purposes under ASC 815 due to insufficient authorized shares to fully settle conversion features of the instruments if exercised. In this case, the Company utilized the latest inception date sequencing method to reclassify outstanding instruments as derivative instruments. These contracts were recognized at fair value with changes in fair value recognized in earnings until such time as the conditions giving rise to such derivative liability classification were settled. The carrying amounts of the Company’s financial assets and liabilities, such as cash, prepaid expenses, other current assets, accounts payable and accrued expenses, certain notes payable and notes payable - related party, approximate their fair values because of the short maturity of these instruments. The following table represents the Company’s derivative instruments that are measured at fair value on a recurring basis as of December 31, 2021 and 2020, for each fair value hierarchy level: SCHEDULE OF DERIVATIVE INSTRUMENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid">December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Derivative Liabilities</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Level I</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pdp0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zoSd8wOONUH4" style="text-align: right" title="Derivative Liabilities">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueNetAssetLiability_iI_pdp0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_znGUA8K1N3Vb" style="text-align: right" title="Total">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Level II</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pdp0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zwIDqiBrtZ27" style="text-align: right" title="Derivative Liabilities">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--FairValueNetAssetLiability_iI_pdp0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zpOdP4BVe08k" style="text-align: right" title="Total">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Level III</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5pWVE7xwpXd" style="width: 16%; text-align: right" title="Derivative Liabilities">20,966,701</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z7AGpDobUM5l" style="width: 16%; text-align: right" title="Total">20,966,701</td><td style="width: 1%; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid">December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Derivative Liabilities</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Level I</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pdp0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z9uZPRvu7mV2" style="text-align: right" title="Derivative Liabilities">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--FairValueNetAssetLiability_iI_pdp0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zeD7fEe7Hug1" style="text-align: right" title="Total">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Level II</td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pdp0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zJe75OYaNxv9" style="text-align: right" title="Derivative Liabilities">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--FairValueNetAssetLiability_iI_pdp0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zDJELCYNeTPc" style="text-align: right" title="Total">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Level III</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zV5hjfQd6sd4" style="width: 16%; text-align: right" title="Derivative Liabilities">3,299,684</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zmIVg0ihwVDi" style="width: 16%; text-align: right" title="Total">3,299,684</td><td style="width: 1%; text-align: left"> </td></tr> </table>

The following table represents the Company’s derivative instruments that are measured at fair value on a recurring basis as of December 31, 2021 and 2020, for each fair value hierarchy level: SCHEDULE OF DERIVATIVE INSTRUMENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid">December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Derivative Liabilities</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Level I</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pdp0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zoSd8wOONUH4" style="text-align: right" title="Derivative Liabilities">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueNetAssetLiability_iI_pdp0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_znGUA8K1N3Vb" style="text-align: right" title="Total">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Level II</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pdp0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zwIDqiBrtZ27" style="text-align: right" title="Derivative Liabilities">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--FairValueNetAssetLiability_iI_pdp0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zpOdP4BVe08k" style="text-align: right" title="Total">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Level III</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5pWVE7xwpXd" style="width: 16%; text-align: right" title="Derivative Liabilities">20,966,701</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z7AGpDobUM5l" style="width: 16%; text-align: right" title="Total">20,966,701</td><td style="width: 1%; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid">December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Derivative Liabilities</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Level I</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pdp0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z9uZPRvu7mV2" style="text-align: right" title="Derivative Liabilities">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--FairValueNetAssetLiability_iI_pdp0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zeD7fEe7Hug1" style="text-align: right" title="Total">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Level II</td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pdp0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zJe75OYaNxv9" style="text-align: right" title="Derivative Liabilities">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--FairValueNetAssetLiability_iI_pdp0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zDJELCYNeTPc" style="text-align: right" title="Total">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Level III</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zV5hjfQd6sd4" style="width: 16%; text-align: right" title="Derivative Liabilities">3,299,684</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zmIVg0ihwVDi" style="width: 16%; text-align: right" title="Total">3,299,684</td><td style="width: 1%; text-align: left"> </td></tr> </table>

20966701

3299684

Leases The Company accounts for leases under ASU 2016-02 (see Note 14), applying the package of practical expedients to leases that commenced before the effective date whereby the Company elected to not reassess the following: (i) whether any expired or existing contracts contain leases; (ii) the lease classification for any expired or existing leases; and (iii) initial direct costs for any existing leases. For contracts entered into on or after the effective date, at the inception of a contract the Company assess whether the contract is, or contains, a lease. Our assessment is based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether we obtain the right to substantially all the economic benefit from the use of the asset throughout the period, and (3) whether we have the right to direct the use of the asset. We allocate the consideration in the contract to each lease component based on its relative stand-alone price to determine the lease payments. Operating lease ROU assets represent the right to use the leased asset for the lease term and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate, the Company used an incremental borrowing rate of 7.5%, for the existing lease, based on the information available at the adoption date in determining the present value of future payments. Operating lease expense is recognized pursuant to on a straight-line basis over the lease term and is included in rent in the condensed consolidated statements of operations.

0.075

Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance on deferred tax assets is established when management considers it is more likely than not that some portion or all of the deferred tax assets will not be realized. Tax benefits from an uncertain tax position are only recognized if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution. Interest and penalties related to unrecognized tax benefits are recorded as incurred as a component of income tax expense. The Company has not recognized any tax benefits from uncertain tax positions for any of the reporting periods presented.

greater than fifty percent

Segment Policy The Company has no reportable segments as it operates in one segment; renewable energy.

Earnings (Loss) Per Share The Company reports earnings (loss) per share in accordance with ASC 260, “Earnings per Share.” Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during each period. Diluted earnings per share is computed by dividing net loss by the weighted-average number of shares of common stock, common stock equivalents and other potentially dilutive securities outstanding during the period. As of December 31, 2021, and 2020, the Company’s dilutive securities are convertible into approximately 7,592,474,061 and 11,223,565,011, respectively, shares of common stock. The following table represents the classes of dilutive securities as of December 31, 2021, and 2020: <p id="xdx_891_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zRpNgslIqbU1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left">Convertible preferred stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zLcI0gi19iu8" style="width: 22%; text-align: right" title="Anti-dilutive shares of common stock">6,918,544,466</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zwODEaRj5xri" style="width: 22%; text-align: right" title="Anti-dilutive shares of common stock">10,193,874,467</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Unexercised common stock purchase warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnexercisedCommonStockPurchaseWarrantsMember_zOs4XZghMqU9" style="text-align: right" title="Anti-dilutive shares of common stock">672,024,518</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnexercisedCommonStockPurchaseWarrantsMember_zbeueMkkLY31" style="text-align: right" title="Anti-dilutive shares of common stock">659,601,638</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Convertible notes payable</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleNotesPayableMember_zeYB872nQOc4" style="text-align: right" title="Anti-dilutive shares of common stock">1,905,077</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleNotesPayableMember_zryYf4Fac2l2" style="text-align: right" title="Anti-dilutive shares of common stock">370,087,556</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Common stock to be issued</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockToBeIssuedMember_zJaG4uCDxJ9c" style="border-bottom: Black 1.5pt solid; text-align: right" title="Anti-dilutive shares of common stock">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockToBeIssuedMember_z17IfAsIt8Wl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Anti-dilutive shares of common stock">1,350</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231_zRqfGxqDg8ha" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive shares of common stock">7,592,474,061</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20201231_zoTFP7vGpEhg" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive shares of common stock">11,223,565,011</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

7592474061

11223565011

<p id="xdx_891_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zRpNgslIqbU1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left">Convertible preferred stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zLcI0gi19iu8" style="width: 22%; text-align: right" title="Anti-dilutive shares of common stock">6,918,544,466</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zwODEaRj5xri" style="width: 22%; text-align: right" title="Anti-dilutive shares of common stock">10,193,874,467</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Unexercised common stock purchase warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnexercisedCommonStockPurchaseWarrantsMember_zOs4XZghMqU9" style="text-align: right" title="Anti-dilutive shares of common stock">672,024,518</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnexercisedCommonStockPurchaseWarrantsMember_zbeueMkkLY31" style="text-align: right" title="Anti-dilutive shares of common stock">659,601,638</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Convertible notes payable</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleNotesPayableMember_zeYB872nQOc4" style="text-align: right" title="Anti-dilutive shares of common stock">1,905,077</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleNotesPayableMember_zryYf4Fac2l2" style="text-align: right" title="Anti-dilutive shares of common stock">370,087,556</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Common stock to be issued</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockToBeIssuedMember_zJaG4uCDxJ9c" style="border-bottom: Black 1.5pt solid; text-align: right" title="Anti-dilutive shares of common stock">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockToBeIssuedMember_z17IfAsIt8Wl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Anti-dilutive shares of common stock">1,350</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231_zRqfGxqDg8ha" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive shares of common stock">7,592,474,061</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20201231_zoTFP7vGpEhg" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive shares of common stock">11,223,565,011</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

6918544466

10193874467

672024518

659601638

1905077

370087556

1350

7592474061

11223565011

Recent Accounting Pronouncements In August 2020, the FASB issued Accounting Standards Update (“ASU”) No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging —Contracts in Entity’ Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’ Own Equity (“ASU 2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception, and it simplifies the diluted earnings per share calculation in certain areas. The Company does not believe the adoption of the ASU will have a material impact on the Company’s financial position, results of operations or cash flows. Other than the above, there have no recent accounting pronouncements or changes in accounting pronouncements during the period ended December 31, 2021, that are of significance or potential significance to the Company.

NOTE 5 – PROPERTY AND EQUIPMENT The following table summarizes the Company’s property and equipment: PROPERTY AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left">Office equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zEtQ8v2S8Ct6" style="width: 22%; text-align: right" title="Office equipment">260,083</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_pp0p0" style="width: 22%; text-align: right" title="Office equipment">143,247</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Accumulated Depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20211231_zwpruKKEX3s" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less: Accumulated Depreciation">(127,194</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20201231_zNtanEC0zcO8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less: Accumulated Depreciation">(82,576</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Property and Equipment, Net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20211231_zdDVxpN985f2" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and Equipment, Net">132,889</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20201231_znaOqdPsFv16" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and Equipment, Net">60,671</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Depreciation expense was $44,618 and $11,857 for the years ended December 31, 2021, and 2020, respectively.

The following table summarizes the Company’s property and equipment: PROPERTY AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left">Office equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zEtQ8v2S8Ct6" style="width: 22%; text-align: right" title="Office equipment">260,083</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_pp0p0" style="width: 22%; text-align: right" title="Office equipment">143,247</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Accumulated Depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20211231_zwpruKKEX3s" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less: Accumulated Depreciation">(127,194</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20201231_zNtanEC0zcO8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less: Accumulated Depreciation">(82,576</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Property and Equipment, Net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20211231_zdDVxpN985f2" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and Equipment, Net">132,889</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20201231_znaOqdPsFv16" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and Equipment, Net">60,671</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

260083

143247

127194

82576

132889

60671

44618

11857

NOTE 6 - CONVERTIBLE NOTES PAYABLE The transaction with PCTI is being accounted for as a business combination and was treated as a reverse acquisition for accounting purposes with PCTI as the accounting acquirer in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 805, Business Combinations (“ASC 805”). In accordance with the accounting treatment for a reverse acquisition, the Company’s historical financial statements prior to the reverse merger were and will be replaced with the historical financial statements of PCTI prior to the reverse merger. The consolidated financial statements after completion of the reverse merger have and will include the assets, liabilities and results of operations of the combined company from and after the closing date of the reverse merger. On July 10, 2020, PCTI (the accounting acquirer) assumed the balance of a past-due 15% convertible note issued by the Company on September 13, 2017. As of December 31, 2021 and 2020, the outstanding principal balance of this note was $25,000. On July 10, 2020, PCTI (the accounting acquirer) assumed the balance of a 12% convertible promissory note issued by the Company on June 1, 2020, (the “Issuance Date”) to an investor, pursuant to a Securities Purchase Agreement. This note matures 6 months after the Issuance Date. This note is convertible into shares of the Company’s common stock beginning on the Issuance Date at $0.025 for the first three months after the Issuance Date. After the first three months after the Issuance Date, the conversion price shall be equal to the lower of (i) $.025 or 50% of the lowest trading price for the thirty-five trading days prior to the conversion. As of July 10, 2020, the outstanding principal balance of this note was $127,500 with a carrying value of $27,625, net of unamortized discounts of $99,875. In conjunction with this note, the Company issued a warrant to purchase 6,375,000 shares of common stock at an exercise price of $0.02, subject to adjustments and expiring on the five-year anniversary of the Issuance Date. For the year December 31, 2021, the investor converted a total of $<span id="xdx_904_eus-gaap--DebtConversionOriginalDebtAmount1_pp0p0_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--TwelvePercentPromissoryNoteMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zVP5zQIdrN6f">127,500 of the face value and $<span id="xdx_905_ecustom--DebtConversionAccruedInterest_pp0p0_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--TwelvePercentPromissoryNoteMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_znUXdPbNatH">14,433 of accrued interest and fees into <span id="xdx_908_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--TwelvePercentPromissoryNoteMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zFxD2rCN0a3b">88,708,118 shares of common stock at an average conversion price of $<span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--TwelvePercentPromissoryNoteMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zEJyp71f1cF4">0.0016. On March 10, 2021, the investor received <span id="xdx_902_ecustom--CommonStockUponCashlessExerciseOfWarrants_c20210308__20210310__us-gaap--DebtInstrumentAxis__custom--TwelvePercentPromissoryNoteMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zi2GRPdsije2">6,355,008 shares of common stock upon the cashless exercise of the warrants. As of December 31, 2021, and 2020, the outstanding principal balance of this note was $-0- and $127,500, respectively. On July 10, 2020, PCTI (the accounting acquirer) assumed the balance of a 15% convertible promissory note issued by the Company on June 30, 2020, (the “Issuance Date”) to an investor, pursuant to a Securities Purchase Agreement. This note matures 6 months after the Issuance Date. This note is convertible into shares of the Company’s common stock beginning on the Issuance Date at $0.025 for the first three months after the Issuance Date. After the first three months after the Issuance Date, the conversion price shall be equal to the lower of (i) $.025 or 50% of the lowest trading price for the thirty-five trading days prior to the conversion. As of July 10, 2020, the outstanding principal balance of this note was $129,500 with a carrying value of $8,375, net of unamortized discounts of $121,125. In conjunction with this note, the Company issued a warrant to purchase 6,375,000 shares of common stock at an exercise price of $0.02, subject to adjustments and expiring on the five-year anniversary of the Issuance Date. For the year December 31, 2021, the investor converted a total of $129,500 of the face value and $30,264 of accrued interest and fees into 110,946,972 shares of common stock at an average conversion price of $0.00144. On March 10, 2021, the investor received 6,355,008 shares of common stock upon the cashless exercise of the warrants. As of December 31, 2021, and 2020, the outstanding principal balance of this note was $-0- and $129,500, respectively, with a carrying value of $111,763 as of December 31, 2020, net of unamortized discounts of $10,416. On July 10, 2020, PCTI (the accounting acquirer) assumed the balance of a 15% convertible promissory note issued by the Company on July 8, 2020, (the “Issuance Date”) to an investor, pursuant to a Securities Purchase Agreement. This note matures 6 months after the Issuance Date. This note is convertible into shares of the Company’s common stock beginning on the Issuance Date at $0.025 for the first three months after the Issuance Date. After the first three months after the Issuance Date, the conversion price shall be equal to the lower of (i) $.025 or 50% of the lowest trading price for the thirty-five trading days prior to the conversion. In conjunction with this note, the Company issued a warrant to purchase 12,500,000 shares of common stock at an exercise price of $0.02, subject to adjustments and expiring on the five-year anniversary of the Issuance Date. For the nine months ended December 31, 2021, amortization of the debt discounts of $10,416 was charged to interest expense. For the year December 31, 2021, the investor converted a total of $250,000 of the face value and $130,044 of accrued interest and fees into 243,012,455 shares of common stock at an average conversion price of $0.00156. On March 10, 2021, the investor received 12,460,800 shares of common stock upon the cashless exercise of the warrants. As of December 31, 2021, and December 31, 2020, the outstanding principal balance of this note was $-0- and $250,000, respectively, with a carrying value of $239,583 as of December 31, 2020, net of unamortized discounts of $10,416. On February 26, 2020, (the “Issuance Date”) PCTI issued a 12% Convertible Promissory Note (the “Note”), in the principal amount of $106,950, to an investor. This note matures 12 months after the Issuance Date. This note is convertible into shares of the Company’s common stock beginning on the Issuance Date at 55% of the lowest trading price for the twenty-five trading days prior to the conversion. If the trading price cannot be calculated for such security on such date, the trading price shall be the fair market value as mutually determined by the Company and the investor for which the calculation of the trading price is required in order to determine the conversion price. PCTI received proceeds of $85,000 on February 26, 2020, and the Note included an original issue discount of $13,950 and lender costs of $8,000. This note proceeds were used by the Company for general working capital purposes. The Note also required a daily payment via ACH of $400. On June 25, 2020, the Note was amended to add $111,225 of additional principal to the outstanding balance. Pursuant to the PCTI transaction with Ozop, on July 10, 2020, the conversion price is equal to <span id="xdx_90B_ecustom--ConversionPricePercentageOfDiscountOnCommonSharePrice_iI_dp_uPure_c20200710__us-gaap--DebtInstrumentAxis__custom--TwelvePercentConvertiblePromissoryNoteTwoMember_z8AFv1DPuUNa" title="Conversion price percentage of discount on common share price">45% multiplied by the lowest closing bid price during the twenty-five-trading day period ending on the last completed trading date in the OTC Markets prior to the date of conversion. Accordingly, the Company determined the conversion feature of the Notes represented an embedded derivative since the note is convertible into a variable number of shares upon conversion, as the note was not considered to be conventional debt under ASC 815 and the embedded conversion feature was bifurcated from the debt host and accounted for as a derivative liability. The embedded feature included in the note resulted in an initial debt discount of $85,000, interest expense of $135,786 and initial derivative liability of $220,786. For the year ended December 31, 2021, amortization of the debt discounts of $17,737 was charged to interest expense. For the year December 31, 2021, the investor converted a total of $50,550 of the face value and $<span id="xdx_901_ecustom--DebtConversionAccruedInterest_pp0p0_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--TwelvePercentConvertiblePromissoryNoteTwoMember_zhrG57P1E5y3" title="Debt conversion accrued interest">11,265 of accrued interest and fees into 20,218,562 shares of common stock at an average conversion price of $0.00306. The Investor also amended the note to deduct the previously added principal amount of $111,225. As of December 31, 2021, and 2020, the outstanding principal balance of this note was $-0- and $161,775, respectively. The Company accounted for the amendment as an extinguishment of debt. On July 15, 2020, (the “Issuance Date”) the Company issued a 15% convertible promissory note, in the principal amount of $127,500, to an investor. This note matures 6 months after the Issuance Date. This note is convertible into shares of the Company’s common stock beginning on the Issuance Date at $0.011 for the first three months after the Issuance Date. After the first three months after the Issuance Date, the conversion price shall be equal to the lower of (i) $.025 or 50% of the lowest trading price for the thirty-five trading days prior to the conversion. The Company received proceeds of $102,000 on July 22, 2020, and this note included an original issue discount of $25,500. This note proceeds will be used by the Company for general working capital purposes. In conjunction with this note, the Company issued a warrant to purchase 6,375,000 shares of common stock at an exercise price of $0.02, subject to adjustments and expiring on the five-year anniversary of the Issuance Date. The Company allocated the proceeds to the debt of $82,068 and to the warrant $19,932 based on the relative fair value. The embedded conversion feature included in this note resulted in an initial derivative liability of $207,699, a debt discount of $82,068 with the excess of $125,541 charged to interest expense of $125,541. On March 10, 2021, the investor received <span id="xdx_90A_ecustom--CommonStockUponCashlessExerciseOfWarrants_c20210308__20210310__us-gaap--DebtInstrumentAxis__custom--TwelvePercentPromissoryNoteMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zUlS3PGzQXgh">6,355,008 shares of common stock upon the cashless exercise of the warrants. For the year ended December 31, 2021, amortization of the debt discounts of $10,792 was charged to interest expense. On May 6, 2021, the Company and the investor entered into a Settlement and Mutual Release Agreement (the “Settlement Agreement”). Pursuant to the Settlement Agreement, the investor agreed to cancel the July 15, 2020, note. The Company accounted for the cancelled note as a gain on debt extinguishment. As of December 31, 2021, and December 31, 2020, the outstanding principal balance of this note was $-0- and $127,500, respectively, with a carrying value of $116,708, net of unamortized discounts of $10,792 as of December 31, 2020. On July 29, 2020, (the “Issuance Date”) the Company issued a 15% convertible promissory note, in the principal amount of $127,500, to an investor. This note matures 6 months after the Issuance Date. This note is convertible into shares of the Company’s common stock beginning on the Issuance Date at $0.011 for the first three months after the Issuance Date. After the first three months after the Issuance Date, the conversion price shall be equal to the lower of (i) $.025 or 50% of the lowest trading price for the thirty-five trading days prior to the conversion. The Company received proceeds of $100,000 on August 3, 2020, and this note included an original issue discount of $25,500. This note proceeds will be used by the Company for general working capital purposes. In conjunction with this note, the Company issued a warrant to purchase 12,750,000 shares of common stock at an exercise price of $0.01, subject to adjustments and expiring on the five-year anniversary of the Issuance Date. The Company allocated the proceeds to the debt $61,733 and warrant $40,267 based on the relative fair value. The embedded conversion feature included in this note resulted in an initial derivative liability of $198,239, a debt discount of $61,733 with the excess of $136,506 charged to interest expense. On March 10, 2021, the investor received <span id="xdx_909_ecustom--CommonStockUponCashlessExerciseOfWarrants_c20210308__20210310__us-gaap--DebtInstrumentAxis__custom--FifteenPercentConvertiblePromissoryNoteThreeMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zDKrGp9gWkcg" title="Common stock upon the cashless exercise of the warrants">12,710,016 shares of common stock upon the cashless exercise of the warrants. For the year ended December 31, 2021, amortization of the debt discounts of $21,583 was charged to interest expense. On May 6, 2021, the investor, pursuant to the Settlement Agreement, agreed to cancel the July 29, 2020, note. The Company accounted for the cancelled note as a gain on debt extinguishment. As of December 31, 2021, and 2020, the outstanding principal balance of this note was $-0- and $127,500 with a carrying value of $105,917, net of unamortized discounts of $21,583 as of December 31, 2020. On November 16, 2020, (the “Issuance Date”) the Company issued a promissory note, in the principal amount of $250,000, to an investor. The note carries a guaranteed interest payment of 15%, which is added to the principal on the Issuance Date. Principal payments shall be made in six instalments of $57,500 commencing May 21, 2021, and continuing each 30 days thereafter for 4 months. The Holder shall have the right from time to time, and at any time following an event of default, as defined on the agreement, to convert all or any part of the outstanding and unpaid principal, interest and any other amounts due into fully paid and non-assessable shares of common stock of the Company. This note is convertible into shares of the Company’s common stock beginning on the Issuance Date at $0.01 for the first three months after the Issuance Date. After the first three months after the Issuance Date, the conversion price shall be equal to the lower of (i) $.01 or the volume weighted average price of the common stock during the five (5) Trading Day period ending on the day prior to conversion. The Company received proceeds of $200,000 on November 19, 2020, and this note included an original issue discount of $50,000. This note proceeds will be used by the Company for general working capital purposes. The embedded conversion feature included in this note resulted in an initial derivative liability of $14,750 and a debt discount of $<span id="xdx_90B_ecustom--DebtInstrumentInitialDebtDiscount_iI_pp0p0_c20201116__us-gaap--DebtInstrumentAxis__custom--FifteenPercentConvertiblePromissoryNoteFourMember_zlUkhHvg2PAb" title="Debt intstrument initial debt discount.">50,000. In conjunction with this note, the Company issued a warrant to purchase 35,000,000 shares of common stock at an exercise price of $0.25, subject to adjustments and expiring on the five-year anniversary of the Issuance Date. The warrants issued resulted in a debt discount of $3,050, with the offset to additional paid in capital. For the year ended December 31, 2021, amortization of the debt discounts of $59,264 was charged to interest expense. On May 6, 2021, the investor, pursuant to the Settlement Agreement, agreed to cancel the November 16, 2020, note and the warrant to purchase 35,000,000 shares. The Company accounted for the cancelled note and warrant as a gain on debt extinguishment. As of December 31, 2021, and December 31, 2020, the outstanding principal balance of this note was $-0- and $250,000 with a carrying value of $190,736, as of December 31, 2020, net of unamortized discounts of $59,264. A summary of the convertible note balance as of December 31, 2021, and 2020, is as follows: SCHEDULE OF DEBT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20211231__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zYbGniHaEfA6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20201231__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zSHpYiYtYDJ2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold"> </td><td style="font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--ConvertibleNotesPayable_iI_maCzpUc_zBemvk8awhLh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Principal balance</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">25,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">1,198,775</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_msCzpUc_zuDeYUPboBhg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Unamortized discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(119,790</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--ConvertibleDebtCurrent_iTI_mtCzpUc_zMnri2D69gPk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Ending balance, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">25,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,078,985</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

25000

This note matures 6 months after the Issuance Date

P6M

This note is convertible into shares of the Company’s common stock beginning on the Issuance Date at $0.025 for the first three months after the Issuance Date

After the first three months after the Issuance Date, the conversion price shall be equal to the lower of (i) $.025 or 50% of the lowest trading price for the thirty-five trading days prior to the conversion

127500

27625

99875

6375000

0.02

127500

14433

88708118

0.0016

6355008

127500

P6M

0.025

129500

8375

121125

6375000

0.02

129500

30264

110946972

0.00144

6355008

129500

111763

10416

0.15

P6M

This note is convertible into shares of the Company’s common stock beginning on the Issuance Date at $0.025 for the first three months after the Issuance Date

12500000

0.02

10416

250000

130044

243012455

0.00156

12460800

250000

239583

10416

0.12

106950

This note matures 12 months after the Issuance Date

0.55

85000

13950

8000

400

111225

0.45 85000

135786

220786

17737

50550

11265

20218562

0.00306

111225

161775

0.15

127500

This note matures 6 months after the Issuance Date

This note is convertible into shares of the Company’s common stock beginning on the Issuance Date at $0.011 for the first three months after the Issuance Date

102000

25500

6375000

0.02

82068

19932

207699

82068

125541

6355008

10792

127500

116708

10792

0.15

127500

P6M

This note is convertible into shares of the Company’s common stock beginning on the Issuance Date at $0.011 for the first three months after the Issuance Date

100000

25500

12750000

0.01

61733

40267

198239

61733

136506

12710016

21583

127500

105917

21583

250000

0.15

57500

0.01

the conversion price shall be equal to the lower of (i) $.01 or the volume weighted average price of the common stock during the five (5) Trading Day period ending on the day prior to conversion

200000

50000

14750

50000

35000000

0.25

3050

59264

35000000

250000

190736

59264

A summary of the convertible note balance as of December 31, 2021, and 2020, is as follows: SCHEDULE OF DEBT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20211231__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zYbGniHaEfA6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20201231__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zSHpYiYtYDJ2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold"> </td><td style="font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--ConvertibleNotesPayable_iI_maCzpUc_zBemvk8awhLh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Principal balance</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">25,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">1,198,775</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_msCzpUc_zuDeYUPboBhg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Unamortized discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(119,790</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--ConvertibleDebtCurrent_iTI_mtCzpUc_zMnri2D69gPk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Ending balance, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">25,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,078,985</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

25000

1198775

119790

25000

1078985

NOTE 7 – DERIVATIVE LIABILITIES The Company determined the conversion feature of the convertible notes, which all contain variable conversion rates, represented an embedded derivative since the notes were convertible into a variable number of shares upon conversion. Accordingly, the notes are not considered to be conventional debt under ASC 815 and the embedded conversion feature was bifurcated from the debt host and accounted for as a derivative liability. At any given time, certain of the Company’s embedded conversion features on debt and outstanding warrants may be treated as derivative liabilities for accounting purposes under ASC 815-40 due to insufficient authorized shares to settle these outstanding contracts. Pursuant to SEC staff guidance that permits a sequencing approach based on the use of ASC 815-15-25 which provides guidance for contracts that permit partial net share settlement. The sequencing approach may be applied in one of two ways: contracts may be evaluated based on (1) earliest issuance date or (2) latest maturity date. Pursuant to the sequencing approach, the Company evaluates its contracts based upon the latest maturity date. The Company valued the derivative liabilities at December 31, 2021, and 2020, at $20,966,701 and $3,299,684, respectively. For the derivative liability associated with convertible notes, the Company used the Monte Carlo simulation valuation model with the following assumptions as of December 31, 2021, and 2020, risk free interest rates at 0.19% and 0.09%, respectively, and volatility of 92% and <span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zOCkp3bxqdD7">48% to <span id="xdx_90B_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_z2qNRUWsAgq6">61%, respectively. During the year ended December 31, 2021, the Company issued 375,000,000 warrants in conjunction with notes payable (see Note 8). Due to insufficient authorized shares (see above), the Company recorded a discount to notes payable of $14,982,815 and interest expense of $38,907,939, with the offset to derivative liabilities for the initial fair value of the warrants based on the Black-Scholes option pricing method of $53,890,754. The following assumptions were utilized in the Black-Scholes valuation, risk free interest rate of <span id="xdx_903_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_z67O4k0YdnXj">.48% to <span id="xdx_902_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zrzmhFOciadd">.99%, volatility of <span id="xdx_90F_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputPriceVolatilityOneMember__srt--RangeAxis__srt--MinimumMember_zPEPCz9j1dvg">344% to <span id="xdx_90B_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputPriceVolatilityOneMember__srt--RangeAxis__srt--MaximumMember_zeP9DbwRunP2">366%, and exercise prices of $<span id="xdx_900_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uUSDPShares_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__srt--RangeAxis__srt--MinimumMember_zbIDMM6D3Di1">0.039 to $<span id="xdx_902_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uUSDPShares_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__srt--RangeAxis__srt--MaximumMember_za685xP3HbG3">0.15. The Company revaluated the warrants outstanding at December 31, 2020, and based on the insufficient authorized shares, the Company determined that the warrants should have been classified as a liability, The accompanying financial statements have been adjusted to reflect the change from an equity classification to a liability classification (see Note 2). A summary of the activity related to derivative liabilities for the years ended December 31, 2021, and 2020, is as follows: SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Derivative liabilities associated with warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Derivative liabilities associated with convertible notes</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total derivative liabilities</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Balance- July 10, 2020, assumed pursuant to PCTI transaction</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20200711__20201231__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithWarrantsMember_zVOuaVfCiRNk" style="width: 16%; text-align: right" title="Derivative liability, beginning balance">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20200711__20201231__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithConvertibleNotesMember_zs5FpqJu5nlb" style="width: 16%; text-align: right" title="Derivative liability, beginning balance">8,743,231</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20200711__20201231_zGiuBf10Jpbi" style="width: 16%; text-align: right" title="Derivative liability, beginning balance">8,743,231</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Issued during period</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--DerivativeLiabilityIssuedDuringPeriod_c20200711__20201231__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithWarrantsMember_z2qLnmDahNG1" style="text-align: right" title="Issued during period">2,061,307</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--DerivativeLiabilityIssuedDuringPeriod_c20200711__20201231__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithConvertibleNotesMember_zH0sbsUR7r1d" style="text-align: right">641,285</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--DerivativeLiabilityIssuedDuringPeriod_c20200711__20201231_zyVCc910FgRe" style="text-align: right">2,702,592</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Converted or paid</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--NotesConvertedOrPaidAndExerciseOfWarrants_c20200711__20201231__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithWarrantsMember_zw5WnlFedkq6" style="text-align: right" title="Converted or paid">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--NotesConvertedOrPaidAndExerciseOfWarrants_c20200711__20201231__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithConvertibleNotesMember_zJlJUAYIiLid" style="text-align: right">(8,322,188</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--NotesConvertedOrPaidAndExerciseOfWarrants_c20200711__20201231_zygmz6EqnsE4" style="text-align: right">(8,322,188</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value recognized in operations</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--DerivativeGainLossOnDerivativeNet_iN_di_c20200711__20201231__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithWarrantsMember_zuoLjjxY2wW3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--DerivativeGainLossOnDerivativeNet_iN_di_c20200711__20201231__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithConvertibleNotesMember_zzv8cSIK5i69" style="border-bottom: Black 1.5pt solid; text-align: right">176,049</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--DerivativeGainLossOnDerivativeNet_iN_di_c20200711__20201231_zIozr1Dfqjt3" style="border-bottom: Black 1.5pt solid; text-align: right">176,049</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance December 31, 2020</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20210101__20211231__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithWarrantsMember_zqY1rKcxM1ve" style="text-align: right" title="Derivative liability, beginning balance">2,061,307</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20210101__20211231__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithConvertibleNotesMember_zCyIV4NZtzv1" style="text-align: right" title="Derivative liability, beginning balance">1,238,377</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20210101__20211231_z3yARq7PsNuj" style="text-align: right" title="Derivative liability, beginning balance">3,299,684</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Fair value of issuances during period</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--DerivativeLiabilityIssuedDuringPeriod_pp0p0_c20210101__20211231__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithWarrantsMember_zS6LzfXYTJQ5" style="text-align: right" title="Fair value of issuances during period">53,890,754</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--DerivativeLiabilityIssuedDuringPeriod_pdp0_c20210101__20211231__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithConvertibleNotesMember_zi7VgG0UBAq9" style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--DerivativeLiabilityIssuedDuringPeriod_pp0p0_c20210101__20211231_z2da8nUFky8l" style="text-align: right">53,890,754</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Notes converted or paid</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--NotesConvertedOrPaidAndExerciseOfWarrants_pdp0_c20210101__20211231__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithWarrantsMember_z72YGqOvVws1" style="text-align: right" title="Notes converted or paid">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--NotesConvertedOrPaidAndExerciseOfWarrants_pp0p0_c20210101__20211231__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithConvertibleNotesMember_zdiUEXQE7RK8" style="text-align: right">(2,246,114</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--NotesConvertedOrPaidAndExerciseOfWarrants_pp0p0_c20210101__20211231_zubEag6L9lm9" style="text-align: right">(2,246,114</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercise of warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_pp0p0_c20210101__20211231__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithWarrantsMember_zJIuHowJW7el" style="text-align: right" title="Exercise of warrants">(48,110,301</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_pdp0_c20210101__20211231__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithConvertibleNotesMember_zuzyBOTwa4j3" style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_pp0p0_c20210101__20211231_zv90bvuvZVh3" style="text-align: right">(48,110,301</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrants cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--WarrantsCancelled_pp0p0_c20210101__20211231__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithWarrantsMember_znsjosEBhoql" style="text-align: right" title="Warrants cancelled">(3,216,397</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--WarrantsCancelled_pdp0_c20210101__20211231__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithConvertibleNotesMember_zhv98SvFQhwd" style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--WarrantsCancelled_pp0p0_c20210101__20211231_ztuq4rHvleEf" style="text-align: right">(3,216,397</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--DerivativeGainLossOnDerivativeNet_iN_pp0p0_di_c20210101__20211231__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithWarrantsMember_zIotPF7DJpXe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value">16,313,392</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--DerivativeGainLossOnDerivativeNet_iN_pp0p0_di_c20210101__20211231__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithConvertibleNotesMember_zF1t1GCk7uHb" style="border-bottom: Black 1.5pt solid; text-align: right">1,035,683</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--DerivativeGainLossOnDerivativeNet_iN_pp0p0_di_c20210101__20211231_zpCxxYuJaIo7" style="border-bottom: Black 1.5pt solid; text-align: right">17,349,075</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance December 31, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--DerivativeLiabilities_iE_pp0p0_c20210101__20211231__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithWarrantsMember_zdaKweGjLnvg" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative liability, ending balance">20,938,755</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--DerivativeLiabilities_iE_pp0p0_c20210101__20211231__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithConvertibleNotesMember_zapHGdSnc8j1" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative liability, ending balance">27,946</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--DerivativeLiabilities_iE_pp0p0_c20210101__20211231_zY21jEdSuX88" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative liability, ending balance">20,966,701</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

20966701

3299684

0.19

0.09

375000000 14982815 38907939

53890754

0.48

0.99

344

366

0.039

0.15

A summary of the activity related to derivative liabilities for the years ended December 31, 2021, and 2020, is as follows: SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Derivative liabilities associated with warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Derivative liabilities associated with convertible notes</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total derivative liabilities</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Balance- July 10, 2020, assumed pursuant to PCTI transaction</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20200711__20201231__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithWarrantsMember_zVOuaVfCiRNk" style="width: 16%; text-align: right" title="Derivative liability, beginning balance">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20200711__20201231__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithConvertibleNotesMember_zs5FpqJu5nlb" style="width: 16%; text-align: right" title="Derivative liability, beginning balance">8,743,231</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20200711__20201231_zGiuBf10Jpbi" style="width: 16%; text-align: right" title="Derivative liability, beginning balance">8,743,231</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Issued during period</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--DerivativeLiabilityIssuedDuringPeriod_c20200711__20201231__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithWarrantsMember_z2qLnmDahNG1" style="text-align: right" title="Issued during period">2,061,307</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--DerivativeLiabilityIssuedDuringPeriod_c20200711__20201231__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithConvertibleNotesMember_zH0sbsUR7r1d" style="text-align: right">641,285</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--DerivativeLiabilityIssuedDuringPeriod_c20200711__20201231_zyVCc910FgRe" style="text-align: right">2,702,592</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Converted or paid</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--NotesConvertedOrPaidAndExerciseOfWarrants_c20200711__20201231__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithWarrantsMember_zw5WnlFedkq6" style="text-align: right" title="Converted or paid">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--NotesConvertedOrPaidAndExerciseOfWarrants_c20200711__20201231__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithConvertibleNotesMember_zJlJUAYIiLid" style="text-align: right">(8,322,188</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--NotesConvertedOrPaidAndExerciseOfWarrants_c20200711__20201231_zygmz6EqnsE4" style="text-align: right">(8,322,188</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value recognized in operations</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--DerivativeGainLossOnDerivativeNet_iN_di_c20200711__20201231__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithWarrantsMember_zuoLjjxY2wW3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--DerivativeGainLossOnDerivativeNet_iN_di_c20200711__20201231__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithConvertibleNotesMember_zzv8cSIK5i69" style="border-bottom: Black 1.5pt solid; text-align: right">176,049</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--DerivativeGainLossOnDerivativeNet_iN_di_c20200711__20201231_zIozr1Dfqjt3" style="border-bottom: Black 1.5pt solid; text-align: right">176,049</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance December 31, 2020</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20210101__20211231__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithWarrantsMember_zqY1rKcxM1ve" style="text-align: right" title="Derivative liability, beginning balance">2,061,307</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20210101__20211231__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithConvertibleNotesMember_zCyIV4NZtzv1" style="text-align: right" title="Derivative liability, beginning balance">1,238,377</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20210101__20211231_z3yARq7PsNuj" style="text-align: right" title="Derivative liability, beginning balance">3,299,684</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Fair value of issuances during period</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--DerivativeLiabilityIssuedDuringPeriod_pp0p0_c20210101__20211231__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithWarrantsMember_zS6LzfXYTJQ5" style="text-align: right" title="Fair value of issuances during period">53,890,754</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--DerivativeLiabilityIssuedDuringPeriod_pdp0_c20210101__20211231__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithConvertibleNotesMember_zi7VgG0UBAq9" style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--DerivativeLiabilityIssuedDuringPeriod_pp0p0_c20210101__20211231_z2da8nUFky8l" style="text-align: right">53,890,754</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Notes converted or paid</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--NotesConvertedOrPaidAndExerciseOfWarrants_pdp0_c20210101__20211231__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithWarrantsMember_z72YGqOvVws1" style="text-align: right" title="Notes converted or paid">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--NotesConvertedOrPaidAndExerciseOfWarrants_pp0p0_c20210101__20211231__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithConvertibleNotesMember_zdiUEXQE7RK8" style="text-align: right">(2,246,114</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--NotesConvertedOrPaidAndExerciseOfWarrants_pp0p0_c20210101__20211231_zubEag6L9lm9" style="text-align: right">(2,246,114</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercise of warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_pp0p0_c20210101__20211231__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithWarrantsMember_zJIuHowJW7el" style="text-align: right" title="Exercise of warrants">(48,110,301</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_pdp0_c20210101__20211231__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithConvertibleNotesMember_zuzyBOTwa4j3" style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_pp0p0_c20210101__20211231_zv90bvuvZVh3" style="text-align: right">(48,110,301</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrants cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--WarrantsCancelled_pp0p0_c20210101__20211231__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithWarrantsMember_znsjosEBhoql" style="text-align: right" title="Warrants cancelled">(3,216,397</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--WarrantsCancelled_pdp0_c20210101__20211231__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithConvertibleNotesMember_zhv98SvFQhwd" style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--WarrantsCancelled_pp0p0_c20210101__20211231_ztuq4rHvleEf" style="text-align: right">(3,216,397</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--DerivativeGainLossOnDerivativeNet_iN_pp0p0_di_c20210101__20211231__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithWarrantsMember_zIotPF7DJpXe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value">16,313,392</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--DerivativeGainLossOnDerivativeNet_iN_pp0p0_di_c20210101__20211231__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithConvertibleNotesMember_zF1t1GCk7uHb" style="border-bottom: Black 1.5pt solid; text-align: right">1,035,683</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--DerivativeGainLossOnDerivativeNet_iN_pp0p0_di_c20210101__20211231_zpCxxYuJaIo7" style="border-bottom: Black 1.5pt solid; text-align: right">17,349,075</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance December 31, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--DerivativeLiabilities_iE_pp0p0_c20210101__20211231__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithWarrantsMember_zdaKweGjLnvg" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative liability, ending balance">20,938,755</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--DerivativeLiabilities_iE_pp0p0_c20210101__20211231__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithConvertibleNotesMember_zapHGdSnc8j1" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative liability, ending balance">27,946</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--DerivativeLiabilities_iE_pp0p0_c20210101__20211231_zY21jEdSuX88" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative liability, ending balance">20,966,701</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

8743231

2061307 641285 2702592 -8322188 -8322188

-176049

2061307

1238377

3299684

53890754 53890754 -2246114 -2246114

-48110301

-3216397 -3216397

-16313392

-1035683

-17349075

20938755

27946

20966701

NOTE 8 – NOTES PAYABLE The Company has the following note payables outstanding: SCHEDULE OF NOTES PAYABLE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20211231_za18pit4NtXk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20201231_zdA1WiyyiJUd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="display: none; text-align: left"/><td style="display: none"> </td> <td style="display: none; text-align: left">$</td><td id="xdx_983_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableMember_z8qWU26gCzOd" style="display: none; text-align: right" title="Sub total notes payable">134,681</td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left">$</td><td id="xdx_985_eus-gaap--NotesPayable_iI_pp0p0_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableMember_zfpclygeMVFg" style="display: none; text-align: right" title="Sub total notes payable">151,469</td><td style="display: none; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left">Note payable bank, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableMember_zqahdUDYU286"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableMember_z8R3tcX7Xyh9" title="Debt Instrument, Interest Rate, Stated Percentage">7.75%, matured <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableMember_zvUomMi0IeK8" title="Debt Instrument, Maturity Date"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_dd_c20200101__20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableMember_ztlosdWktnSl">December 5, 2021, currently in default</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableMember_z1kx1efFQoZ8" style="width: 22%; text-align: right" title="Sub total notes payable">134,681</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--NotesPayable_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableMember_pp0p0" style="width: 22%; text-align: right" title="Sub total notes payable">151,469</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Note payable bank, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableOneMember_zEGdGI5ygH74"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableOneMember_z5AaRGkPJq0a">6.5%, matures <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableOneMember_z0L0PqwSktke"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_dd_c20200101__20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableOneMember_ziqZIsnAFJYi">December 26, 2021, in default</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableOneMember_z1GLuAjvnNql" style="text-align: right" title="Sub total notes payable">344,166</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--NotesPayable_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableOneMember_pp0p0" style="text-align: right" title="Sub total notes payable">345,211</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Economic Injury Disaster Loan</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--EconomicInjuryDisasterLoanMember_zOiQ9JRoVwad" style="text-align: right" title="Sub total notes payable">10,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--NotesPayable_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--EconomicInjuryDisasterLoanMember_pp0p0" style="text-align: right" title="Sub total notes payable">10,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Paycheck Protection Program loan</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--PaycheckProtectionProgramloanMember_zwXFywFqKbK4" style="text-align: right" title="Sub total notes payable">100,400</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--NotesPayable_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--PaycheckProtectionProgramloanMember_pp0p0" style="text-align: right" title="Sub total notes payable">100,400</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Notes payable, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwoMember_zNxYJF9dnysa"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwoMember_zoisJ1luBRwd">8%, matured <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwoMember_zVUgNKvGVnYf"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_dd_c20200101__20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwoMember_z0vTeWYpSeMa">January 5, 2020, in default</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwoMember_zPMTokBHRbKk" style="text-align: right" title="Sub total notes payable">45,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--NotesPayable_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwoMember_pp0p0" style="text-align: right" title="Sub total notes payable">45,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other, due on demand, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--OtherMember_zmWJOy8mXxwf"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--OtherMember_zroWwLF5raOc">6%, currently in default</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--OtherMember_zLHjfIX6O12" style="text-align: right" title="Sub total notes payable">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--NotesPayable_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--OtherMember_pp0p0" style="text-align: right" title="Sub total notes payable">50,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Note payable $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_zDIHPpsVJKP3"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_zgg1NS2MWS9e">203,000 face value, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_zKVjki1fiuP7"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_zt25Ql88Ud39">12%, matured <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_zSQDecty4z3f"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_dd_c20200101__20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_z2xGPBs1tZ7i">June 25, 2021, net of discount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_zMbSGDtqEUYh"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_zE85kkq7ZJn1">13,185 at December 31, 2020</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_zFHxiaNGZJh9" style="text-align: right" title="Sub total notes payable">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--NotesPayable_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_pp0p0" style="text-align: right" title="Sub total notes payable">189,815</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Note payable $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zeDfYPFgTra6"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zBv1kbd7F5il">750,000 face value, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_z4JjzNB1lEQ8"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zYzcAUmp2jfi">12%, matured <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_z26aA9oXyWg3"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--DebtInstrumentMaturityDate_dd_c20200101__20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zbzRHUyuJJJk">August 24, 2021, net of discount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zhveUe4trQIg">540,562 (2020), in default</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zioqWaUxuXoh" style="text-align: right" title="Sub total notes payable">375,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--NotesPayable_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_pp0p0" style="text-align: right" title="Sub total notes payable">209,438</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Note payable $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_zUtDB8pTJVh7"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_zZvRJTj6QDMc">389,423 face value, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_zkHMCfCdUY77"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_z5xZsv3Ke3s1">18%, matures <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_z8MdGHdKYTE6"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_dd_c20200101__20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_za2NcfU3HMud">November 6, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_zgRAL10y6jb4" style="text-align: right" title="Sub total notes payable">389,423</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--NotesPayable_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_pp0p0" style="text-align: right" title="Sub total notes payable">389,423</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Note payable $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_zQngCr2kqRv9"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_zjfNVuGqjidb">1,000,000 face value, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_z0xl5aLn6vr1"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_zg7GkjUiYDeg">12%, matures <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_ziMpP76j079g"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_dd_c20200101__20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_zMYXpi25hDb6">November 13, 2021, net of discount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_zHbzJUTmCbub">971,250 (2020), in default</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_z8tiiiz6fhtd" style="text-align: right" title="Sub total notes payable">1,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--NotesPayable_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_pp0p0" style="text-align: right" title="Sub total notes payable">28,750</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Note payable $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_zClM2SHx8s66"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_z8ZrJWRW2AHg">2,200,000 face value, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_zaevZceLB417"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_z23o0Un0eYE3">12%, matures <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_zze64bZcmOgh"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_dd_c20200101__20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_zU8LslwRn0d5">February 9, 2022, net of discount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_zsMaV17NYvM5"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_zOIVPZBhv872">243,833</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_zpAbv6atftm7" style="text-align: right" title="Sub total notes payable">1,956,167</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--NotesPayable_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_pp0p0" style="text-align: right" title="Sub total notes payable">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Note payable $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_zKXRZAUEq1nh"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_zDBNWU3Wf1f9">11,110,000 face value, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_zvCjLbxq34i6"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_zseacKQanvc9">12%, matures <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_zqwzElWVYQm9"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_dd_c20200101__20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_zuyNoVDKjg9i">March 17, 2022, net of discount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_zc4krHMfLl7k"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_zJ9PcC6azMW3">2,314,583</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_zdYJAz8X79h7" style="text-align: right" title="Sub total notes payable">8,795,417</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--NotesPayable_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_pp0p0" style="text-align: right" title="Sub total notes payable">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Note payable $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableNineMember_zgepXEnrsECf" title="Debt Instrument, face amount"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableNineMember_zkbGDdEyXDIk">3,300,000 face value, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableNineMember_zmLsp7IX2JS3"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableNineMember_z8sI0ySYqHp3" title="Debt Instrument, interest rate, stated percentage">12%, matures <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableNineMember_zhdjbfpSaLPa"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_dd_c20200101__20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableNineMember_zUpwIpmYQR71" title="Debt Instrument, maturity date">December 7, 2022, net of discount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableNineMember_z26FhFYE6jde"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableNineMember_zsH2FPDHa2za" title="Debt Instrument, unamortized discount">3,099,524</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableNineMember_zRVPPkMvOpq3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Sub total notes payable">200,476</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--NotesPayable_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Sub- total notes payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,400,730</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,519,506</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LongTermNotesPayable_iI_pp0p0_zgurHr5iWZgc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less long-term portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">389,423</td><td style="padding-bottom: 1.5pt; text-align: left"/><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">389,423</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--NotesPayableCurrent_iI_pp0p0_zzW1CcT1g0w" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Current portion of notes payable, net of discount</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,011,307</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,130,083</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> On December 7, 2021, the Company entered into a <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211207__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_zyq2iIg3IQR2">12%, $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20211207__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_z2WkXVv4dVu2">3,300,000 face value promissory note with a third- party lender with a maturity date of <span id="xdx_907_eus-gaap--DebtInstrumentMaturityDate_dd_c20211205__20211207__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_zJQny4zTHfb8">December 7, 2022. In exchange for the issuance of the $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20211207__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_zdTwu2D44ev1">3,300,000 note, inclusive of an original issue discount of $<span id="xdx_909_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20211207__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_zlKEchCtuHW4">300,000, the Company received proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromNotesPayable_pp0p0_c20211212__20211213__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_zS7uqXIlvMT1">3,000,000 on December 13, 2021, from the lender. In conjunction with the note, the Company issued a warrant to purchase <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211207__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_zehhXI7WSdTg">75,000,000 shares of common stock at $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20211207__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_zdFeh1lNFT18">0.039 per share (subject to adjustments) with an expiry date on the three- year anniversary of the note. For the year ended December 31, 2021, amortization of the costs of $<span id="xdx_90D_eus-gaap--AmortizationOfDebtDiscountPremium_pp0p0_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_zzswkSfsgFZb">16,750 was charged to interest expense. The fair value of the warrant calculated by the Black- Scholes option pricing method of $<span id="xdx_909_eus-gaap--InterestExpense_pp0p0_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_z65mg246nzPj">2,982,815 has been recorded as an initial debt and an initial derivative liability of $<span id="xdx_904_eus-gaap--DerivativeLiabilities_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LendersMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_zUwD9H4n40wd">2,982,815. For the year ended December 31, 2021, amortization of the warrant discount of $<span id="xdx_90D_ecustom--AmortizationOfWarrantDiscount_iI_pp0p0_c20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_zddceo117Rp5">166,540 was charged to interest expense. As of December 31, 2021, the outstanding principal balance of this note was $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20211231__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_zFmuN89ZMR2a">3,300,000 with a carrying value of $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_zOQEys6fFwqg">200,476, net of unamortized discounts of $<span id="xdx_90F_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_zEgDoTBVqJJ4">3,099,524. On March 17, 2021, the Company entered into a <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210317__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember_znPw2U2GJjP6">12%, $11,110,000 face value promissory note with a third- party lender with a maturity date of March 17, 2022. In exchange for the issuance of the $11,110,000 note, inclusive of an original issue discount of $1,000,000 and lender costs of $<span id="xdx_90B_ecustom--LenderCosts_pp0p0_c20210316__20210317__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember_ztxzDIsbpCkh" title="Lender costs">110,000 the Company received proceeds of $10,000,000 on March 23, 2021, from the lender. In conjunction with the note, the Company issued a warrant to purchase <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20210317__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember_pdd">250,000,000 shares of common stock at $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20210317__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember_zYYsqKOVA1x2">0.13 per share (subject to adjustments) with an expiry date on the three- year anniversary of the note. For the year ended December 31, 2021, amortization of the costs of $<span id="xdx_90C_eus-gaap--AmortizationOfDebtDiscountPremium_pp0p0_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember_zXyV9zZP7onk">878,750 was charged to interest expense. The fair value of the warrant calculated by the Black- Scholes option pricing method of $<span id="xdx_90F_eus-gaap--FairValueAdjustmentOfWarrants_pp0p0_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueOptionPricingModelMember_zw4OF7ZT0BJ5" title="Fair value of adjustment of warrants">33,248,433 has been recorded as an initial debt discount of $<span id="xdx_900_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueOptionPricingModelMember_zu0zgkx0NK64">10,000,000, interest expense of $<span id="xdx_906_eus-gaap--InterestExpense_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueOptionPricingModelMember_zNrflmWtrTV3">23,248,433 and initial derivative liability of $<span id="xdx_905_eus-gaap--DerivativeLiabilities_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueOptionPricingModelMember_zyB0aneWNv2g">32,248,433. For the year ended December 31, 2021, amortization of the warrant discount of $7,916,667 was charged to interest expense. As of December 31, 2021, the outstanding principal balance of this note was $11,110,000 with a carrying value of $8,795,417, net of unamortized discounts of $2,314,583. The Company is in discussions with the lender regarding the extension of the maturity date of this note. On February 9, 2021, the Company entered into a <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210209__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember__srt--TitleOfIndividualAxis__custom--LenderMember_zGGRzdvnxr85">12%, $2,200,000 face value promissory note with a third- party lender with a maturity date of February 9, 2022. In exchange for the issuance of the $2,200,000 note, inclusive of an original issue discount of $200,000 the Company received proceeds of $2,000,000 on February 16, 2021, from the lender. In conjunction with the note, the Company issued a warrant to purchase <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20210209__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember__srt--TitleOfIndividualAxis__custom--LenderMember_zys8hNJFK7pl">50,000,000 shares of common stock at $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20210209__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember__srt--TitleOfIndividualAxis__custom--LenderMember_z7OuOI49J4P4">0.15 per share (subject to adjustments) with an expiry date on the three- year anniversary of the note. For the year ended December 31, 2021, amortization of the costs of $<span id="xdx_90E_eus-gaap--AmortizationOfDebtDiscountPremium_pp0p0_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember__srt--TitleOfIndividualAxis__custom--LenderMember_z6LopmLv9dM3">177,833 was charged to interest expense. The fair value of the warrant calculated by the Black- Scholes option pricing method of $<span id="xdx_90B_eus-gaap--FairValueAdjustmentOfWarrants_pp0p0_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueOptionPricingModelMember_zoM7JSW1uLUb" title="Fair value of adjustment of warrants">17,659,506 has been recorded as an initial debt discount of $<span id="xdx_906_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueOptionPricingModelMember_zj2wZp3GFxmh">2,000,000, interest expense of $<span id="xdx_90D_eus-gaap--InterestExpense_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueOptionPricingModelMember_zLkFvKXmnT6e">15,659,506 and initial derivative liability of $<span id="xdx_902_eus-gaap--DerivativeLiabilities_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember__srt--TitleOfIndividualAxis__custom--LendersMember__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueOptionPricingModelMember_z4zvp8ewZREb">17,659,506. For the year ended December 31, 2021, amortization of the warrant discount of $1,778,333 was charged to interest expense. As of December 31, 2021, the outstanding principal balance of this note was $2,200,000 with a carrying value of $1,956,167, net of unamortized discounts of $243,833. The Company is in discussions with the lender regarding the extension of the maturity date of this note. On November 13, 2020, the Company entered into a <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20201113__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_z7lUND4NbAd4">12%, $1,000,000 face value promissory note with a third-party due November 13, 2021. Principal payments shall be made in six instalments of $166,667 commencing 180 days from the issue date and continuing each 30 days thereafter for 5 months and the final payment of principal and interest due on the maturity date. The Company received proceeds of $890,000 on November 20, 2020, and the Company reimbursed the investor for expenses for legal fees and due diligence of $110,000. For the year ended December 31, 2021, amortization of the costs of $<span id="xdx_90C_eus-gaap--AmortizationOfDebtDiscountPremium_pp0p0_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember__srt--TitleOfIndividualAxis__custom--HolderMember_z2Ygs1iYIj76">96,250 was charged to interest expense. In conjunction with this note, the Company issued 2 common stock purchase warrants; each warrant entitles the Holder to purchase 125,000,000 shares of common stock at an exercise price of $0.008, subject to adjustments and expires on the five-year anniversary of the issue date. The warrants issued resulted in a debt discount of $<span id="xdx_900_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_pp0p0_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember__srt--TitleOfIndividualAxis__custom--HolderMember_zuj2HQzkOuM3">1,000,000. For the year ended December 31, 2021, amortization of the warrant discount of $875,000 was charged to interest expense. As of December 31, 2021, and December 31, 2020, the outstanding principal balance of this note was $1,000,000 with a carrying value of $1,000,000 and $28,750, respectively, net of unamortized discounts of $971,250. This note is in default and the interest rate from the date of default is the lesser of 24% or the highest amount permitted by law. As of December 31, 2021, the accrued interest is $<span id="xdx_902_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember__srt--TitleOfIndividualAxis__custom--ThirdPartyMember_zuD3tBkvlLLd">135,452. The Company is in discussions with the lender regarding the extension of the maturity date of this note. On November 6, 2020, the Company entered into a Settlement Agreement with the holder of $120,000 of convertible notes with accrued and unpaid interest of $8,716 and a $210,000 Promissory Noted dated June 23, 2020 with accrued and unpaid interest of $15,707. The Company issued a new <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20201106__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zPY7STpxyDL4">12% Promissory Note with a face value of $389,423 and a maturity date of November 6, 2023. In conjunction with this settlement, the Company issued a warrant to purchase <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20201106__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zvLf1gFo5jGh">60,000,000 shares of common stock at an exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20201106__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zaeySToHmGMe">0.0075, subject to adjustments and expires on the <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtYxL_c20201106__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zauG4sedxbB6" title="::XDX::5">five-year anniversary of the issue date. The Company analyzed the transaction and concluded that this was a modification to the existing debt. The investor exercised the warrant on January 14, 2021. On October 26, 2016, PCTI entered into a $210,000 note payable with a bank. On March 15, 2021, due to defaults with the terms of the note, the note was amended with the outstanding balance due December 5, 2021, and the interest rate changed to 7.75%. Borrowings are collateralized by substantially all of the assets of PCTI and the personal guarantee of PCTI’s former President. As of December 31, 2021, and December 31, 2020, $134,681 and $151,469, respectively, was outstanding on the note payable. This note is in default. On March 15, 2021, PCTI renewed their $350,000 promissory note with a bank that provides for borrowings of up to $350,000. Interest is due monthly and the principal is due on December 26, 2021, interest rate changed to the prime rate plus <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_c20210315__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_z6Cfdhyccwnb">3.25% (6.5% at March 15, 2021). Borrowings are collateralized by substantially all of the assets of PCTI and the personal guarantee of PCTI’s former President. As of December 31, 2021, and December 31, 2020, $344,166 and $345,211, respectively, was outstanding on the promissory note. This note is in default. On August 24, 2020 (the “Issue Date”), the Company entered into a <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20200824__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zc9dzhwpSVbj">12%, $750,000 face value promissory note with a third-party (the “Holder”) due August 24, 2021 (the “Maturity Date”). Principal payments shall be made in six instalments of $125,000 commencing 180 days from the Issue Date and continuing each 30 days thereafter for 5 months and the final payment of principal and interest due on the Maturity Date. The Holder shall have the right from time to time, and at any time following an event of default, as defined on the agreement, to convert all or any part of the outstanding and unpaid principal, interest and any other amounts due into fully paid and non-assessable shares of common stock of the Company, at the lower of i) the Trading Price (as defined in the agreement) during the previous five trading days prior to the Issuance Date or ii) the volume weighted average price during the five trading days ending on the day preceding the conversion date. The Company received proceeds of $663,000 on August 25, 2020, and the Company reimbursed the investor for expenses for legal fees and due diligence of $87,000. For the year ended December 31, 2021, amortization of the costs of $<span id="xdx_90F_eus-gaap--InterestExpense_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember__us-gaap--TypeOfArrangementAxis__custom--NineInstalmentsMember_ziaZGIiZgQI9">56,188 was charged to interest expense. In conjunction with this Note, the Company issued 2 common stock purchase warrants; each warrant entitles the Holder to purchase <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20200824__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zWzFjq0zeoFk">122,950,819 shares of common stock at an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20200824__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zvweQb0a7CRh">0.0061, subject to adjustments and expires on the <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtYxL_c20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zZ3cENtwbobk" title="::XDX::5">five-year anniversary of the Issue Date. The warrants issued resulted in a debt discount of $<span id="xdx_90B_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember__us-gaap--TypeOfArrangementAxis__custom--NineInstalmentsMember_z0TzDnUTX4M">750,000. For the year ended December 31, 2021, amortization of the debt discount of $484,376 was charged to interest expense. During the year ended December 31, 2021, the Company paid $375,000 to the Holder. On May 3, 2021, the Company issued 75,000,000 shares of common stock to the Holder, upon the cashless exercise of a portion of the warrants. As of December 31, 2021, and 2020, the outstanding principal balance of this note was $375,000 and $750,000, respectively, with a carrying value of $375,000 and $209,438, net of unamortized discounts of $540,562 as of December 31, 2020. This note is in default and the interest rate from the date of default is the lesser of 24% or the highest amount permitted by law. As of December 31, 2021, the accrued interest is $90,247. The Company is in discussions with the lender regarding the extension of the maturity date of this note. On April 20, 2020, PCTI was granted a loan from Huntington Bank in the amount of $100,400, pursuant to the Paycheck Protection Program (“PPP”) under Division A, Title I of the CARES Act, which was enacted March 27, 2020. The loan matures on April 20, 2022 and bears interest at a rate of 1.0% per annum, payable monthly beginning on November 20, 2020. The loan may be prepaid at any time prior to maturity with no prepayment penalties. Payments are deferred until the SBA determines the amount to be forgiven. The Company utilized the proceeds of the PPP loan in a manner which will enable qualification as a forgivable loan. On March 26, 2021, the Company received notice from Huntington Bank the they have determined that PCTI’s loan forgiveness application has been approved and has been submitted to the SBA. On December 2, 2021, PCTI received a notice from Huntington Bank that the SBA has denied PCTI’s application for loan forgiveness, due to inaccurate statements in the loan application as submitted by the former CEO of PCTI. The balance on this PPP loan was $100,400 as of December 31, 2021, and 2020 and has been classified in notes payable. On July 14, 2020, PCTI received $10,000 grant under the Economic Injury Disaster Loan (“EIDL”) program. Up to $10,000 of the EIDL can be forgiven as long as such funds were utilized to provide working capital. The first payment due is deferred one year. The loan as of December 31, 2021, and 2020 and has been classified in notes payable. The following note was assumed on July 10, 2020, pursuant to the PCTI transaction: On June 25, 2020, the Company entered into a <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20200625__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zuQf3Kr1ytE6">12%, $203,000 face value promissory note with a third-party lender with a maturity date of June 25, 2021. Principal payments shall be made in six instalments of $33,333 commencing 180 days from the issue date and continuing each 30 days thereafter for 5 months and the final payment of principal and interest due on the maturity date. The Holder shall have the right from time to time, and at any time following an event of default, as defined on the agreement, to convert all or any part of the outstanding and unpaid principal, interest and any other amounts due into fully paid and non-assessable shares of common stock of the Company, at the lower of i) the Trading Price (as defined in the agreement) during the previous five trading days prior to the issuance date or ii) the volume weighted average price during the five trading days ending on the day preceding the conversion date. The Company received proceeds of $176,000 on June 26, 2020, and the Company reimbursed the investor for expenses for legal fees and due diligence of $27,000. For the year ended December 31, 2021, amortization of the costs of $13,185 was charged to interest expense. In conjunction with this Note, the Company issued 2 common stock purchase warrants; each warrant entitles the Holder to purchase <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20200625__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_za2BTB0NtQc3">10,000,000 shares of common stock at an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zDNqpxJaj9tb">0.02, subject to adjustments and expires on the <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtYxL_c20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zRBHT9sb1SIk" title="::XDX::5">five-year anniversary of the Issue Date. During the year ended December 31, 2021, the investor converted a total of $203,000 of the face value and $15,899 of accrued interest and fees into <span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember_zvC6KVfQpJff">20,268,511 shares of common stock at an average conversion price of $0.0108. On January 8, 2021, and January 15, 2021, the investor received <span id="xdx_90F_ecustom--NumberSharesIssuedForCashlessExerciseOfWarrants_pid_c20210107__20210108__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zzvkRrfBsHub">100,668,692 and <span id="xdx_90C_ecustom--NumberSharesIssuedForCashlessExerciseOfWarrants_pid_c20210113__20210115__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zwJ0ZtSjvq6g" title="Number shares issued for cashless">9,121,265 shares of common stock, respectively, upon the cashless exercise of the warrants. As of December 31, 2021, and December 31, 2020, the outstanding principal balance of this note was $-0- and $203,000, respectively. The Company has the following note payables outstanding: SCHEDULE OF NOTES PAYABLE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20211231_za18pit4NtXk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20201231_zdA1WiyyiJUd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="display: none; text-align: left"/><td style="display: none"> </td> <td style="display: none; text-align: left">$</td><td id="xdx_983_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableMember_z8qWU26gCzOd" style="display: none; text-align: right" title="Sub total notes payable">134,681</td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left">$</td><td id="xdx_985_eus-gaap--NotesPayable_iI_pp0p0_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableMember_zfpclygeMVFg" style="display: none; text-align: right" title="Sub total notes payable">151,469</td><td style="display: none; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left">Note payable bank, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableMember_zqahdUDYU286"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableMember_z8R3tcX7Xyh9" title="Debt Instrument, Interest Rate, Stated Percentage">7.75%, matured <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableMember_zvUomMi0IeK8" title="Debt Instrument, Maturity Date"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_dd_c20200101__20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableMember_ztlosdWktnSl">December 5, 2021, currently in default</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableMember_z1kx1efFQoZ8" style="width: 22%; text-align: right" title="Sub total notes payable">134,681</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--NotesPayable_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableMember_pp0p0" style="width: 22%; text-align: right" title="Sub total notes payable">151,469</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Note payable bank, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableOneMember_zEGdGI5ygH74"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableOneMember_z5AaRGkPJq0a">6.5%, matures <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableOneMember_z0L0PqwSktke"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_dd_c20200101__20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableOneMember_ziqZIsnAFJYi">December 26, 2021, in default</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableOneMember_z1GLuAjvnNql" style="text-align: right" title="Sub total notes payable">344,166</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--NotesPayable_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableOneMember_pp0p0" style="text-align: right" title="Sub total notes payable">345,211</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Economic Injury Disaster Loan</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--EconomicInjuryDisasterLoanMember_zOiQ9JRoVwad" style="text-align: right" title="Sub total notes payable">10,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--NotesPayable_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--EconomicInjuryDisasterLoanMember_pp0p0" style="text-align: right" title="Sub total notes payable">10,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Paycheck Protection Program loan</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--PaycheckProtectionProgramloanMember_zwXFywFqKbK4" style="text-align: right" title="Sub total notes payable">100,400</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--NotesPayable_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--PaycheckProtectionProgramloanMember_pp0p0" style="text-align: right" title="Sub total notes payable">100,400</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Notes payable, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwoMember_zNxYJF9dnysa"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwoMember_zoisJ1luBRwd">8%, matured <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwoMember_zVUgNKvGVnYf"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_dd_c20200101__20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwoMember_z0vTeWYpSeMa">January 5, 2020, in default</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwoMember_zPMTokBHRbKk" style="text-align: right" title="Sub total notes payable">45,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--NotesPayable_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwoMember_pp0p0" style="text-align: right" title="Sub total notes payable">45,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other, due on demand, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--OtherMember_zmWJOy8mXxwf"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--OtherMember_zroWwLF5raOc">6%, currently in default</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--OtherMember_zLHjfIX6O12" style="text-align: right" title="Sub total notes payable">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--NotesPayable_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--OtherMember_pp0p0" style="text-align: right" title="Sub total notes payable">50,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Note payable $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_zDIHPpsVJKP3"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_zgg1NS2MWS9e">203,000 face value, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_zKVjki1fiuP7"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_zt25Ql88Ud39">12%, matured <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_zSQDecty4z3f"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_dd_c20200101__20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_z2xGPBs1tZ7i">June 25, 2021, net of discount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_zMbSGDtqEUYh"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_zE85kkq7ZJn1">13,185 at December 31, 2020</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_zFHxiaNGZJh9" style="text-align: right" title="Sub total notes payable">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--NotesPayable_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_pp0p0" style="text-align: right" title="Sub total notes payable">189,815</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Note payable $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zeDfYPFgTra6"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zBv1kbd7F5il">750,000 face value, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_z4JjzNB1lEQ8"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zYzcAUmp2jfi">12%, matured <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_z26aA9oXyWg3"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--DebtInstrumentMaturityDate_dd_c20200101__20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zbzRHUyuJJJk">August 24, 2021, net of discount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zhveUe4trQIg">540,562 (2020), in default</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zioqWaUxuXoh" style="text-align: right" title="Sub total notes payable">375,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--NotesPayable_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_pp0p0" style="text-align: right" title="Sub total notes payable">209,438</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Note payable $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_zUtDB8pTJVh7"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_zZvRJTj6QDMc">389,423 face value, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_zkHMCfCdUY77"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_z5xZsv3Ke3s1">18%, matures <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_z8MdGHdKYTE6"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_dd_c20200101__20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_za2NcfU3HMud">November 6, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_zgRAL10y6jb4" style="text-align: right" title="Sub total notes payable">389,423</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--NotesPayable_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_pp0p0" style="text-align: right" title="Sub total notes payable">389,423</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Note payable $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_zQngCr2kqRv9"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_zjfNVuGqjidb">1,000,000 face value, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_z0xl5aLn6vr1"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_zg7GkjUiYDeg">12%, matures <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_ziMpP76j079g"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_dd_c20200101__20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_zMYXpi25hDb6">November 13, 2021, net of discount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_zHbzJUTmCbub">971,250 (2020), in default</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_z8tiiiz6fhtd" style="text-align: right" title="Sub total notes payable">1,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--NotesPayable_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_pp0p0" style="text-align: right" title="Sub total notes payable">28,750</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Note payable $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_zClM2SHx8s66"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_z8ZrJWRW2AHg">2,200,000 face value, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_zaevZceLB417"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_z23o0Un0eYE3">12%, matures <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_zze64bZcmOgh"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_dd_c20200101__20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_zU8LslwRn0d5">February 9, 2022, net of discount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_zsMaV17NYvM5"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_zOIVPZBhv872">243,833</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_zpAbv6atftm7" style="text-align: right" title="Sub total notes payable">1,956,167</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--NotesPayable_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_pp0p0" style="text-align: right" title="Sub total notes payable">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Note payable $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_zKXRZAUEq1nh"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_zDBNWU3Wf1f9">11,110,000 face value, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_zvCjLbxq34i6"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_zseacKQanvc9">12%, matures <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_zqwzElWVYQm9"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_dd_c20200101__20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_zuyNoVDKjg9i">March 17, 2022, net of discount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_zc4krHMfLl7k"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_zJ9PcC6azMW3">2,314,583</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_zdYJAz8X79h7" style="text-align: right" title="Sub total notes payable">8,795,417</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--NotesPayable_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_pp0p0" style="text-align: right" title="Sub total notes payable">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Note payable $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableNineMember_zgepXEnrsECf" title="Debt Instrument, face amount"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableNineMember_zkbGDdEyXDIk">3,300,000 face value, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableNineMember_zmLsp7IX2JS3"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableNineMember_z8sI0ySYqHp3" title="Debt Instrument, interest rate, stated percentage">12%, matures <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableNineMember_zhdjbfpSaLPa"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_dd_c20200101__20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableNineMember_zUpwIpmYQR71" title="Debt Instrument, maturity date">December 7, 2022, net of discount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableNineMember_z26FhFYE6jde"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableNineMember_zsH2FPDHa2za" title="Debt Instrument, unamortized discount">3,099,524</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableNineMember_zRVPPkMvOpq3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Sub total notes payable">200,476</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--NotesPayable_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Sub- total notes payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,400,730</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,519,506</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LongTermNotesPayable_iI_pp0p0_zgurHr5iWZgc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less long-term portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">389,423</td><td style="padding-bottom: 1.5pt; text-align: left"/><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">389,423</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--NotesPayableCurrent_iI_pp0p0_zzW1CcT1g0w" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Current portion of notes payable, net of discount</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,011,307</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,130,083</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

134681

151469

0.0775

2021-12-05

134681

151469

0.065

2021-12-26

344166

345211

10000

100400

0.08

2020-01-05

45000

0.06

50000

203000

0.12

2021-06-25

13185

189815

750000

0.12

2021-08-24

540562

375000

209438

389423

0.18

2023-11-06

389423

1000000

0.12

2021-11-13

971250

1000000

28750

2200000

0.12

2022-02-09

243833

1956167

11110000

0.12

2022-03-17

2314583

8795417

3300000

0.12

2022-12-07

3099524

200476

13400730

1519506

389423

13011307

1130083

0.12

3300000

2022-12-07

3300000

300000

3000000

75000000

0.039

16750

2982815

166540

3300000

200476

3099524

0.12

11110000

2022-03-17

11110000

1000000

110000

10000000

250000000

0.13

878750

33248433

10000000

23248433

32248433

7916667

11110000

8795417

2314583

0.12

2200000

2022-02-09

2200000

200000

2000000

50000000

0.15

177833

17659506

2000000

15659506

17659506

1778333

2200000

1956167

243833

0.12

1000000

2021-11-13

Principal payments shall be made in six instalments of $166,667 commencing 180 days from the issue date and continuing each 30 days thereafter for 5 months and the final payment of principal and interest due on the maturity date

890000

110000

96250

125000000

0.008

1000000

875000

1000000

28750

971250

135452

120000

8716

210000

15707

0.12

389423

2023-11-06

60000000

0.0075

210000

0.0775

134681

151469

350000

2021-12-26

3.25

0.065

344166

345211

0.12

750000

Principal payments shall be made in six instalments of $125,000 commencing 180 days from the Issue Date and continuing each 30 days thereafter for 5 months and the final payment of principal and interest due on the Maturity Date. The Holder shall have the right from time to time, and at any time following an event of default, as defined on the agreement, to convert all or any part of the outstanding and unpaid principal, interest and any other amounts due into fully paid and non-assessable shares of common stock of the Company, at the lower of i) the Trading Price (as defined in the agreement) during the previous five trading days prior to the Issuance Date or ii) the volume weighted average price during the five trading days ending on the day preceding the conversion date

663000

87000

56188

122950819

0.0061

750000

484376

375000

75000000

375000

750000

375000

209438

540562

90247

100400

2022-04-20

0.010

100400

10000

The first payment due is deferred one year. The loan as of December 31, 2021, and 2020 and has been classified in notes payable

0.12

203000

2021-06-25

Principal payments shall be made in six instalments of $33,333 commencing 180 days from the issue date and continuing each 30 days thereafter for 5 months and the final payment of principal and interest due on the maturity date. The Holder shall have the right from time to time, and at any time following an event of default, as defined on the agreement, to convert all or any part of the outstanding and unpaid principal, interest and any other amounts due into fully paid and non-assessable shares of common stock of the Company, at the lower of i) the Trading Price (as defined in the agreement) during the previous five trading days prior to the issuance date or ii) the volume weighted average price during the five trading days ending on the day preceding the conversion date

176000

27000

13185

10000000

0.02

203000

15899

20268511

0.0108

100668692 9121265

203000

NOTE 9 – DEFERRED LIABILITY On September 2, 2020, PCTI entered into an agreement with a third- party. Pursuant to the terms of the agreement, in exchange for $<span id="xdx_900_ecustom--DeferredLiabilityCurrent_iI_pp0p0_c20200902__dei--LegalEntityAxis__custom--PCTIMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_z08if34TKB1b" title="Deferred liability, current">750,000, PCTI agreed to pay the third-party a perpetual three percent (<span id="xdx_90A_eus-gaap--ProductLiabilityContingencyThirdPartyRecoveryPercentage_pid_dp_c20200830__20200902__dei--LegalEntityAxis__custom--PCTIMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_zSdF9douQP7e" title="Product liability contingency, third party recovery, percentage">3%) payment of revenues, as defined in the agreement. Payments are due ninety (90) days after each calendar quarter, with the first payment due on or before March 31, 2021, for revenues for the quarter ending December 31, 2020. The Company has recorded the $750,000 as deferred liability on the December 31, 2021, and 2020, consolidated balance sheet. No payments have been made and the Company is in default of the agreement. On February 26, 2021, the agreement was assigned to Ozop and on March 4, 2021, the note was amended, whereby in exchange for <span id="xdx_901_eus-gaap--DeferredCompensationArrangementWithIndividualSharesIssued_pid_c20210225__20210226__dei--LegalEntityAxis__custom--PCTIMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_zv3pwg307d7j" title="Deferred compensation exchanged for common stock">175,000,000 shares of common stock, the royalty percentage was amended to <span id="xdx_90F_ecustom--RoyaltyPercentage_pid_dp_c20210225__20210226__dei--LegalEntityAxis__custom--PCTIMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_zAdBoNccxvs8" title="Royalty percentage">1.8%. The Company valued the shares at $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20211231__dei--LegalEntityAxis__custom--PCTIMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_zKIdRZzbbHd9" title="Shares issued, price per share">0.094 per share (the market value of the common stock on the date of the agreement) and recorded $<span id="xdx_905_eus-gaap--PaymentsOfDebtRestructuringCosts_pp0p0_c20210101__20211231__dei--LegalEntityAxis__custom--PCTIMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_zKqukDd6sB3g" title="Payments of debt restructuring costs">16,450,000 as debt restructure expense on the consolidated statement of operations for the year ended December 31, 2021. As of December 31, 2021, the Company has recorded an expense and a liability of $215,151 on the consolidated financial statements. 750000

0.03

750000 750000

175000000

0.018

0.094

16450000

215151

NOTE 10 – DEFERRED REVENUE During the year ended December 31, 2020, the Company received $64,353 form a customer for a payment of a three- year extended warranty. The extended warranty period is from, March 2021 through February 2024, and accordingly the Company will recognize the revenue over such period. For the year ended December 31, 2021, the Company recognized $17,876, of revenue. Of the remaining deferred revenue of $46,477, $21,451 is recognized as the current portion of deferred revenue and $25,026 is classified as a long- term liability on the consolidated financial statements. As of December 31, 2020, $17,876 is classified as the current portion and $46,477 is classified as a long- term liability on the consolidated financial statements.

64353

payment of a three- year extended warranty

17876

46477

21451

25026

17876

46477

NOTE 11 – RELATED PARTY TRANSACTIONS Employment Agreement On July 10, 2020, pursuant to the PCTI transaction, the Company assumed an employment contract entered into on February 28, 2020, between the Company and Mr. Conway (the “Employment Agreement”). Pursuant to the terms of the Employment Agreement, Mr. Conway is to receive an initial annual salary of $<span id="xdx_90B_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_pip0_c20200225__20200228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrConwayMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zk1Q1OfRRsA1" title="Amount of initial annual salary">120,000, for his position of CEO of the Company, payable monthly. Mr. Conway was issued <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20200225__20200228__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zlrDSoxmBSUk" title="Number of shares issued, shares">2,500 shares of Series C Preferred Stock. The Company valued the shares at $5,000. On August 28, 2020, Mr. Conway was issued <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20200827__20200828__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrConwayMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zmti0d6YeIq2" title="Number of shares issued, shares">1,333 shares of Series D Preferred stock and <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20200827__20200828__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrConwayMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zy5GUHkFfXlg" title="Number of shares issued, shares">500 shares of Series E Preferred Stock. The aggregate shares of Series D Preferred Stock in its entirety, is convertible into one and one-half times the number of shares of common stock outstanding at the time of conversion. On August 28, 2020, Mr. Conway owned <span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionRatio1_pid_dp_uPure_c20200827__20200828__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrConwayMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zMMnk1X3AXkj" title="Debt owned percentage">6.67% of the issued and outstanding Series D Preferred Stock, and based on the <span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_iI_c20200828__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrConwayMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_z1TpRAVDZmRi" title="Number of common stock shares outstanding">3,107,037,634 shares outstanding on August 28, 2020, Mr. Conway’s Preferred Stock was convertible into <span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20200828__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrConwayMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_ziBqxSIbIzpb" title="Number of shares converted">621,253,401 shares of common stock. Based on the share price of the common stock on that date of $<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_c20200828__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrConwayMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zhhYUC0Hha78" title="Shares issued price per shares">0.0065, the shares were valued at $<span id="xdx_904_eus-gaap--CommonStockValueOutstanding_iI_pp0p0_c20200828__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrConwayMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zggJHz8o6Lui" title="Number of common stock shares outstanding, value">4,286,648 and recognized as compensation during the year ended December 31, 2020. Effective January 1, 2021, Mr. Conway’s compensation is $<span id="xdx_90B_eus-gaap--OfficersCompensation_pp0p0_c20210101__20211231__us-gaap--AwardDateAxis__custom--PerMonthMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrConwayMember_zQbDTsRf66Ye" title="Compensation value">20,000 per month, and effective September 1, 2021, Mr. Conway is receiving $<span id="xdx_902_ecustom--OfficersCompensationReceived_pp0p0_c20210101__20211231__us-gaap--AwardDateAxis__custom--PerMonthMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrConwayMember_zq6wK2hShOR2" title="Officers compensation received">10,000 per month from Ozop Capital. Series E Preferred Stock On March 21, 2021, the Company issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20210320__20210321__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zbuXDPSDaF8d" title="Number of shares issued, shares">2,000 shares of Series E Preferred Stock (see Note 12), <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210320__20210321__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrConwayMember_zEAWRuJe8yf6" title="Number of shares issued, shares">1,800 of the shares were issued to Mr. Conway. Pursuant to the terms and conditions of the Certificate of Designation of the Series E Preferred Stock, including the redemption value of $<span id="xdx_90E_eus-gaap--PreferredStockRedemptionPricePerShare_iI_c20210321__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrConwayMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zjdppCOtLCii" title="Preferred stock redemption price per share">1,000 per share, the Company recorded $<span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210320__20210321__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrConwayMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zGQEJWTFCg88" title="Stock based compensation">1,800,000 as stock compensation expense for the Series E shares issued to Mr. Conway. On April 16, 2021, the Board of Directors (the “BOD”) of the Company authorized the issuance <span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_pp0p0_c20210416__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zZPV36SHJhTf" title="Number of preferred stock shares authorized">2,000 shares of Series E Preferred stock, of which <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210415__20210416__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrConwayMember_zPoKoy7CITEc" title="Number of shares issued, shares">1,050 were issued to Mr. Conway. The Company recorded $<span id="xdx_90C_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210415__20210416__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrConwayMember_zUCJ3lhGt0o7" title="Stock based compensation">1,050,000 of expense related to the shares issued to Mr. Conway. During the year ended December 31, 2021, the Company redeemed the <span id="xdx_90C_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrConwayMember_zGgdozZn6qL1" title="Number of redeemed shares issued">2,850 shares issued to Mr. Conway. Management Fees and related party payables For the years ended December 31, 2021, and 2020, the Company recorded expenses to its officers in the following amounts: SCHEDULE OF EXPENSES TO OFFICERS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20210101__20211231_zAWTg2pkAoj3" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20200101__20201231_z0WsPEE7gIP8" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_408_eus-gaap--SalariesWagesAndOfficersCompensation_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zR3Ow9wnvmU8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">CEO, parent (includes $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVYUEVOU0VTIFRPIE9GRklDRVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20201231_zGEcMEFt2OCe" title="Stock based compensation">5,000 stock-based compensation year ended December 31, 2020)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">812,099</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">377,804</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--SalariesWagesAndOfficersCompensation_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveOfficerSeriesEPreferredStockMember_z6VHc0zLjC7i" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">CEO, parent- Series E Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,850,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--SalariesWagesAndOfficersCompensation_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveOfficerSeriesDPreferredStockMember_zPBK7oBLLFqk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">CEO, parent- Series D Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,286,648</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--SalariesWagesAndOfficersCompensation_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PresidentSubsidiaryMember_zT5tadk5x9Ha" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">President, subsidiary (resigned July 2021)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">141,666</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">83,500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--SalariesWagesAndOfficersCompensation_z2jaTxLQjHT9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,803,765</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,747,952</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> As of December 31, 2020, included in related party payable is $9,120 for the amount owed the former President of PCTI (resigned in July 2021). Redemption of Series C and Series D Preferred Stock On July 13, 2021, the Company entered into a Definitive Agreement (the “Agreement”) with Chis to purchase the <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20210712__20210713__us-gaap--TypeOfArrangementAxis__custom--DefinitiveAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zoWuW754RSXh" title="Number of shares purchased">47,500 shares of the Company’s Series C Preferred Stock held by Chis and the <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_pid_c20210712__20210713__us-gaap--TypeOfArrangementAxis__custom--DefinitiveAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_z3Gi5RN9RPhl" title="Number of shares purchased">18,667 shares of the Company’s Series D Preferred Stock held by Chis for the total purchase price of $<span id="xdx_90B_ecustom--StockIssuedDuringPeriodValuePurchased_c20210712__20210713__us-gaap--TypeOfArrangementAxis__custom--DefinitiveAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zSePXmqFhV91" title="Number of shares purchased, value">11,250,000. In conjunction with the Agreement, Chis resigned from any and all positions held in the Company’s wholly owned subsidiary, PCTI. Further, Chis agreed that upon her resignation and for a period of five years thereafter (the “Restriction Period”), she shall not, directly or indirectly, solicit the employment of, assist in the soliciting of the employment of, or hire any employee or officer of the Company, including those of any of its present or future subsidiaries, or induce any person who is an employee, officer, agent, consultant or contractor of the Company to terminate such relationship with the Company. Additionally, Chis agreed that during the Restriction Period, she shall not compete with the Company or PCTI anywhere worldwide or be employed by any competitor of the Company.

120000

2500

5000

1333

500

0.0667

3107037634

621253401

0.0065

4286648

20000

10000

2000

1800

1000

1800000

2000

1050

1050000

2850

For the years ended December 31, 2021, and 2020, the Company recorded expenses to its officers in the following amounts: SCHEDULE OF EXPENSES TO OFFICERS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20210101__20211231_zAWTg2pkAoj3" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20200101__20201231_z0WsPEE7gIP8" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_408_eus-gaap--SalariesWagesAndOfficersCompensation_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zR3Ow9wnvmU8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">CEO, parent (includes $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVYUEVOU0VTIFRPIE9GRklDRVJTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20201231_zGEcMEFt2OCe" title="Stock based compensation">5,000 stock-based compensation year ended December 31, 2020)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">812,099</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">377,804</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--SalariesWagesAndOfficersCompensation_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveOfficerSeriesEPreferredStockMember_z6VHc0zLjC7i" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">CEO, parent- Series E Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,850,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--SalariesWagesAndOfficersCompensation_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveOfficerSeriesDPreferredStockMember_zPBK7oBLLFqk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">CEO, parent- Series D Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,286,648</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--SalariesWagesAndOfficersCompensation_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PresidentSubsidiaryMember_zT5tadk5x9Ha" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">President, subsidiary (resigned July 2021)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">141,666</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">83,500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--SalariesWagesAndOfficersCompensation_z2jaTxLQjHT9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,803,765</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,747,952</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

5000

812099

377804

2850000

4286648

141666

83500

3803765

4747952

9120

47500

18667

11250000

NOTE 12 – COMMITMENTS AND CONTINGENCIES Leases On January 2, 2021, the Company entered into a ten (10) year lease for a 6-bay garage storage facility of approximately 2,500 square feet. Pursuant to the lease the Company agreed to issue <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20210101__20210102__us-gaap--TypeOfArrangementAxis__custom--GarageStorageFacilityMember_zAcdLyo6QxHj" title="Number of restricted stock issued">100,000,000 shares of restricted common stock. The shares were certificated on March 8, 2021, with an effective date of January 2, 2021. The Company valued the shares $0.0063, (the market value of the common stock on the date of the agreement) and has recorded $630,000 as a prepaid expense. The Company has not yet taken occupancy of the space, Agreements On September 1, 2021, Ozop Capital entered into an advisory agreement (the “RMA Agreement”) with Risk Management Advisors, Inc. (“RMA”). Pursuant to the terms of the RMA Agreement, RMA will assist Ozop Capital in analyzing, structuring, and coordinating Ozop Capital’s participation in a captive insurance company. RMA will coordinate legal, accounting, tax, actuarial and other services necessary to implement the Company’s participation in a captive insurance company, including, but not limited to, the preparation of an actuarial feasibility study, filing of all required regulatory applications, domicile selection, structural selection, and coordination of the preparation of legal documentation. In connection with the services listed above, Ozop Capital agreed to pay $50,000 and to issue $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20210828__20210902__us-gaap--TypeOfArrangementAxis__custom--RMAAgreementMember_zb42Fc5QMRG7" title="Number of restricted stock issued, value">50,000 of shares of restricted common stock. One-half of the cash and stock were due upon the signing of the RMA Agreement. Accordingly, RMA received $25,000 and <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20210903__20210930__us-gaap--TypeOfArrangementAxis__custom--RMAAgreementMember_zG7AyTolFljj" title="Number of restricted stock issued, value">452,080 shares of restricted common stock of the Company in September 2021. The balance of the cash and stock became due on October 29, 2021, upon the issuance of the captive insurance company’s certificate of authority from the state of Delaware. The Company paid the $5,000 balance and recorded 637,755 shares of common stock to be issued. For the year ended December 31, 2021, the Company recorded $50,000 as stock compensation expense. On April 13, 2021, the Company agreed to engage PJN Strategies, LLC (“PJN”) as a consultant. Pursuant to the agreement, the Company agreed to compensate PJN $20,000 per month. Effective September 1, 2021, a new agreement was entered into between PJN and Ozop Capital. Pursuant to the terms of the new one- year agreement Ozop Capital agreed to compensate PJN $84,000 per month. For the year ended December 31, 2021, the Company recorded $436,000,of consulting expenses. On April 16, 2021, the Company signed a letter of agreement with Rubenstein Public Relations, Inc. (“RPR”). Pursuant to the letter of agreement, the Company agreed to engage RPR, effective May 1, 2021, on a month-to-month basis for $17,000 per month. For the year ended December 31, 2021, the Company recorded $102,000 of consulting expenses. The Company terminated the agreement in October 2021. On March 30, 2021, OES hired 2 individuals as Co-Directors of Sales. Pursuant to their respective offers of employment, the Company agreed to an annual salary of $130,000 with a signing bonus of $20,000 for each and to issue each <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210329__20210330__srt--TitleOfIndividualAxis__custom--CoDirectorsOfSalesMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zwS8H3TAEpji" title="Number of shares issued, shares">2,500,000 shares of restricted common stock upon the execution of the agreements and every 90 days thereafter for the first year as long as the employee is still employed. The Company valued the initial shares at $<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20210330__srt--TitleOfIndividualAxis__custom--CoDirectorsOfSalesMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zwsPT3IMHdE1" title="Shares issued, price per share">0.092 per share (the market price of the common stock on the date of the agreement), and $<span id="xdx_90F_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20211231__srt--TitleOfIndividualAxis__custom--CoDirectorsOfSalesMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zws04hHAo9z4" title="Share based payment expense">460,000 is included in stock-based compensation expense for the year ended December 31, 2021. On July 1, 2021, the Company issued each of the Co-Directors the 2,500,000 shares due after the first ninety days of employment. The shares were valued at $0.0745 per share (the market price of the common stock on the date of the issuance), and $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20211231__srt--TitleOfIndividualAxis__custom--CoDirectorsOfSalesMember_zRpEeT2WV1gd" title="Share based compensation expenses">372,500 is included in stock-based compensation expense for the year ended December 31, 2021. On October 1, 2021, the Company issued each of the Co-Directors the 2,500,000 shares due after the first one hundred eighty days of employment. The shares were valued at $0.0445 per share (the market price of the common stock on the date of the issuance), and $227,500 is included in stock-based compensation expense for the year ended December 31, 2021. One of the individuals resigned on January 24, 2022. On March 15, 2021, the Company entered into a consulting agreement with Aurora Enterprises (“Aurora”). Mr. Steven Martello is a principal of Aurora. Pursuant to the agreement Mr. Martello will provide strategic analysis regarding existing markets and revenue streams as well as the development of new lines of revenue. The Company agreed to a monthly retainer fee of $<span id="xdx_909_eus-gaap--LegalFees_pp0p0_c20210314__20210315__srt--TitleOfIndividualAxis__custom--MrStevenMartelloMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--AuroraEnterprisesMember_zqzFxyHnMsrk" title="Legal fees">10,000 and to issue to Aurora or their designee <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20210314__20210315__srt--TitleOfIndividualAxis__custom--MrStevenMartelloMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--AuroraEnterprisesMember_zNkOtMUZA2R4" title="Number of restricted shares issued">5,000,000 shares of restricted common stock. The shares were issued in April 2021. Aurora designated the shares to be issued to Pegasus Partners, Inc. The Company valued the shares at $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20210315__srt--TitleOfIndividualAxis__custom--MrStevenMartelloMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--AuroraEnterprisesMember_zTuBdPZzglE8" title="Shares issued, price per share">0.1392 per share (the market price of the common stock on the date of the agreement), and $<span id="xdx_90C_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20211231__srt--TitleOfIndividualAxis__custom--MrStevenMartelloMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--AuroraEnterprisesMember_zCZbuthICF9l" title="Share based compensation expenses">696,000 is included in stock-based compensation expense for the year ended December 31, 2021. For the year ended December 31, 2021, the Company has recorded $<span id="xdx_902_ecustom--ConsultingExpense_pp0p0_c20210101__20211231__srt--TitleOfIndividualAxis__custom--MrStevenMartelloMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--AuroraEnterprisesMember_znby3Eifm916" title="Consulting expenses">90,000 of consulting expenses. On February 24, 2021, the Company entered into a consulting agreement with Christopher Ruppel. Pursuant to the agreement Mr. Ruppel was to join the Ozop Advisory Board. During the year ended December 31, 2021, the Company issued <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20210101__20211231__srt--TitleOfIndividualAxis__custom--ChristopherRuppelMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_znYP7pG04q38" title="Number of restricted shares issued">10,000,000 shares of restricted common stock to Mr. Ruppel and agreed to a monthly fee of $<span id="xdx_90B_eus-gaap--ProfessionalFees_pp0p0_c20210101__20211231__srt--TitleOfIndividualAxis__custom--ChristopherRuppelMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zSFVXjY1H1rk" title="Professional fees">2,500. The Company valued the shares at $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20211231__srt--TitleOfIndividualAxis__custom--ChristopherRuppelMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zp6mpzKWRzCd" title="Shares issued, price per share">0.2386 per share (the market price of the common stock on the date of the agreement), and $<span id="xdx_90C_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20211231__srt--TitleOfIndividualAxis__custom--ChristopherRuppelMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zoPKd0nNKcaa" title="Share based compensation expenses">2,386,000 is included in stock-based compensation expense for the year ended December 31, 2021. Effective April 1, 2021, the agreement was amended to $<span id="xdx_907_eus-gaap--ProfessionalFees_pp0p0_c20210101__20211231__srt--TitleOfIndividualAxis__custom--ChristopherRuppelMember__us-gaap--AwardDateAxis__custom--AprilOneTwoThousandAndTwentyOneMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z1F7goixYUyi" title="Professional fees">10,000 per month. Effective May 1, 2021, the Company was no longer using the services of Mr. Ruppel. For the year ended December 31, 2021, the Company recorded $<span id="xdx_906_ecustom--ConsultingExpense_pp0p0_c20210101__20211231__srt--TitleOfIndividualAxis__custom--ChristopherRuppelMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z9gQ0yNAHcX2" title="Consulting expense">12,500 of consulting expenses. On February 19, 2021, the Company entered into a Joint Business Alliance agreement with Grid and Energy Master Planning, LLC (“GEMM”). GEMM will provide advisory, financing and implementation solutions for behind-the-meter customers in the areas of energy efficiency, solar, EV charging, and battery storage for OES. The GEMM services allows OES to provide one-stop-shopping in these emerging and maturing sectors. As of December 31, 2021, there has not been any transactions related to this agreement and the Company is continuing to evaluate the accounting treatment of any future transactions. On January 22, 2021, the Company issued <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20210121__20210122__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zWk5xTpScPza" title="Number of restricted shares issued">10,000,000 shares of restricted common stock for legal services performed in 2020 and approved by the BOD of the Company on December 1, 2020. The Company valued the shares at $0.0056 per share (the market price of the common stock on the date of the agreement), and $56,000 is included in stock-based compensation expense for the year ended December 31, 2021. On January 14, 2021, the Company entered into a Consulting Agreement with Mr. Allen Sosis. Pursuant to the agreement, Mr. Sosis will provide services as the Director of Business Development for the Company’s wholly owned subsidiary. Pursuant to the agreement, as amended, the Company will pay Mr. Sosis a monthly fee of $<span id="xdx_902_eus-gaap--DueToOfficersOrStockholdersCurrentAndNoncurrent_iI_pp0p0_c20210114__srt--TitleOfIndividualAxis__custom--MrAllenSosisMember__us-gaap--StatementClassOfStockAxis__custom--RestrictedCommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_z5GKckPQyFhh" title="Due to officers or stockholders">15,000 and an additional $<span id="xdx_906_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pp0p0_c20210114__srt--TitleOfIndividualAxis__custom--MrAllenSosisMember__us-gaap--StatementClassOfStockAxis__custom--RestrictedCommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zAF0pYNkq8M8" title="Accrued employee benefits, current">1,000 in benefits. The Company also agreed to issue Mr. Sosis <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20210113__20210114__srt--TitleOfIndividualAxis__custom--MrAllenSosisMember__us-gaap--StatementClassOfStockAxis__custom--RestrictedCommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zTFLUKVX9dog" title="Number of restricted shares issued">5,000,000 shares of restricted common stock. The shares were issued in April 2021. The Company valued the shares at $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20210114__srt--TitleOfIndividualAxis__custom--MrAllenSosisMember__us-gaap--StatementClassOfStockAxis__custom--RestrictedCommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zSftiQ98gX9l" title="Shares issued, price per share">0.20 per share (the market price of the common stock on the date of the agreement), and $<span id="xdx_905_eus-gaap--DeferredCompensationEquity_iI_pp0p0_c20210114__srt--TitleOfIndividualAxis__custom--MrAllenSosisMember__us-gaap--StatementClassOfStockAxis__custom--RestrictedCommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zKDcjR4gR7U2" title="Deferred compensation equity">1,000,000 was recorded as deferred stock compensation, to be amortized over the one-year term of the agreement. The Company terminated Mr. Sosis’s employment in October 2021, and accordingly, for the year ended December 31, 2021, $<span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20211231__srt--TitleOfIndividualAxis__custom--MrAllenSosisMember__us-gaap--StatementClassOfStockAxis__custom--RestrictedCommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zYPHMK5MEBlk" title="Share based compensation expenses">1,000,000 is included in stock-based compensation expense. For the year ended December 31, 2021, the Company recorded $<span id="xdx_900_ecustom--ConsultingExpense_pp0p0_c20210101__20211231__srt--TitleOfIndividualAxis__custom--MrAllenSosisMember__us-gaap--StatementClassOfStockAxis__custom--RestrictedCommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zEhlrIeOoZjf" title="Consulting expense">75,500 of consulting expenses, and effective June 1, 2021, Mr. Sosis became an employee of the Company through his termination with a $<span id="xdx_902_ecustom--Salary_iI_pp0p0_c20210114__srt--TitleOfIndividualAxis__custom--MrAllenSosisMember__us-gaap--StatementClassOfStockAxis__custom--RestrictedCommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zFAd081WbyJi" title="Salary">15,000 per month salary. On January 6, 2021, the Company entered into a consulting agreement with Ezra Green to begin on February 8, 2021. The Company agreed to issue <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20210105__20210106__srt--TitleOfIndividualAxis__custom--EzraGreenMember__us-gaap--StatementClassOfStockAxis__custom--RestrictedCommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zlLJaDmcYZA1" title="Number of restricted shares issued">10,000,000 shares of restricted common stock to Mr. Green and to a monthly fee of $<span id="xdx_90F_eus-gaap--ProfessionalFees_pp0p0_c20210105__20210106__srt--TitleOfIndividualAxis__custom--EzraGreenMember__us-gaap--StatementClassOfStockAxis__custom--RestrictedCommonStockMember_zBxqR2FrPx7h" title="Professional fees">2,500. The Company valued the shares at $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20210106__srt--TitleOfIndividualAxis__custom--EzraGreenMember__us-gaap--StatementClassOfStockAxis__custom--RestrictedCommonStockMember_zdmTYLMMFebl" title="Shares issued, price per share">0.0076 per share (the market price of the common stock on the date of the agreement), and $<span id="xdx_90B_eus-gaap--DeferredCompensationEquity_iI_pp0p0_c20210106__srt--TitleOfIndividualAxis__custom--EzraGreenMember__us-gaap--StatementClassOfStockAxis__custom--RestrictedCommonStockMember_z4jfrZnSecg6" title="Deferred compensation equity">76,000 was recorded as deferred stock-based compensation, to be amortized over the one-year term of the agreement. For the year ended December 31, 2021, the Company recorded $<span id="xdx_90B_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EzraGreenMember__us-gaap--StatementClassOfStockAxis__custom--RestrictedCommonStockMember_zfYKrqD2ubfl" title="Share based compensation expenses">74,751 as stock-based compensation expense. Effective April 1, 2021, the agreement was amended to $<span id="xdx_903_eus-gaap--DueToOfficersOrStockholdersCurrentAndNoncurrent_iI_pp0p0_c20210106__srt--TitleOfIndividualAxis__custom--EzraGreenMember__us-gaap--StatementClassOfStockAxis__custom--RestrictedCommonStockMember_zm7n1on5LFSa" title="Due to officers or stockholders">10,000 per month. On March 9, 2021, Mr. Green filed a provisional patent with the USPTO. The provisional patent covers proprietary methods and procedures that, will allow the expansion of OES into the EV charging and support industry. The provisional patent relates to the more efficient production, distribution, and delivery of energy, particularly renewable energy, to the EV end consumer and enables OES to build the support systems for such. For the year ended December 31, 2021, the Company recorded $<span id="xdx_902_ecustom--ConsultingExpense_pp0p0_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EzraGreenMember__us-gaap--StatementClassOfStockAxis__custom--RestrictedCommonStockMember_zWAtEFmq0x7i" title="Consulting expense">94,500 of consulting expenses. On March 4, 2019, the Company entered into a Separation Agreement (the “Separation Agreement”) with Salman J. Chaudhry, pursuant to which the Company agreed to pay Mr. Chaudry $<span id="xdx_90D_eus-gaap--DueToOfficersOrStockholdersCurrent_iI_pp0p0_c20190304__srt--TitleOfIndividualAxis__custom--SalmanJChaudhryMember__us-gaap--TypeOfArrangementAxis__custom--SeparationAgreementMember_zilVm0yJqd4h" title="Due to officers or stockholders, current">227,200 (the “Outstanding Fees”) in certain increments as set forth in the Separation Agreement. As of December 31, 2021 and 2020, the balance owed Mr. Chaudhry is $<span id="xdx_900_eus-gaap--NotesPayable_iI_pp0p0_c20211231__srt--TitleOfIndividualAxis__custom--SalmanJChaudhryMember__us-gaap--TypeOfArrangementAxis__custom--SeparationAgreementMember_zQZTOGS1oQ0k" title="Notes payable"><span id="xdx_901_eus-gaap--NotesPayable_iI_pp0p0_c20201231__srt--TitleOfIndividualAxis__custom--SalmanJChaudhryMember__us-gaap--TypeOfArrangementAxis__custom--SeparationAgreementMember_zl47sCRU4uD3" title="Notes payable">162,085. On September 2, 2020, PCTI entered into an Agreement with a third- party. Pursuant to the terms of the agreement, in exchange for $<span id="xdx_908_eus-gaap--ProfessionalFees_pp0p0_c20200901__20200902__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__dei--LegalEntityAxis__custom--PCTIMember_zHSriOuHQNd4" title="Professional fees">750,000, <span id="xdx_903_eus-gaap--CollaborativeArrangementRightsAndObligations_c20200901__20200902__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__dei--LegalEntityAxis__custom--PCTIMember_z8OT4EemVkUj" title="Collaborative arrangement, rights and obligations">PCTI agreed to pay the third-party a perpetual three percent (3%) payment of revenues, as defined in the agreement. On February 26, 2021, the agreement was assigned to Ozop and on March 4, 2021, the agreement was amended, whereby in exchange for <span id="xdx_90F_eus-gaap--DeferredCompensationArrangementWithIndividualSharesIssued_pid_c20210225__20210226__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__dei--LegalEntityAxis__custom--PCTIMember_zv8yHHetwc91" title="Number of common stock exchanged">175,000,000 shares of common stock, the royalty percentage was amended to <span id="xdx_904_ecustom--RoyaltyPercentage_pid_dp_uPure_c20210225__20210226__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__dei--LegalEntityAxis__custom--PCTIMember_zt24J16vEk4" title="Royalty percentage">1.8% (see Note 9). The Company valued the shares at $<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20211231__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__dei--LegalEntityAxis__custom--PCTIMember_zOiVsiuORTS8" title="Shares issued, price per share">0.094 per share (the market value of the common stock on the date of the agreement) and recorded $<span id="xdx_90F_eus-gaap--PaymentsOfDebtRestructuringCosts_pp0p0_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__dei--LegalEntityAxis__custom--PCTIMember_zhKANXi73Ikg" title="Payments of debt restructuring costs">16,450,000 as debt restructure expense on the consolidated statement of operations for the year ended December 31, 2021. As of December 31, 2021, the Company has recorded $215,171 and is included in accounts payable and accrued expenses on the consolidated balance sheet presented herein. Legal matters We know of no material, existing or pending legal proceedings against our Company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our interest.

P10Y

2500

100000000

0.0063

630000

50000

25000

452080

5000

637755

50000

20000 84000 436000 17000 102000

130000

20000

2500000

0.092

460000

2500000

0.0745

372500

2500000

0.0445

227500

10000

5000000

0.1392

696000

90000

10000000

2500

0.2386

2386000

10000

12500

10000000

0.0056

56000

15000

1000

5000000

0.20

1000000

75500 15000

10000000

2500

0.0076

76000

74751

10000

94500

227200

162085

750000

PCTI agreed to pay the third-party a perpetual three percent (3%) payment of revenues, as defined in the agreement

175000000

0.018

0.094

16450000

215171

NOTE 13– STOCKHOLDERS’ EQUITY Common stock During the period from January 1, 2021, to December 31, 2021, holders of an aggregate of $760,550 in principal and $201,905 of accrued interest and fees of convertible and promissory notes, converted their debt into 483,154,618 shares of our common stock at an average conversion price of $0.002 per share. During the year ended December 31, 2021, the Company also issued the following shares of restricted common stock: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zJXLkRbWLJbj" title="Number of shares issued, shares">100,000,000 shares of restricted common stock pursuant to a lease agreement (see Note 10).</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_900_eus-gaap--DeferredCompensationArrangementWithIndividualSharesIssued_pid_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--RestructuringAgreementMember_zhqMt1aYJ73d" title="Deferred compensation shares issued">175,000000 shares of restricted common stock pursuant to restructuring agreement related to a deferred liability (see Note 9).</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_znptdWuuyPH" title="Number of shares issued, shares">55,452,080 shares of restricted common stock in the aggregate for services and consulting agreements.</td></tr> </table> During the year ended December 31, 2021, the Company also issued 405,797,987 shares of common stock upon the cashless exercise of common stock purchase warrants. As of December 31, 2021, the Company has 4,990,000,000 shares of $0.001 par value common stock authorized and there are 4,617,362,997 shares of common stock issued and outstanding. Preferred stock As of December 31, 2021, 10,000,000 shares have been authorized as preferred stock, par value $0.001 (the “Preferred Stock”), which such Preferred Stock shall be issuable in such series, and with such designations, rights and preferences as the Board of Directors may determine from time to time. Series C Preferred Stock On July 7, 2020, the Company filed an Amended and Restated Certificate of Designation with the State of Nevada of the Company’s Series C Preferred Stock. Under the terms of the Amendment to Certificate of Designation of Series C Preferred Stock, <span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20200707__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--CertificatesOfDesignationMember_zTKSRDlfpXl2" title="Preferred stock, shares authorized">50,000 shares of the Company’s preferred remain designated as Series C Preferred Stock. <span id="xdx_90A_eus-gaap--PreferredStockVotingRights_c20200706__20200707__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--CertificatesOfDesignationMember_zpxdNcOfVr79" title="Preferred stock, voting rights">The holders of Series C Preferred Stock have no conversion rights and no dividend rights. For so long as any shares of the Series C Preferred Stock remain issued and outstanding, the Holder thereof, voting separately as a class, shall have the right to vote on all shareholder matters equal to sixty-seven (67%) percent of the total vote. On July 10, 2020, pursuant to the SPA with PCTI, the Company issued <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20200706__20200710__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--PCTIMember_zR8ToOEEyifi" title="Number of shares issued, shares">47,500 shares of Series C preferred Stock to Chis. On July 13, 2021, the Company purchased <span id="xdx_905_eus-gaap--StockRepurchasedDuringPeriodShares_pid_c20210701__20210713__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__dei--LegalEntityAxis__custom--ChisMember_zXt7ZN88KrP6" title="Stock repurchased, shares">47,500 shares of the Company’s Series C Preferred Stock held by Chis (see Note 11). As of December 31, 2021, and 2020, there were <span id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z0i0os9BgKPe" title="Preferred stock shares outstanding">2,500 and <span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z6wUTkrSSgOd" title="Preferred stock shares outstanding">50,000 shares, respectively, of Series C Preferred Stock issued and outstanding, of which 2,500 shares are held by Mr. Conway. Series D Preferred Stock On July 7, 2020, the Company filed a Certificate of Designation with the State of Nevada of the Company’s Series D Preferred Stock. Under the terms of the Certificate of Designation of Series D Preferred Stock, <span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20200707__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--CertificatesOfDesignationMember_zmKG0VL63253" title="Preferred stock, shares authorized">20,000 shares of the Company’s preferred stock have been designated as Series D Convertible Preferred Stock. The holders of the Series D Convertible Preferred Stock shall not be entitled to receive dividends. The holders as a group may, at any time convert all of the shares of Series D Convertible Preferred Stock into a number of fully paid and nonassessable shares of common stock determined by multiplying the number of issued and outstanding shares of common stock of the Company on the date of conversion, by 3. Except as provided in the Certificate of Designation or as otherwise required by law, no holder of the Series D Convertible Preferred Stock shall be entitled to vote on any matter submitted to the shareholders of the Company for their vote, waiver, release or other action. The Series D Convertible Preferred Stock shall not bear any liquidation rights. On July 10, 2020, pursuant to the SPA with PCTI, the Company issued <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20200706__20200710__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--PCTIMember_zptzGUKIE8Y9" title="Number of shares issued, shares">18,667 shares of Series D preferred Stock to Chis, and on August 28, 2020, pursuant to Mr. Conway’s employment agreement, the Company issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20200827__20200828__srt--TitleOfIndividualAxis__custom--MrConvayMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z5itG3YMZNek" title="Number of shares issued, shares">1,333 shares of Series D Preferred Stock to Mr. Conway. Accordingly, on August 28, 2020, Mr. Conway owned <span id="xdx_907_ecustom--PreferredStockIssuedAndOustandingPercentage_iI_pid_dp_uPure_c20200828__srt--TitleOfIndividualAxis__custom--MrConvayMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zeVE9TtCcWVe" title="Preferred stock issued and oustanding percentage">6.67% of the issued and outstanding Series D Preferred Stock, and based on the <span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20200828__srt--TitleOfIndividualAxis__custom--MrConvayMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zb8OUQQ4O8qh" title="Preferred stock, shares outstanding">3,107,037,634 shares outstanding on August 28, 2020, Mr. Conway’s Preferred Stock was convertible into <span id="xdx_90B_eus-gaap--ConversionOfStockSharesConverted1_pid_c20200827__20200828__srt--TitleOfIndividualAxis__custom--MrConvayMember__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_zswYYI9ytGU6" title="Conversion of stock, shares converted">621,253,401 shares of common stock. Based on the share price of the common stock on that date of $<span id="xdx_903_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20200828__srt--TitleOfIndividualAxis__custom--MrConvayMember__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_zpjgpGdQ5tte" title="Common stock, price per share">0.0065, the shares were valued at $<span id="xdx_907_eus-gaap--CommonStockValue_iI_pdp0_c20200828__srt--TitleOfIndividualAxis__custom--MrConvayMember__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_zJc9uJYDumY4" title="Common stock, value, issued">4,286,648. On July 13, 2021, the Company purchased <span id="xdx_900_eus-gaap--StockRepurchasedDuringPeriodShares_pid_c20210701__20210713__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__dei--LegalEntityAxis__custom--ChisMember_ziNJGYRQVlM" title="Number of purchased shares">18,667 shares of the Company’s Series D Preferred Stock held by Chis (see Note 11). On July 27, 2021, the Company filed with the Secretary of State of the State of Nevada an Amended and Restated Certificate of Designation of Series D Preferred Stock (the “Series D Amendment”). Under the terms of the Series D Amendment, <span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20210727__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SeriesDAmendmentMember_zR8UQo1pLPi9">4,570 shares of the Company’s preferred stock will be designated as Series D Convertible Preferred Stock. The holders of the Series D Convertible Preferred Stock shall not be entitled to receive dividends. Any holder may, at any time convert any number of shares of Series D Convertible Preferred Stock held by such holder into a number of fully paid and nonassessable shares of common stock determined by multiplying the number of issued and outstanding shares of common stock of the Company on the date of conversion, by <span id="xdx_90D_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20210727__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SeriesDAmendmentMember_zbkC0pErT8L2" title="Preferred stock, convertible, conversion price">1.5 and dividing that number by the number of shares of Series D Convertible Preferred Stock being converted. Except as provided in the Series D Amendment or as otherwise required by law, no holder of the Series D Convertible Preferred Stock shall be entitled to vote on any matter submitted to the shareholders of the Company for their vote, waiver, release or other action. The Series D Convertible Preferred Stock shall not bear any liquidation rights. On July 28, 2021, the Company closed on a Stock and Warrant Purchase Agreement (the “Series D SPA”). Pursuant to the terms of Series D SPA, an investor in exchange for $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_pp0p0_c20210701__20210728__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SeriesDSPAMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zm9Rw9ZrBwYd" title="Proceeds from issuance of preferred stock">13,200,000 purchased one share of Series D Preferred Stock, and a warrant to acquire <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20210728__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SeriesDSPAMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zBCv1voEBl03" title="Purchase of warrants">3,236 shares of Series D Preferred Stock. As of December 31, 2021, and 2020, there were <span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zCDM0GvLReD2" title="Preferred stock, shares outstanding">1,334 and <span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zM2NGS4Dd5Jk" title="Preferred stock shares outstanding">20,000 shares, respectively, of Series D Preferred Stock issued and outstanding and warrants to purchase <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zlmN15aySvs1" title="Purchase of warrants">3,236 shares of Series D Preferred Stock are outstanding as of December 31, 2021. The warrant has a 15- year term and Partial Warrant Lock Up and Leak-Out Period. The Holder may only exercise the Warrant and purchase Warrant Shares as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 120px"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">i.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Up to <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zkVBjqWUruJg" title="Warrant exercise">162 (one hundred and sixty-two) Warrant Shares, at any time or times on or after the Initial Exercise Date and no later than on or before the Termination Date; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">ii.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Remainder of the Warrant representing up to <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RemainingWarrantSharesMember_zV3daHrWjxYf" title="Warrant exercise">3,074 (three thousand and seventy-four) Warrant Shares (“Remaining Warrant Shares”) shall be locked up for a period of 36 (thirty-six) months from the Initial Exercise Date (“Lock Up Period”) and shall become exercisable at any time or times from the date that is the 36 (thirty-six) month anniversary of the Initial Exercise Date (“Lock Up Period Termination Date”) and no later than on or before the Termination Date, as follows:</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 216px"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">a.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During every 1(one) year period, starting on the day that is the Lock Up Period Termination Date, the Holder shall have the right to exercise the Remainder of the Warrant up to a maximum number of Remaining Warrant Shares that, if converted, would be equal to no more than a maximum of 5% (five percent) of the total number of outstanding shares of Common Stock of the Company during such given year (“Leak-Out Period”). The Leak-Out Period shall come into effect on the day that is the Lock Up Period Termination Date and remain effective on a yearly basis, for a period of 10 (ten) years thereafter, after which the Leak-Out Period will automatically terminate and become null and void. For clarity purposes the Remainder of the Warrant shall become freely exercisable at any time or times beginning on June 29, 2034 and until the Termination Date.</td></tr> </table> Series E Preferred Stock On July 7, 2020, the Company filed a Certificate of Designation with the State of Nevada of the Company’s Series E Preferred Stock. Under the terms of the Certificate of Designation of Series E Preferred Stock, <span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20200707__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--CertificatesOfDesignationMember_zC5h5aQzjBZc" title="Preferred stock, shares authorized">3,000 shares of the Company’s preferred stock have been designated as Series E Preferred Stock. The holders of the Series E Convertible Preferred Stock shall not be entitled to receive dividends. No holder of the Series E Preferred Stock shall be entitled to vote on any matter submitted to the shareholders of the Corporation for their vote, waiver, release or other action, except as may be otherwise expressly required by law. At any time, the Corporation may redeem for cash out of funds legally available therefor, any or all of the outstanding Preferred Stock (“Optional Redemption”) at $<span id="xdx_90F_eus-gaap--PreferredStockRedemptionAmount_iI_pp0p0_c20200707__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--CertificatesOfDesignationMember_zpcvzRDyjB1i" title="Preferred stock, redemption amount">1,000 (one thousand dollars) per share. The shares of Series E Preferred Stock have not been registered under the Securities Act of 1933 or the laws of any state of the United States and may not be transferred without such registration or an exemption from registration. On July 10, 2020, pursuant to the SPA with PCTI, the Company issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20200706__20200710__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--PCTIMember_zEyMwupw4Bbl" title="Number of shares issued, shares">500 shares of Series E preferred Stock to Chis, and on August 28, 2020. Pursuant to Mr. Conway’s employment agreement, the Company issued <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20200706__20200710__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrConwayMember_z26Wx8etPLtf" title="Number of shares issued, shares">500 shares of Series E Preferred Stock to Mr. Conway. On March 2, 2021, the BOD authorized the issuance of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210301__20210302__srt--TitleOfIndividualAxis__custom--MrConvayMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zPvwO9w0YvMc" title="Number of shares issued, shares">1,800 shares of Series E Preferred Stock to Mr. Conway and <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210301__20210302__srt--TitleOfIndividualAxis__custom--ThirdPartyMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zGA09CiNE4fa" title="Number of shares issued, shares">200 shares of Series E Preferred Stock to a third-party service provider. The issuances were for services performed. Pursuant to the terms and conditions of the Certificate of Designation of the Series E Preferred Stock, including the redemption value of $<span id="xdx_904_eus-gaap--PreferredStockRedemptionPricePerShare_iI_pid_c20210302__srt--TitleOfIndividualAxis__custom--MrConvayMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_ze0TX2a1H1Y7" title="Preferred stock, redemption price per share">1,000 per share, the Company recorded $<span id="xdx_90C_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20211231__srt--TitleOfIndividualAxis__custom--MrConvayMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zHX5WFo3ZTrl" title="Share-based payment arrangement, expense">2,000,000 as stock-based compensation expense for year ended December 31, 2021. On March 24, 2021, the Company redeemed the <span id="xdx_903_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_pid_c20210322__20210324__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zMsGloE8qqnb" title="Number of stock Redeemed">3,000 shares of Series E Preferred Stock outstanding on that date. On April 16, 2021, the BOD authorized the issuance of <span id="xdx_908_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_pid_c20210415__20210416__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zEkJSRP7TjIa" title="Number of stock redeemed">2,000 shares of Series E Preferred stock, of which <span id="xdx_904_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_pid_c20210415__20210416__srt--TitleOfIndividualAxis__custom--MrConvayMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zI2Ckp98tmZe" title="Number of stock redeemed">1,050 were granted to Mr. Conway. The issuances were for services performed. Pursuant to the terms and conditions of the Certificate of Designation of the Series E Preferred Stock, including the redemption value of $<span id="xdx_909_eus-gaap--PreferredStockRedemptionPricePerShare_iI_pid_c20210416__srt--TitleOfIndividualAxis__custom--MrConvayMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zio7oZpooRNi" title="Preferred stock, redemption price per share">1,000 per share, the Company recorded $<span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20211231__srt--TitleOfIndividualAxis__custom--MrConvayMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zjmS80MRpphi" title="Share-based payment arrangement, expense">2,000,000 as stock-based compensation expense for the year ended December 31, 2021. As of December 31, 2021, and 2020, there were -<span id="xdx_909_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_z7ifrQgMMpKd" title="Preferred stock shares outstanding">0- and <span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zMF38mAs9X7i" title="Preferred stock shares outstanding">1,000 shares of Series E Preferred Stock issued and outstanding, respectively.

760550

201905

483154618

0.002

100000000

175000000

55452080

405797987

4990000000

0.001

4617362997

10000000

0.001

50000

The holders of Series C Preferred Stock have no conversion rights and no dividend rights. For so long as any shares of the Series C Preferred Stock remain issued and outstanding, the Holder thereof, voting separately as a class, shall have the right to vote on all shareholder matters equal to sixty-seven (67%) percent of the total vote

47500

2500

50000

2500

20000

18667

1333

0.0667

3107037634

621253401

0.0065

4286648

18667

4570

1.5

13200000

3236

1334

20000

3236

P15Y

162

3074

3000

1000

500

1800

200

1000

2000000

3000

2000

1050

1000

2000000

1000

NOTE 14 – NONCONTROLLING INTEREST On August 19, 2021, the Company formed Ozop Capital. Upon formation, the Company owned 51% with PJN owning 49%. Brian Conway was appointed as the sole officer and director of Ozop Capital and has voting control of Ozop Capital. The Company presents interest held by noncontrolling interest holders within noncontrolling interest in the consolidated financial statements. During the year ended December 31, 2021, there was no change in the ownership percentages. For the year ended December 31, 2021, Ozop Capital incurred a loss of $520,623, of which $255,105 is the loss attributed to the noncontrolling interest.

0.51

0.49

520623

-255105

NOTE 15 - OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES On October 25, 2019, PCTI executed a non-cancellable lease for office and industrial space which began December 1, 2019 and expires on November 30, 2022. Operating lease right-of-use assets and liabilities are recognized at the present value of the future lease payments at the lease commencement date. The interest rate used to determine the present value is our incremental borrowing rate, estimated to be 7.5%, as the interest rate implicit in most of our leases is not readily determinable. Prior to July 10, 2020, PCTI recorded monthly lease expense pursuant to the lease agreement and effective July 10, 2020, pursuant to the PCTI transaction, operating lease expense is recognized pursuant to ASC Topic 842. Leases (Topic 842) over the lease term. During the years ended December 31, 2020, the Company recorded $84,278 for rent expense. During the year ended December 31, 2020, upon adoption of ASC Topic 842, the Company recorded right-of-use assets and lease liabilities of $<span id="xdx_90A_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20201231__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201602Member_zMjW9oW5Mul8" title="RIght of use of asset"><span id="xdx_90A_eus-gaap--OperatingLeaseLiability_iI_c20201231__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201602Member_z9R7yjRAnDDd" title="Operating lease liability">185,139 for this lease. On April 14, 2021, the Company entered into a five-year lease which began on June 1, 2021, for approximately 8,100 square feet of office and warehouse space in Carlsbad, California, expiring May 31, 2026. Initial lease payments of $13,148 begin on June 1, 2021, and increase by approximately 2.4% annually thereafter. The interest rate used to determine the present value is our incremental borrowing rate, estimated to be 7.5%, as the interest rate implicit in most of our leases is not readily determinable. During the six months ended June 1, 2021, upon adoption of ASC Topic 842, the Company recorded right-of-use assets and lease liabilities of $<span id="xdx_90F_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20210604__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201602Member_zgXRPwPSo4Lj" title="RIght of use of asset"><span id="xdx_909_eus-gaap--OperatingLeaseLiability_iI_c20210601__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201602Member_z4gvCglGXmJl" title="Operating lease liability">702,888 for this lease. In adopting Topic 842, the Company has elected the ‘package of practical expedients’, which permit it not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. The Company did not elect the use-of-hindsight or the practical expedient pertaining to land easements; the latter is not applicable to the Company. In addition, the Company elected not to apply ASC Topic 842 to arrangements with lease terms of 12 months or less. Right-of- use assets are summarized below: SCHEDULE OF RIGHT-OF-USE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20211231_z4GeBaPydc12" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_401_ecustom--OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization_iI_maOLROUzy53_z5juwIm45V56" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left">Office and warehouse lease</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 22%; text-align: right">888,026</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--OperatingLeaseRightOfUseAssetAccumulatedAmortization_iNI_di_msOLROUzy53_z8dVZRJ4QZ4g" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less accumulated amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(180,340</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--OperatingLeaseRightOfUseAsset_iTI_mtOLROUzy53_zA4evX8dsMwe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Right-of-us assets, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">707,686</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Operating lease liabilities are summarized as follows: SCHEDULE OF OPERATING LEASE LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20211231_zzc9yGkQBfka" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_408_eus-gaap--OperatingLeaseLiability_iI_zp9WdPfTSsxh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left">Lease liability</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 22%; text-align: right">712,256</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_zZ39DRphfTga" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(194,366</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zx7awBIMsuw7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Long term portion</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">517,890</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Maturity of lease liabilities are as follows: SCHEDULE OF MATURITY OF LEASE LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20211231_zTkTHBAFMzX" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzRWM_zt1sfOzWhu4j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: justify">For the year ending December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 22%; text-align: right">240,991</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzRWM_zoU4E7baeeBf" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">For the year ending December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">167,858</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzRWM_zCzYGNVXRgg7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">For the year ended December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">171,840</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzRWM_zv6ywfTdLQXd" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">For the year ended December 31, 2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">175,942</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPzRWM_zfVV91zmaQf6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">For the year ended December 31, 2026</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">74,030</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzRWM_ztCkw0gasP2d" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Total</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">830,661</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zw4rBRijPF49" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Less: present value discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(118,405</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--OperatingLeaseLiability_iI_z3HBrZb7eu99" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Lease liability</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">712,256</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

2022-11-30

0.075

84278

185139

8100

2026-05-31

13148

0.024

0.075

702888

Right-of- use assets are summarized below: SCHEDULE OF RIGHT-OF-USE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20211231_z4GeBaPydc12" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_401_ecustom--OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization_iI_maOLROUzy53_z5juwIm45V56" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left">Office and warehouse lease</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 22%; text-align: right">888,026</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--OperatingLeaseRightOfUseAssetAccumulatedAmortization_iNI_di_msOLROUzy53_z8dVZRJ4QZ4g" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less accumulated amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(180,340</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--OperatingLeaseRightOfUseAsset_iTI_mtOLROUzy53_zA4evX8dsMwe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Right-of-us assets, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">707,686</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 888026 180340

707686

Operating lease liabilities are summarized as follows: SCHEDULE OF OPERATING LEASE LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20211231_zzc9yGkQBfka" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_408_eus-gaap--OperatingLeaseLiability_iI_zp9WdPfTSsxh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left">Lease liability</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 22%; text-align: right">712,256</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_zZ39DRphfTga" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(194,366</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zx7awBIMsuw7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Long term portion</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">517,890</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

712256

194366

517890

Maturity of lease liabilities are as follows: SCHEDULE OF MATURITY OF LEASE LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20211231_zTkTHBAFMzX" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzRWM_zt1sfOzWhu4j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: justify">For the year ending December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 22%; text-align: right">240,991</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzRWM_zoU4E7baeeBf" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">For the year ending December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">167,858</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzRWM_zCzYGNVXRgg7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">For the year ended December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">171,840</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzRWM_zv6ywfTdLQXd" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">For the year ended December 31, 2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">175,942</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPzRWM_zfVV91zmaQf6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">For the year ended December 31, 2026</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">74,030</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzRWM_ztCkw0gasP2d" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Total</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">830,661</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zw4rBRijPF49" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Less: present value discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(118,405</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--OperatingLeaseLiability_iI_z3HBrZb7eu99" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Lease liability</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">712,256</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

240991

167858

171840

175942

74030

830661

118405

712256

NOTE 16 – SUBSEQUENT EVENTS Effective January 1, 2022, the Company entered into a new employment agreement with Mr. Conway. Pursuant to the agreement, Mr. Conway received a $<span id="xdx_905_ecustom--ContractRenewalBonus_c20211229__20220102__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--MrConwayMember__us-gaap--TypeOfArrangementAxis__custom--NewEmploymentAgreementMember_z8cntYmKj1Z7" title="Contract renewal bonus">250,000 contract renewal bonus and will receive an annual compensation of $<span id="xdx_90F_ecustom--AnnualCompensation_c20211229__20220102__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--MrConwayMember__us-gaap--TypeOfArrangementAxis__custom--NewEmploymentAgreementMember_zL2VCRhuGQD1" title="Annual compensation">240,000 from the Company and will also be eligible to receive bonuses and equity grants at the discretion of the BOD. The Company also agreed to compensate Mr. Conway for services provided directly to any of the Company’s subsidiaries. Ozop Capital began compensating Mr. Conway $<span id="xdx_904_ecustom--AnnualCompensation_c20211229__20220102__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--MrConwayMember__dei--LegalEntityAxis__custom--OzopCapitalMember__us-gaap--TypeOfArrangementAxis__custom--NewEmploymentAgreementMember_zRlRPE6BbJWh" title="Annual compensation">20,000 per month in January 2022 and OES began compensating Mr. Conway $<span id="xdx_902_ecustom--AnnualCompensation_c20211229__20220102__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--MrConwayMember__dei--LegalEntityAxis__custom--OESMember__us-gaap--TypeOfArrangementAxis__custom--NewEmploymentAgreementMember_zFrg1qlpoAGk" title="Annual compensation">20,000 in March 2022. On February 25, 2022, the Company formed Ozop Engineering and Design, Inc. (“OED”) a Nevada corporation, as a wholly owned subsidiary of the Company. OED was formed to become a premier engineering and lighting control design firm. OED offers product and design support for lighting and solar projects with a focus on fast lead times and technical support. OED and our partners are able to offer the resources needed for lighting, solar and electrical design projects. OED will provide customers systems to coordinate the understanding of electrical usage with the relationship between lighting design and lighting controls, by developing more efficient ecofriendly designs. We work with architects, engineers, facility managers, electrical contractors and engineers. On April 4th, 2022, the Company and GHS Investments LLC (“GHS”). signed a Securities Purchase Agreement (the “GHS Purchase Agreement”) for the sale of up to Two Hundred Million (<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220401__20220404__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--RegistrationStatementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--GHSInvestmentsMember_zNVahjMH9Fql" title="Number of shares issued, shares">200,000,000) shares of the Company’s common stock to GHS. We may sell shares of our common stock from time to time over a six (6)- month period ending <span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_c20220401__20220404__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--RegistrationStatementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--GHSInvestmentsMember_z1FDkyXpcaJ3" title="Common stock maturity period">October 4, 2022, at our sole discretion, to GHS under the GHS Purchase Agreement. The purchase price shall be 85% of lowest VWAP for the ten (10) days preceding the Company’s notice to GHS for the sale of the Company’s common stock. On April 8, 2022, the Company filed a Prospectus Supplement to the Registration Statement dated October 14, 2021, regarding the GHS Purchase Agreement. The Company has evaluated subsequent events through the date the financial statements were issued. The Company has determined that there are no other such events that warrant disclosure or recognition in the financial statements, except as stated herein.

250000 240000 20000 20000

200000000

2022-10-04

EXCEL 77 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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ΐ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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 79 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 80 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 408 373 1 false 134 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://ir.ozopsurgical.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheet Sheet http://ir.ozopsurgical.com/role/BalanceSheet Consolidated Balance Sheet Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheet (Parenthetical) Sheet http://ir.ozopsurgical.com/role/BalanceSheetParenthetical Consolidated Balance Sheet (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statement of Comprehensive Income (Loss) Sheet http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss Consolidated Statement of Comprehensive Income (Loss) Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statement of Changes in Stockholders' Equity (Deficit) Sheet http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit Consolidated Statement of Changes in Stockholders' Equity (Deficit) Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statement of Cash Flows Sheet http://ir.ozopsurgical.com/role/StatementOfCashFlows Consolidated Statement of Cash Flows Statements 6 false false R7.htm 00000007 - Disclosure - ORGANIZATION Sheet http://ir.ozopsurgical.com/role/Organization ORGANIZATION Notes 7 false false R8.htm 00000008 - Disclosure - RESTATEMENT Sheet http://ir.ozopsurgical.com/role/Restatement RESTATEMENT Notes 8 false false R9.htm 00000009 - Disclosure - GOING CONCERN AND MANAGEMENT???S PLANS Sheet http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlans GOING CONCERN AND MANAGEMENT???S PLANS Notes 9 false false R10.htm 00000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS Sheet http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncements SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS Notes 10 false false R11.htm 00000011 - Disclosure - PROPERTY AND EQUIPMENT Sheet http://ir.ozopsurgical.com/role/PropertyAndEquipment PROPERTY AND EQUIPMENT Notes 11 false false R12.htm 00000012 - Disclosure - CONVERTIBLE NOTES PAYABLE Notes http://ir.ozopsurgical.com/role/ConvertibleNotesPayable CONVERTIBLE NOTES PAYABLE Notes 12 false false R13.htm 00000013 - Disclosure - DERIVATIVE LIABILITIES Sheet http://ir.ozopsurgical.com/role/DerivativeLiabilities DERIVATIVE LIABILITIES Notes 13 false false R14.htm 00000014 - Disclosure - NOTES PAYABLE Notes http://ir.ozopsurgical.com/role/NotesPayable NOTES PAYABLE Notes 14 false false R15.htm 00000015 - Disclosure - DEFERRED LIABILITY Sheet http://ir.ozopsurgical.com/role/DeferredLiability DEFERRED LIABILITY Notes 15 false false R16.htm 00000016 - Disclosure - DEFERRED REVENUE Sheet http://ir.ozopsurgical.com/role/DeferredRevenue DEFERRED REVENUE Notes 16 false false R17.htm 00000017 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://ir.ozopsurgical.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 17 false false R18.htm 00000018 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://ir.ozopsurgical.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 18 false false R19.htm 00000019 - Disclosure - STOCKHOLDERS??? EQUITY Sheet http://ir.ozopsurgical.com/role/StockholdersEquity STOCKHOLDERS??? EQUITY Notes 19 false false R20.htm 00000020 - Disclosure - NONCONTROLLING INTEREST Sheet http://ir.ozopsurgical.com/role/NoncontrollingInterest NONCONTROLLING INTEREST Notes 20 false false R21.htm 00000021 - Disclosure - OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES Sheet http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilities OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES Notes 21 false false R22.htm 00000022 - Disclosure - SUBSEQUENT EVENTS Sheet http://ir.ozopsurgical.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 22 false false R23.htm 00000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Policies) Sheet http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Policies) Policies 23 false false R24.htm 00000024 - Disclosure - ORGANIZATION (Tables) Sheet http://ir.ozopsurgical.com/role/OrganizationTables ORGANIZATION (Tables) Tables http://ir.ozopsurgical.com/role/Organization 24 false false R25.htm 00000025 - Disclosure - RESTATEMENT (Tables) Sheet http://ir.ozopsurgical.com/role/RestatementTables RESTATEMENT (Tables) Tables http://ir.ozopsurgical.com/role/Restatement 25 false false R26.htm 00000026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Tables) Sheet http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsTables SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Tables) Tables http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncements 26 false false R27.htm 00000027 - Disclosure - PROPERTY AND EQUIPMENT (Tables) Sheet http://ir.ozopsurgical.com/role/PropertyAndEquipmentTables PROPERTY AND EQUIPMENT (Tables) Tables http://ir.ozopsurgical.com/role/PropertyAndEquipment 27 false false R28.htm 00000028 - Disclosure - CONVERTIBLE NOTES PAYABLE (Tables) Notes http://ir.ozopsurgical.com/role/ConvertibleNotesPayableTables CONVERTIBLE NOTES PAYABLE (Tables) Tables http://ir.ozopsurgical.com/role/ConvertibleNotesPayable 28 false false R29.htm 00000029 - Disclosure - DERIVATIVE LIABILITIES (Tables) Sheet http://ir.ozopsurgical.com/role/DerivativeLiabilitiesTables DERIVATIVE LIABILITIES (Tables) Tables http://ir.ozopsurgical.com/role/DerivativeLiabilities 29 false false R30.htm 00000030 - Disclosure - NOTES PAYABLE (Tables) Notes http://ir.ozopsurgical.com/role/NotesPayableTables NOTES PAYABLE (Tables) Tables http://ir.ozopsurgical.com/role/NotesPayable 30 false false R31.htm 00000031 - Disclosure - RELATED PARTY TRANSACTIONS (Tables) Sheet http://ir.ozopsurgical.com/role/RelatedPartyTransactionsTables RELATED PARTY TRANSACTIONS (Tables) Tables http://ir.ozopsurgical.com/role/RelatedPartyTransactions 31 false false R32.htm 00000032 - Disclosure - OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES (Tables) Sheet http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesTables OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES (Tables) Tables http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilities 32 false false R33.htm 00000033 - Disclosure - SCHEDULE OF RECOGNIZED IDENTIFIED ASSETS ACQUIRED AND LIABILITIES ASSUMED (Details) Sheet http://ir.ozopsurgical.com/role/ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails SCHEDULE OF RECOGNIZED IDENTIFIED ASSETS ACQUIRED AND LIABILITIES ASSUMED (Details) Details 33 false false R34.htm 00000034 - Disclosure - ORGANIZATION (Details Narrative) Sheet http://ir.ozopsurgical.com/role/OrganizationDetailsNarrative ORGANIZATION (Details Narrative) Details http://ir.ozopsurgical.com/role/OrganizationTables 34 false false R35.htm 00000035 - Disclosure - SCHEDULE OF ERROR CORRECTIONS AND PRIOR PERIOD ADJUSTMENTS (Details) Sheet http://ir.ozopsurgical.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails SCHEDULE OF ERROR CORRECTIONS AND PRIOR PERIOD ADJUSTMENTS (Details) Details 35 false false R36.htm 00000036 - Disclosure - RESTATEMENT (Details Narrative) Sheet http://ir.ozopsurgical.com/role/RestatementDetailsNarrative RESTATEMENT (Details Narrative) Details http://ir.ozopsurgical.com/role/RestatementTables 36 false false R37.htm 00000037 - Disclosure - GOING CONCERN AND MANAGEMENT???S PLANS (Details Narrative) Sheet http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative GOING CONCERN AND MANAGEMENT???S PLANS (Details Narrative) Details http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlans 37 false false R38.htm 00000038 - Disclosure - SCHEDULES OF CONCENTRATION OF RISK, BY RISK FACTOR (Details) Sheet http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails SCHEDULES OF CONCENTRATION OF RISK, BY RISK FACTOR (Details) Details 38 false false R39.htm 00000039 - Disclosure - SCHEDULE OF INVENTORY (Details) Sheet http://ir.ozopsurgical.com/role/ScheduleOfInventoryDetails SCHEDULE OF INVENTORY (Details) Details 39 false false R40.htm 00000040 - Disclosure - SCHEDULE OF USEFUL LIFE OF PROPERTY AND EQUIPMENT ASSETS (Details) Sheet http://ir.ozopsurgical.com/role/ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsDetails SCHEDULE OF USEFUL LIFE OF PROPERTY AND EQUIPMENT ASSETS (Details) Details 40 false false R41.htm 00000041 - Disclosure - DISAGGREGATION OF REVENUE (Details) Sheet http://ir.ozopsurgical.com/role/DisaggregationOfRevenueDetails DISAGGREGATION OF REVENUE (Details) Details 41 false false R42.htm 00000042 - Disclosure - SCHEDULE OF DERIVATIVE INSTRUMENTS (Details) Sheet http://ir.ozopsurgical.com/role/ScheduleOfDerivativeInstrumentsDetails SCHEDULE OF DERIVATIVE INSTRUMENTS (Details) Details 42 false false R43.htm 00000043 - Disclosure - SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) Sheet http://ir.ozopsurgical.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) Details 43 false false R44.htm 00000044 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Details Narrative) Sheet http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Details Narrative) Details http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsTables 44 false false R45.htm 00000045 - Disclosure - PROPERTY AND EQUIPMENT (Details) Sheet http://ir.ozopsurgical.com/role/PropertyAndEquipmentDetails PROPERTY AND EQUIPMENT (Details) Details http://ir.ozopsurgical.com/role/PropertyAndEquipmentTables 45 false false R46.htm 00000046 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative) Sheet http://ir.ozopsurgical.com/role/PropertyAndEquipmentDetailsNarrative PROPERTY AND EQUIPMENT (Details Narrative) Details http://ir.ozopsurgical.com/role/PropertyAndEquipmentTables 46 false false R47.htm 00000047 - Disclosure - SCHEDULE OF DEBT (Details) Sheet http://ir.ozopsurgical.com/role/ScheduleOfDebtDetails SCHEDULE OF DEBT (Details) Details 47 false false R48.htm 00000048 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details Narrative) Notes http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative CONVERTIBLE NOTES PAYABLE (Details Narrative) Details http://ir.ozopsurgical.com/role/ConvertibleNotesPayableTables 48 false false R49.htm 00000049 - Disclosure - SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE (Details) Sheet http://ir.ozopsurgical.com/role/ScheduleOfDerivativeLiabilitiesAtFairValueDetails SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE (Details) Details 49 false false R50.htm 00000050 - Disclosure - DERIVATIVE LIABILITIES (Details Narrative) Sheet http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative DERIVATIVE LIABILITIES (Details Narrative) Details http://ir.ozopsurgical.com/role/DerivativeLiabilitiesTables 50 false false R51.htm 00000051 - Disclosure - SCHEDULE OF NOTES PAYABLE (Details) Notes http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails SCHEDULE OF NOTES PAYABLE (Details) Details 51 false false R52.htm 00000052 - Disclosure - SCHEDULE OF NOTES PAYABLE (Details) (Parenthetical) Notes http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical SCHEDULE OF NOTES PAYABLE (Details) (Parenthetical) Details 52 false false R53.htm 00000053 - Disclosure - NOTES PAYABLE (Details Narrative) Notes http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative NOTES PAYABLE (Details Narrative) Details http://ir.ozopsurgical.com/role/NotesPayableTables 53 false false R54.htm 00000054 - Disclosure - DEFERRED LIABILITY (Details Narrative) Sheet http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative DEFERRED LIABILITY (Details Narrative) Details http://ir.ozopsurgical.com/role/DeferredLiability 54 false false R55.htm 00000055 - Disclosure - DEFERRED REVENUE (Details Narrative) Sheet http://ir.ozopsurgical.com/role/DeferredRevenueDetailsNarrative DEFERRED REVENUE (Details Narrative) Details http://ir.ozopsurgical.com/role/DeferredRevenue 55 false false R56.htm 00000056 - Disclosure - SCHEDULE OF EXPENSES TO OFFICERS (Details) Sheet http://ir.ozopsurgical.com/role/ScheduleOfExpensesToOfficersDetails SCHEDULE OF EXPENSES TO OFFICERS (Details) Details 56 false false R57.htm 00000057 - Disclosure - SCHEDULE OF EXPENSES TO OFFICERS (Details) (Parenthetical) Sheet http://ir.ozopsurgical.com/role/ScheduleOfExpensesToOfficersDetailsParenthetical SCHEDULE OF EXPENSES TO OFFICERS (Details) (Parenthetical) Details 57 false false R58.htm 00000058 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://ir.ozopsurgical.com/role/RelatedPartyTransactionsTables 58 false false R59.htm 00000059 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://ir.ozopsurgical.com/role/CommitmentsAndContingencies 59 false false R60.htm 00000060 - Disclosure - STOCKHOLDERS??? EQUITY (Details Narrative) Sheet http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative STOCKHOLDERS??? EQUITY (Details Narrative) Details http://ir.ozopsurgical.com/role/StockholdersEquity 60 false false R61.htm 00000061 - Disclosure - NONCONTROLLING INTEREST (Details Narrative) Sheet http://ir.ozopsurgical.com/role/NoncontrollingInterestDetailsNarrative NONCONTROLLING INTEREST (Details Narrative) Details http://ir.ozopsurgical.com/role/NoncontrollingInterest 61 false false R62.htm 00000062 - Disclosure - SCHEDULE OF RIGHT-OF-USE ASSETS (Details) Sheet http://ir.ozopsurgical.com/role/ScheduleOfRight-of-useAssetsDetails SCHEDULE OF RIGHT-OF-USE ASSETS (Details) Details 62 false false R63.htm 00000063 - Disclosure - SCHEDULE OF OPERATING LEASE LIABILITIES (Details) Sheet http://ir.ozopsurgical.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails SCHEDULE OF OPERATING LEASE LIABILITIES (Details) Details 63 false false R64.htm 00000064 - Disclosure - SCHEDULE OF MATURITY OF LEASE LIABILITIES (Details) Sheet http://ir.ozopsurgical.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails SCHEDULE OF MATURITY OF LEASE LIABILITIES (Details) Details 64 false false R65.htm 00000065 - Disclosure - OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES (Details Narrative) Sheet http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES (Details Narrative) Details http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesTables 65 false false R66.htm 00000066 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://ir.ozopsurgical.com/role/SubsequentEvents 66 false false All Reports Book All Reports form10-k.htm ex31-1.htm ex31-2.htm ex32-1.htm ozsc-20211231.xsd ozsc-20211231_cal.xml ozsc-20211231_def.xml ozsc-20211231_lab.xml ozsc-20211231_pre.xml http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 83 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10-k.htm": { "axisCustom": 0, "axisStandard": 29, "contextCount": 408, "dts": { "calculationLink": { "local": [ "ozsc-20211231_cal.xml" ] }, "definitionLink": { "local": [ "ozsc-20211231_def.xml" ] }, "inline": { "local": [ "form10-k.htm" ] }, "labelLink": { "local": [ "ozsc-20211231_lab.xml" ] }, "presentationLink": { "local": [ "ozsc-20211231_pre.xml" ] }, "schema": { "local": [ "ozsc-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 655, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 143, "http://ir.ozopsurgical.com/20211231": 78, "http://xbrl.sec.gov/dei/2021q4": 3, "total": 224 }, "keyCustom": 75, "keyStandard": 298, "memberCustom": 91, "memberStandard": 37, "nsprefix": "OZSC", "nsuri": "http://ir.ozopsurgical.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://ir.ozopsurgical.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS", "role": "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncements", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - PROPERTY AND EQUIPMENT", "role": "http://ir.ozopsurgical.com/role/PropertyAndEquipment", "shortName": "PROPERTY AND EQUIPMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - CONVERTIBLE NOTES PAYABLE", "role": "http://ir.ozopsurgical.com/role/ConvertibleNotesPayable", "shortName": "CONVERTIBLE NOTES PAYABLE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativesAndFairValueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - DERIVATIVE LIABILITIES", "role": "http://ir.ozopsurgical.com/role/DerivativeLiabilities", "shortName": "DERIVATIVE LIABILITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativesAndFairValueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "OZSC:NotesPayableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - NOTES PAYABLE", "role": "http://ir.ozopsurgical.com/role/NotesPayable", "shortName": "NOTES PAYABLE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "OZSC:NotesPayableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "OZSC:DeferredLiabilityTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - DEFERRED LIABILITY", "role": "http://ir.ozopsurgical.com/role/DeferredLiability", "shortName": "DEFERRED LIABILITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "OZSC:DeferredLiabilityTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - DEFERRED REVENUE", "role": "http://ir.ozopsurgical.com/role/DeferredRevenue", "shortName": "DEFERRED REVENUE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - RELATED PARTY TRANSACTIONS", "role": "http://ir.ozopsurgical.com/role/RelatedPartyTransactions", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://ir.ozopsurgical.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - STOCKHOLDERS\u2019 EQUITY", "role": "http://ir.ozopsurgical.com/role/StockholdersEquity", "shortName": "STOCKHOLDERS\u2019 EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Consolidated Balance Sheet", "role": "http://ir.ozopsurgical.com/role/BalanceSheet", "shortName": "Consolidated Balance Sheet", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeNoncontrollingInterestTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - NONCONTROLLING INTEREST", "role": "http://ir.ozopsurgical.com/role/NoncontrollingInterest", "shortName": "NONCONTROLLING INTEREST", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeNoncontrollingInterestTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES", "role": "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilities", "shortName": "OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - SUBSEQUENT EVENTS", "role": "http://ir.ozopsurgical.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Policies)", "role": "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - ORGANIZATION (Tables)", "role": "http://ir.ozopsurgical.com/role/OrganizationTables", "shortName": "ORGANIZATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:ErrorCorrectionTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - RESTATEMENT (Tables)", "role": "http://ir.ozopsurgical.com/role/RestatementTables", "shortName": "RESTATEMENT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ErrorCorrectionTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:ConcentrationRiskCreditRisk", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Tables)", "role": "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsTables", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ConcentrationRiskCreditRisk", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - PROPERTY AND EQUIPMENT (Tables)", "role": "http://ir.ozopsurgical.com/role/PropertyAndEquipmentTables", "shortName": "PROPERTY AND EQUIPMENT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - CONVERTIBLE NOTES PAYABLE (Tables)", "role": "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableTables", "shortName": "CONVERTIBLE NOTES PAYABLE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:DerivativesAndFairValueTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - DERIVATIVE LIABILITIES (Tables)", "role": "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesTables", "shortName": "DERIVATIVE LIABILITIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DerivativesAndFairValueTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Consolidated Balance Sheet (Parenthetical)", "role": "http://ir.ozopsurgical.com/role/BalanceSheetParenthetical", "shortName": "Consolidated Balance Sheet (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "lang": null, "name": "OZSC:CommonStockYetToBeIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "OZSC:NotesPayableTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "OZSC:ScheduleOfNotesPayableTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - NOTES PAYABLE (Tables)", "role": "http://ir.ozopsurgical.com/role/NotesPayableTables", "shortName": "NOTES PAYABLE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "OZSC:NotesPayableTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "OZSC:ScheduleOfNotesPayableTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)", "role": "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsTables", "shortName": "RELATED PARTY TRANSACTIONS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "OZSC:ScheduleOfRightofUseAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES (Tables)", "role": "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesTables", "shortName": "OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "OZSC:ScheduleOfRightofUseAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "OZSC:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFairValueOfConsiderationIssued", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - SCHEDULE OF RECOGNIZED IDENTIFIED ASSETS ACQUIRED AND LIABILITIES ASSUMED (Details)", "role": "http://ir.ozopsurgical.com/role/ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails", "shortName": "SCHEDULE OF RECOGNIZED IDENTIFIED ASSETS ACQUIRED AND LIABILITIES ASSUMED (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "OZSC:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFairValueOfConsiderationIssued", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-012020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GoodwillImpairmentLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - ORGANIZATION (Details Narrative)", "role": "http://ir.ozopsurgical.com/role/OrganizationDetailsNarrative", "shortName": "ORGANIZATION (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-012020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GoodwillImpairmentLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Assets", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - SCHEDULE OF ERROR CORRECTIONS AND PRIOR PERIOD ADJUSTMENTS (Details)", "role": "http://ir.ozopsurgical.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails", "shortName": "SCHEDULE OF ERROR CORRECTIONS AND PRIOR PERIOD ADJUSTMENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "us-gaap:ErrorCorrectionTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember", "decimals": "0", "lang": null, "name": "us-gaap:Assets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DerivativesAndFairValueTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FairValueAdjustmentOfWarrants", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - RESTATEMENT (Details Narrative)", "role": "http://ir.ozopsurgical.com/role/RestatementDetailsNarrative", "shortName": "RESTATEMENT (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:ErrorCorrectionTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-012020-12-31", "decimals": "0", "lang": null, "name": "us-gaap:IncreaseDecreaseInNotesPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - GOING CONCERN AND MANAGEMENT\u2019S PLANS (Details Narrative)", "role": "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "shortName": "GOING CONCERN AND MANAGEMENT\u2019S PLANS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "lang": null, "name": "OZSC:WorkingCapitalDeficit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "us-gaap:ConcentrationRiskCreditRisk", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31_custom_CustomerAMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - SCHEDULES OF CONCENTRATION OF RISK, BY RISK FACTOR (Details)", "role": "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails", "shortName": "SCHEDULES OF CONCENTRATION OF RISK, BY RISK FACTOR (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "us-gaap:ConcentrationRiskCreditRisk", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31_custom_CustomerAMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - SCHEDULE OF INVENTORY (Details)", "role": "http://ir.ozopsurgical.com/role/ScheduleOfInventoryDetails", "shortName": "SCHEDULE OF INVENTORY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Consolidated Statement of Comprehensive Income (Loss)", "role": "http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss", "shortName": "Consolidated Statement of Comprehensive Income (Loss)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "OZSC:ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-012021-12-31_custom_WarehouseEquipmentMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000040 - Disclosure - SCHEDULE OF USEFUL LIFE OF PROPERTY AND EQUIPMENT ASSETS (Details)", "role": "http://ir.ozopsurgical.com/role/ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsDetails", "shortName": "SCHEDULE OF USEFUL LIFE OF PROPERTY AND EQUIPMENT ASSETS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "OZSC:ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-012021-12-31_custom_WarehouseEquipmentMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000041 - Disclosure - DISAGGREGATION OF REVENUE (Details)", "role": "http://ir.ozopsurgical.com/role/DisaggregationOfRevenueDetails", "shortName": "DISAGGREGATION OF REVENUE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-012021-12-31_custom_SourcedAndDistributedProductsMember", "decimals": "0", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000042 - Disclosure - SCHEDULE OF DERIVATIVE INSTRUMENTS (Details)", "role": "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeInstrumentsDetails", "shortName": "SCHEDULE OF DERIVATIVE INSTRUMENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000043 - Disclosure - SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details)", "role": "http://ir.ozopsurgical.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "shortName": "SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000044 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Details Narrative)", "role": "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000045 - Disclosure - PROPERTY AND EQUIPMENT (Details)", "role": "http://ir.ozopsurgical.com/role/PropertyAndEquipmentDetails", "shortName": "PROPERTY AND EQUIPMENT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000046 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)", "role": "http://ir.ozopsurgical.com/role/PropertyAndEquipmentDetailsNarrative", "shortName": "PROPERTY AND EQUIPMENT (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31_us-gaap_ConvertibleDebtMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ConvertibleNotesPayable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000047 - Disclosure - SCHEDULE OF DEBT (Details)", "role": "http://ir.ozopsurgical.com/role/ScheduleOfDebtDetails", "shortName": "SCHEDULE OF DEBT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31_us-gaap_ConvertibleDebtMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ConvertibleNotesPayable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000048 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details Narrative)", "role": "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative", "shortName": "CONVERTIBLE NOTES PAYABLE (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-05-06_custom_SettlementAgreementMember", "decimals": "INF", "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "us-gaap:DerivativesAndFairValueTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-07-10", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilities", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000049 - Disclosure - SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE (Details)", "role": "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeLiabilitiesAtFairValueDetails", "shortName": "SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "us-gaap:DerivativesAndFairValueTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-07-112020-12-31", "decimals": "0", "lang": null, "name": "OZSC:DerivativeLiabilityIssuedDuringPeriod", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2019-12-31_us-gaap_SeriesCPreferredStockMember_us-gaap_PreferredStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Consolidated Statement of Changes in Stockholders' Equity (Deficit)", "role": "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit", "shortName": "Consolidated Statement of Changes in Stockholders' Equity (Deficit)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2019-12-31_us-gaap_SeriesCPreferredStockMember_us-gaap_PreferredStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DerivativesAndFairValueTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilities", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000050 - Disclosure - DERIVATIVE LIABILITIES (Details Narrative)", "role": "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative", "shortName": "DERIVATIVE LIABILITIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DerivativesAndFairValueTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "lang": null, "name": "OZSC:WarrantsInConjunctionWithNotesPayable", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "OZSC:ScheduleOfNotesPayableTableTextBlock", "OZSC:NotesPayableTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayable", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000051 - Disclosure - SCHEDULE OF NOTES PAYABLE (Details)", "role": "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails", "shortName": "SCHEDULE OF NOTES PAYABLE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "OZSC:ScheduleOfNotesPayableTableTextBlock", "OZSC:NotesPayableTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31_custom_NotePayableMember", "decimals": "0", "lang": null, "name": "us-gaap:NotesPayable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-02-26", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000052 - Disclosure - SCHEDULE OF NOTES PAYABLE (Details) (Parenthetical)", "role": "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical", "shortName": "SCHEDULE OF NOTES PAYABLE (Details) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "OZSC:ScheduleOfNotesPayableTableTextBlock", "OZSC:NotesPayableTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31_custom_NotePayableMember", "decimals": "INF", "lang": null, "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-02-26", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000053 - Disclosure - NOTES PAYABLE (Details Narrative)", "role": "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "shortName": "NOTES PAYABLE (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "OZSC:NotesPayableTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-03-15", "decimals": "0", "lang": null, "name": "us-gaap:NotesPayableToBank", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "OZSC:DeferredLiabilityCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000054 - Disclosure - DEFERRED LIABILITY (Details Narrative)", "role": "http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative", "shortName": "DEFERRED LIABILITY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "OZSC:DeferredLiabilityTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-09-02_custom_PCTIMember_custom_ExchangeAgreementMember", "decimals": "0", "lang": null, "name": "OZSC:DeferredLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-012020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncreaseDecreaseInDueToRelatedParties", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000055 - Disclosure - DEFERRED REVENUE (Details Narrative)", "role": "http://ir.ozopsurgical.com/role/DeferredRevenueDetailsNarrative", "shortName": "DEFERRED REVENUE (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-012020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncreaseDecreaseInDueToRelatedParties", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SalariesWagesAndOfficersCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000056 - Disclosure - SCHEDULE OF EXPENSES TO OFFICERS (Details)", "role": "http://ir.ozopsurgical.com/role/ScheduleOfExpensesToOfficersDetails", "shortName": "SCHEDULE OF EXPENSES TO OFFICERS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SalariesWagesAndOfficersCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000057 - Disclosure - SCHEDULE OF EXPENSES TO OFFICERS (Details) (Parenthetical)", "role": "http://ir.ozopsurgical.com/role/ScheduleOfExpensesToOfficersDetailsParenthetical", "shortName": "SCHEDULE OF EXPENSES TO OFFICERS (Details) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R58": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:EmployeeBenefitsAndShareBasedCompensation", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000058 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)", "role": "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-02-252020-02-28", "decimals": "0", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsForParticipationLiabilities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000059 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)", "role": "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsForParticipationLiabilities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Consolidated Statement of Cash Flows", "role": "http://ir.ozopsurgical.com/role/StatementOfCashFlows", "shortName": "Consolidated Statement of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "lang": null, "name": "us-gaap:DepreciationAmortizationAndAccretionNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-13", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000060 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Details Narrative)", "role": "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative", "shortName": "STOCKHOLDERS\u2019 EQUITY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:CommonStockSharesAuthorized", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:OtherComprehensiveIncomeNoncontrollingInterestTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeLossAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000061 - Disclosure - NONCONTROLLING INTEREST (Details Narrative)", "role": "http://ir.ozopsurgical.com/role/NoncontrollingInterestDetailsNarrative", "shortName": "NONCONTROLLING INTEREST (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:OtherComprehensiveIncomeNoncontrollingInterestTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeLossAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "OZSC:ScheduleOfRightofUseAssetsTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "OZSC:OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000062 - Disclosure - SCHEDULE OF RIGHT-OF-USE ASSETS (Details)", "role": "http://ir.ozopsurgical.com/role/ScheduleOfRight-of-useAssetsDetails", "shortName": "SCHEDULE OF RIGHT-OF-USE ASSETS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "OZSC:ScheduleOfRightofUseAssetsTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "OZSC:OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "OZSC:ScheduleOfOperatingLeaseLiabilitiesTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLiability", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000063 - Disclosure - SCHEDULE OF OPERATING LEASE LIABILITIES (Details)", "role": "http://ir.ozopsurgical.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails", "shortName": "SCHEDULE OF OPERATING LEASE LIABILITIES (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R64": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000064 - Disclosure - SCHEDULE OF MATURITY OF LEASE LIABILITIES (Details)", "role": "http://ir.ozopsurgical.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails", "shortName": "SCHEDULE OF MATURITY OF LEASE LIABILITIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseExpirationDate1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000065 - Disclosure - OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES (Details Narrative)", "role": "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative", "shortName": "OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseExpirationDate1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "span", "p", "OZSC:NotesPayableTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-03-142021-03-15", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentMaturityDate", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000066 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)", "role": "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative", "shortName": "SUBSEQUENT EVENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-04-012022-04-04_us-gaap_SubsequentEventMember_custom_RegistrationStatementMember_us-gaap_CommonStockMember_custom_GHSInvestmentsMember", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - ORGANIZATION", "role": "http://ir.ozopsurgical.com/role/Organization", "shortName": "ORGANIZATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ErrorCorrectionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - RESTATEMENT", "role": "http://ir.ozopsurgical.com/role/Restatement", "shortName": "RESTATEMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ErrorCorrectionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - GOING CONCERN AND MANAGEMENT\u2019S PLANS", "role": "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlans", "shortName": "GOING CONCERN AND MANAGEMENT\u2019S PLANS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 134, "tag": { "OZSC_AmortizationOfWarrantDiscount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amortization Of Warrant Discount", "label": "[custom:AmortizationOfWarrantDiscount-0]" } } }, "localname": "AmortizationOfWarrantDiscount", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "OZSC_AnnualCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Annual compensation.", "label": "Annual compensation" } } }, "localname": "AnnualCompensation", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "OZSC_AprilOneTwoThousandAndTwentyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "April 1, 2021 [Member]", "label": "April 1, 2021 [Member]" } } }, "localname": "AprilOneTwoThousandAndTwentyOneMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_AuroraEnterprisesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aurora Enterprises [Member]", "label": "Aurora Enterprises [Member]" } } }, "localname": "AuroraEnterprisesMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_BonusAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Bonus amount.", "label": "Bonus amount" } } }, "localname": "BonusAmount", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "OZSC_BrianConwayMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Brian Conway [Member]", "label": "Brian Conway [Member]" } } }, "localname": "BrianConwayMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/NoncontrollingInterestDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_BusinessAcquisitionNumberOfSharesAcquired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares acquired.", "label": "Number of shares acquired" } } }, "localname": "BusinessAcquisitionNumberOfSharesAcquired", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/OrganizationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "OZSC_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFairValueOfConsiderationIssued": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of consideration issued.", "label": "Fair value of OZOP equity consideration issued" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFairValueOfConsiderationIssued", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "OZSC_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipmentAssetsAcquired": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Assets acquired.", "label": "Assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipmentAssetsAcquired", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "OZSC_CertificatesOfDesignationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Certificates of Designation [Member]", "label": "Certificates of Designation [Member]" } } }, "localname": "CertificatesOfDesignationMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_ChiefExecutiveOfficerSeriesDPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Chief Executive Officer Series D Preferred Stock [Member]", "label": "Chief Executive Officer Series D Preferred Stock [Member]" } } }, "localname": "ChiefExecutiveOfficerSeriesDPreferredStockMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfExpensesToOfficersDetails" ], "xbrltype": "domainItemType" }, "OZSC_ChiefExecutiveOfficerSeriesEPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Chief Executive Officer Series E Preferred Stock [Member]", "label": "Chief Executive Officer Series E Preferred Stock [Member]" } } }, "localname": "ChiefExecutiveOfficerSeriesEPreferredStockMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfExpensesToOfficersDetails" ], "xbrltype": "domainItemType" }, "OZSC_ChisMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Chis [Member]", "label": "Chis [Member]" } } }, "localname": "ChisMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_ChristopherRuppelMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Christopher Ruppel [Member]", "label": "Christopher Ruppel [Member]" } } }, "localname": "ChristopherRuppelMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_CoDirectorsOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Co-Directors of Sales [Member]", "label": "Co-Directors of Sales [Member]" } } }, "localname": "CoDirectorsOfSalesMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_CommonStockToBeIssued": { "auth_ref": [], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Common stock to be issued.", "label": "Common stock to be issued; 637,755 shares as of December 31, 2021" } } }, "localname": "CommonStockToBeIssued", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "OZSC_CommonStockToBeIssuedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock To Be Issued [Member]", "label": "Common Stock To Be Issued [Member]" } } }, "localname": "CommonStockToBeIssuedMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "OZSC_CommonStockUponCashlessExerciseOfWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock upon cashless exercise of warrants", "label": "Common stock upon the cashless exercise of the warrants" } } }, "localname": "CommonStockUponCashlessExerciseOfWarrants", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "sharesItemType" }, "OZSC_CommonStockYetToBeIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock yet to be issued.", "label": "common stock to be issued" } } }, "localname": "CommonStockYetToBeIssued", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheetParenthetical" ], "xbrltype": "sharesItemType" }, "OZSC_ConsultingAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consulting Agreement [Member]", "label": "Consulting Agreement [Member]" } } }, "localname": "ConsultingAgreementMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_ConsultingExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Consulting Expense.", "label": "Consulting expense" } } }, "localname": "ConsultingExpense", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "OZSC_ContractRenewalBonus": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Contract renewal bonus.", "label": "Contract renewal bonus" } } }, "localname": "ContractRenewalBonus", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "OZSC_ConversionPricePercentageOfDiscountOnCommonSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion price percentage of discount on common share price", "label": "Conversion price percentage of discount on common share price" } } }, "localname": "ConversionPricePercentageOfDiscountOnCommonSharePrice", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "OZSC_ConvertibleInstrumentsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible instruments [Policy Text Block]", "label": "Convertible Instruments" } } }, "localname": "ConvertibleInstrumentsPolicyTextBlock", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "OZSC_ConvertibleNotesPayableNet": { "auth_ref": [], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Convertible notes payable net.", "label": "Convertible notes payable, net of discounts" } } }, "localname": "ConvertibleNotesPayableNet", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "OZSC_CustomerAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer A [Member]", "label": "Customer A [Member]" } } }, "localname": "CustomerAMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails" ], "xbrltype": "domainItemType" }, "OZSC_CustomerBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer B [Member]", "label": "Customer B [Member]" } } }, "localname": "CustomerBMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails" ], "xbrltype": "domainItemType" }, "OZSC_CustomerCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer C [Member]", "label": "Customer C [Member]" } } }, "localname": "CustomerCMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails" ], "xbrltype": "domainItemType" }, "OZSC_CustomerDeposits": { "auth_ref": [], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Customer deposits.", "label": "Customer deposits" } } }, "localname": "CustomerDeposits", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "OZSC_DebtAdditionalDefaultLongtermDebtAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Debt additional default debt amount" } } }, "localname": "DebtAdditionalDefaultLongtermDebtAmount", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "OZSC_DebtConversionAccruedInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt conversion accrued interest", "label": "Debt conversion accrued interest" } } }, "localname": "DebtConversionAccruedInterest", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "OZSC_DebtInstrumentInitialDebtDiscount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt instrument initial debt discount", "label": "Debt intstrument initial debt discount." } } }, "localname": "DebtInstrumentInitialDebtDiscount", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "OZSC_DebtRestructureExpense": { "auth_ref": [], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt restructure expense", "label": "Debt restructure expense" } } }, "localname": "DebtRestructureExpense", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows", "http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "OZSC_DecemberSevenTwoThousandTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "December Seven Two Thousand Twenty Two [Member]", "label": "December Seven Two Thousand Twenty Two [Member]" } } }, "localname": "DecemberSevenTwoThousandTwentyTwoMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_DeferredLiabilityCurrent": { "auth_ref": [], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred liability current.", "label": "Deferred liability", "verboseLabel": "Deferred liability, current" } } }, "localname": "DeferredLiabilityCurrent", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet", "http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "OZSC_DeferredLiabilityTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred Liability [Text Block]", "label": "DEFERRED LIABILITY" } } }, "localname": "DeferredLiabilityTextBlock", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/DeferredLiability" ], "xbrltype": "textBlockItemType" }, "OZSC_DefinitiveAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Definitive Agreement [Member]", "label": "Definitive Agreement [Member]" } } }, "localname": "DefinitiveAgreementMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_DerivativeLiabilitiesAssociatedWithConvertibleNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derivative Liabilities Associated With Convertible Notes [Member]", "label": "Derivative Liabilities Associated With Convertible Notes [Member]" } } }, "localname": "DerivativeLiabilitiesAssociatedWithConvertibleNotesMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeLiabilitiesAtFairValueDetails" ], "xbrltype": "domainItemType" }, "OZSC_DerivativeLiabilitiesAssociatedWithWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derivative Liabilities Associated With Warrants [Member]", "label": "Derivative Liabilities Associated With Warrants [Member]" } } }, "localname": "DerivativeLiabilitiesAssociatedWithWarrantsMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeLiabilitiesAtFairValueDetails" ], "xbrltype": "domainItemType" }, "OZSC_DerivativeLiabilityInterestExpense": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Derivative liability interest expense", "label": "Derivative liability interest expense" } } }, "localname": "DerivativeLiabilityInterestExpense", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "OZSC_DerivativeLiabilityIssuedDuringPeriod": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Derivative Liability Issued During Period", "label": "Fair value of issuances during period" } } }, "localname": "DerivativeLiabilityIssuedDuringPeriod", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeLiabilitiesAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "OZSC_DisclosureDeferredLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Liability" } } }, "localname": "DisclosureDeferredLiabilityAbstract", "nsuri": "http://ir.ozopsurgical.com/20211231", "xbrltype": "stringItemType" }, "OZSC_DisclosureDerivativeLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Liabilities" } } }, "localname": "DisclosureDerivativeLiabilitiesAbstract", "nsuri": "http://ir.ozopsurgical.com/20211231", "xbrltype": "stringItemType" }, "OZSC_DisclosureNotesPayableAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes Payable" } } }, "localname": "DisclosureNotesPayableAbstract", "nsuri": "http://ir.ozopsurgical.com/20211231", "xbrltype": "stringItemType" }, "OZSC_DisclosureOperatingLeaseRightofuseAssetsAndOperatingLeaseLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Lease Right-of-use Assets And Operating Lease Liabilities", "terseLabel": "Schedule Of Operating Lease Liabilities", "verboseLabel": "Schedule Of Right-of-use Assets" } } }, "localname": "DisclosureOperatingLeaseRightofuseAssetsAndOperatingLeaseLiabilitiesAbstract", "nsuri": "http://ir.ozopsurgical.com/20211231", "xbrltype": "stringItemType" }, "OZSC_EconomicInjuryDisasterLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Economic Injury Disaster Loan [Member]", "label": "Economic Injury Disaster Loan [Member]" } } }, "localname": "EconomicInjuryDisasterLoanMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "domainItemType" }, "OZSC_EmploymentAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employment Agreement [Member]", "label": "Employment Agreement [Member]" } } }, "localname": "EmploymentAgreementMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_ExchangeAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exchange Agreement [Member]", "label": "Exchange Agreement [Member]" } } }, "localname": "ExchangeAgreementMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_EzraGreenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ezra Green [Member]", "label": "Ezra Green [Member]" } } }, "localname": "EzraGreenMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_FifteenPercentConvertiblePromissoryNoteFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "15% Convertible Promissory Note Four [Member]", "label": "15% Convertible Promissory Note Four [Member]" } } }, "localname": "FifteenPercentConvertiblePromissoryNoteFourMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_FifteenPercentConvertiblePromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "15% Convertible Promissory Note [Member]", "label": "15% Convertible Promissory Note [Member]" } } }, "localname": "FifteenPercentConvertiblePromissoryNoteMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_FifteenPercentConvertiblePromissoryNoteOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "15% Convertible Promissory Note One [Member]", "label": "15% Convertible Promissory Note One [Member]" } } }, "localname": "FifteenPercentConvertiblePromissoryNoteOneMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_FifteenPercentConvertiblePromissoryNoteThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "15% Convertible Promissory Note Three [Member]", "label": "15% Convertible Promissory Note Three [Member]" } } }, "localname": "FifteenPercentConvertiblePromissoryNoteThreeMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_FifteenPercentConvertiblePromissoryNoteTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "15% Convertible Promissory Note Two [Member]", "label": "15% Convertible Promissory Note Two [Member]" } } }, "localname": "FifteenPercentConvertiblePromissoryNoteTwoMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_FifteenPercentPromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "15% Promissory Note [Member]", "label": "15% Promissory Note [Member]" } } }, "localname": "FifteenPercentPromissoryNoteMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_FundRaisedForBusinessOperations": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fund raised for business operations.", "label": "Fund raised for business operations" } } }, "localname": "FundRaisedForBusinessOperations", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "OZSC_GHSInvestmentsLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "GHS Investments LLC [Member]", "label": "GHS Investments LLC [Member]" } } }, "localname": "GHSInvestmentsLLCMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_GHSInvestmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "GHS Investments [Member]", "label": "GHS Investments [Member]" } } }, "localname": "GHSInvestmentsMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_GarageStorageFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Garage Storage Facility [Member]", "label": "Garage Storage Facility [Member]" } } }, "localname": "GarageStorageFacilityMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_GeneralAndAdministrativeRelatedParties": { "auth_ref": [], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "General and administrative related parties", "label": "General and administrative, related parties" } } }, "localname": "GeneralAndAdministrativeRelatedParties", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "OZSC_HolderMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Holder [Member]", "label": "Holder [Member]" } } }, "localname": "HolderMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_HoldersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Holders [Member]", "label": "Holders [Member]" } } }, "localname": "HoldersMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_IncreaseDecreaseInVendorDeposits": { "auth_ref": [], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in vendor deposits", "label": "IncreaseDecreaseInVendorDeposits", "negatedLabel": "Vendor deposits" } } }, "localname": "IncreaseDecreaseInVendorDeposits", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "OZSC_IncrementalBorrowingPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incremental borrowing percentage.", "label": "Incremental borrowing percentage" } } }, "localname": "IncrementalBorrowingPercentage", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "percentItemType" }, "OZSC_IssuanceOfCommonStockAndPreferredStockForConsultingFeesAndCompensation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of common stock and preferred stock for consulting fees and compensation", "label": "Issuance of common stock and preferred stock for consulting fees and compensation" } } }, "localname": "IssuanceOfCommonStockAndPreferredStockForConsultingFeesAndCompensation", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "OZSC_IssuanceOfCommonStockForDebtRestructuring": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of common stock for debt restructuring", "label": "Issuance of common stock for debt restructuring" } } }, "localname": "IssuanceOfCommonStockForDebtRestructuring", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "OZSC_IssuanceOfCommonStockForLeaseAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of common stock for lease agreement", "label": "Issuance of common stock for lease agreement" } } }, "localname": "IssuanceOfCommonStockForLeaseAgreement", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "OZSC_IssuanceOfCommonStockUponConvertibleNoteAndAccruedInterestConversion": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of common stock upon convertible note and accrued interest conversion", "label": "Issuance of common stock upon convertible note and accrued interest conversion" } } }, "localname": "IssuanceOfCommonStockUponConvertibleNoteAndAccruedInterestConversion", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "OZSC_IssuanceOfSeriesEPreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of Series E Preferred Stock.", "label": "Issuance of Series E Preferred Stock" } } }, "localname": "IssuanceOfSeriesEPreferredStock", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "OZSC_IssuanceOfSeriesEPreferredStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance of series e preferred stock shares", "label": "Issuance of Series E Preferred Stock, shares" } } }, "localname": "IssuanceOfSeriesEPreferredStockShares", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "OZSC_LeaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease Agreement [Member]", "label": "Lease Agreement [Member]" } } }, "localname": "LeaseAgreementMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_LenderCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Lender Costs", "label": "Lender costs" } } }, "localname": "LenderCosts", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "OZSC_LenderMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lender [Member]", "label": "Lender [Member]" } } }, "localname": "LenderMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_LendersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lenders [Member]", "label": "Lenders [Member]" } } }, "localname": "LendersMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_LossOnFairValueChangeOfDerivatives": { "auth_ref": [], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Loss on fair value change of derivatives" } } }, "localname": "LossOnFairValueChangeOfDerivatives", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "OZSC_ManufacturedProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Manufactured Products [Member]", "label": "Manufactured Products [Member]" } } }, "localname": "ManufacturedProductsMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/DisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "OZSC_MeasurementInputPriceVolatilityOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement Input Price Volatility One [Member]", "label": "Measurement Input Price Volatility One [Member]" } } }, "localname": "MeasurementInputPriceVolatilityOneMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_MrAllenSosisMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mr Allen Sosis [Member]", "label": "Mr Allen Sosis [Member]" } } }, "localname": "MrAllenSosisMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_MrConvayMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mr. Convay [Member].", "label": "Mr. Convay [Member]" } } }, "localname": "MrConvayMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_MrConwayMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mr Conway [Member]", "label": "Mr Conway [Member]" } } }, "localname": "MrConwayMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative", "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_MrStevenMartelloMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mr Steven Martello [Member]", "label": "Mr Steven Martello [Member]" } } }, "localname": "MrStevenMartelloMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_NewEmploymentAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "New Employment Agreement [Member]", "label": "New Employment Agreement [Member]" } } }, "localname": "NewEmploymentAgreementMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_NineInstalmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Nine Instalments [Member]", "label": "Nine Instalments [Member]" } } }, "localname": "NineInstalmentsMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_NotePayableEightMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note Payable Eight [Member]", "label": "Note Payable Eight [Member]" } } }, "localname": "NotePayableEightMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "OZSC_NotePayableFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note Payable Five [Member]", "label": "Note Payable Five [Member]" } } }, "localname": "NotePayableFiveMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "OZSC_NotePayableFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note Payable Four [Member]", "label": "Note Payable Four [Member]" } } }, "localname": "NotePayableFourMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "OZSC_NotePayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note Payable [Member]", "label": "Note Payable [Member]" } } }, "localname": "NotePayableMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "OZSC_NotePayableNineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note Payable Nine [Member]", "label": "Note Payable Nine [Member]" } } }, "localname": "NotePayableNineMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "OZSC_NotePayableOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note Payable One [Member]", "label": "Note Payable One [Member]" } } }, "localname": "NotePayableOneMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "OZSC_NotePayableSevenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note Payable Seven [Member]", "label": "Note Payable Seven [Member]" } } }, "localname": "NotePayableSevenMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "OZSC_NotePayableSixMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note Payable Six [Member]", "label": "Note Payable Six [Member]" } } }, "localname": "NotePayableSixMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "OZSC_NotePayableThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note PayableThree [Member]", "label": "Note PayableThree [Member]" } } }, "localname": "NotePayableThreeMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "OZSC_NotePayableTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note Payable Two [Member]", "label": "Note Payable Two [Member]" } } }, "localname": "NotePayableTwoMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "OZSC_NotesConvertedOrPaidAndExerciseOfWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Notes converted or paid and exercise of warrants", "label": "Notes converted or paid" } } }, "localname": "NotesConvertedOrPaidAndExerciseOfWarrants", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeLiabilitiesAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "OZSC_NotesPayableDiscount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Notes payable discount", "label": "Notes payable discount" } } }, "localname": "NotesPayableDiscount", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "OZSC_NotesPayableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Notes Payable [Text Block]", "label": "NOTES PAYABLE" } } }, "localname": "NotesPayableTextBlock", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayable" ], "xbrltype": "textBlockItemType" }, "OZSC_NumberSharesIssuedForCashlessExerciseOfWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number shares issued for cashless exercise of warrants", "label": "Number shares issued for cashless" } } }, "localname": "NumberSharesIssuedForCashlessExerciseOfWarrants", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "sharesItemType" }, "OZSC_OESMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "OES [Member]", "label": "OES [Member]" } } }, "localname": "OESMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_OfficeFurnitureAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Office Furniture And Equipment [Member]", "label": "Office Furniture And Equipment [Member]" } } }, "localname": "OfficeFurnitureAndEquipmentMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsDetails" ], "xbrltype": "domainItemType" }, "OZSC_OfficersCompensationReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Officers Compensation Received", "label": "Officers compensation received" } } }, "localname": "OfficersCompensationReceived", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "OZSC_OperatingLeaseRightOfUseAssetAccumulatedAmortization": { "auth_ref": [], "calculation": { "http://ir.ozopsurgical.com/role/ScheduleOfRight-of-useAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseRightOfUseAsset", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amortization.", "label": "OperatingLeaseRightOfUseAssetAccumulatedAmortization", "negatedLabel": "Less accumulated amortization" } } }, "localname": "OperatingLeaseRightOfUseAssetAccumulatedAmortization", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfRight-of-useAssetsDetails" ], "xbrltype": "monetaryItemType" }, "OZSC_OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization": { "auth_ref": [], "calculation": { "http://ir.ozopsurgical.com/role/ScheduleOfRight-of-useAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseRightOfUseAsset", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Office and warehouse lease.", "label": "Office and warehouse lease" } } }, "localname": "OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfRight-of-useAssetsDetails" ], "xbrltype": "monetaryItemType" }, "OZSC_OperatingLeaseRightofuseAssetsAndLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating lease right of use assets and liabilities", "label": "Operating lease right-of-use assets and liabilities" } } }, "localname": "OperatingLeaseRightofuseAssetsAndLiabilities", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "OZSC_OriginalIssueDiscountIncludedInNotesPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Original issue discount included in notes payable", "label": "Original issue discount included in notes payable" } } }, "localname": "OriginalIssueDiscountIncludedInNotesPayable", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "OZSC_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other comprehensive income loss foreign currency translation adjustment net of tax.", "label": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax", "verboseLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "OZSC_OtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other [Member]", "label": "Other [Member]" } } }, "localname": "OtherMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "OZSC_OzopCapitalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ozop Capital [Member]", "label": "Ozop Capital [Member]" } } }, "localname": "OzopCapitalMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_PCTIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "PCTI [Member]", "label": "PCTI [Member]" } } }, "localname": "PCTIMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_PJNStrategiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "PJN Strategies [Member]", "label": "PJN Strategies [Member]" } } }, "localname": "PJNStrategiesMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/NoncontrollingInterestDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_PaycheckProtectionProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Paycheck Protection Program [Member]", "label": "Paycheck Protection Program [Member]" } } }, "localname": "PaycheckProtectionProgramMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_PaycheckProtectionProgramloanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Paycheck Protection Programloan [Member]", "label": "Paycheck Protection Programloan [Member]" } } }, "localname": "PaycheckProtectionProgramloanMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "domainItemType" }, "OZSC_PaymentsToShareholders": { "auth_ref": [], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments to shareholders", "label": "PaymentsToShareholders", "negatedLabel": "Payments to shareholders" } } }, "localname": "PaymentsToShareholders", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "OZSC_PennsylvaniaCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pennsylvania corporation [Member].", "label": "Pennsylvania corporation [Member]" } } }, "localname": "PennsylvaniaCorporationMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/OrganizationDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_PerMonthMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per Month [Member]", "label": "Per Month [Member]" } } }, "localname": "PerMonthMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_PersonalGuaranteeOfChisMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Personal Guarantee Of Chis [Member]", "label": "Personal Guarantee Of Chis [Member]" } } }, "localname": "PersonalGuaranteeOfChisMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_PreferredStockIssuedAndOustandingPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred stock issued and oustanding percentage.", "label": "Preferred stock issued and oustanding percentage" } } }, "localname": "PreferredStockIssuedAndOustandingPercentage", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "percentItemType" }, "OZSC_PreferredStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred stock shares", "label": "Preferred stock, shares" } } }, "localname": "PreferredStockShares", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "OZSC_PresidentSubsidiaryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "President Subsidiary [Member]", "label": "President Subsidiary [Member]" } } }, "localname": "PresidentSubsidiaryMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfExpensesToOfficersDetails" ], "xbrltype": "domainItemType" }, "OZSC_ProceedsFromEconomicDisasterLoan": { "auth_ref": [], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from economic disaster loan", "label": "Proceeds from Economic Disaster Loan" } } }, "localname": "ProceedsFromEconomicDisasterLoan", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "OZSC_ProceedsFromPayrollProtectionProgram": { "auth_ref": [], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from payroll protection program", "label": "Proceeds from Payroll Protection Program" } } }, "localname": "ProceedsFromPayrollProtectionProgram", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "OZSC_ProceedsFromSaleOfSeriesDPreferredStockAndWarrants": { "auth_ref": [], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from sale of series d preferred stock and warrants", "label": "Proceeds from sale of Series D preferred stock and warrants" } } }, "localname": "ProceedsFromSaleOfSeriesDPreferredStockAndWarrants", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "OZSC_ProceedsFromShareholders": { "auth_ref": [], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from shareholders", "label": "Proceeds from shareholders" } } }, "localname": "ProceedsFromShareholders", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "OZSC_ProceedsReceivedOnDeferredLiability": { "auth_ref": [], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds received on deferred liability.", "label": "Proceeds received on deferred liability" } } }, "localname": "ProceedsReceivedOnDeferredLiability", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "OZSC_ProceedsRedemptionOfSeriesEPreferredStock": { "auth_ref": [], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Proceeds redemption of series e preferred stock", "label": "ProceedsRedemptionOfSeriesEPreferredStock", "negatedLabel": "Redemption of Series E Preferred Stock" } } }, "localname": "ProceedsRedemptionOfSeriesEPreferredStock", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "OZSC_PromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Promissory Note [Member]", "label": "Promissory Note [Member]" } } }, "localname": "PromissoryNoteMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_PromissoryNoteOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Promissory Note One [Member]", "label": "Promissory Note One [Member]" } } }, "localname": "PromissoryNoteOneMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_PurchaseConcentrationPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase concentration [Policy Text Block]", "label": "Purchase concentration" } } }, "localname": "PurchaseConcentrationPolicyTextBlock", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "OZSC_RMAAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RMA Agreement [Member]", "label": "RMA Agreement [Member]" } } }, "localname": "RMAAgreementMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_RedemptionOfSeriesCAndSeriesDPreferredStock": { "auth_ref": [], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Redemption of series c and series d preferred stock", "label": "RedemptionOfSeriesCAndSeriesDPreferredStock", "negatedLabel": "Redemption of Series C and Series D Preferred Stock" } } }, "localname": "RedemptionOfSeriesCAndSeriesDPreferredStock", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "OZSC_RedemptionOfSeriesEPreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Redemption of Series E Preferred Stock.", "label": "Redemption of Series E Preferred Stock" } } }, "localname": "RedemptionOfSeriesEPreferredStock", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "OZSC_RedemptionOfSeriesEPreferredStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Redemption of series e preferred stock shares", "label": "Redemption of Series E Preferred Stock, shares" } } }, "localname": "RedemptionOfSeriesEPreferredStockShares", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "OZSC_RegistrationStatementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Registration Statement [Member]", "label": "Registration Statement [Member]" } } }, "localname": "RegistrationStatementMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_RemainingWarrantSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Remaining Warrant Shares [Member]", "label": "Remaining Warrant Shares [Member]" } } }, "localname": "RemainingWarrantSharesMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_RestrictedCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted Common Stock [Member]", "label": "Restricted Common Stock [Member]" } } }, "localname": "RestrictedCommonStockMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_RestructuringAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restructuring Agreement [Member]", "label": "Restructuring Agreement [Member]" } } }, "localname": "RestructuringAgreementMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_RoyaltyPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty percentage", "label": "Royalty percentage" } } }, "localname": "RoyaltyPercentage", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative" ], "xbrltype": "percentItemType" }, "OZSC_RubensteinPublicRelationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rubenstein Public Relations, Inc. [Member]", "label": "Rubenstein Public Relations, Inc. [Member]" } } }, "localname": "RubensteinPublicRelationsMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_Salary": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Salary.", "label": "Salary" } } }, "localname": "Salary", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "OZSC_SalmanJChaudhryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Salman J. Chaudhry [Member]", "label": "Salman J. Chaudhry [Member]" } } }, "localname": "SalmanJChaudhryMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_ScheduleOfNotesPayableTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Notes Payable [Table Text Block]", "label": "SCHEDULE OF NOTES PAYABLE" } } }, "localname": "ScheduleOfNotesPayableTableTextBlock", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableTables" ], "xbrltype": "textBlockItemType" }, "OZSC_ScheduleOfOperatingLeaseLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of operating lease liabilities [Table Text Block]", "label": "SCHEDULE OF OPERATING LEASE LIABILITIES" } } }, "localname": "ScheduleOfOperatingLeaseLiabilitiesTableTextBlock", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "OZSC_ScheduleOfRightofUseAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of right of use assets [Table Text Block]", "label": "SCHEDULE OF RIGHT-OF-USE ASSETS" } } }, "localname": "ScheduleOfRightofUseAssetsTableTextBlock", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "OZSC_ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Useful Life Of Property And Equipment Assets [Table Text Block]", "label": "SCHEDULE OF USEFUL LIFE OF PROPERTY AND EQUIPMENT ASSETS" } } }, "localname": "ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsTableTextBlock", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsTables" ], "xbrltype": "textBlockItemType" }, "OZSC_SecuritiesPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Securities Purchase Agreement [Member]", "label": "Securities Purchase Agreement [Member]" } } }, "localname": "SecuritiesPurchaseAgreementMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/OrganizationDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_SeparationAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Seperation Agreement [Member]", "label": "Seperation Agreement [Member]" } } }, "localname": "SeparationAgreementMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_SeriesDAmendmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series D Amendment [Member]", "label": "Series D Amendment [Member]" } } }, "localname": "SeriesDAmendmentMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_SeriesDSPAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series DSPA [Member]", "label": "Series DSPA [Member]" } } }, "localname": "SeriesDSPAMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_SettlementAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Settlement Agreement [Member]", "label": "Settlement Agreement [Member]" } } }, "localname": "SettlementAgreementMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_SharesIssuedUponCashlessExerciseOfWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Shares issued upon cashless exercise of warrants.", "label": "Shares issued upon cashless exercise of warrants" } } }, "localname": "SharesIssuedUponCashlessExerciseOfWarrants", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "OZSC_SharesIssuedUponCashlessExerciseOfWarrantsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares Issued Upon Cashless Exercise Of Warrants Shares", "label": "Shares issued upon cashless exercise of warrants, shares" } } }, "localname": "SharesIssuedUponCashlessExerciseOfWarrantsShares", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "OZSC_SourcedAndDistributedProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sourced and Distributed Products [Member]", "label": "Sourced and Distributed Products [Member]" } } }, "localname": "SourcedAndDistributedProductsMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/DisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "OZSC_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock and warrants issued during period shares preferred stock and warrants", "label": "Sale of Series D Preferred Stock and warrants, shares" } } }, "localname": "StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "OZSC_StockIssuedDuringPeriodSharesNewIssuesForLeaseAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares new issues for lease agreement", "label": "Shares issued for lease agreement, shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssuesForLeaseAgreement", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "OZSC_StockIssuedDuringPeriodValueNewIssuesForLeaseAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period value new issues for lease agreement", "label": "Shares issued for lease agreement" } } }, "localname": "StockIssuedDuringPeriodValueNewIssuesForLeaseAgreement", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "OZSC_StockIssuedDuringPeriodValuePurchased": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period value purchased.", "label": "Number of shares purchased, value" } } }, "localname": "StockIssuedDuringPeriodValuePurchased", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "OZSC_SuppliersOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Suppliers One [Member]", "label": "Suppliers One [Member]" } } }, "localname": "SuppliersOneMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_SuppliersTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Suppliers Two [Member]", "label": "Suppliers Two [Member]" } } }, "localname": "SuppliersTwoMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_ThereafterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Thereafter [Member]", "label": "Thereafter [Member]" } } }, "localname": "ThereafterMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_ThirdPartyLenderMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third Party Lender [Member]", "label": "Third Party Lender [Member]" } } }, "localname": "ThirdPartyLenderMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_ThirdPartyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third-Party [Member]", "label": "Third-Party [Member]" } } }, "localname": "ThirdPartyMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_TwelvePercentConvertiblePromissoryNoteTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "12% Convertible Promissory Note Two [Member]", "label": "12% Convertible Promissory Note Two [Member]" } } }, "localname": "TwelvePercentConvertiblePromissoryNoteTwoMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_TwelvePercentPromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "12% Promissory Note [Member]", "label": "12% Promissory Note [Member]" } } }, "localname": "TwelvePercentPromissoryNoteMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_TwoVendorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Vendor [Member]", "label": "Two Vendor [Member]" } } }, "localname": "TwoVendorMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_UnexercisedCommonStockPurchaseWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unexercised Common Stock Purchase Warrants [Member]", "label": "Unexercised Common Stock Purchase Warrants [Member]" } } }, "localname": "UnexercisedCommonStockPurchaseWarrantsMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "OZSC_WarehouseEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warehouse Equipment [Member]", "label": "Warehouse Equipment [Member]" } } }, "localname": "WarehouseEquipmentMember", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsDetails" ], "xbrltype": "domainItemType" }, "OZSC_WarrantsCancelled": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Warrants cancelled", "label": "Warrants cancelled" } } }, "localname": "WarrantsCancelled", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeLiabilitiesAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "OZSC_WarrantsExpirationTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants expiration term", "label": "Warrant term" } } }, "localname": "WarrantsExpirationTerm", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "durationItemType" }, "OZSC_WarrantsInConjunctionWithNotesPayable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants In Conjunction With Notes Payable", "label": "Warrants in conjunction with notes payable" } } }, "localname": "WarrantsInConjunctionWithNotesPayable", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "OZSC_WarrantsIssuedInConnectionWithIssuanceOfDebt": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Warrants issued in connection with issuance of debt", "label": "Warrants issued in connection with issuance of debt" } } }, "localname": "WarrantsIssuedInConnectionWithIssuanceOfDebt", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "OZSC_WorkingCapitalDeficit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Working capital deficit.", "label": "Working capital deficit" } } }, "localname": "WorkingCapitalDeficit", "nsuri": "http://ir.ozopsurgical.com/20211231", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "country_CA": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CANADA" } } }, "localname": "CA", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r705" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r705" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r702", "r704", "r705" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r702", "r704", "r705" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r702", "r704", "r705" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r704" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r702", "r704", "r705" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r703" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r691" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r704" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r704" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r706" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r694" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r697" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r693" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative", "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r693" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r717" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r693" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r714" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r705" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r693" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r693" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r693" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r693" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r715" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r702", "r704", "r705" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative", "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r704" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r698" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r699" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r692" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r696" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r695" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r700" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r701" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r716" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r209" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfExpensesToOfficersDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r208", "r375", "r381", "r652" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails", "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r284", "r329", "r398", "r400", "r554", "r555", "r556", "r557", "r558", "r559", "r578", "r649", "r653", "r688", "r689" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r284", "r329", "r398", "r400", "r554", "r555", "r556", "r557", "r558", "r559", "r578", "r649", "r653", "r688", "r689" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r208", "r375", "r381", "r652" ], "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails", "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/NoncontrollingInterestDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/NoncontrollingInterestDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r205", "r375", "r379", "r582", "r648", "r650" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/DisaggregationOfRevenueDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r205", "r375", "r379", "r582", "r648", "r650" ], "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/DisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r284", "r329", "r383", "r398", "r400", "r554", "r555", "r556", "r557", "r558", "r559", "r578", "r649", "r653", "r688", "r689" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r284", "r329", "r383", "r398", "r400", "r554", "r555", "r556", "r557", "r558", "r559", "r578", "r649", "r653", "r688", "r689" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsDetails" ], "xbrltype": "domainItemType" }, "srt_RestatementAxis": { "auth_ref": [ "r3", "r134", "r135", "r136", "r138", "r139", "r143", "r144", "r145", "r146", "r148", "r149", "r150", "r151", "r152", "r153", "r165", "r231", "r232", "r417", "r433", "r475", "r479", "r480", "r481", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r721", "r722" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Axis]" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [ "r3", "r134", "r135", "r136", "r138", "r139", "r143", "r144", "r145", "r146", "r148", "r149", "r150", "r151", "r152", "r153", "r165", "r231", "r232", "r417", "r433", "r475", "r479", "r480", "r481", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r721", "r722" ], "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails" ], "xbrltype": "domainItemType" }, "srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember": { "auth_ref": [ "r143", "r144", "r145", "r148", "r149", "r151", "r152" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period, Error Correction, Adjustment [Member]" } } }, "localname": "RevisionOfPriorPeriodErrorCorrectionAdjustmentMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioPreviouslyReportedMember": { "auth_ref": [ "r3", "r134", "r136", "r138", "r139", "r143", "r144", "r145", "r146", "r148", "r149", "r151", "r152", "r165", "r231", "r232", "r417", "r433", "r475", "r479", "r480", "r481", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r721", "r722" ], "lang": { "en-us": { "role": { "label": "Previously Reported [Member]" } } }, "localname": "ScenarioPreviouslyReportedMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r206", "r207", "r375", "r380", "r651", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687" ], "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r206", "r207", "r375", "r380", "r651", "r672", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r209", "r538" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative", "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative", "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Changes and Error Corrections [Abstract]" } } }, "localname": "AccountingChangesAndErrorCorrectionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r520" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update 2016-02 [Member]" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r47" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r607", "r639" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.", "label": "Accounts Payable and Accrued Liabilities", "verboseLabel": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableInterestBearingInterestRate": { "auth_ref": [ "r512", "r513", "r515", "r516" ], "lang": { "en-us": { "role": { "documentation": "Reflects the effective interest rate as of the balance sheet date on interest-bearing trade payables.", "label": "Accounts Payable, Interest-bearing, Interest Rate" } } }, "localname": "AccountsPayableInterestBearingInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_AccountsPayableMember": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Obligations incurred and payable to vendors for goods and services received.", "label": "Accounts Payable [Member]" } } }, "localname": "AccountsPayableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r674" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNet": { "auth_ref": [ "r28", "r627", "r673" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.", "label": "Accounts Receivable, after Allowance for Credit Loss" } } }, "localname": "AccountsReceivableNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r10", "r28", "r210", "r211" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "auth_ref": [ "r13", "r14", "r49" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued employee benefits, current" } } }, "localname": "AccruedEmployeeBenefitsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r42", "r253" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: Accumulated Depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r31", "r74", "r75", "r76", "r631", "r661", "r665" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 7.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r73", "r76", "r83", "r84", "r85", "r134", "r135", "r136", "r452", "r656", "r657", "r722" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r29", "r417", "r544" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r134", "r135", "r136", "r414", "r415", "r416", "r479" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r138", "r139", "r140", "r141", "r153", "r219", "r220", "r227", "r228", "r229", "r230", "r231", "r232", "r265", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r430", "r431", "r432", "r433", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r532", "r583", "r584", "r585", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r718", "r719", "r720", "r721", "r722" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r280", "r343", "r352" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Adjustments to Additional Paid in Capital, Warrant Issued" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operations" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r419" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising and Marketing Expenses" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r403", "r407", "r418" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Stock based compensation", "terseLabel": "Share-based payment arrangement, expense", "verboseLabel": "Share based compensation expenses" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfExpensesToOfficersDetailsParenthetical", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r99", "r113", "r304", "r514" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Non-cash interest expense", "verboseLabel": "Amortization of Debt Discount (Premium)" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r163" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Anti-dilutive shares of common stock" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r163" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r163" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AreaOfLand": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of land held.", "label": "Area of land" } } }, "localname": "AreaOfLand", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative" ], "xbrltype": "areaItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative", "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/OrganizationDetailsNarrative", "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative", "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r129", "r188", "r197", "r203", "r226", "r266", "r267", "r268", "r270", "r271", "r272", "r273", "r274", "r275", "r277", "r278", "r447", "r453", "r494", "r542", "r544", "r601", "r628" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Total assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet", "http://ir.ozopsurgical.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r11", "r12", "r68", "r129", "r226", "r266", "r267", "r268", "r270", "r271", "r272", "r273", "r274", "r275", "r277", "r278", "r447", "r453", "r494", "r542", "r544" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total Current Assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateAxis": { "auth_ref": [ "r404", "r409" ], "lang": { "en-us": { "role": { "documentation": "Information by date or year award under share-based payment arrangement is granted.", "label": "Award Date [Axis]" } } }, "localname": "AwardDateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date or year award under share-based payment arrangement is granted." } } }, "localname": "AwardDateDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r404", "r409" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r397", "r399" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/OrganizationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r397", "r399", "r436", "r437" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/OrganizationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "auth_ref": [ "r438" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "negatedLabel": "Liabilities assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r438" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "Total purchase price allocation" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAcquiredFromAcquisition": { "auth_ref": [ "r100" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).", "label": "Cash acquired in acquisition" } } }, "localname": "CashAcquiredFromAcquisition", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r8", "r39", "r115" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r18", "r116" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r109", "r115", "r121" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash, End of year", "periodStartLabel": "Cash, Beginning of year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r109", "r503" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r39" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash equivalents" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of non-cash Investing or Financing Activity:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r126", "r129", "r154", "r155", "r158", "r160", "r162", "r168", "r169", "r170", "r226", "r266", "r271", "r272", "r273", "r277", "r278", "r326", "r327", "r332", "r336", "r494", "r707" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet", "http://ir.ozopsurgical.com/role/BalanceSheetParenthetical", "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/OrganizationDetailsNarrative", "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "verboseLabel": "Purchase of warrants" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of reason for issuing warrant or right.", "label": "Warrant exercise, description" } } }, "localname": "ClassOfWarrantOrRightReasonForIssuingToNonemployees", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementRightsAndObligations": { "auth_ref": [ "r440" ], "lang": { "en-us": { "role": { "documentation": "Description of rights and obligations under the collaborative arrangements.", "label": "Collaborative arrangement, rights and obligations" } } }, "localname": "CollaborativeArrangementRightsAndObligations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/OrganizationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r55", "r259", "r611", "r636" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r256", "r257", "r258", "r262", "r675" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r134", "r135", "r479" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit", "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value", "verboseLabel": "Common stock, price per share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheetParenthetical", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheetParenthetical", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued", "terseLabel": "Common stock, shares, issued", "verboseLabel": "Common Stock, Shares, Issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheetParenthetical", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r27", "r343" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding", "terseLabel": "Common stock, shares, outstanding", "verboseLabel": "Number of common stock shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheetParenthetical", "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r27", "r544" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock (4,990,000,000 shares authorized par value $0.001; 4,617,362,997 (2021) and 3,397,958,292 (2020) shares issued and outstanding)", "verboseLabel": "Common stock, value, issued" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockValueOutstanding": { "auth_ref": [ "r27" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.", "label": "Number of common stock shares outstanding, value" } } }, "localname": "CommonStockValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r78", "r80", "r81", "r91", "r616", "r645" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss attributable to Ozop Energy Solutions, Inc." } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "auth_ref": [ "r78", "r80", "r90", "r445", "r446", "r457", "r615", "r644" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Less: comprehensive loss attributable to noncontrolling interest" } } }, "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r78", "r80", "r89", "r444", "r457", "r614", "r643" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r178", "r179", "r208", "r491", "r492", "r674" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails", "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r178", "r179", "r208", "r491", "r492", "r666", "r674" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails", "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r178", "r179", "r208", "r491", "r492", "r666", "r674" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails", "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r173", "r623" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Sales Concentration and credit risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r178", "r179", "r208", "r491", "r492" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "verboseLabel": "Concentration of credit risk" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails", "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r178", "r179", "r208", "r491", "r492", "r674" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails", "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetNetCurrent": { "auth_ref": [ "r356", "r357", "r376" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.", "label": "Vendor deposits" } } }, "localname": "ContractWithCustomerAssetNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r377" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Revenue recognized" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/DeferredRevenueDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockSharesConverted1": { "auth_ref": [ "r118", "r119", "r120" ], "lang": { "en-us": { "role": { "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of stock, shares converted" } } }, "localname": "ConversionOfStockSharesConverted1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertibleDebtCurrent": { "auth_ref": [ "r22" ], "calculation": { "http://ir.ozopsurgical.com/role/ScheduleOfDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Convertible Debt, Current", "totalLabel": "Ending balance, net" } } }, "localname": "ConvertibleDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r279", "r281", "r282", "r284", "r294", "r295", "r296", "r300", "r301", "r302", "r303", "r304", "r314", "r315", "r316", "r317" ], "lang": { "en-us": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleNotesPayable": { "auth_ref": [ "r24", "r603", "r629", "r668" ], "calculation": { "http://ir.ozopsurgical.com/role/ScheduleOfDebtDetails": { "order": 1.0, "parentTag": "us-gaap_ConvertibleDebtCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.", "label": "Principal balance" } } }, "localname": "ConvertibleNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayableMember": { "auth_ref": [ "r22", "r602", "r625", "r668" ], "lang": { "en-us": { "role": { "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible Notes Payable [Member]" } } }, "localname": "ConvertibleNotesPayableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertiblePreferredStockMember": { "auth_ref": [ "r326", "r327", "r332" ], "lang": { "en-us": { "role": { "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Convertible Preferred Stock [Member]" } } }, "localname": "ConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r95", "r582" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of goods sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r177", "r208" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r118", "r120" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Converted Instrument, Amount" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r118", "r120" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Debt Conversion, Converted Instrument, Shares Issued", "verboseLabel": "Debt conversion, converted instrument, shares issued" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtConversionDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Description" } } }, "localname": "DebtConversionDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtConversionOriginalDebtAmount1": { "auth_ref": [ "r118", "r120" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Original Debt, Amount" } } }, "localname": "DebtConversionOriginalDebtAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDefaultLongtermDebtAmount": { "auth_ref": [ "r125" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of outstanding long-term debt or borrowing associated with any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at the end of the period and subsequently has not been cured.", "label": "Debt instrument default amount" } } }, "localname": "DebtDefaultLongtermDebtAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r125", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r298", "r305", "r306", "r308", "r320" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "CONVERTIBLE NOTES PAYABLE" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r22", "r23", "r24", "r128", "r132", "r281", "r282", "r283", "r284", "r285", "r286", "r288", "r294", "r295", "r296", "r297", "r299", "r300", "r301", "r302", "r303", "r304", "r314", "r315", "r316", "r317", "r517", "r602", "r603", "r625" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r24", "r309", "r603", "r625" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long term debt, gross" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r283", "r311" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price", "terseLabel": "Debt instrument, convertible, conversion price", "verboseLabel": "Number of shares converted" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "auth_ref": [ "r53", "r283", "r344", "r348", "r350" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.", "label": "Debt owned percentage" } } }, "localname": "DebtInstrumentConvertibleConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "pureItemType" }, "us-gaap_DebtInstrumentDecreaseForgiveness": { "auth_ref": [ "r128" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.", "label": "Forgiveness of debt" } } }, "localname": "DebtInstrumentDecreaseForgiveness", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentDescription": { "auth_ref": [ "r22", "r24", "r344", "r602", "r603", "r620", "r625" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.", "label": "Agreement description", "verboseLabel": "Debt Instrument, Description" } } }, "localname": "DebtInstrumentDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r281", "r314", "r315", "r515", "r517", "r518" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Debt instrument principal", "verboseLabel": "Debt Instrument, face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentIncreaseAccruedInterest": { "auth_ref": [ "r128" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period.", "label": "Debt Instrument, Increase, Accrued Interest", "verboseLabel": "Debt instrument, accrued interest" } } }, "localname": "DebtInstrumentIncreaseAccruedInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r51", "r312", "r515", "r517" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt instrument insterest rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r51", "r282" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "verboseLabel": "Debt Instrument, interest rate, stated percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r52", "r284", "r485" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Common stock maturity period", "terseLabel": "Debt Instrument, Maturity Date", "verboseLabel": "Debt Instrument, maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical", "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentMaturityDateDescription": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.", "label": "Debt Instrument, Maturity Date, Description" } } }, "localname": "DebtInstrumentMaturityDateDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r54", "r128", "r132", "r281", "r282", "r283", "r284", "r285", "r286", "r288", "r294", "r295", "r296", "r297", "r299", "r300", "r301", "r302", "r303", "r304", "r314", "r315", "r316", "r317", "r517" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPeriodicPayment": { "auth_ref": [ "r54", "r621" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments including both interest and principal payments.", "label": "Debt Instrument, Periodic Payment" } } }, "localname": "DebtInstrumentPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": { "auth_ref": [ "r54" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments applied to principal.", "label": "Debt Instrument, Periodic Payment, Principal" } } }, "localname": "DebtInstrumentPeriodicPaymentPrincipal", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r54", "r128", "r132", "r281", "r282", "r283", "r284", "r285", "r286", "r288", "r294", "r295", "r296", "r297", "r299", "r300", "r301", "r302", "r303", "r304", "r307", "r314", "r315", "r316", "r317", "r344", "r349", "r350", "r351", "r514", "r515", "r517", "r518", "r622" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r294", "r514", "r518" ], "calculation": { "http://ir.ozopsurgical.com/role/ScheduleOfDebtDetails": { "order": 2.0, "parentTag": "us-gaap_ConvertibleDebtCurrent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "negatedLabel": "Unamortized discount", "verboseLabel": "Debt Instrument, unamortized discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfDebtDetails", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable": { "auth_ref": [ "r234" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about allowance for credit loss on investment in debt security measured at amortized cost (held-to-maturity).", "label": "Debt Securities, Held-to-maturity, Allowance for Credit Loss [Table]" } } }, "localname": "DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeLiabilitiesAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]" } } }, "localname": "DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeLiabilitiesAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued pursuant to the terms of a deferred compensation arrangement.", "label": "Deferred compensation exchanged for common stock", "terseLabel": "Deferred compensation shares issued", "verboseLabel": "Number of common stock exchanged" } } }, "localname": "DeferredCompensationArrangementWithIndividualSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_DeferredCompensationEquity": { "auth_ref": [ "r61", "r401" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued under share-based plans to employees or officers which is the unearned portion, accounted for under the fair value method.", "label": "Deferred compensation equity" } } }, "localname": "DeferredCompensationEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenue": { "auth_ref": [ "r35" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Deferred Revenue", "verboseLabel": "Deferred revenue" } } }, "localname": "DeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/DeferredRevenueDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r35" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 9.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.", "label": "Current portion of deferred revenues", "verboseLabel": "Deferred revenue, current" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet", "http://ir.ozopsurgical.com/role/DeferredRevenueDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueNoncurrent": { "auth_ref": [ "r35" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Deferred revenue, net of current portion", "verboseLabel": "Deferred revenue, non-current" } } }, "localname": "DeferredRevenueNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet", "http://ir.ozopsurgical.com/role/DeferredRevenueDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r113", "r251" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAmortizationAndAccretionNet": { "auth_ref": [ "r113" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization and depreciation" } } }, "localname": "DepreciationAmortizationAndAccretionNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet": { "auth_ref": [ "r459" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments.", "label": "Derivative Assets (Liabilities), at Fair Value, Net", "verboseLabel": "Derivative Liabilities" } } }, "localname": "DerivativeAssetsLiabilitiesAtFairValueNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r465" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Gain (Loss) on Derivative, Net", "negatedLabel": "Change in fair value" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeLiabilitiesAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r69", "r70", "r71", "r490" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "periodEndLabel": "Derivative liability, ending balance", "periodStartLabel": "Derivative liability, beginning balance" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeLiabilitiesAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesCurrent": { "auth_ref": [ "r69" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative liabilities", "verboseLabel": "Derivative Liability, Current" } } }, "localname": "DerivativeLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet", "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityMeasurementInput": { "auth_ref": [ "r485" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure derivative liability.", "label": "Derivative Liability, Measurement Input" } } }, "localname": "DerivativeLiabilityMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "decimalItemType" }, "us-gaap_DerivativeLossOnDerivative": { "auth_ref": [ "r465" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in the fair value of derivatives recognized in the income statement.", "label": "Loss on change in fair value of derivatives" } } }, "localname": "DerivativeLossOnDerivative", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativesAndFairValueTextBlock": { "auth_ref": [ "r482", "r488" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivatives and fair value of assets and liabilities.", "label": "DERIVATIVE LIABILITIES" } } }, "localname": "DerivativesAndFairValueTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/DerivativeLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "DISAGGREGATION OF REVENUE" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DueToOfficersOrStockholdersCurrent": { "auth_ref": [ "r21", "r536", "r626", "r667" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amounts due to recorded owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to officers or stockholders, current" } } }, "localname": "DueToOfficersOrStockholdersCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent": { "auth_ref": [ "r536", "r609", "r641", "r669" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amounts due to recorded owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company.", "label": "Due to officers or stockholders" } } }, "localname": "DueToOfficersOrStockholdersCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r45", "r131", "r269", "r271", "r272", "r276", "r277", "r278", "r536" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Related party liabilities" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r131", "r269", "r271", "r272", "r276", "r277", "r278", "r536", "r608", "r641" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.", "label": "Due to related party payable" } } }, "localname": "DueToRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r161" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Income (loss) per share basic and fully diluted" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r163", "r164" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings (Loss) Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r503" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effects of exchange rate on cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeBenefitsAndShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for employee benefit and equity-based compensation.", "label": "Amount of initial annual salary", "verboseLabel": "Stock based compensation expense" } } }, "localname": "EmployeeBenefitsAndShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r2", "r83", "r84", "r85", "r134", "r135", "r136", "r139", "r149", "r152", "r167", "r230", "r343", "r352", "r414", "r415", "r416", "r432", "r433", "r479", "r504", "r505", "r506", "r507", "r508", "r509", "r656", "r657", "r658", "r722" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit", "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ErrorCorrectionTextBlock": { "auth_ref": [ "r150" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting error correction.", "label": "RESTATEMENT" } } }, "localname": "ErrorCorrectionTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/Restatement" ], "xbrltype": "textBlockItemType" }, "us-gaap_ExtendedProductWarrantyDescription": { "auth_ref": [ "r263" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of the extended product warranties, which generally require additional fees to be paid by the buyer, and other guarantee contracts excluded from the initial recognition and initial measurement requirements. Does not include disclosures for standard product warranties, which typically have substantially shorter periods of time or provide less coverage, or both.", "label": "Extended product warranty description" } } }, "localname": "ExtendedProductWarrantyDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/DeferredRevenueDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r113", "r321" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair value adjustment of warrants", "terseLabel": "Fair value of adjustment of warrants", "verboseLabel": "Fair Value Adjustment of Warrants" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/RestatementDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r296", "r314", "r315", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r396", "r483", "r551", "r552", "r553" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r296", "r384", "r385", "r390", "r396", "r483", "r551" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r296", "r314", "r315", "r384", "r385", "r390", "r396", "r483", "r552" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r296", "r314", "r315", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r396", "r483", "r553" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r296", "r314", "r315", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r396", "r551", "r552", "r553" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueNetAssetLiability": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of asset after deduction of liability.", "label": "Total" } } }, "localname": "FairValueNetAssetLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss": { "auth_ref": [ "r486" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) recognized in income for derivative asset (liability) after deduction of derivative liability (asset), measured at fair value using unobservable input (level 3) and still held.", "label": "Exercise of warrants" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeLiabilitiesAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r487", "r489" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r221", "r222", "r223", "r224", "r225", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r307", "r341", "r470", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r707", "r708", "r709", "r710", "r711", "r712", "r713" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeLiabilitiesAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r113", "r318", "r319" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedLabel": "(Gain) loss on extinguishment of debt", "negatedTerseLabel": "Loss (gain) on extinguishment of debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows", "http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r245", "r247", "r544", "r600" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r113", "r246", "r248", "r249" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/OrganizationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r93", "r129", "r188", "r196", "r199", "r202", "r204", "r226", "r266", "r267", "r268", "r271", "r272", "r273", "r274", "r275", "r277", "r278", "r494" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "auth_ref": [ "r113", "r250" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.", "label": "Impairment of intangible assets", "verboseLabel": "Impairment" } } }, "localname": "ImpairmentOfIntangibleAssetsFinitelived", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows", "http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r85", "r94" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of income (loss) attributable to noncontrolling interest. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.", "label": "Noncontrolling interest loss" } } }, "localname": "IncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/NoncontrollingInterestDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r87", "r188", "r196", "r199", "r202", "r204", "r599", "r612", "r618", "r646" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Net loss from continuing operations", "totalLabel": "Income (loss) before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows", "http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement": { "auth_ref": [ "r421", "r425" ], "lang": { "en-us": { "role": { "documentation": "Description of the likelihood that an uncertainty in income taxes will not be sustained as a result of the examination by the taxing authority.", "label": "Income Tax Examination, Likelihood of Unfavorable Settlement" } } }, "localname": "IncomeTaxExaminationLikelihoodOfUnfavorableSettlement", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r130", "r151", "r152", "r187", "r424", "r434", "r435", "r647" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income tax provision" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r82", "r422", "r423", "r426", "r427", "r428", "r429" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r117" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r112" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "verboseLabel": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r112" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r112", "r579" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "verboseLabel": "Customer deposits" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r112" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDueToRelatedParties": { "auth_ref": [ "r112" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.", "label": "Due from related parties" } } }, "localname": "IncreaseDecreaseInDueToRelatedParties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/DeferredRevenueDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r112" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInNotesPayableCurrent": { "auth_ref": [ "r112" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in current portion (due within one year or one business cycle) of obligations evidenced by formal promissory notes.", "label": "Increase (decrease) in notes payable, current" } } }, "localname": "IncreaseDecreaseInNotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/RestatementDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r112", "r526" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r112" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": { "auth_ref": [ "r156", "r157", "r162" ], "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.", "label": "Dilutive securities common stock, shares" } } }, "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r86", "r186", "r511", "r516", "r617" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r99", "r302", "r313", "r316", "r317" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseOther": { "auth_ref": [], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense classified as other.", "label": "Interest expense" } } }, "localname": "InterestExpenseOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r107", "r110", "r117" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r14", "r15", "r49" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest Payable, Current" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "auth_ref": [ "r610", "r638" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.", "label": "Accrued interest" } } }, "localname": "InterestPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r63" ], "calculation": { "http://ir.ozopsurgical.com/role/ScheduleOfInventoryDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r9", "r66", "r544" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://ir.ozopsurgical.com/role/ScheduleOfInventoryDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory", "totalLabel": "Inventory net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet", "http://ir.ozopsurgical.com/role/ScheduleOfInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r16", "r67", "r123", "r166", "r242", "r243", "r244", "r580" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "verboseLabel": "Inventory" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r65" ], "calculation": { "http://ir.ozopsurgical.com/role/ScheduleOfInventoryDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r64" ], "calculation": { "http://ir.ozopsurgical.com/role/ScheduleOfInventoryDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Work in process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestorMember": { "auth_ref": [ "r535", "r536" ], "lang": { "en-us": { "role": { "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value.", "label": "Investor [Member]" } } }, "localname": "InvestorMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LandSubjectToGroundLeases": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of land subject to a ground lease.", "label": "Land subject to ground leases" } } }, "localname": "LandSubjectToGroundLeases", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "areaItemType" }, "us-gaap_LeaseExpirationDate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.", "label": "Lease expiration date" } } }, "localname": "LeaseExpirationDate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_LegalFees": { "auth_ref": [ "r96" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.", "label": "Legal Fees", "verboseLabel": "Legal fees" } } }, "localname": "LegalFees", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r524" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r528" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "SCHEDULE OF MATURITY OF LEASE LIABILITIES" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r528" ], "calculation": { "http://ir.ozopsurgical.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r528" ], "calculation": { "http://ir.ozopsurgical.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "For the year ending December 31, 2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r528" ], "calculation": { "http://ir.ozopsurgical.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "For the year ended December 31, 2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r528" ], "calculation": { "http://ir.ozopsurgical.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "For the year ended December 31, 2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r528" ], "calculation": { "http://ir.ozopsurgical.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "For the year ended December 31, 2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r528" ], "calculation": { "http://ir.ozopsurgical.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "For the year ending December 31, 2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r528" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: present value discount" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lease term", "verboseLabel": "Operating lease term" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r530" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorOperatingLeaseTermOfContract": { "auth_ref": [ "r531" ], "lang": { "en-us": { "role": { "documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessor, Operating Lease, Term of Contract", "verboseLabel": "Lease term" } } }, "localname": "LessorOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r48", "r129", "r198", "r226", "r266", "r267", "r268", "r271", "r272", "r273", "r274", "r275", "r277", "r278", "r448", "r453", "r454", "r494", "r542", "r543" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Total liabilities", "totalLabel": "TOTAL LIABILITIES", "verboseLabel": "Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet", "http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r34", "r129", "r226", "r494", "r544", "r605", "r634" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY (DEFICIT)" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY (DEFICIT)" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r50", "r129", "r226", "r266", "r267", "r268", "r271", "r272", "r273", "r274", "r275", "r277", "r278", "r448", "r453", "r454", "r494", "r542", "r543", "r544" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Current liabilities", "totalLabel": "Total Current Liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet", "http://ir.ozopsurgical.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long Term Liabilities" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LoansPayableToBank": { "auth_ref": [ "r24", "r603", "r624" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of loans from a bank with maturities initially due after one year or beyond the normal operating cycle if longer.", "label": "Loans Payable to Bank" } } }, "localname": "LoansPayableToBank", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r24", "r295", "r310", "r314", "r315", "r603", "r630" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermNotesPayable": { "auth_ref": [ "r54" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Note payable, net of discount", "verboseLabel": "Less long-term portion" } } }, "localname": "LongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermPurchaseCommitmentAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment.", "label": "Long-term purchase commitment, amount" } } }, "localname": "LongTermPurchaseCommitmentAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r54" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r54", "r264" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MarketingAndAdvertisingExpense": { "auth_ref": [ "r97" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total expense recognized in the period for promotion, public relations, and brand or product advertising.", "label": "Marketing and Advertising Expense" } } }, "localname": "MarketingAndAdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_MeasurementInputExercisePriceMember": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using agreed upon price for exchange of underlying asset.", "label": "Measurement Input, Exercise Price [Member]" } } }, "localname": "MeasurementInputExercisePriceMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability." } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r62", "r129", "r226", "r266", "r271", "r272", "r273", "r277", "r278", "r494", "r604", "r633" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Noncontrolling interest", "negatedLabel": "Noncontrolling interest" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet", "http://ir.ozopsurgical.com/role/NoncontrollingInterestDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.", "label": "Noncontrolling interest percentage" } } }, "localname": "MinorityInterestOwnershipPercentageByParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/NoncontrollingInterestDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r109" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r109" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in (provided by) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r109", "r111", "r114" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r5", "r77", "r79", "r85", "r88", "r114", "r129", "r138", "r143", "r144", "r146", "r147", "r151", "r152", "r159", "r188", "r196", "r199", "r202", "r204", "r226", "r266", "r267", "r268", "r271", "r272", "r273", "r274", "r275", "r277", "r278", "r481", "r494", "r613", "r642" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net loss attributable to Ozop Energy Solutions, Inc." } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r77", "r79", "r85", "r151", "r152", "r450", "r456" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Less: net loss attributable to noncontrolling interest" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r137", "r138", "r139", "r140", "r141", "r142", "r146", "r153", "r165", "r219", "r220", "r227", "r228", "r229", "r230", "r231", "r232", "r265", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r430", "r431", "r432", "r433", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r532", "r583", "r584", "r585", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r718", "r719", "r720", "r721", "r722" ], "lang": { "en-us": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "Accounting Standards Update and Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r134", "r135", "r136", "r352", "r442" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r98" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "negatedTotalLabel": "Total Other (Income) Expenses" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other (income) expenses:" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r24", "r603", "r630" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Sub- total notes payable", "terseLabel": "Notes payable", "verboseLabel": "Notes Payable" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r47" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Current portion of notes payable, net of discounts", "verboseLabel": "Current portion of notes payable, net of discount" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableToBank": { "auth_ref": [ "r24", "r603", "r630" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, the carrying value as of the balance sheet date of notes payable to banks, excluding mortgage notes, initially due beyond one year or beyond the operating cycle if longer.", "label": "Notes Payable to Bank" } } }, "localname": "NotesPayableToBank", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.", "label": "Office Equipment [Member]" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OfficersCompensation": { "auth_ref": [ "r92" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Compensation value", "verboseLabel": "Annual salary" } } }, "localname": "OfficersCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r188", "r196", "r199", "r202", "r204" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r522" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Lease liability", "verboseLabel": "Operating lease liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails", "http://ir.ozopsurgical.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r522" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating lease liability, current portion", "negatedLabel": "Less current portion" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet", "http://ir.ozopsurgical.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r522" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating lease liability, net of current portion", "verboseLabel": "Long term portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet", "http://ir.ozopsurgical.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r523", "r526" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating lease payments" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r521" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://ir.ozopsurgical.com/role/ScheduleOfRight-of-useAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating lease right-of-use asset, net", "totalLabel": "Right-of-us assets, net", "verboseLabel": "RIght of use of asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet", "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfRight-of-useAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r527", "r529" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "operating lease disount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeasesRentExpenseNet": { "auth_ref": [ "r519" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.", "label": "operating lease rent expense" } } }, "localname": "OperatingLeasesRentExpenseNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r7", "r458" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "ORGANIZATION" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/Organization" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r43" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r72" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other comprehensive loss:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeNoncontrollingInterestTextBlock": { "auth_ref": [ "r458" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for tabular information relating to Other Comprehensive Income (OCI) as is applicable to noncontrolling interests. This text block may also include OCI relative to the filing entity, the aforementioned noncontrolling interest OCI, as well as OCI on a consolidated basis.", "label": "NONCONTROLLING INTEREST" } } }, "localname": "OtherComprehensiveIncomeNoncontrollingInterestTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/NoncontrollingInterest" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherGeneralAndAdministrativeExpense": { "auth_ref": [ "r97" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of general and administrative expense classified as other.", "label": "General and administrative, other" } } }, "localname": "OtherGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForParticipationLiabilities": { "auth_ref": [ "r586" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash payments related to participation costs.", "label": "Cash payments" } } }, "localname": "PaymentsForParticipationLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r105" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtRestructuringCosts": { "auth_ref": [ "r106" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred in the modification of term of existing debt agreement in order for the entity to achieve some advantage.", "label": "Payments of debt restructuring costs" } } }, "localname": "PaymentsOfDebtRestructuringCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r106" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of stock issuance costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r101" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of office and computer equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockConvertibleConversionPrice": { "auth_ref": [ "r328" ], "lang": { "en-us": { "role": { "documentation": "Per share conversion price of preferred stock.", "label": "Preferred stock, convertible, conversion price" } } }, "localname": "PreferredStockConvertibleConversionPrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r26", "r326" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value", "verboseLabel": "Preferred stock, price per share" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheetParenthetical", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockRedemptionAmount": { "auth_ref": [ "r56", "r325" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The redemption (or callable) amount of currently redeemable preferred stock. Includes amounts representing dividends not currently declared or paid but which will be payable under the redemption features or for which ultimate payment is solely within the control of the issuer.", "label": "Redemption amount", "verboseLabel": "Preferred stock, redemption amount" } } }, "localname": "PreferredStockRedemptionAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockRedemptionPricePerShare": { "auth_ref": [ "r325", "r344", "r346" ], "lang": { "en-us": { "role": { "documentation": "The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer.", "label": "Preferred stock redemption price per share", "verboseLabel": "Preferred stock, redemption price per share" } } }, "localname": "PreferredStockRedemptionPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized", "verboseLabel": "Number of preferred stock shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheetParenthetical", "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r26", "r326" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued", "verboseLabel": "Preferred stock shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheetParenthetical", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding", "verboseLabel": "Preferred stock shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheetParenthetical", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r26", "r544" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock Value" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockVotingRights": { "auth_ref": [ "r26", "r344" ], "lang": { "en-us": { "role": { "documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Preferred stock, voting rights" } } }, "localname": "PreferredStockVotingRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PrepaidExpenseAndOtherAssets": { "auth_ref": [], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.", "label": "Prepaid assets" } } }, "localname": "PrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrentAndNoncurrent": { "auth_ref": [ "r606", "r637" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.", "label": "Prepaid expense" } } }, "localname": "PrepaidExpenseCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrimeRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.", "label": "Prime Rate [Member]" } } }, "localname": "PrimeRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r103" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from issuances of convertible notes payable", "verboseLabel": "Proceeds from Convertible Debt" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "auth_ref": [ "r102" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.", "label": "Proceeds from issuance of preferred stock" } } }, "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r102" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds from Issuance or Sale of Equity", "verboseLabel": "Payments of stock issuance costs" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromNotesPayable": { "auth_ref": [ "r103" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.", "label": "Proceeds from issuances of notes payable", "verboseLabel": "Proceeds from Notes Payable" } } }, "localname": "ProceedsFromNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRelatedPartyDebt": { "auth_ref": [ "r103" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.", "label": "Advance from affiliate" } } }, "localname": "ProceedsFromRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Product Information [Line Items]" } } }, "localname": "ProductInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/DisaggregationOfRevenueDetails", "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails", "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ProductLiabilityContingencyThirdPartyRecoveryPercentage": { "auth_ref": [ "r260", "r261" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the estimated recovery from third parties recorded in the period pertaining to product liability damages from specified products.", "label": "Product liability contingency, third party recovery, percentage" } } }, "localname": "ProductLiabilityContingencyThirdPartyRecoveryPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ProfessionalFees": { "auth_ref": [ "r670", "r671" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.", "label": "Professional fees" } } }, "localname": "ProfessionalFees", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r5", "r77", "r79", "r85", "r108", "r129", "r138", "r151", "r152", "r188", "r196", "r199", "r202", "r204", "r226", "r266", "r267", "r268", "r271", "r272", "r273", "r274", "r275", "r277", "r278", "r444", "r449", "r451", "r456", "r457", "r481", "r494", "r618" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net loss", "totalLabel": "Net Income (loss)" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit", "http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r42", "r254" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/PropertyAndEquipmentDetails", "http://ir.ozopsurgical.com/role/ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r255", "r676", "r677", "r678" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "PROPERTY AND EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/PropertyAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r41", "r252" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Office equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/PropertyAndEquipmentDetails", "http://ir.ozopsurgical.com/role/ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r19", "r20", "r254", "r544", "r619", "r635" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net", "verboseLabel": "Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet", "http://ir.ozopsurgical.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r40", "r254", "r676", "r677" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, plant and equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r19", "r254" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "verboseLabel": "PROPERTY AND EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/PropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r19", "r252" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/PropertyAndEquipmentDetails", "http://ir.ozopsurgical.com/role/ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r391", "r535", "r536" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfExpensesToOfficersDetails", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfExpensesToOfficersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r391", "r535", "r539", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfExpensesToOfficersDetails", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r533", "r534", "r536", "r540", "r541" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfNotesPayable": { "auth_ref": [ "r104" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.", "label": "Repayments of Notes Payable", "negatedLabel": "Payments of principal of convertible note payable and notes payable" } } }, "localname": "RepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r420", "r581", "r690" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development expense" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r420" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r163" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r30", "r352", "r417", "r544", "r632", "r660", "r665" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated Deficit", "negatedLabel": "Retained Earnings (Accumulated Deficit)" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet", "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r2", "r134", "r135", "r136", "r139", "r149", "r152", "r230", "r414", "r415", "r416", "r432", "r433", "r479", "r656", "r658" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r184", "r185", "r195", "r200", "r201", "r205", "r206", "r208", "r374", "r375", "r582" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue", "verboseLabel": "Total" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/DisaggregationOfRevenueDetails", "http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r124", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r382" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r378", "r382" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "DEFERRED REVENUE" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/DeferredRevenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_SalariesWagesAndOfficersCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Salary and Wage, Excluding Cost of Good and Service Sold", "verboseLabel": "Total" } } }, "localname": "SalariesWagesAndOfficersCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfExpensesToOfficersDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r163" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r163" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r441" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/OrganizationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "SCHEDULE OF DEBT" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r392", "r393", "r394", "r395", "r396" ], "lang": { "en-us": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": { "auth_ref": [ "r460", "r461", "r462", "r463", "r464", "r466", "r467", "r468", "r469" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "SCHEDULE OF DERIVATIVE INSTRUMENTS" } } }, "localname": "ScheduleOfDerivativeInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derivative liabilities at fair value.", "label": "SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE" } } }, "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock": { "auth_ref": [ "r150", "r151", "r152" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.", "label": "SCHEDULE OF ERROR CORRECTIONS AND PRIOR PERIOD ADJUSTMENTS" } } }, "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/RestatementTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r16", "r36", "r37", "r38" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "SCHEDULE OF INVENTORY" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.", "label": "Schedule of Product Information [Table]" } } }, "localname": "ScheduleOfProductInformationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/DisaggregationOfRevenueDetails", "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails", "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r42", "r254" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/PropertyAndEquipmentDetails", "http://ir.ozopsurgical.com/role/ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "SCHEDULE OF RECOGNIZED IDENTIFIED ASSETS ACQUIRED AND LIABILITIES ASSUMED" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/OrganizationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r537", "r539" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfExpensesToOfficersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.", "label": "SCHEDULE OF EXPENSES TO OFFICERS" } } }, "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r404", "r409" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r57", "r126", "r168", "r169", "r322", "r323", "r324", "r326", "r327", "r329", "r330", "r332", "r336", "r341", "r344", "r345", "r347", "r349", "r350", "r351", "r352" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "auth_ref": [ "r176", "r178", "r179", "r180", "r491", "r493" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "SCHEDULES OF CONCENTRATION OF RISK, BY RISK FACTOR" } } }, "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r189", "r190", "r191", "r192", "r193", "r194", "r206" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Policy" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeriesCPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series C preferred stock or outstanding series C preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series C Preferred Stock [Member]" } } }, "localname": "SeriesCPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet", "http://ir.ozopsurgical.com/role/BalanceSheetParenthetical", "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/OrganizationDetailsNarrative", "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesDPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series D preferred stock or outstanding series D preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series D Preferred Stock [Member]" } } }, "localname": "SeriesDPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet", "http://ir.ozopsurgical.com/role/BalanceSheetParenthetical", "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/OrganizationDetailsNarrative", "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesEPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series E preferred stock or outstanding series E preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series E Preferred Stock [Member]" } } }, "localname": "SeriesEPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet", "http://ir.ozopsurgical.com/role/BalanceSheetParenthetical", "http://ir.ozopsurgical.com/role/OrganizationDetailsNarrative", "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r112" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "Number of non-option equity instruments exercised by participants.", "label": "Warrant exercise" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": { "auth_ref": [ "r402", "r409" ], "lang": { "en-us": { "role": { "documentation": "Number of shares purchased for issuance under share-based payment arrangement.", "label": "Number of shares purchased" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r402", "r405" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Issuance of common stock" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares issued, price per share", "verboseLabel": "Shares issued price per shares" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative", "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Shares, Outstanding, Ending Balance", "periodStartLabel": "Shares, Outstanding, Beginning Balance" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermBankLoansAndNotesPayable": { "auth_ref": [ "r44", "r640" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer.", "label": "Short-term Bank Loans and Notes Payable" } } }, "localname": "ShortTermBankLoansAndNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r45" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r122", "r133" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncements" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r25", "r26", "r27", "r126", "r129", "r154", "r155", "r158", "r160", "r162", "r168", "r169", "r170", "r226", "r266", "r271", "r272", "r273", "r277", "r278", "r326", "r327", "r332", "r336", "r343", "r494", "r707" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet", "http://ir.ozopsurgical.com/role/BalanceSheetParenthetical", "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/OrganizationDetailsNarrative", "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r2", "r60", "r83", "r84", "r85", "r134", "r135", "r136", "r139", "r149", "r152", "r167", "r230", "r343", "r352", "r414", "r415", "r416", "r432", "r433", "r479", "r504", "r505", "r506", "r507", "r508", "r509", "r656", "r657", "r658", "r722" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit", "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet", "http://ir.ozopsurgical.com/role/BalanceSheetParenthetical", "http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative", "http://ir.ozopsurgical.com/role/NoncontrollingInterestDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative", "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r134", "r135", "r136", "r167", "r582" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet", "http://ir.ozopsurgical.com/role/BalanceSheetParenthetical", "http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative", "http://ir.ozopsurgical.com/role/NoncontrollingInterestDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative", "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of preferred stock and warrants for common stock issued.", "label": "Sale of Series D Preferred Stock and warrants" } } }, "localname": "StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r26", "r27", "r352" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Stock Issued During Period, Shares, Acquisitions", "verboseLabel": "Stock issued during period, shares, acquisitions" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/OrganizationDetailsNarrative", "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r59", "r299", "r343", "r344", "r352" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Shares issued for conversions of notes and interest payable, shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Shares issued and to be issued for fees and services, shares" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r26", "r27", "r343", "r352" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Number of shares issued, shares", "verboseLabel": "Stock issued during the period" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative", "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Shares issued for debt restructure, shares" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r343", "r352" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Number of restricted shares issued" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r60", "r343", "r352" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Reverse merger transaction" } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r60", "r343", "r352" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Shares issued for conversions of note and interest payable" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Shares issued and to be issued for fees and services" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r26", "r27", "r343", "r352" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Shares issued pursuant to CEO contract", "verboseLabel": "Number of shares issued, value" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Shares issued for debt restructure" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r26", "r27", "r343", "r352" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "Number of restricted stock issued, value" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRedeemedOrCalledDuringPeriodShares": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "Number of stock bought back by the entity at the exercise price or redemption price.", "label": "Number of redeemed shares issued", "verboseLabel": "Number of stock redeemed" } } }, "localname": "StockRedeemedOrCalledDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r26", "r27", "r343", "r352" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Number of purchased shares" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r27", "r32", "r33", "r129", "r217", "r226", "r494", "r544" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Total stockholders\u2019 deficit", "totalLabel": "Total Ozop Energy Systems, Inc. stockholders\u2019 equity (deficit)" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet", "http://ir.ozopsurgical.com/role/ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity (Deficit)" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r2", "r3", "r84", "r129", "r134", "r135", "r136", "r139", "r149", "r226", "r230", "r352", "r414", "r415", "r416", "r432", "r433", "r442", "r443", "r455", "r479", "r494", "r504", "r505", "r509", "r657", "r658", "r722" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "TOTAL STOCKHOLDERS\u2019 EQUITY (DEFICIT)" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet", "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r127", "r327", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r342", "r352", "r355" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r510", "r546" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r510", "r546" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r510", "r546" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r510", "r546" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r545", "r547" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "GOING CONCERN AND MANAGEMENT\u2019S PLANS" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_SupplierConcentrationRiskMember": { "auth_ref": [ "r177" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services.", "label": "Supplier Concentration Risk [Member]" } } }, "localname": "SupplierConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r212", "r213", "r214", "r215", "r216", "r218" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r221", "r222", "r223", "r224", "r225", "r307", "r341", "r470", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r707", "r708", "r709", "r710", "r711", "r712", "r713" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeLiabilitiesAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r58", "r353" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r27", "r343", "r352" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Purchase of Series C and Series D stock for Treasury, shares" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r58", "r353", "r354" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Treasury Stock" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r343", "r352", "r353" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "negatedLabel": "Purchase of Series C and Series D stock for Treasury" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r138", "r139", "r140", "r141", "r153", "r219", "r220", "r227", "r228", "r229", "r230", "r231", "r232", "r265", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r430", "r431", "r432", "r433", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r532", "r583", "r584", "r585", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r718", "r719", "r720", "r721", "r722" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards." } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r441" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative", "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/OrganizationDetailsNarrative", "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative", "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r171", "r172", "r174", "r175", "r181", "r182", "r183" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationTechniqueAxis": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "documentation": "Information by valuation approach and technique.", "label": "Valuation Approach and Technique [Axis]" } } }, "localname": "ValuationTechniqueAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationTechniqueDomain": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "documentation": "Valuation approach and technique." } } }, "localname": "ValuationTechniqueDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationTechniqueOptionPricingModelMember": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "documentation": "Valuation technique calculating price of option.", "label": "Valuation Technique, Option Pricing Model [Member]" } } }, "localname": "ValuationTechniqueOptionPricingModelMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r485" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants and Rights Outstanding, Term", "verboseLabel": "Warrants term" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Basic and diluted" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r133": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2029-109256" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r244": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r255": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r258": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r262": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S65", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21564-112644" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r355": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r382": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121825205&loc=d3e27249-109313" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613674-111683" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r458": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=117331979&loc=d3e41228-113958" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r482": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r488": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "820", "URI": "http://asc.fasb.org/topic&trid=2155941" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=29642582&loc=d3e27862-108397" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=29642582&loc=d3e27881-108397" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41499-112717" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL77916155-209984" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919359-209981" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r541": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r547": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.27(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=6473203&loc=d3e55336-107963" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r6": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=51888271" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(1),(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(3),(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(24))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(25))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(a)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16)(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(17))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.10)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.16)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(20))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(21))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04.12(a)(1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(k)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123366838&loc=d3e3073-115593" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r691": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r692": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r693": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r694": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r695": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r696": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r697": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r698": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r699": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r700": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r701": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r702": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r703": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r704": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r705": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r706": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r707": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r708": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r709": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r710": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r711": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r712": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r713": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r714": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r715": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r716": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r717": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(22))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(23))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.19)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" } }, "version": "2.1" } ZIP 84 0001493152-22-010106-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-010106-xbrl.zip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